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Abstract 
 
 
BACKGROUND: Rapid advances in the treatment of the hepatitis C virus (HCV) have 
been witnessed in clinical practice over the last five years.  Pharmacological 
developments have ended the reliance on the drug interferon-α as a component of 
successful therapy, heralding the dawn of a new era in the fight against the disease.  
How this new era is being understood and experienced by those individuals living with 
the virus is currently unknown. 
METHODS: A purposive sample of 20 individuals participated in face-to-face semi-
structured interviews exploring their experience of living with HCV.  Eight of these 
participants were interviewed again following a period of interferon-free treatment.  
All interviews were conducted between June 2015 and March 2016.  The interviews 
were transcribed verbatim and explored using thematic analysis, underpinned by social 
phenomenological theory.   
RESULTS: Analysis of the corpus of data resulted in three overarching themes entitled 
‘positioning HCV’, ‘beyond a physical burden’ and ‘reconstructing uncertainty’.  These 
themes offer original insight into how this new era of therapy is being realised by those 
living with the virus.  The experience of interferon-free treatment was also explored 
through the narratives of those individuals who participated in a further post-
treatment interview.  Three further themes entitled ‘expectations and realisations’, ‘an 
honour and a pleasure’ and ‘treatment needs’ encapsulate their experience. 
DISCUSSION:  The findings from this study recontextualise the lived experience of HCV 
within a new era of treatment.  In doing so, they expose social and emotional spheres 
of illness, and a perception of illness chronicity, which remain untouched by the 
treatment revolution.  Further, this work emphasises how treatment inequalities 
fundamentally underpin multiple aspects of the daily lived experience, and are integral 
to how those living with HCV articulate the disease.  The implications of this work 
challenge current HCV policy and clinical practice. 
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Chapter 1 
Why hepatitis C, and why now? 
 
1.1 Introduction 
1.1.1 Thesis aim and rationale 
This thesis concerns the experience of individuals living with the hepatitis C virus 
(HCV).  Whilst a noteworthy corpus of research already exists in this field, the majority 
of published works were conducted during an era when treatment of the disease was 
renowned for its prolonged, laborious, and often unsuccessful nature, and options for 
those infected were limited.  In contrast, this thesis takes as its backdrop the 
significant advances which have occurred, and which continue to occur, in the 
treatment of the disease in recent years.  These therapeutic advances have been much 
vaunted in the scientific and popular press, celebrated as a revolution in the fight 
against the disease, and heralded as a new era of treatment (Bertino et al, 2016).  It is 
this changing landscape of HCV, this ‘new era’ of therapy, which provides this study’s 
rationale for the timely re-examination of the lived experience of HCV.   
 
The thesis is based on an empirical study involving qualitative interviews with 20 
individuals living with HCV in Edinburgh, Scotland.  Through a thematic analysis of the 
participants’ narratives, it seeks to provide contemporary insights into the experiences 
of living with HCV in this new era of therapy, in addition to exploring the experience of 
undertaking a period of HCV treatment with these novel drugs.  It is on the basis of 
these insights and explorations that the importance of considering the lived experience 
of HCV within policy and practice will be demonstrated. 
 
1.1.2 Thesis structure 
The thesis adopts a conventional structure.  This introductory chapter aims to set the 
research into a wider context, focusing on the global magnitude of the HCV problem.  
It considers how the construction of HCV as a worldwide public health priority has 
gained authority in recent years, confronting prevailing understandings of HCV as a 
disease primarily associated with drug use and addiction.  It argues that the impetus 
for the much celebrated developments in treatment has been largely shaped by socio-
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cultural, economic and political agendas, rather than an approach which primarily 
seeks to protect and treat those most affected by the virus.  The chapter provides 
some social historical background to the subsequent literature review in chapter two, 
which focuses on the experience of illness from the patient perspective, critiquing the 
results of both quantitative and qualitative patient-reported outcome measures for 
HCV.  This goes on to identify the significant gap in the literature which this thesis aims 
to address, and states the research questions which shape and direct the empirical 
work.  Chapter three builds on this foundation, and describes the methodology and 
methods employed, asserting the ontological, epistemological and theoretical 
underpinnings of the endeavour, and giving a detailed account of the specifics of data 
collection and analysis.  Following this are four chapters of findings.  Chapters four to 
six each focus on one of the main themes evident within the data, exploring the lived 
experience of HCV.  Chapter seven stands apart from the main body of the thesis, and 
specifically focuses on the experience of interferon-free HCV treatment.  Chapter eight 
then considers these findings as a whole, and discusses their meaning in light of the 
research questions posed.  The thesis draws to a close by considering the implications 
of this work for policy, treatment delivery and clinical practice. 
 
1.1.3 Chapter aim 
Evidently, the advances in drug therapy which provide the rationale for this study did 
not occur in a vacuum, and this first chapter aims to supply some background as to 
how the construction of HCV as a global public health priority has gained increasing 
authority (World Health Assembly, 2016).  It begins by describing the scale of the HCV 
epidemic, and providing further detail of the pharmacological advances in HCV 
treatment which have arrived in clinical practice over the last five years.  My personal 
connection to the study is then briefly considered.  The bulk of this chapter 
concentrates on placing the pharmacological advances within their historical, socio-
cultural, economic and political context by tracing how HCV has been constructed and 
reconstructed as a disease of addiction and a public health priority. 
 
1.1.4 Epidemiology 
Worldwide, it is estimated that over 185 million individuals are living with HCV (Mohd 
Hanafiah, Groeger, Flaxman and Wiersma, 2013).  Injecting drug use is the cause of a 
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substantial proportion of the global burden of HCV disease, with injecting drug use-
attributable HCV highest in high-income nations (Degenhardt et al, 2013; Degenhardt 
et al, 2016).  Within the UK, the most recent national estimates suggest around 
214,000 individuals are infected, of which approximately 36,700 reside in Scotland 
(Public Health England, 2015).  This includes an estimated 5,234 in the NHS Lothian 
Health Board area (Health Protection Scotland, 2015).  Of those who are living in 
Scotland, approximately 39% are unaware of their HCV positive status, and of those 
who have been diagnosed, the latest figures estimate only 28% attended a specialist 
centre for treatment and care in 2014 (Public Health England, 2015). 
 
1.1.5 Drug developments 
Recent years have witnessed a rapid evolution in the treatment available for people 
living with HCV in Scotland.  Until 2011, the treatment for this blood-borne viral 
infection had been stubbornly based around a drug called interferon-α (hereafter 
referred to as interferon), a notoriously unpleasant immunomodulating agent, with an 
extensive catalogue of both physical and neuropsychiatric side-effects (Manns, 
Wedemeyer and Cornberg, 2006).  The pegylation of interferon1, plus its combination 
with the nucleoside analogue ribavirin, led to the dual therapy standard of care for 
chronic HCV which endured throughout the 2000s and into the early part of this 
decade.  These drugs needed to be taken for up to 48 weeks, and achieved sustained 
virological response (SVR) rates which could be described as mediocre at best.  Only 
approximately 40-50% of those with HCV genotype 12 attained a cure (Fried et al, 
2002). 
 
The autumn of 2011 saw the approval of two new HCV drugs for use in clinical 
practice: boceprevir (Scottish Medicines Consortium [SMC], 2011a) and telaprevir 
(SMC, 2011b), signalling the start of a wave of new medications whose mechanism of 
action directly inhibited HCV viral replication, and which became known appropriately 
                                                          
1 A chemical modification giving the drug greater stability and in vivo activity (Foster, 2010). 
2 HCV exhibits substantial variability within its viral genome, allowing the distinction of separate 
genotypes and multiple subtypes within each genotype class (Zein, 2000).  Genotypic prevalence varies 
around the world, with genotype 1 being the most common strain overall worldwide, and genotypes 1 
and 3 constituting the majority of infection within the UK (Messina et al, 2015). 
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as direct-acting antivirals (DAAs).  These drugs were originally added into the existing 
treatment regimen of pegylated-interferon and ribavirin.  However, swift 
developments over the space of a few years resulted in the advent of new DAAs which 
no longer required the interferon backbone (Pawlotsky, Feld, Zeuzem and Hoofnagle, 
2015a).  These interferon-free therapies have drastically shortened the length of 
treatment required to twelve weeks or less; report a considerable reduction in side-
effects compared to interferon-based regimens; and have radically improved SVR rates 
to over 90% (Asselah, Boyer, Saadoun, Martinot-Peignoux and Marcellin, 2016). 
 
The arrival of interferon-free regimens for the treatment of HCV has been heralded 
worldwide as a medical triumph, and described as the dawn of a new era in HCV 
therapy (Chung and Baumert, 2014).  To underline this fact, The New England Journal 
of Medicine published no fewer than ten original articles and four associated editorials 
within the space of only a few months in 2014 documenting the progress made in the 
field of interferon-free HCV therapies (Pockros, 2014).  It is worth noting at this point 
that, despite these medications achieving remarkable results, their worldwide use has 
been hampered by their considerable costs and ensuing debates about their cost-
effectiveness (Najafzadeh et al, 2015).  As a result, HCV treatment guidelines in 
Scotland recommended both interferon-free and interferon-based therapies during 
the timeframe of this study, subject to specific criteria being met (Healthcare 
Improvement Scotland [HIS] and National Health Service [NHS] National Services 
Scotland, 2015a).  The costs of these drugs will be discussed further in due course 
(section 1.2.5). 
 
1.1.6 A personal interest 
It was shortly prior to the dawn of these much celebrated developments in treatment 
that I first began work as a HCV clinical nurse specialist in 2009.  Prior to this, I had 
worked within the dual specialities of infectious diseases and genitourinary medicine 
as a staff nurse.  However, the HCV nurse specialist role allowed me to narrow my 
focus to this particular cohort of patients, and concentrate my attentions on their 
specific set of healthcare needs.  The role ignited my curiosity into a viral infection that 
I had perhaps seen as less interesting and less weighty than more media-friendly 
infections such as the human immunodeficiency virus (HIV). 
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The work proved both enjoyable and often emotionally draining.  The prolonged 
nature of HCV treatment at the time, and the laborious pre-treatment work-up 
patients were required to engage with, provided time for close ties to be formed and 
durable therapeutic relationships built.  Nursing care extended beyond the notional 
‘HCV nurse specialist’ title, encompassing emotional and practical support with worries 
that eclipsed the viral infection, and proved a higher priority for the individuals 
concerned.  Days were filled identifying and initiating appropriate person-centred 
approaches to help address drug use, alcoholism, homelessness, financial adversity, 
immigration status, domestic abuse as well as various physical and psychological 
comorbidities.  Referrals were made, followed-up, remade and pursued.  My clinics 
moved out of the hospital and into the community, to needle exchanges, harm 
reduction services and prisons, and the professional relationship and bond with my 
patients grew. 
 
As the new era of HCV treatment dawned, international conferences and hepatology 
journals became filled with data announcing rising SVR rates, reduced treatment 
length and improved adverse event profiles.  Whilst these developments were clearly 
welcomed, the pharmacological progresses seemed to side-line and drown out the 
individual patient stories that I had come to know so well.  As the refrain that HCV 
treatment was getting ‘easier’ flourished, the individuals with the disease seemed to 
matter less.  When the opportunity arose for me to undertake a doctorate degree, my 
instinct was to honour these individuals, and the disarming honesty and candour with 
which they had allowed me into their lives over the years, and focus on their stories, 
their experiences: their voice.  I wanted to know how these developments in 
treatment, these medical triumphs, were being experienced and understood by the 
very people who were living with the virus. 
 
To begin, however, it is necessary to provide some wider context for this work, and 
address how the disease of HCV has been socially constructed and reconstructed over 
time, underscoring the constructivist epistemology which guides this undertaking 
(which itself will be justified within chapter three).  By tracing the social history of HCV 
through the examination of key policy documents and associated scientific literature, 
the factors which have contributed to its prioritisation on the world stage can be 
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examined, and the present study which is concerned with the contemporary 
experience of being HCV positive, can be placed within an historical, socio-cultural, 
economic and political landscape. 
 
1.2 Constructing hepatitis C 
1.2.1 The social construction of disease 
The essential ability and need to categorise the world is fundamental and intricately 
embedded into our lives: to classify is human (Bowker and Star, 1999).  Formal and 
informal systems of classification are interwoven throughout society, and assert an 
indisputable and inescapable influence, establishing social and moral order.  Within 
the field of health and illness, the reductionist biomedical model of medicine has 
historically maintained a dominant role in the classification of disease.  However, this 
paradigm has been increasingly challenged and critiqued in recent decades for its 
failure to locate disease and illness within its social, environmental and cultural setting 
(Nettleton, 2006).  In contrast, numerous medical sociologists have engaged in 
inquiries concerning the socio-cultural dimensions of disease for many years, with 
social constructionism emerging as a dominant theoretical perspective underpinning 
their work (Lupton, 2007).  Within this paradigm, disease is the result of social and 
interpretive processes which transform collections of symptoms into discrete entities, 
placing disease classification not merely within the realms of anatomy and traditional 
medical authority, but within wider social, temporal and cultural contexts.  As 
Rosenberg (1989) asserted, disease does not exist until we have agreed that it does.   
 
The process by which a particular condition becomes categorised as a disease, and 
how that disease is shaped and understood, is therefore influenced by social, cultural 
and political factors.  Consider the case of Chronic Fatigue Syndrome (CFS), a condition 
of unknown aetiology characterised by unexplained and persistent fatigue coupled 
with a marked decline in social functioning (Richman, Jason, Taylor and Jahn, 2000).  
Historically termed neurasthenia, this condition was originally framed as a somatic 
disease of the nervous system, mainly affecting the highly educated upper classes, who 
engaged in prolonged and intense intellectual work (Lian and Bondevik, 2015).  During 
the twentieth century, organic explanations were gradually replaced by more 
psychogenic ones as a biomedical cause remained elusive, and a pejorative 
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construction of CFS as an inability to cope emerged, shaped by the predominant 
cultural norms and values of the time (Jason, 2012).  CFS became framed derogatively 
in the media as ‘yuppie flu’, with sufferers often regarded as malingerers and shirkers 
of their normative societal roles.  Long-term exhaustion was no longer a high-status 
badge of honour as it had been in the late nineteenth century, but a dubious and 
contested diagnosis which stigmatised and blamed the sufferer for their apparent 
weakness and failure in dealing with contemporary society (Lian and Bondevik, 2015).  
The same cluster of symptoms had been constructed and reconstructed in popular and 
professional discourse over time, relocating it from a somatic biological disease to a 
questionable psychogenic syndrome, which ultimately delegitimised the patient 
experience (Ware, 1992). 
  
A social constructionist approach therefore emphasises how disease is constituted 
within institutional and cultural traditions, shifting frameworks of knowledge, and 
relations of power (Conrad and Barker, 2010).  However, discussion of disease as a 
purely socially considered collection of symptoms does not quite ring true.  What of 
biological factors, pathophysiology and diagnostic technologies?  The rise of laboratory 
medicine has moved the traditional locus of disease away from collections of 
symptoms to the cellular level (Gardner, 2014), making biological explanations for 
illness increasingly relevant in society, as illustrated by the case of CFS.  Timmermans 
and Haas (2008) note that sociologists often have an aversion for taking biological 
factors into consideration, standing with their backs to the heart of medicine and 
studying the social phenomena encircling it.  Such authors discuss endemic concerns 
amongst sociologists that recognition of biological factors implies an automatic 
devaluation of social factors in the construction of disease.  Similarly, in his call for a 
sociology of diagnosis, Brown (1995) queries why an appreciation of causative 
biological pathogens must automatically prevent us from grasping the social 
construction of the resulting conditions.  Within a critical-realist perspective, the 
existence of pathogenic microorganisms is not contested.  However, they are not 
viewed as objects which have fixed and given identities, but rather as entities that 
gradually come into being as human consciousness and scientific attention are 
directed towards them.  Biological factors and social constructionism are therefore 
necessarily intertwined.  As something becomes defined and measureable, it becomes 
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clinically actionable and socially, politically and culturally resonant.  In other words, 
what comes to count as disease and the consequences of this can be biological, but are 
always socially produced.  As Fraser and Seear (2011) note, disease is a gathering, 
made by social practices, values and conventions as much as by microbes. 
 
This discussion has particular significance in the case of HCV.  The identification of a 
causative microorganism in 1989 allowed a framing and shaping of the disease, 
constructing an identity which had political, cultural, economic and social 
connotations.  Hepatitis C does not simply designate an invariant biological reality, but 
has been created and recreated through the language, practices, social interactions 
and negotiations which surround it (Nettleton, 2006).  The remainder of this chapter 
draws on the work of Suzanne Fraser and Kate Seear, who analysed HCV from a 
cultural and social perspective in their book Making Disease, Making Citizens (2011), 
providing powerful insight into how political and social forces have shaped and 
reshaped the disease.  Their work in turn acknowledges the influence of numerous 
other scholars, notably Annemarie Mol (1999), who argued that constructions of 
disease are made and remade by multiple processes of constitution, continually 
iterated rather than singular and immutable.  Understandings and constructions of 
HCV are therefore plural, constituted by the cultural, political and societal contexts in 
which they are found (Duffin, 2005).  As Fraser (2010) remarks, HCV is more than one 
and less than many. 
 
The relative authorities of multiple disease constructions has significant implications.  
For example, the reconstruction of HIV/AIDS from a ‘gay plague’ to a chronic illness 
during the 1990s remade the cultural perception of people with HIV/AIDS as long-term 
survivors rather than terminally ill, which in turn resulted in a revision of governmental 
and community priorities for the support of people with the disease (Paterson, Butt, 
McGuinness and Moffat, 2006).  The cultural meaning of a disease therefore shapes 
how society responds to it, and powerfully influences the lived experience of those 
individuals afflicted by the condition (Conrad and Barker, 2010).  In order to 
understand a disease, therefore, the multiple discourses in which it is embedded must 
be examined. 
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1.2.2 Non-A, non-B hepatitis 
From the 1960s, viral hepatitis was considered to represent two clinically distinct 
diseases: infectious hepatitis (or hepatitis A) and serum hepatitis (or hepatitis B) which 
was corroborated by diagnostic technologies available at that time (Pawlotsky et al, 
2015a).  Advances in serological assays during the 1970s allowed the screening of 
blood donations for both hepatitis A and B.  Despite this, a significant percentage of 
patients continued to be affected by hepatitis following blood transfusions, implying a 
third form of viral hepatitis could be present (Feinstone, Kapikian, Purcell, Alter and 
Holland, 1975).  This third form was termed non-A, non-B hepatitis, indicating an 
exclusion of exposure to hepatitis A or B, but acknowledging an awareness that more 
than one other viral agent was likely to be responsible for this group of infections 
(Gitnick, 1984).  Despite this early work, the biomedical categorisation of the non-A 
non-B infectious agents remained elusive for well over a decade (Houghton, 2009). 
 
The early construction of HCV disease was therefore indistinct and unclear.  It was 
neither one thing nor the other, an unknown, lumped together with other viral 
hepatitides yet to be recognised.  However, despite its ambiguous identity, the political 
influence of non-A non-B hepatitis was beginning to be felt.  In the USA, the incidence 
of post-transfusion hepatitis due to non-A non-B was observed to occur significantly 
more frequently following transfusion of commercially derived blood than following 
receipt of blood derived from volunteer sources (Purcell, Alter and Dienstag, 1976).  
This observation contributed to a resolution by the World Health Assembly urging 
Member States to promote the development of national blood services based on 
voluntary non-remunerated donations (World Health Assembly, 1975).  In addition, 
reports were emerging of high levels of non-A non-B hepatitis in people who inject 
drugs (PWID) (e.g. Fielding, Shattock, Doyle and Kelly, 1983), and the gradual 
integration of the prefixes ‘post-transfusion’ and ‘community acquired’ filtered into 
the non-A, non-B hepatitis discourse (e.g. Sampliner et al, 1984).  These epithets were 
value-laden: a passive nosocomial infection versus a disease that had been actively 
acquired in the community.  In applying these prefixes, the social causation of non-A 
non-B hepatitis was written into its identity, creating a disease which affected 
individuals who could be labelled as accidental victims (innocent) or warranted 
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recipients (guilty) (Duffin, 2005).  Even prior to being identified and named, the 
building blocks of HCV disease were being laid down. 
 
1.2.3 A disease of addiction 
The identification and description of HCV in 1989 (Choo et al, 1989) had significant 
implications for the disease.  Whilst non-A, non-B hepatitis encapsulated a collection of 
unknowns, the name HCV presented the virus as a singular entity (despite growing 
awareness of its genetic heterogeneity [Bukh, Miller and Purcell, 1995]), making it 
specific and allowing a diagnosis.  Diagnosis is integral to the system of medicine and 
the way it creates social order, embodying the time and place when permission is 
given to be ‘ill’, and conferring legitimacy on a condition (Jutel, 2009).  This legitimacy 
can entitle the sufferer to compassion and sympathy, however, a diagnostic label can 
also attract stigma and generate stereotypical perceptions depending how the disease 
is characterised (Garand, Lingler, Conner and Dew, 2009).  In high- and middle-income 
countries, diagnosis also provides a licence to access resources, support and assistance 
which may otherwise be unavailable, although in low-income countries where 
resources and treatment are scarce, the act of diagnosing can be surrounded by 
considerable ethical dilemmas (Rennie and Behets, 2006).  In this case, the 
identification of HCV also brought practical benefits and meant that donated blood 
could be effectively screened (Houghton, 2009) and the risks of post-transfusion HCV 
began to decline significantly in high- and middle-income countries (Donahue et al, 
1992)3.  In the West therefore, the risks of obtaining HCV through blood transfusion 
faded, and discussion surrounding entitlement to compensation for those who had 
previously been infected arose (Angelotta et al, 2007).  The prefixes of ‘post-
transfusion’ and ‘community acquired’ gradually faded from use in line with the 
reduced risks of contracting HCV through iatrogenic means.  In consequence, the social 
perception of HCV in Western countries began to focus almost exclusively on those 
deemed most at risk of spreading and acquiring the infection. 
 
Throughout the 1990s and 2000s, HCV was depicted as a disease of misadventure. It 
was for those who injected drugs, had rough and unprotected sex, required medical 
                                                          
3 although iatrogenic spread remained (and remains) the most common route of transmission globally 
(Pawlotsky et al, 2015a) 
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treatment abroad or adorned themselves with tattoos and body piercings.  This was no 
longer a disease you could accidentally contract, it was one you had to go out and 
actively find.  Chief amongst these risks was the intravenous injection of drugs, and 
prevailing societal understandings towards drug use and PWID became inextricably 
enmeshed in the construction of HCV.  In the same way that negative attitudes 
towards HIV/AIDS had been associated with negative attitudes towards gay men, so 
judgements towards HCV and PWID were comparably entwined (Brener and Von 
Hippel, 2008).  For example, intensely negative public attitudes towards opioid 
substitution therapy for PWID have been aligned with a belief that addiction is self-
inflicted (Matheson et al, 2014).  In much the same way, HCV also became understood 
as a disease that was the result of the sufferer’s irresponsible behaviour rather than ill-
fortune.  Accounts of stigma and discrimination in relation to HCV were often 
tenaciously associated with illicit drug use irrespective of the mode of acquisition 
(Butt, Paterson and McGuinness, 2008; Hill, Pfeil, Moore and Richardson, 2015), and 
health promotion literature concerning HCV became (and remains) almost exclusively 
aimed at PWID, often conflating HCV and drug use within the texts, inextricably tying 
them together (Fraser and Seear, 2011).  Hepatitis C, more than ever, became a 
disease of addiction, and, as such, the social appetite for addressing the epidemic was 
muted.  Further, whilst HIV/AIDS may have benefited from its association with the 
politically and economically empowered gay community (Fee and Krieger, 1993), HCV 
had few similarly influential or mobilised groups beating its drum.  
 
The media styling of HCV as ‘a silent killer’ reinforced the lack of impetus.  As Sontag 
(1979) contended, metaphors are not just evocative figures of speech, they have the 
power to shape and construct our understanding.  A perception of HCV as a silent killer 
implies the disease is too unpredictable, insidious and complex to be ultimately 
manageable, tacitly shaping the impression that there is little that can be done (Fraser 
and Seear, 2011).  Silent killers are not often caught.  Consider this in relation to the 
language and metaphor used in other diseases.  For example, cancer is something 
which is battled and can be beaten.  The discourse around cancer is rich in military 
metaphor (Harrington, 2012), galvanising public opinion that a war on cancer is one 
that ought to be fought, and constructing a disease that can be overcome given 
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enough resources and time.  In contrast, the advance of HCV is silent and undetected 
until its victory is secured; a disease for which battle is futile. 
 
1.2.4 A delayed response 
The construction of HCV as a disease of addiction and one for which little could be 
done placed it at a distinct disadvantage politically, contributing to a lethargic global 
policy response at odds with other major communicable diseases.  Not until 2010 did 
the World Health Assembly adopt its first ever resolution on viral hepatitis - WHA 
63.18 - acknowledging the global public health problem and calling for a 
comprehensive approach to prevention and control (World Health Assembly, 2010).  
As a contribution towards that objective, the World Health Organisation (WHO) 
published a strategic framework to guide Member States in progressing their national 
action plans (WHO, 2012) in addition to conducting a survey aimed at gathering 
country-specific baseline data on hepatitis policies from individual governments (WHO, 
2013).  The results of this survey revealed a sporadic and erratic global response to 
HCV, with just 37.3% of the Member States who responded4 reporting the existence of 
a written national strategy or plan focussing exclusively or primarily on viral hepatitis.  
Furthermore, the response to this report from patient groups, non-governmental 
organisations, academic institutions and medical associations questioned the accuracy 
of much of the published governmental data, disputing key claims regarding viral 
hepatitis prevention and control, and highlighting a lack of engagement between 
governments and civil society stakeholders (World Hepatitis Alliance, 2014).  A further 
resolution from the World Health Assembly duly followed - WHA 67.6 - calling more 
forcefully for a comprehensive global strategy in the face of a growing public health 
problem (World Health Assembly, 2014).  However, it was not until 2016, 27 years 
after the identification of HCV, that the World Health Assembly adopted the Global 
Health Sector Strategy on viral hepatitis, with the goal of eliminating HCV as a major 
public health threat by 2030 (World Health Assembly, 2016). 
 
At a European Union (EU) level, the response to HCV has been even more sluggish.  In 
2007, the European Parliament adopted Written Declaration 0087/2006, calling for 
                                                          
4 In total, 126 Member States submitted the survey for a response rate of 64.9% (WHO, 2013). 
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recognition of HCV as an urgent public health issue (Dičkutė, Bowis, Hughes, Ries and 
Ulmer, 2006).  However, despite including viral hepatitis in its priorities for 2008, the 
EU agency responsible for disease-specific data collection did not begin enhanced 
surveillance of HCV within Europe until 2011 (European Centre for Disease Prevention 
and Control, 2013).  Further, the lack of consistent and harmonised surveillance 
mechanisms within Member States presented concern over the reliability of the data 
collected, and constituted a significant gap in EU legislation (Ulmer and Hughes, 2013).  
A further Written Declaration, 0023/2013, calling on more action by the European 
Parliament in respect to the “urgent public health issue” of HCV (Ţicău et al, 2013) 
lapsed in 2014 after failing to gather sufficient signatories, and across Europe a 
uniform approach to the management of the disease remains absent.  Pockets of work 
continue however, and in 2016 the first high-level European policy summit in relation 
to HCV took place (Hepatitis B and C Public Policy Association, 2016) resulting in a 
manifesto in line with the World Health Assembly objective: the elimination of HCV in 
Europe by 2030. 
 
Whilst a languid international response to HCV can be traced through the exploration 
of grey literature and key policy documents, a more dynamic national response has 
been evident in some countries.  Within the UK, where most health policy is a 
devolved matter, the then Scottish Executive declared in 2004 that HCV was one of the 
most serious and significant public health risks of our generation, and a nationally 
coordinated and government funded two-phase Hepatitis C Action Plan was 
subsequently initiated in 2006 (Scottish Executive, 2006).  The impetus for this 
vigorous response to HCV came from two main sources: an unusually vocal and 
determined group of HCV positive individuals whose lobbying instigated a report on 
HCV by the Scottish Needs Assessment Programme (SNAP, 2000), and a Consensus 
Statement on HCV which emerged from the Royal College of Physicians in Edinburgh in 
April 2004 highlighting the growing burden of infection and liver disease on existing 
services (Scottish Executive, 2005).  These documents galvanised a political response 
to the growing epidemic in Scotland by identifying the prevention of HCV transmission 
and increasing diagnosis of HCV as their primary objectives.  The treatment of those 
infected was framed as a subordinate consideration.  Indeed, on-going injecting drug 
use was noted as an explicit contra-indication for receiving therapy (Scottish Executive, 
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2005).  As this discourse developed and the Action Plan matured, subsequent 
improvements in testing, treatment, care and support were implemented from 2008 
accompanied by major governmental investment of £43 million over three years 
(Scottish Government, 2008).  In 2011, the Hepatitis C Action Plan was incorporated 
into a new policy framework integrating sexual health and blood borne viruses 
(Scottish Government, 2011), and remains globally renowned and considered as 
leading best practice in a national response to tackling and treating HCV (Ulmer and 
Hughes, 2013). 
 
Despite examples of best practice in specific regions, the overall global response to 
HCV has been hindered and shackled by cultural perceptions of the disease.  The social 
stigmatisation associated with injecting drug use is not only subjectively internalised by 
HCV positive individuals (Paterson, Backmund, Hirsch and Yim, 2007), but also tacitly 
influences decisions by social and healthcare agencies, and sways governmental policy 
(Room, 2005).  Consider the discourse surrounding compensation claims for those 
iatrogenically infected through blood products.  Whilst countries such as Canada, 
Ireland and the UK eventually allocated compensation and ex gratia payment funds, 
the response from other nations has been markedly subdued (Angelotta et al, 2007).  
For example, a Written Declaration to the European Parliament in 2011 calling on the 
need to provide appropriate compensation for victims of infected blood failed to 
garner support (Rossi, 2011).  In contrast, most developed countries implemented a 
broad range of political and legal responses to the contamination of the blood supply 
with HIV in the 1980s.  More than 20 countries offered financial compensation to 
people with haemophilia who had contracted HIV through infected blood; health 
officials in Japan and France were convicted of criminal negligence; and civil lawsuits 
against suppliers of HIV contaminated blood were adjudicated resulting in blood 
product suppliers providing financial recompense (Angelotta et al, 2007).  Once again, 
whilst HIV benefitted from its association with a politically empowered and vociferous 
section of the gay community, HCV floundered due to its lack of campaigning voice and 
intimate association with illegal drug use. 
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1.2.5 Pharmaceutical developments 
At odds with the lethargic and disjointed global political response, the recent 
developments in the treatment of HCV by the pharmaceutical industry have been 
framed as a rapid ‘medical triumph’ and the culmination of successive biomedical 
advances (Chung and Baumert, 2014).  The historical HCV treatment of interferon (and 
later pegylated-interferon) and ribavirin has been transformed with the advent of the 
DAA era (Thiagarajan and Ryder, 2015), a therapeutic revolution hailed as truly 
remarkable given it has occurred less than 25 years since the identification of the virus.   
There are now numerous combinations of drugs available for HCV treatment, with 
many more in phase II and phase III clinical trials (Pawlotsky et al, 2015a).  However, 
whilst often framed as a progressive succession of discoveries over this time, the 
advances in HCV treatment have not been as rapid as retrospective accounts suggest.  
The first DAAs did not arrive in clinical practice until 2011, 22 years after HCV was 
identified (Thiagarajan and Ryder, 2015).  The ‘treatment revolution’ has therefore 
only moved out of the laboratory in the last five years, meaning that throughout the 
1990s and 2000s a disease which disproportionately afflicts the most disenfranchised 
sections of society endured an arduous, challenging and lengthy therapy which had a 
limited efficacy of approximately 40-80% (Thiagarajan and Ryder, 2015).  Over 
approximately the same period of time, some 25 different drugs in six different classes, 
as well as a variety of fixed dose combination pills, were developed and licensed for 
the treatment of HIV (Zolopa, 2010), inferring the delays in new therapies emerging for 
HCV were not solely limited by the virological technologies of the day. 
 
Whilst advances in drug therapy are now encouraging and enabling academic 
discussion of global HCV eradication (Hagan and Schinazi, 2013), there is a colossal 
difference between large pharmaceutical companies producing a product that can cure 
a disease, and afflicted people around the world obtaining the drugs.  The high cost of 
DAAs precludes their use in most infected patients in low- and middle-income 
countries, and in high-income countries fiscal considerations and insurance provider 
policies have resulted in selective use (Chung and Baumert, 2014).  For example, in 
America, State Medicaid programmes, which provide healthcare for families and 
individuals on low incomes and with limited resources, have restricted access to DAAs 
due to their substantial costs (Canary, Klevens and Holmberg, 2015).  In response, the 
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Centres for Medicare and Medicaid Services (CMS) released a guidance document 
highlighting restrictions on access to treatment which they deemed were 
unreasonable (CMS, 2015), however, it remains to be seen what impact this guidance 
will have.  Even in Scotland, a benchmark for excellence in terms of national strategy, 
the SMC continued to only approve DAAs for restricted use due to financial concerns 
during the timeframe of this study (e.g. SMC, 2015a).  As Nettleton (2006) has noted, a 
‘medical triumph’ is not determined by technological advances, but rather is the 
outcome of the socio-political struggles that surround technology and its application.  
Patient groups concur, emphasising the significance of the social aspects of HCV and 
questioning any assertion that the disease could be brought under control by science 
alone (World Hepatitis Alliance, 2014). 
 
1.2.6 A public health priority 
After languishing as a disease of addiction for over twenty years, why was HCV 
eventually thrust onto the global public health agenda?  What factors served to 
promote the framing of HCV as a public health priority, and generate sufficient 
economic impetus to drive the pharmaceutical arms race currently being witnessed?  
The increasing prevalence of HCV is an obvious rejoinder.  However, this had been 
monitored by the WHO, amongst others, for many years with little sign of momentous 
change.  In 1997, the WHO estimated a global prevalence of approximately 3% with 
the virus affecting more than 170 million people worldwide (WHO, 1997), a figure 
which was subsequently revised down to 2.2% by further WHO funded work in 2004 
(The Global Burden of Hepatitis C Working Group, 2004). The most recent estimates of 
disease burden suggest an increase in global seroprevalence from 2.3% in 1990 to 2.8% 
in 2005, equating to over 185 million infections worldwide, with significant variations 
between geographic regions (Mohd Hanafiah et al, 2013).  Early estimates of the global 
prevalence of HCV have not therefore drastically changed between the late 1990s and 
more recent assessments, suggesting that the emerging and increasing contemporary 
discourse of HCV as a global public health emergency is not solely driven by the 
number of individuals living with the disease. The public health emergency has always 
been there, yet its public profile was historically subdued.  It is necessary therefore to 
consider other influences which contributed to the social reconstruction and 
underscoring of HCV as a public health priority. 
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A strong and persuasive narrative emerges from patient advocacy groups.  Initially 
disparate and isolated, they gradually came together during the first decade of the 
twenty-first century and mobilised under the World Hepatitis Alliance umbrella, in 
direct response to the absence of an international public discourse around the disease.  
In addition to raising the public profile of HCV through originating World Hepatitis Day 
in 2008, they were also instrumental in demonstrating the need for both World Health 
Assembly resolutions, advocating and lobbying Member States to adopt the proposals 
(World Hepatitis Alliance, 2016).  Within Europe, the European Liver Patients’ 
Association (ELPA) brought together national liver patient groups from across the 
continent, successfully influencing the European Parliament’s adoption of their 
Written Declaration in 2007 (Piorkowsky, 2009).  A louder and more powerful patient 
voice had emerged, directly at odds with the dominant perception of HCV patients 
constructed throughout the previous decades, which had been easy to ignore.  
Hepatitis C patients were becoming visible and empowered on the international stage, 
using their collective presence to influence the global health agenda.  The recent 
pharmaceutical advances have themselves spurred further patient advocacy, as 
disparity of access to new DAAs presents a new banner under which to mobilise 
(Trooskin, Reynolds and Kostman, 2015). 
 
It is worth briefly considering how patient advocacy groups achieved this dynamic 
global voice.  Fraser and Seear (2011) observed that the model of the ‘politically active 
patient’ is inapposite to the majority of individuals affected by HCV in high-income 
nations, indeed, those with HCV are more commonly cast as PWID risk-takers, framed 
as lacking in self-control and deemed ‘guilty’ for their infection (as previously 
described).  Such individuals are positioned as undeserving of patient citizenship, with 
little connection to community activism and little entitlement to treatment and care 
(Rhodes, Harris and Martin, 2013).  In order to make their voice heard therefore, 
patient advocacy groups have distanced themselves from ‘guilty’ distinctions of HCV, 
aligning more visibly with less culpable or morally questionable individuals who 
acquired the disease through iatrogenic means5 – the ‘innocent’ parties (Duffin, 2005).  
This positioning allowed a presentation of HCV positive individuals as victims of an 
                                                          
5 For example, consider the much publicised patronage of the Hepatitis C Trust by Anita Roddick, who 
acquired HCV through a blood transfusion during the birth of her son in the 1970s. 
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unforeseen tragedy, eliciting emotions of sympathy and rightful anger (Seear, Fraser 
and Lenton, 2010) which carried greater political weight.  The advocacy movement 
speaks for all, but is strategic in how it achieves this. 
 
Patient activism alone is not the whole story, however, as multiple narratives and 
authorities have served to reconstruct HCV into a global public health priority.  Whilst 
retrospective accounts tend to frame the belated prioritisation of HCV as a result of 
scientific and political pressure to address health inequalities in marginalised 
populations (e.g. Wylie, Hutchinson, Liddell and Rowan, 2014), economic motivations 
were also considerable factors.  The early economic discourse around HCV focused on 
the cost-effectiveness of specific treatments, but lack of certainty around long-term 
clinical outcomes and questionable efficacy of the drug available at the time made this 
a particularly inexact science (Koff, 1997; Shiell, Briggs and Farrell, 1994).  Slowly, 
however, a narrative arose concerning the future costs to the healthcare system of 
HCV sequelae from untreated infections.  Early work from Australia in 1998 estimated 
that the costs of treating chronic hepatitis, cirrhosis, liver failure and hepatocellular 
carcinoma amongst their population of PWID over the next 60 years could total AUS$4 
billion, and called for urgent action from national policy-makers to forestall this 
predicted bill (Brown and Crofts, 1998).  A wider discourse on disease burden 
subsequently emerged with assessments of the accumulated costs of HCV-related liver 
disease in other countries appearing within the literature.  Sheerin, Green and Sellman 
(2003) estimated the accrued costs related to HCV within the PWID cohort in New 
Zealand to be in the region of NZ$166-400 million whilst in America the predicted 
direct medical costs to treat future HCV-related disease was conservatively estimated 
between US$6.5-13.6 billion with societal costs adding an additional US$21.3-54.2 
billion over ten years (Wong, McQuillan, McHutchison and Poynard, 2000).  Similarly 
costly forecasts followed from other regions (e.g. Saadany, Coyle, Giulivi and Afzal, 
2005; Vandijck et al, 2014), with global estimates of the cost of HCV-related disease 
eventually taking shape (El Khoury, Wallace, Klimack and Razavi, 2012). 
 
The importance of this narrative to contemporary discourse is evident.  The published 
academic literature continues to sound warning sirens at the downstream healthcare 
costs associated with HCV (Gordon et al, 2013; Harris et al, 2014), and current 
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international and national public health policy places the pecuniary burden of HCV 
disease at its heart.  The first WHO guidelines for the care and treatment of people 
with HCV notes that new treatments have the potential to reduce dramatically the 
health and economic burdens associated with the infection (WHO, 2014) whilst the 
foreword to a recent account of HCV in the UK states that it “highlights the work that 
still needs to be done to curtail the increasing burden of end stage liver disease and 
liver cancer caused by hepatitis C infection” (Public Health England, 2015, p.5).  Echoes 
of this narrative are also found in professional guidance for healthcare practitioners.  
Both the American Association for the Study of Liver Disease (AASLD, 2015) and the 
European Association for the Study of the Liver (EASL, 2015) have previously 
advocated prioritising the treatment of those individuals with a greater degree of liver 
damage (Metavir stage F3 and F4) where resources are limited.  Whilst distributive 
justice in terms of liver disease prioritises those most at risk of immediate ill health, it 
also implicitly prioritises those who are more likely to incur downstream healthcare 
costs due to the complications of cirrhosis and hepatocellular carcinoma (Tapper et al, 
2016).  This is more salient when the evidence suggesting earlier treatment for HCV, 
that is, treatment of those with minimal fibrosis, offers a better response to therapy 
and improved long-term survival (e.g. Jézéquel et al, 2015). 
 
1.2.7 Summary 
As previously stated, in order to understand a disease and society’s responses to it, the 
discourses in which it is embedded need to be examined.  A social constructionist 
critique of HCV demonstrates how the disease is more than simply the name given to a 
collection of biological pathogens: it is an evolving and dynamic social entity that 
invokes certain logics of treatment and care.  This summary of the socio-cultural and 
political history of HCV has drawn on diverse bodies and sources of literature from 
over 40 years.  It has done so in order to situate the disease within its wider context, 
and provide the biomedical history of HCV disease with a complementary 
interpretation which resonates with the theoretical foundations of this thesis.  Social, 
cultural, political and economic forces have contributed to shaping and reshaping 
understandings of HCV which are replete with assumptions and opinions about what 
the disease means and what it merits.   
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Since its identification, HCV has been predominately shaped within high-income 
countries as a disease entwined with illicit drug use, tainted by the stigma, 
discrimination and negative societal judgements that this practice attracts.  Treatment 
of those most affected by the disease has also been primarily about engaging with a 
population of largely demonised PWID, individuals deemed guilty for their infection 
and with little claim to therapeutic citizenship.  These constructions permitted a 
restrained political response to the growing epidemic, until an increasing awareness 
amongst policy- and decision-makers of the predicted financial burden that HCV 
threatens globally necessitated a shift in the public discourse from a disease which 
affected a marginalised and socially stigmatised group, to one which was relevant to 
wider sections of society.  To address the predicted financial burden of HCV, society’s 
understanding of it needed to be refocused, disentangling its identity from illicit drug 
use and shaping a predominant understanding of HCV as a public health priority.  
Hepatitis C has been reconstructed within the global arena as a disease with broader 
social and economic implications, galvanising governmental responses and creating an 
environment ripe for pharmaceutical investment.  The mobilisation of the response to 
HCV has appeared in line with the gradual movement of a broader public health 
narrative to centre stage.  This narrative focuses on the burden of disease and its 
implications for health services and service providers rather than the physical and 
emotional costs to individuals and their families.  A disease deemed to affect primarily 
PWID has been remade in terms of something wider sections of society can empathise 
with: money.  Whilst this focus on HCV as a public health priority has stimulated the 
current momentum to address the disease, there is a danger that it may also serve to 
silence personal experience and individual suffering. 
 
Within this chapter, I have endeavoured to demonstrate how socio-cultural, political 
and economic forces have contributed to the construction and reconstruction of HCV 
over the last 40 years in order to situate the disease and this thesis within its temporal 
context.  In doing so, I have composed a narrative situated decisively within the 
Western world, and of relevance to the local situation in Scotland, as the global 
response to HCV and its assembly as a public health priority have been driven by 
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wealthier industrialised nations6.  This discussion provides context to the 
developments in drug therapy which provide the rationale for this thesis, and also 
begins to offer justification for the focus given to the patient experience and 
understanding of the disease.  As a nurse, understanding the meanings, implications 
and consequences of HCV from the point of view of the people most affected, provides 
insights which can only enhance and develop better clinical care. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
6 The areas of highest HCV prevalence are found in Central and Eastern Asia, North Africa and sections of 
the Middle East (Mohd Hanafiah et al, 2013) where resources are limited and strategies to address the 
epidemic are correspondingly embryonic.  It remains to be seen how the HCV public health agenda, 
driven by resource-rich and globally influential countries, manifests itself in the poorer regions of the 
world where the disease is most widespread. 
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Chapter 2 
Living with hepatitis C:  a review of the literature 
 
2.1 Introduction 
Having considered the wider socio-cultural, economic and political contexts in which 
this thesis is situated, the aim of this chapter is to review the extant body of literature 
focusing on the perspective of those living with HCV.  This is achieved through the 
examination of studies which have reported either quantitative or qualitative patient-
reported outcome measures.  Firstly, the quantitative assessment of health-related 
quality of life in individuals with HCV is presented, revealing a significant decrement 
compared to population norms.  This body of work also investigates the multifactorial 
underlying cause, and the effects of HCV treatment.  Secondly, the qualitative 
literature pertaining to the lived experience of HCV is explored, and the limitations of 
the quantitative approach critically considered.  An argument is then made that 
qualitative research in this area not only aids the interpretation of the quantitative 
data, but offers deeper and more nuanced insights into a complex phenomenon7.  This 
discussion also highlights the significant gap in knowledge which this thesis aims to fill, 
and ends by stating the research questions which guide the empirical work described 
in the subsequent chapters. 
 
2.2 Search strategy 
The search strategy focused on seven medical, sociological, psychological and nursing 
databases: Medline; CINAHL; Embase; Cochrane Library; JBI COnNECT+; PsycINFO and 
ASSIA.  Two separate search strategies were developed to identify both quantitative 
and qualitative reports.  For quantitative papers, comparable search terms for 
‘hepatitis C’, ‘health-related quality of life’ (including common abbreviated forms) and 
‘patient reported outcomes’ were used, accounting for variation in the subject index 
terms specific to each search engine.  For qualitative papers, comparable search terms 
for ‘hepatitis C’, ‘quality of life’ or ‘life experience’, and ‘qualitative research’ or 
‘interview’ were used, again accounting for variation in specific subject index terms8.  
                                                          
7 A published version of this literature review can be found in appendix A. 
8 The term ‘quality of life’ is used more generally within the qualitative literature than the more specific 
‘health-related quality of life’. 
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In order to obtain papers that provided a detailed historical and contextual view as 
well as giving contemporary relevance, databases were searched to the extent of their 
temporal limits, preceding the publication announcing the isolation of HCV (Choo et al, 
1989) in most cases9. 
 
The quantitative search strategy used the following initial inclusion/exclusion criteria: 
inclusion criteria were adult participants, an English language abstract, and specific 
quantitative HCV health-related quality of life data provided.  Excluded papers were 
those dealing solely with other liver disease aetiologies, and papers concentrating on 
those undergoing haemodialysis or liver transplantation.  These articles primarily 
described the impact of those specific interventions which is not the focus of this 
thesis.  The inclusion criteria for the qualitative arm were as follows: adult participants, 
an English language abstract, ‘life experience’ focus and qualitative data reported.  
Exclusion criteria remained the same as for the quantitative search strategy.  Both 
observational and interventional studies were included, as were reviews at this initial 
stage.  Duplicate entries for the same article appearing in multiple search engines were 
removed. 
 
The remaining articles were retrieved, and the reference lists examined for any further 
studies which had not been identified to date.  Once complete, review articles were 
then excluded as primary data sources.  Data were extracted from the remaining 
studies using a data extraction sheet which identified the author(s), date and source of 
publication, study design, key findings, limitations and recommendations.  Using these 
data, key, dominant themes were identified for each research paradigm, which 
provided the foundation for the formulation of results and the synthesis of a coherent 
narrative. 
 
2.3 The literature review 
2.3.1 Patient-reported outcomes measures 
Objective measures of patient outcome are of clear importance within healthcare.  
However, they do not necessarily include or align with the benefits or most pressing 
                                                          
9 Appendix B demonstrates the initial results of the search strategies for each paradigm. 
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concerns perceived by the patients themselves.  With the historical move from a 
disease-centred model of medicine to a more biopsychosocial paradigm, a focus 
emerged on not only the biomedical decrements of illness and curative benefits of 
treatment, but also the experience of illness and treatment from the patient 
perspective.  Increasingly, this experiential focus is being given central importance in 
the planning of future healthcare improvements (e.g. Scottish Government, 2010), and 
in the licencing of new medications (Food and Drug Administration, 2009).  In addition, 
an understanding of the patient experience of illness and treatment can also inform 
clinical practice, aiding interaction and communication with patients and clients on a 
one-to-one basis (Wu and Snyder, 2012). 
 
Insights into the patient experience of illness and treatment are gained through 
patient-reported outcome measures (PROMs), an umbrella term used to encompass 
any report coming directly from a patient about their health condition and treatment.  
PROMs can therefore be both quantitative and qualitative in nature, although are most 
frequently reported using data from quantitative self-completed questionnaires.  
These questionnaires are often specific to a particular symptom such as fatigue (e.g. 
Fatigue Severity Scale [Krupp, LaRocca, Muir-Nash and Steinberg, 1989]) or pain (e.g. 
Brief Pain Inventory [Cleeland and Ryan, 1994]), both of which have obvious benefits 
as these events are generally unobservable and/or unquantifiable from the clinician’s 
perspective.  More broadly, however, some tools have been developed to assess 
multiple health concepts, incorporating physical, emotional and social domains, to 
provide a multidimensional construct of an individual’s health-related quality of life10 
(HRQoL).  These quantitative tools can be generic, assessing the HRQoL across patients 
living with a variety of conditions, or validated in more condition-specific populations. 
 
Health-related quality of life within HCV is most recurrently measured by the Short-
Form (SF)-36 Health Survey (Ware and Sherbourne, 1992).  This generic self-
administered questionnaire consists of 36 items divided into eight domains: physical 
functioning; role – physical; bodily pain; general health; vitality; social functioning; role 
                                                          
10 This is still a loosely-defined term, used to distinguish between aspects of life affected by disease or 
treatment for disease, and those broader quality of life issues such as access to green space within 
towns and cities (Fayers and Machin, 2007).   
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– emotional and mental health.  Of these, vitality, general health, physical functioning 
and social functioning are thought to be where the impact of HCV is most pronounced 
(Speigel et al, 2005).  These domains can then be aggregated into two summary scores: 
physical component summary and the mental component summary.  This tool has 
been validated in various condition-specific patient populations, and can also be 
compared to population norms (Foster, 2009).  A supplemented HCV-specific version 
of this tool is also employed within the literature (the Hepatitis Quality of Life 
Questionnaire [HQLQ] [Bayliss et al, 1998]) but as Foster (2009) notes, whilst this has 
the advantage of capturing disease-specific data, a more generic tool allows cross-
disease comparison.  Whilst these tools are the most common, there is no overriding 
consensus or standardization on their exclusive use within HCV, and other tools also 
appear within the literature, for example the EQ-5D (Vera-Llonch et al, 2013) and the 
WHOQOL-BREF (Fábregas et al, 2013), whilst new instruments continue to be 
developed, evaluated and validated (e.g. Anderson et al, 2014; Armstrong et al, 2016). 
 
2.3.2 HRQoL in individuals living with HCV 
2.3.2.1 Causal investigation: virus-related factors 
The quantitative literature demonstrates HCV positive individuals have reduced HRQoL 
in comparison to healthy controls or population norms (table 1) and goes onto 
investigate and debate the underlying cause. 
 
 
Table 1: Studies comparing HRQoL in individuals with HCV versus healthy controls or population norms, 
using SF-36 or HQLQ tools. 
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Foster, Goldin and Thomas (1998) reported a reduced HRQoL in patients with HCV 
which could not be attributed to either the degree of liver disease, or association with 
a history of injecting drug use, concluding the decrement was attributable to HCV per 
se.  Clearly, whilst only looking at these two parameters there remained the possibility 
that the differences observed could be due to other, as yet unmeasured factors.  
Bonkovsky et al (1999) sought to address this by observing the effect that successful 
antiviral treatment had on patients’ HRQoL.  They hypothesised that if HRQoL 
improved upon effective removal of the virus, then the virus itself was the true cause 
of the impairment.  They reported data from a large multi-centre drug trial which 
supported this hypothesis, concluding that HCV infection reduces HRQoL independent 
of comorbidities or factors associated with the virus (Bonkovsky et al, 1999)11.  
Research from real-world populations has also given weight to the argument that viral 
factors contribute to HRQoL independent of host-factors (John-Baptiste et al, 2009; 
Strauss, Porto-Ferreira, Almeida-Neto and Teixeira, 2014), and whilst the mechanism 
for this is still debated, evidence of viral replication within the central nervous system 
adds weight to the argument (Forton, Karayiannis, Mahmud, Taylor-Robinson and 
Thomas, 2004). 
 
Despite such persuasive assertions, it is unlikely that any one factor is solely 
responsible for reduced HRQoL, and a complex multifactorial cause is a more likely 
explanation.  Virus-related factors and associated extra-hepatic manifestations of HCV, 
combined with host-related factors, psychiatric and medical co-morbidities and the 
pressure of societal stigma are all likely to be significant contributors (Daltro-Oliveira, 
Morais-de-Jesus, Pettersen, Paraná and Quarantini, 2013; Häuser, Zimmer, 
Schiedermaier and Grandt, 2004; Helbling et al, 2008; Hsu et al, 2012; Lowry et al, 
2016).  These factors will now be examined. 
 
2.3.2.2 Causal investigation: extra-hepatic manifestations of HCV 
Extra-hepatic manifestations of HCV encompass any condition or symptom that affects 
any organ other than the liver.  Among the most common complaints of patients with 
                                                          
11 It should be noted, that patients enrolled in clinical trials represent highly selected populations (Van 
Spall, Toren, Kiss and Fowler, 2007), and it is not clear whether these results are generalizable, 
particularly as very little demographic data is given.  This will be discussed in greater detail in due 
course. 
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HCV is cognitive impairment (commonly referred to as ‘brain-fog’) which occurs 
independent of the degree of liver disease present (Forton et al, 2002; Kramer et al, 
2002), but can be more marked in patients with cirrhosis due to the effects of hepatic 
encephalopathy (Córdoba et al, 2003).  There is some evidence that the aetiology of 
cognitive impairment contains a biological cause (Forton et al, 2002; Forton et al, 
2004), implying a direct action of HCV on the brain (Kramer et al, 2002; Lowry, 
Coughlin, McCarthy and Crowe, 2010).  It has also been demonstrated that cognitive 
function improves in patients who are successfully treated for HCV infection (Kraus et 
al, 2013; Thein et al, 2007) adding weight to the argument for a direct viral effect.  To 
what degree any subsequent impairment in HRQoL derives from this effect is 
debatable, as negative decrements have been shown even in the absence of significant 
cognitive abnormalities (Córdoba et al, 2003; Kramer et al, 2002).  However, it is 
possible the tools used to measure cognitive abnormalities in these studies lacked 
sufficient sensitivity.  A further consideration is the role of comorbid substance use in 
cognitive impairment for individuals with HCV.  Donoghue and Doody (2012) suggest 
substance using individuals with HCV may experience a ‘double-deficit’ in cognitive 
impairment, impinging more profoundly on their HRQoL.  The relationship between 
HCV, cognitive impairment and HRQoL is therefore not straightforward.  Indeed, 
recent research from Ireland reported little evidence of significant cognitive 
dysfunction in those with mild liver disease, questioning earlier work in this area 
(Lowry et al, 2016). 
 
Fatigue is also a commonly reported extra-hepatic manifestation of HCV, although the 
pathophysiology remains poorly understood.  It has been found to be independently 
associated with impairment of HRQoL, and unrelated to the severity of liver disease 
(Fábregas et al, 2013; Kramer et al, 2005).  A further study supported this assertion 
and concluded that disabling fatigue was the most important factor contributing to 
lower HRQoL in HCV patients (Kallman et al, 2007).  Fatigue has also been shown to 
improve following successful therapy supporting the argument that there is a direct or 
indirect viral effect causing fatigue-related HRQoL reduction (Bernstein, Kleinman, 
Barker, Revicki and Green, 2002; Gerber et al, 2016; Hassanein et al, 2004; Rasenack et 
al, 2003).  Interestingly, a study examining biopsychosocial variables in HCV patients 
found poor social functioning was the most significant predictor of fatigue (Hilsabeck, 
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Hassanein and Perry, 2005), and fatigue has also been closely linked to the incidence of 
depression amongst individuals with HCV (Yamini et al, 2011).  These findings highlight 
the difficulties that lie in disentangling what can be attributed to viral factors, and 
what can be attributed elsewhere. 
 
Whether depression is an extra-hepatic manifestation of HCV and/or a separate 
underlying pre-morbid psychiatric condition due to associated host-related factors is 
unproven.  However, its presence within the HCV population is common and its effect 
on HRQoL has been shown (Barboza et al, 2016; Lowry et al, 2016).  Gallegos-Orozco et 
al (2003) reported a 59% incidence of depression in HCV patients, and demonstrated 
lower HRQoL in this cohort compared to non-depressed HCV patients.  Of note, none 
of the patients in this study had any additional comorbidities, history of injecting drug 
use or alcohol dependence, suggesting these often cited host-factors did not 
contribute in this instance, and a viral cause may be involved.  Dan et al (2006) also 
highlighted the strongly predictive role a history of depression and pre-treatment 
depressive symptoms play in HRQoL for patients undergoing treatment, a finding 
supported by separate work conducted with American Veterans (Rowan et al, 2005). 
 
2.3.2.3 Causal investigation: host-related factors 
The role of illicit drug use in relation to HRQoL decrements is an important 
consideration, given the high incidence of current or former PWID within this patient 
population (Hutchinson et al, 2006).  People who inject drugs experience a lower 
HRQoL than population norms irrespective of their HCV status (Dalgard, Egeland, 
Skaug, Vilimas and Steen, 2004; Fischer, Conrad, Clavarino, Kemp and Najman, 2013; 
Gjeruldsen, Loge, Myrvang and Opjordsmoen, 2006; McDonald et al, 2013), and 
former PWID who have HCV have been shown to have lower HRQoL than individuals 
who acquired HCV by another route (Foster et al, 1998; Hollander, Foster and Weiland, 
2006).  Untreated HCV patients on methadone maintenance therapy have also been 
shown to have lower HRQoL when compared to untreated HCV patients without a 
substance use diagnosis (Batki, Canfield, Smyth and Ploutz-Snyder, 2009). 
 
Of interest, a study by Dalgard et al (2004) reported that active PWID who believed 
they were infected with HCV had poorer HRQoL than those who did not or who did not 
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know their status, irrespective of their actual serostatus.  This implies the knowledge 
(or assumed knowledge) of HCV positive status impacts HRQoL in addition to actually 
being infected with the virus (the so-called ‘labelling effect’12).  This echoes earlier 
work from a much smaller sample which found PWID who were unaware of their HCV 
positive status had better HRQoL than those who were aware of their infection 26 
years after being infected (Rodger, Jolley, Thompson, Lanigan and Crofts, 1999).  A 
recent much larger study from Scotland supports these findings. McDonald et al (2013) 
assessed almost 3000 current PWID accessing injecting equipment provision services in 
Scotland using the EQ-5D questionnaire and anonymised dried bloodspot testing.  
They reported a reduction in HRQoL between those who were aware of their HCV 
positive status and those who were not.  Additionally, no difference in HRQoL was 
found between HCV negative PWID and those who were positive but unaware of their 
infection, supporting other work suggesting the impact of an undiagnosed HCV 
infection upon groups with already lower HRQoL than population norms places little 
additional burden, possibly due to the extent of co-morbidities present and overall 
lower HRQoL anyway (e.g. Schwarzinger et al, 2004; Thein et al, 2006). 
 
In exploring the reasons for these findings, it becomes evident that the quantitative 
data available fails to provide sufficient insight.  Why does undiagnosed HCV fail to 
impact on HRQoL for this population when it has been demonstrated to have a 
detrimental effect in other groups such as blood donors (e.g. Ferreira, de Almeida-
Neto, Teixeira and Strauss, 2015; Strauss et al, 2014)?  Is the negative ‘label’ of HCV 
constructed around preconceptions to the chronic nature of the virus and its poor 
treatment outlook, or from external influences such as societal stigma?  These points 
will be returned to in due course, when the qualitative literature surrounding the lived 
experience of HCV is examined. 
 
In addition to substance use, other comorbid psychiatric and medical problems have 
been implicated in reducing HRQoL for individuals with HCV (Hsu et al, 2012; Taliani et 
al, 2007).  Häuser et al (2004) noted that comorbidity is the best predictor of overall 
                                                          
12 Labelling theory was first described by sociologists in relation to deviance and criminal behaviour, 
focusing on the tendency of populations to negatively label minorities who deviate from cultural norms.  
The theory has been modified and expanded in several fields, describing how an individual can 
incorporate a negative label into their own self-concept. 
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HRQoL reduction in patients with HCV, describing both psychiatric illness and somatic 
medical problems as equally relevant.  Further studies also highlighted the importance 
of underlying medical and psychiatric comorbidities in reductions to both the mental 
health domains (Lim et al, 2006; Snow et al, 2010) and the physical domains (Kwan et 
al, 2008) of HRQoL.   
 
Various demographic factors have also been demonstrated to have an effect over 
HRQoL in HCV patients, although the evidence is inconsistent.  Female gender has 
been reported to both affect (Bezemer et al, 2012; Bonkovsky et al, 2007; Kallman et 
al, 2007; Kuwashiro et al, 2014; Miller, Hiller and Shaw, 2001; Taliani et al, 2007; 
Younossi et al, 2016e) and not affect (Bonkovsky et al, 1999; de Souza, Villar, Garbin, 
Rovida and Garbin, 2015; Fábregas et al, 2013; Helbling et al, 2008) HRQoL, and, 
similarly, age has shown decrements for those less than 40 years old (Miller et al, 
2001) as well as those in the over 40 year old age bracket (Bezemer et al, 2012; El 
Khoury, Vietri and Prajapati, 2014; Kramer et al, 2005).  Other factors such as non-
married status (e.g. Fábregas et al, 2013; Hsu et al, 2009; Hsu et al, 2012), cigarette 
smoking (Balfour et al, 2006), low household income (Alves et al, 2012; de Souza et al, 
2015; Hsu et al, 2009) and lower as well as higher educational level (Alves et al, 2012; 
El-Seoud et al, 2008) have also been cited as a reason for poorer HRQoL in HCV 
patients in studies where this data has been collected.  Such findings emphasise the 
fact that only those sociodemographic factors collected in individual studies can be 
tested for significance, providing no indication of whether a particular potentially 
unreported factor may also be causing HRQoL decrements and actually be of greater 
significance to the patients themselves. 
 
2.3.2.4 Causal investigation: stigma 
A final factor to note with respect to HRQoL decrements is that of societal stigma 
towards individuals with HCV.  As already described, PWID who were aware of their 
infection had lower HRQoL than those who were unaware (Rodger et al, 1999; 
McDonald et al, 2013) with the authors noting that this may be due in part to the 
effects of stigmatisation towards these individuals and also of ‘self-labelling’ affecting 
personal psychological health (Rodger et al, 1999).  In one of the very few studies to 
combine a qualitative approach with a quantitative HRQoL questionnaire, Miller et al 
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(2001) described patients’ distress by the perceived stigma associated with HCV.  
However, without this qualitative adjunct the effects of stigma may be lost, or only 
theorised about, in the majority of HRQoL quantitative research.  Paterson et al (2007) 
note that infectious diseases (such as HCV), mental illness, and drug and alcohol 
dependence carry particularly strong societal stigma.  Therefore, being unable to 
account for this specific effect is a major limitation for the majority of PROM 
questionnaire-based HRQoL research given the population being studied.  This point 
will be returned to when the qualitative literature around this topic is examined. 
 
2.3.3 HRQoL pre-treatment 
The impairment in HRQoL for individuals with HCV has been shown to be equivalent 
to, or more severe than, the impact on physical and general health experienced by 
individuals with other chronic conditions such as hypertension, type II diabetes, 
arthritis or depression (Bayliss et al, 1998; Bonkovsky et al, 1999; Kallman et al, 2007).   
Hepatitis C has greater impact on the physical domains of HRQoL than hepatitis B in 
mono-infection (Bondini et al, 2007; Foster et al, 1998) and when studied in HIV co-
infected individuals (Gillis et al, 2013).  Of note, HCV also significantly impacts mental 
health, an area in which decrements in other conditions are generally smaller (Foster, 
2009; Tillmann et al, 2011).  This reduction in HRQoL can occur even in the absence of 
cirrhosis or significant liver disease (Bonkovsky et al, 1999; Córdoba et al, 2003; Foster 
et al, 1998; Häuser et al, 2004; Helbling et al, 2008; Rowan et al, 2005), and does not 
appear to be associated with Alanine Aminotransferase (ALT) levels13 (Arora et al, 
2006; Foster et al, 1998; Helbling et al, 2008; Miller et al, 2001; von Wagner et al, 
2006).  Where advanced significant liver disease does occur, however, further 
reductions in HRQoL are reported on a sliding continuum from advanced bridging 
fibrosis, to compensated cirrhosis to decompensation (Björnsson et al, 2009; 
Bonkovsky et al, 2007; Córdoba et al, 2003; Kallman et al, 2007; Snow et al, 2010).  
Although most HRQoL domains are affected, reductions in the physical components 
are most frequently noted as being most sensitive to the negative impact of cirrhosis 
(Bayliss et al, 1998; Bonkovsky et al, 2007; Córdoba et al, 2003; Kallman et al, 2007; 
Mandorfer et al, 2014).  This low HRQoL in untreated HCV patients has been reported 
                                                          
13 ALT is an enzyme mainly found in the liver, although low levels are also normally found within the 
blood.  A rise in ALT levels in the blood can indicate the liver is damaged or diseased. 
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to have substantial economic costs to society, through loss of productivity, increased 
absenteeism from work and increased use of healthcare resources (El Khoury, Vietri 
and Prajapati, 2012; Liu et al, 2012). 
 
2.3.4 HRQoL during treatment 
2.3.4.1 The early years 
The treatment of HCV has long been associated with a further transient reduction in 
HRQoL, largely attributed to the drugs used during therapy.  Individuals treated with 
interferon, with or without ribavirin, demonstrated a significant increase in depression 
(Hunt et al, 1997), severe treatment-related distress (Bianchi et al, 2000) and a general 
decline in HRQoL during their period of therapy.  These then returned to or surpassed 
baseline levels by 24 weeks post-treatment for those who achieved an SVR 
(McHutchison et al, 2001; Ware, Bayliss, Mannocchia, Davis and the International 
Hepatitis Interventional Therapy Group, 1999).  With the pegylation of interferon, a 
reduced impairment in HRQoL and less fatigue were reported during pegylated-
interferon and ribavirin therapy compared to interferon and ribavirin, especially in the 
initial 12-24 weeks, which had important implications for reducing treatment 
discontinuation (Bernstein et al, 2002; Hassanein et al, 2004; Mathew, Peiffer, 
Rhoades and McGarrity, 2006; Rasenack et al, 2003).  Although improved, the pattern 
of transient reduction in HRQoL during therapy persisted (e.g. Grotzinger et al, 2016), 
and whilst the majority of these findings were from large multi-centre randomised 
controlled trials (RCTs), a similar pattern of transient decrement in HRQoL has been 
described in real-world cohorts (Doyle et al, 2016; Hollander et al, 2006; Kang, Hwang, 
Lee, Chang and Lee, 2005; Marcellin et al, 2011; Matsushita et al, 2014; Sinakos et al, 
2010) and in HIV/HCV co-infection (Kemmer et al, 2012; Mandorfer et al, 2014; Thein 
et al, 2007). 
 
2.3.4.2 The arrival of the DAAs 
The advent of triple therapy for HCV saw the standard of care for HCV genotype 1 
evolve, with the addition of DAAs to the existing pegylated-interferon and ribavirin 
regimen (SIGN, 2013).  The first of these drugs to become available were the NS3/4A 
protease inhibitors telaprevir and boceprevir.  Vera-Llonch et al (2013) reported data 
from a phase III, placebo-controlled RCT which assessed the efficacy of various 
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telaprevir-based regimens in comparison to 48 weeks of pegylated-interferon and 
ribavirin.  They reported a greater transient reduction in HRQoL during the first 12 
weeks of therapy in the telaprevir arms of the study, which negatively affected work 
productivity and may also have had implications for treatment adherence (Aggarwal et 
al, 2015). 
 
This exacerbation of the on-treatment decrement in HRQoL was short-lived, however.  
As HCV treatment continued its rapid evolution, pangenotypic data from RCTs 
involving second generation DAAs became available for HRQoL timeously alongside 
hard biomedical endpoints such as SVR.  The RCTs involving the polymerase inhibitor 
sofosbuvir were the first to report HRQoL data for interferon-free regimens.  These 
showed significantly less impairment during therapy, although a modest decrement 
still remained during the twelve-week treatment duration (Younossi et al, 2014a; 
Younossi et al, 2014b).  This decrement was attributed mainly to ribavirin and its 
associated side effects by the authors, and improved upon treatment cessation 
(Younossi et al, 2014b; Younossi et al, 2014c; Younossi et al, 2016a)14.  Similar 
improvements in HRQoL with other interferon-free regimens have reported similar 
findings (Dore et al, 2016). 
 
The arrival of interferon- and ribavirin-free regimens has, for the first time, seen 
reports of significant and persistent improvements in HRQoL during treatment, rather 
than a transient decline (Lawitz et al, 2016; Younossi, Stepanova, Nader, Lam and 
Hunt, 2015; Younossi et al, 2016a; 2016b; 2016c; Younossi, Stepanova, Nader and 
Henry, 2016d).  Such improvements have been described as early as four weeks into 
therapy, and linked to viral eradication rather than simply the ‘excitement’ of receiving 
these new, highly efficacious treatments (Younossi et al, 2016c).  Improvements in 
                                                          
14 The role of ribavirin in HCV treatment bears brief, closer inspection, as it has often been overlooked 
due to the comparative severity of interferon-related side effects.  In early studies comparing pegylated-
interferon monotherapy with (pegylated-) interferon and ribavirin dual therapy regimes, the observed 
impairments in HRQoL during therapy were substantially exacerbated by ribavirin (Hassanein et al, 
2004; Perrillo et al, 2004).  A possible mechanism for this is ribavirin-associated haemolytic anaemia, 
which is an important factor in determining HRQoL during anti-viral therapy, impacting physical 
functioning, work-related activities and fatigue (Dan et al, 2006; Falasca et al, 2009; Hollander et al, 
2006; Mandorfer et al, 2014).  Perhaps surprisingly therefore, Younossi et al (2014b) report that in 
patients receiving sofosbuvir and ribavirin, a more profound and clinically significant decrement is seen 
in the mental health aspects of HRQoL compared to the physical parameters.  They hypothesised that 
previously suspected neuropsychiatric side effects of ribavirin may be involved. 
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HRQoL during interferon- and ribavirin-free treatment have been shown in both HCV 
mono-infected and HIV/HCV co-infected individuals (Younossi et al, 2016e; 2016f).  In 
addition, specific work focused on Asian cohorts has reported similar findings (Ikeda et 
al, 2016; Younossi et al, 2016a; 2016g; 2016h).  However, as this data is exclusively 
from RCTs it remains to be seen whether a similar scenario is observed in more 
representative patient populations. 
 
2.3.5 HRQoL post-treatment 
For patients who persist with therapy and achieve an SVR, benefits of treatment have 
been reflected in improvements to both physical and mental health domains of their 
HRQoL compared to non-responders, and in relation to their own baseline scores 
(table 2).  This applies in patients with persistently normal ALT (Arora et al, 2006; Bini 
and Mehandru, 2006) as well as those with advanced fibrosis and cirrhosis (Bernstein 
et al, 2002; Bonkovsky et al, 2007; Younossi et al, 2014a).  Individuals who are co-
infected with HIV/HCV who achieve SVR have also similarly shown improvements in 
physical and general health, fatigue, and cognitive function (Kemmer et al, 2012; 
Mandorfer et al, 2014).  Studies in non-Western populations confirm similar findings 
(Kang et al, 2005). 
 
 
Table 2: Studies comparing HRQoL in individuals with HCV who achieve SVR compared to their baseline 
levels, using the SF-36 or HQLQ tools (*indicates SVR12 reported) 
 
W
are et al (1999)
Bonkovsky et al (1999)
M
cHutchison et al (2001)
Bernstein et al (2002)
Rasenack et al (2003)
Hassanein et al (2004)
Kang et al (2005)
M
athew
 et al (2006)
Hollander et al (2006)
Bini &
 M
ehandru (2006)                                                        
(Results for norm
al ALT group)
Bini &
 M
ehandru (2006)                                 
(Results for elevated ALT group)
Arora et al (2006)
Bonkovsky et al (2007)
Thein et al (2007)
M
arcellin et al (2011)
Bezem
er et al (2012)
Isaacs et al (2013)
Younossi et al (2014a)*
Younossi et al (2014c)*
Younossi et al (2016c)*
324 704 912 1441 531 1121 371 152 147 46 92 491 1144 34 1860 128 118 192 334 215 201 327 624
               
Physical Function S S S S S S S S S S S S
Role Physical S S S S S S S S S S S S T S
Bodily Pain S S S S S S S
General Health S S S S S S S S S S S S S S S S S S
Vitality S S S S S S S T S T S S S S S S S S S
Social Functioning S S S S S S S T S T S S S S S
Role-Emotional S S S T S S S S S
Mental Health S S S S S S S S
Physical Component Score (PCS) S S S S S S S S S T S S
Mental Compoenent Score (MCS) S S S S S S S
Sleep S T
Health-Distress S S
CHC Health-Distress S T S
CHC Limitations S S S
SF-36 Subscales
HQ
LQ
 
Additional 
Scales
Author and Year
Younossi et al (2014b)*
n =
Clinical Trial Data?
Significant (S) Improvement or Trend Towards (T) at SVR Compared to Baseline Reading
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The HRQoL domains in which improvements are reported following SVR are not 
consistent however (table 2), and indeed in some studies have not been found at all 
(Tillmann et al, 2011).  A number of studies found improvement only in physical 
domains compared to baseline readings (Bonkovsky et al, 1999; Hollander et al, 2006; 
Isaacs, Abdelaziz, Keller, Tibble and Haq, 2013; McHutchison et al, 2001; Ware et al, 
1999) with others reporting only physical and not emotional increments when patients 
who achieve SVR are compared with those who remain viraemic (Helbling et al, 2008).  
Another study also showed less improvement in mental health scores compared to 
physical and sexual health leading the authors to argue that HCV per se has minimal 
effect on emotional states (Bonkovsky et al, 2007).  Conversely, a study of co-infected 
HIV/HCV patients found some benefit to mental health (but not physical health) for 
patients who did not achieve an SVR, theorising that a reduction in HCV viral load 
during treatment may provide some benefit to patients (Thein et al, 2007).  With the 
major differences between results from the reported studies, it is important to 
examine the various limitations that may have influenced these findings. 
 
2.3.5.1 Limitations and weaknesses 
The time-point at which post-treatment HRQoL is measured could potentially influence 
the results obtained.  For example, Pojoga, Dumitraşcu, Pascu and Grigorescu (2006) 
concluded that antiviral therapy does not improve HRQoL, but took their post-
treatment measurement immediately after interferon and ribavirin therapy had 
finished.  In contrast, John-Baptiste et al (2009) took a cross-sectional approach and 
reported that patients who had achieved an SVR had improved HRQoL, higher 
employment and better productivity at work, leisure and around the house at an 
average of 3.7 years post-therapy (although due to its cross-sectional nature, this 
result is limited by the retrospective recollection of respondents).  The majority of 
studies have measured for improvement in HRQoL alongside the hard medical 
endpoint at 24 weeks post end of treatment.  However, this is generally for the 
convenience of data collection and from a HRQoL viewpoint is an arbitrary time-point.  
Helbling et al (2008) also note that at this point the positive emotional response due to 
treatment success is still strong, possibly influencing responses.  More recently, 
measurement of SVR at week 12 post-treatment has been accepted as a primary end 
point for most clinical trials (Chen et al, 2013) meaning the published trials using DAAs 
36 
 
are reporting HRQoL data from patients at SVR12 and not SVR24 (e.g. Dore et al, 2016; 
Younossi et al, 2014a; Younossi et al, 2014b; Younossi et al, 2016a; Younossi et al, 
2016b), possibly when the emotional response is even stronger, or the effects of 
treatment are still being felt. 
 
Another frequently reported limitation in the literature is that of patient awareness of 
their serological result prior to completion of the study PROM tools.  In the same way 
that knowledge of being HCV positive influences HRQoL (Häuser et al, 2004, McDonald 
et al, 2013; Rodger et al, 1999), do patients feel better, simply because they know they 
have now cleared the infection? McHutchison et al (2001) argued that as changes in 
HRQoL are seen in different SF-36 domains and not reported ‘across-the-board’, it was 
unlikely that awareness of SVR was entirely responsible for the observed 
improvements.  A later study which blinded serological results to patients and 
investigators found improvements in mental health for patients who had undetectable 
HCV RNA at week 12 of therapy compared to those who remained detectable 
(Quarantini et al, 2008), supporting the theory that knowledge of infection cannot 
account for all HRQoL increases alone. 
 
2.3.6 A different paradigm 
The quantitative literature deals primarily with HRQoL cause and effect, reducing the 
burden of illness to numeric estimates which may demonstrate statistical and clinical 
significance, but the patient experience, and the patient voice, remains silent.  
However, as previously stated, PROMs is an umbrella term incorporating any report 
coming directly from a patient about their health condition and treatment.  With this 
in mind, there is also a body of qualitative research providing more in-depth 
exploration of the lived experience of HCV.  This qualitative approach can be used to 
add ‘flesh-to-the-bones’ of what has been reported within the quantitative literature.  
For example, Hopwood and Treloar (2005) explored the reported on-treatment 
decrement in HRQoL by using patients’ narratives to gain an insight into their 
experience of side-effects, and how coping with these impacted on their daily lives.  
However, qualitative data can do more, as demonstrated by Miller et al (2001) in their 
mixed methods study.  It can illuminate impairments not captured by HRQoL 
instruments such as the role of stigma, and explore social and psychological factors 
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impacting on HRQoL and day-to-day living that are beyond what is measureable by 
psychometric questionnaires such as the SF-36.  In doing so, a more detailed and vivid 
picture of the impact of HCV can be built.  With this in mind, we turn to the qualitative 
literature focused on the lived experience of HCV, and examine the main themes 
present in that body of work, beginning with the experience of diagnosis. 
 
2.3.7 Diagnosis 
A number of studies have drawn on the theory of chronic illness as biographical 
disruption (Bury, 1982) to provide insight into their participants’ narratives of HCV 
diagnosis15.  For many, an initial reaction of shock was accompanied by overwhelming 
feelings of fear, denial, anger and depression (Glacken, Kernohan and Coates, 2001; 
Groessl et al, 2008; Janke, McGraw, Garcia-Tsao and Fraenkel, 2008; Olsen, Banwell 
and Dance, 2012; Sgorbini, O’Brien and Jackson, 2009; Sutton and Treloar, 2007; 
Tompkins, Wright and Jones, 2005).  Faye and Irurita (2003) describe their participants 
feeling condemned, with their futures being forfeited: 
 
It was a death sentence.  Not knowing a lot about it, and asking my doctor if I 
was going to die in ten years and he couldn’t tell me. 
 
(Faye and Irurita, 2003, p.94) 
 
This ‘fear of the unknown’ was an emerging theme from a number of studies around 
this time (Carrier, LaPlante and Bruneau, 2005; Groessl et al, 2008).  However, due to 
how rapidly HCV knowledge has grown over the last decade, it should be viewed 
within the context of when the research was undertaken.  That said, a more recent 
article by Hill et al (2015) suggests that the sustained uncertainties of life with HCV 
results in individuals feeling their futures are uncontrollably dictated by the virus. 
 
For participants who had a history of injecting drug use, reactions to HCV diagnosis 
were sometimes modified and tempered, either because they suspected they were 
                                                          
15 Medically, HCV is defined as a chronic infection if it does not spontaneously resolve within the first six 
months following acquisition (Seeff, 2002).  Chronicity within the context of theoretical models, and this 
literature review, is taken to mean an individual’s perception that their condition will be one which is 
long-term.  The social construction of chronic illness literature gives phenomenological perspectives on 
personal naturalistic accounts of ‘lived illness’, which provides a basis for this understanding (Martin and 
Peterson, 2009). 
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HCV positive anyway (Olsen et al, 2012; Temple-Smith, Gifford and Stoové, 2004), or 
because of multiple HCV diagnoses within their peer group around the same time.  
These provided context and mitigated the impact (Fry and Bates, 2012).  It also served 
as an unwelcome reminder of a previous time in their lives, potentially exposing an 
earlier identity that many had worked hard to put behind them (Fry and Bates, 2012; 
Grundy and Beeching, 2004; Hill et al, 2015; Olsen et al, 2012): 
 
I was thrown right back there and it was awfully upsetting because I really did 
think that that time of my life was past and that I’d come to terms with grief 
and difficulty and all sorts of things in my life.  And what happened?  The 
legacy… 
 
(Fry and Bates, 2012 p.467) 
 
 
For individuals who had been experiencing significant symptoms of HCV such as 
unexplained fatigue, the intensely negative reaction to their HCV diagnosis also came 
with a sense of relief as their health problems had finally been formally identified and 
medically labelled (Copeland, 2004; Glacken et al, 2001; Groessl et al, 2008).  
Interestingly, the reaction of current PWID to a HCV diagnosis appears to be 
significantly less traumatic, not conforming to Bury’s (1982) concept and perhaps 
representing more ‘biographical reinforcement’ (Carricaburu and Pierret, 1995) than 
‘biographical disruption’.  This issue will be discussed in greater detail in due course. 
 
Following diagnosis, the re-evaluation of an individual’s life and an attempt to regain 
control are commonly reported.  Glacken et al (2001) describe diagnosis as a catalyst 
for the re-examination of life priorities, often resulting in making more time for 
partners and children.  Faye and Irurita (2003) describe this process as ‘balancing 
perspective’, integrating HCV into a comfortable, acceptable and balanced future life.  
For many, instigating positive health behaviours which served to exert control over 
HCV was important, including changes to dietary habits, exercise regimes and drinking 
patterns (Fry and Bates, 2012, Glacken et al, 2001; Hill et al, 2015; Paterson et al, 2006; 
Roy, Nonn, Haley and Cox, 2007; Sutton and Treloar, 2007).  However, by making these 
changes, life could feel restricted and no longer normal (Conrad, Garrett, Cooksley, 
Dunne and MacDonald, 2006; Hill et al, 2015).  A lack of information and 
understanding of HCV at diagnosis could also hinder this process, denying the sought 
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after sense of control and exacerbating prognostic uncertainty (Glacken et al, 2001; 
Sutton and Treloar, 2007).  Many people actively sought out information in order to 
expand their knowledge on the nature of the condition post-diagnosis (Fry and Bates, 
2012; Glacken et al, 2001; Groessl et al, 2008; Jiwani, Begum Gal, Ali, Salih and 
Hanzala, 2013; Roy et al, 2007; Tompkins et al, 2005) helping them to engage in their 
re-evaluation of life.  This process also encompassed a passage of time, which has been 
described as another key dimension moderating the accommodation of HCV into 
future life plans (Treloar and Rhodes, 2009). 
 
This literature provides insight into the way HCV is viewed as a chronic condition 
following diagnosis, and how individuals seek ways in which they are able to live with 
the disease.  However, the delivery of healthcare is dominated by an acute care model 
focused on treatment and cure which can create frustration due to competing agendas 
(Paterson et al, 2006).  The self-management strategies outlined above can be 
catalysed by the narrow focus of the medical model experienced from healthcare 
professionals (Fry and Bates, 2012), with psychosocial aspects of the disease often 
remaining unaddressed by providers (Hill et al, 2015; Paterson et al, 2006; Sheppard 
and Hubbert, 2006).  A further problem arises from the adoption of an acute medical 
model for patients who achieve SVR yet remain symptomatic post-treatment and 
continue to view themselves as chronically ill.  Hepatitis C providers consider them 
cured and will no longer care for them (Hopwood, 2013; Paterson et al, 2006).  The 
exploration of reaction to a HCV diagnosis, and subsequent theoretical modelling of 
chronic illness has to date been conducted within the era of pegylated-interferon 
monotherapy, or pegylated-interferon and ribavirin dual therapy.  With the treatment 
landscape rapidly evolving, and drug efficacy and tolerability making astounding 
improvements in recent years, it is unclear whether chronic illness models remain 
relevant to a disease that is becoming increasingly curable for those who access 
treatment. 
 
2.3.8 The lived experience of HCV 
2.3.8.1 Fatigue 
Fatigue is one of the most commonly reported symptoms of HCV (Conrad et al, 2006; 
Fry and Bates, 2012; Glacken et al, 2001; Glacken, Coates, Kernohan and Hegarty, 
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2003; Groessl et al, 2008; Jiwani et al, 2013; Zalai, Carney, Sherman, Shapiro and 
McShane, 2016), and a greater understanding of how this impacts HRQoL starts to 
emerge when reviewing the qualitative data.  Sutton and Treloar (2007) describe 
individuals losing their strength and energy, affecting performance at work, in sport 
and socially.  The need to prioritise what energy they have in both the short- and long-
term also appears important.  Short-term strategies include withdrawing from social 
activities, and reducing their share of parenting and domestic duties.  Long-term 
approaches may include deciding to have fewer children or altering broader life plans 
(Fry and Bates, 2012).  Unsurprisingly, such prioritisation can lead to relationship stress 
and personal feelings of uselessness, which will further impact on HRQoL and add 
additional dimensions to the experience of HCV fatigue (Fry and Bates, 2012; Zalai et 
al, 2016).  The fatigue experienced has been described as discernible from ‘normal 
fatigue’ and multidimensional in nature, perniciously impacting on physical, cognitive 
and affective dimensions, creating a whole body feeling of fatigue that cannot be 
relieved by rest (Glacken et al, 2001; Glacken et al, 2003): 
 
You cannot fight it; it is not a tiredness that you can fight like a normal 
tiredness.  A normal tiredness, you can fight it and get a second wind or if you 
had a few cups of coffee, it would keep you going.  None of this works with this 
tiredness 
 (Glacken et al, 2003 p.247) 
 
 
The unpredictability of symptoms has also proved challenging.  A number of studies 
describe sporadic and episodic experiences of HCV illness (Conrad et al, 2006; Sutton 
and Treloar, 2007) which have a high impact on life when they occur, but, when 
absent, serve to reinforce a notion that the virus is not currently affecting health (Swan 
et al, 2010).  This fluctuating and almost arbitrary nature of symptoms makes forward-
planning difficult, creating significant uncertainty (Hill et al, 2015). 
 
2.3.8.2 Onward transmission 
The possibility of inflicting the virus on others has evoked strong reactions in a number 
of studies, with some participants citing it as a far greater HRQoL issue than any 
physical symptoms experienced (Conrad et al, 2006).  Fears around accidently 
transmitting HCV have been described, with individuals taking overly cautious 
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household precautions (Grundy and Beeching, 2004) or displaying more extreme 
behaviour changes such as a fear of leaving the house in case they become involved in 
an accident (Fraser and Treloar, 2006).  Women have discussed worries over vertical 
transmission to children (Conrad et al, 2006; Temple-Smith et al, 2004), which in 
addition to causing possible disruption to plans for a family, can also impact sex lives 
and relationships (Grundy and Beeching, 2004; Jiwani et al, 2013).  The knowledge that 
HCV is contagious, and subsequent fear of transmission to others, forms a large part of 
the psychological impact of living with HCV, eliciting constant feelings of anxiety and 
sadness (Hill et al, 2015).  Further, expectations of finding a partner and eventually 
having children are re-evaluated in light of a diagnosis with a contagious disease (Faye 
and Irurita, 2003; Sutton and Treloar, 2007; Tompkins et al, 2005).   
 
2.3.8.3 Impact on PWID 
As previously mentioned, the reaction of active PWID to a HCV diagnosis appears 
significantly less traumatic than those who stopped injecting many years ago and those 
who acquired HCV through another route.  A lack of shock following the diagnosis is 
described in a number of studies (Faye and Irurita, 2003; Groessl et al, 2008; Harris, 
2009) accompanied by a sense of inevitability due to its prevalence within their social 
networks (Hill et al, 2015; Olsen et al, 2012; Sutton and Treloar, 2007).  A commonly 
reported consequence of HCV diagnosis is an intense and overwhelming depression.  
However, in PWID this has been described as shallow, and nothing to be dwelt on 
(Faye and Irurita, 2003) epitomised by a “what’s done is done, I can’t change it now…” 
attitude (Tompkins et al, 2005, p.265).  Davis and Rhodes (2004) note that HCV is 
constructed as something acquired rather than caught among the sample of PWID 
they interviewed in London, language that implies transmission is unavoidable, 
normalized and almost acquired over time.  They remark that due to messages about 
how transmissible HCV is in comparison to HIV, individuals were left with the 
understanding that HCV was everywhere and therefore a ubiquitous risk (Davis and 
Rhodes, 2004).  Wozniak, Prakash, Taylor and Wild (2007) explored in more detail this 
normalization of HCV amongst PWID in Canada, describing social accommodation of 
the infection, and HCV as a defining characteristic of injecting drug use.  Further work 
from Australia reiterates these perceptions, with one study participant articulating her 
experience: 
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And nobody talked about hep C really.  I mean you know, in passing, it was just 
so assumed everybody had it.  And nobody saw it as a big deal.  No-one was 
thinking about it.  Nobody thought it was anything other than just a complete 
minor detail that had no bearing on life at all. 
(Harris, 2009 p.1032) 
 
 
Hepatitis C is therefore viewed as part of the identity of being a person who injects 
drugs by individuals within that social network (Olsen et al, 2012; Roy et al, 2007).  This 
resonates with studies focused on other conditions; for example, how HIV has become 
more normalized and socially accommodated amongst gay men (Deacon, Mooney-
Somers, Treloar and Maher, 2013).  Roy et al (2007) suggest that an HCV diagnosis 
could actually have a positive significance for some, as it enables the individual to feel 
just like everyone else in their situation, or “… one of the gang, like” (Roy et al, 2007 
p.400).  These ambivalent views towards disease diagnosis are at odds with Bury’s 
(1982) account of biographical disruption, and instead appear to reinforce conceptions 
of self-identity and personal biography (Carricaburu and Pierret, 1995) adopting a 
discourse of normalization (Davis and Rhodes, 2004; Harris, 2009; Wozniak et al, 
2007).  HCV infection is synonymous with injecting drug use, and therefore injecting 
drug use will naturally lead to HCV infection (Olsen et al, 2012).  Even without 
normalization or social accommodation of the disease amongst PWID, Harris (2009) 
discusses the contextual nature of biographical disruption, and notes that HCV may 
still have limited impact on life as the diagnosis is often lost in a sea of multiple 
disruptions.  Copeland (2004) describes a similar experience from her work with PWID 
in Edinburgh, with apathy towards having HCV perhaps stemming from multiple 
traumas faced in day-to-day lives, and the significance of being HCV positive eclipsed 
by their problematic existences and identity as a ‘problem drug user’.  For those with 
an uncontrolled drug addiction, life can be spent finding money to feed the habit, 
crowding out other non-drug related concerns so it “just consumes every part of you” 
(Swan et al, 2010 p.759).  If the severity of HCV in relation to other more immediate 
life-threatening conditions (such as overdose) is considered, health problems that may 
not develop for many years such as those linked to HCV are unlikely to be overly 
concerning or prioritised (Roy et al, 2007).  In their study of Australian women with 
HCV, Olsen et al (2012) note that those currently injecting had fewer social and 
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economic resources (were more likely to be unemployed, poorly educated, and reliant 
on housing and financial benefits) which reflected in their HCV discourse: 
 
Within this lifestyle I tend to forget I’ve got it [HCV] most of the time…when 
people ask me what’s wrong with me I sort of reel off the list and that’s the 
last thing – ‘oh that’s right, I’ve got hep C’ 
(Olsen et al, 2012 p.535) 
 
Many PWID are familiar with material hardship, pain, suffering and the possibility of 
death long before they receive an HCV diagnosis, accounting for how little disruption 
that diagnosis often brings to their lives (Harris, 2009).  Williams (2000) astutely notes 
that biographical disruption is perhaps more keenly felt among the privileged rather 
than disadvantaged sections of society.  In addition to having little immediate impact, 
the nature of an injecting drug-use lifestyle means PWID often do not hold long-term 
future life perspectives, instead focusing on more immediate day-to-day problems 
(Faye and Irurita, 2003). Copeland (2004) suggests that low self-esteem and a sense of 
worthlessness forged from traumatic childhood experiences, and an underlying sense 
of hopelessness amongst PWID contribute to an inability to look to the future.  
Activities that therefore seek to improve an unimaginable future, such as HCV 
treatment, are not options worth considering or investing in (Roy et al, 2007). 
 
As well as being contextualised within an individual’s life, a diagnosis of HCV is often 
described in relation to HIV/AIDS (Copeland, 2004; Cullen, Kelly, Stanley, Langton and 
Bury, 2005; Davis and Rhodes, 2004; Harris, 2009; Roy et al, 2007; Swan et al, 2010; 
Tompkins et al, 2005; Wozniak et al, 2007).  HIV is often defined as the primary viral 
risk for injecting drug use, with the seriousness of HCV being undermined by HIV (Davis 
and Rhodes, 2004).  Comments from a couple of studies demonstrating participants’ 
reactions at diagnosis serve to highlight this point well: 
 
I wouldn’t mind but I was in bits waiting for the results…the doctor was there 
going ‘now…you have hepatitis C.’ I was there going ‘hurry up and tell me 
about the [HIV] virus’ 
(Cullen et al, 2005 p.74) 
 
She told me ‘everything looks fine, except it’s written positive next to hepatitis 
C’.  So I said to her, ‘can I see? I hope I don’t have AIDS’ 
 
(Roy et al, 2007 p.400) 
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Even in HIV/HCV co-infection, a diagnosis of HCV can be over-shadowed by already 
having HIV (Copeland, 2004).  As public health strategies such as needle exchanges 
were initially introduced to combat HIV transmission (Robertson and Richardson, 
2007), the focus on initial harm-reduction messages for people who use drugs centred 
on HIV prevention, with HCV appearing within this framework later as an additional 
concern (Davis and Rhodes, 2004; Harris, 2009).  This ‘lesser of two evils’ perception 
appears to pervade, with HCV presented as relatively benign in comparison to HIV, and 
cited as a reason why further investigations and treatment are not accessed post-
diagnosis (Swan et al, 2010). 
 
The fact that HCV is often asymptomatic can also contribute to its low priority status in 
lives with many competing demands.  Although fatigue, cognitive impairment and 
depression have all been previously described, these are not ubiquitous.  Where they 
do occur, they may not always be attributed to HCV by the individual, particularly 
where there is co-morbid active substance use.  Due to the lack of physical impact 
there is no sense of threat from harbouring the virus (Fraenkel, McGraw, 
Wongcharatrawee and Garcia-Tsao, 2005) and it can therefore become an insignificant 
part of people’s lives (Sutton and Treloar, 2007).  Witnessing PWID ‘living normally’ 
and showing no signs of sickness can reinforce the normalisation and social 
accommodation of HCV within social networks, psychologically and socially preparing 
other members for a potential diagnosis (Carrier et al, 2005; Faye and Irurita, 2003). 
 
Reviewing these narratives as a whole, it could be easy to construe that all PWID are 
disinterested in their health.  However, despite repeated reports of a HCV diagnosis 
having little impact upon lives (Faye and Irurita, 2003; Olsen et al, 2012; Sutton and 
Treloar, 2007), there are incidences of individuals reacting badly to the news (Sutton 
and Treloar, 2007; Tompkins et al, 2005).  For some, an overwhelming sense of 
contamination has been described accompanied by a response characterized by 
despair (Fraser and Treloar, 2006).  Rather than focusing the individual to address the 
cause, however, (by potentially seeking treatment), a number of accounts relate a 
sense that the infection is now with them for life, and, as such, interest in their health 
may actually decrease: 
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Oh what’s the use? You’ve got it, it’s not going to go away, what’s the use?  
 
(Fraser and Treloar, 2006 p.106) 
 
“What’s the point? I’m either going to die from drugs or from liver disease”16 
 
(Groessl et al, 2008 p.1961) 
 
 
It is often only when individuals move away from substance use and disengage from 
those social networks that help is sought for HCV.  Harris (2009) describes one 
participant moving away from the drug using community and starting a relationship 
with a non-drug using man, and only at that point being exposed to what HCV means 
in the ‘mainstream world’.  Similarly, Roy et al (2007) note that disengagement from 
substance use and starting to integrate into mainstream society aids an understanding 
of the health significance of HCV that was previously absent. People who inject drugs 
going through an intense period of consumption are less concerned about HCV (Roy et 
al, 2007), and becoming clean and sober appears to facilitate engagement with HCV 
services (Groessl et al, 2008).   
 
2.3.8.4 Stigma 
The preponderance of accounts detailing individuals’ experience of stigma in relation 
to HCV create an overriding and pervasive theme within the qualitative literature, and 
again highlight its relative absence from the quantitative paradigm.  The stigma 
experienced is multifaceted, incorporating a number of factors including the 
involvement of an infectious agent (Conrad et al, 2006; Faye and Irurita, 2003; Fraser 
and Treloar, 2006) and an association with HIV/AIDS (Zickmund, Ho, Masuda, Ippolito 
and LaBrecque, 2003).  However, the most frequently described association is with 
illicit injecting drug use (Butt et al, 2008; Conrad et al, 2006; Faye and Irurita, 2003; 
Paterson et al, 2006; Zickmund et al, 2003) propagating the belief that the disease has 
been acquired through the fault of the sufferer (Fraser and Treloar, 2006).  This link to 
drug use is persistent and tenacious, and stigma and discrimination related to drug use 
have been experienced by many individuals with HCV irrespective of their mode of 
                                                          
16 The authors note that immediately after diagnosis, this participant began using drugs again. 
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acquisition (Butt et al, 2008; Faye and Irurita, 2003; Fry and Bates, 2012; Hill et al, 
2015).  This is neatly summed up by a quote from a study which included participants 
who contracted HCV from a variety of different sources, but excluded PWID: 
 
We are all tarred with the same brush.  People think ‘hepatitis’, yeah they’re 
all drug addicts, and they think ‘they’ve done something wrong’ 
 
(Hill et al, 2015 p.5) 
 
 
The wish to avoid this association can lead to disclosure of HCV positive status being 
followed up with an account of how it was acquired through blood transfusion, 
irrespective of how the virus was actually caught (Conrad et al, 2006).  Women have 
been described as more likely to experience stigma than men (Swan et al, 2010; 
Zickmund et al, 2003), although insights from Temple-Smith et al (2004) suggest that 
women may just be more affected by it, rather than experiencing a greater frequency 
of exposure.  They describe HCV positive men as harbouring expectations to be treated 
poorly because of their serostatus, which justifies stigmatizing behaviour from others 
when it is encountered and lessens the impact (Temple-Smith et al, 2004).  
Interestingly, there are also reports of individuals experiencing the stigmatising 
consequences of having a contagious disease associated with drug use, even after they 
have cleared the virus (Carrier et al, 2005). 
 
These stigmatising attitudes are found amongst family, friends and colleagues (Butt et 
al, 2008; Janke et al, 2008; Jiwani et al, 2013; Zickmund et al, 2003).  However, within 
the healthcare setting and during interactions with healthcare professionals, these 
stigmatising attitudes and behaviours are also frequently encountered (Butt et al, 
2008; Fry and Bates, 2012; Grundy and Beeching, 2004; Hill et al, 2015; Janke et al, 
2008; Jiwani et al, 2013; Miller et al, 2001; Sgorbini et al, 2009; Temple-Smith et al, 
2004; Tompkins et al, 2005; Zickmund et al, 2003).  In wider society, stigma towards 
HCV has also been reported from communities that attract discriminatory societal 
attitudes themselves, such as the LGBT community (Deacon et al, 2013).  Whilst a 
diagnosis of HIV for a gay man may become part of his gay identity and be accepted 
within that community, HCV is viewed as a ‘straight disease’ associated with injecting 
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drug use and therefore a gay man with HCV becomes a ‘junkie’ and risks losing his 
previous identity and place within that group (Deacon et al, 2013). 
 
The narratives found within this body of work also demonstrate an internalised stigma, 
where HCV positive individuals assimilate these widely held societal views.  For 
example, multiple references are made to people feeling contaminated, dirty or ‘like a 
leper’ (Fraser and Treloar, 2006; Glacken et al, 2001; Grundy and Beeching, 2004; Hill 
et al, 2015; Miller et al, 2001; Sutton and Treloar, 2007; Zickmund et al, 2003), 
demonstrating a self-image that has been significantly affected by the diagnosis (Butt 
et al, 2008).  This also highlights that even where their diagnosis is not explicitly known 
to others, internalised stigma can be an ever-present and disruptive influence on 
people’s lives, eliciting fear over the possibility they may be exposed, and also guilt 
because of their perceived dishonesty in non-disclosure (Fraser and Treloar, 2006). 
 
The decision not to disclose a HCV positive status is often borne out of fears around 
subsequent stigmatisation (Butt et al, 2008; Conrad et al, 2006; Faye and Irurita, 2003; 
Fraser and Treloar, 2006; Glacken et al, 2001; Hill et al, 2015; Jiwani et al, 2013; 
Sgorbini et al, 2009; Sutton and Treloar, 2007; Tompkins et al, 2005).  However, non-
disclosure also appears to carry significant personal cost and has a substantial impact 
on people’s lives.  By not identifying as HCV positive, the opportunity to obtain support 
from peers, colleagues and HCV-focused organisations is lost (Faye and Irurita, 2003; 
Hill et al, 2015).  In addition, any causal explanation for symptoms being experienced is 
removed, meaning individuals may have to continue working whilst extremely 
fatigued, or deny any emotional stress they may be suffering (Butt et al, 2008; Fry and 
Bates, 2012): 
 
It requires a constant vigilance on my part not to let it slip…you always have to 
appear ‘normal’ regardless of how you are really feeling 
 
(Glacken et al, 2001 p.110) 
 
 
Non-disclosure can also have more wide-reaching implications.  Butt et al (2008) 
describe how one participant in their study quit his job and withdrew socially to 
conceal the diagnosis and associated symptoms.  This voluntary social withdrawal may 
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seem an extreme reaction.  However, it serves to illustrate the impact of deep-seated 
and entrenched discrimination and stigmatization towards HCV which pervades 
unchanged throughout the historic literature up to the present day.  The case 
described is also not unique.  Janke et al (2008) offer further reasons for individuals 
voluntarily socially isolating themselves besides concerns over stigma, including 
emotional volatility and symptom management, as well as a loss of desire to seek out 
social contact and feeling confused and overwhelmed.  These findings are echoed in 
other studies (Blasiole, Shinkunas, LaBrecque, Arnold and Zickmund, 2006; Tompkins 
et al, 2005). 
 
Clearly, social isolation is not purely a voluntary undertaking however.  Glacken et al 
(2001) describe the diagnosis of HCV resulting in participants feeling their ‘social 
identity’ had been stripped away, preventing them from maintaining their previous 
social relationships.  Altered behaviour from others due to stigma can also impact on 
social networks.  Fears of contagion and the potential for viral transmission can lead to 
isolation from loved ones (Blasiole et al, 2006; Groessl et al, 2008; North, Devereaux, 
Pollio, Hong and Jain, 2014; Zickmund et al, 2003), in addition to ignorance 
surrounding the disease leading to frank discrimination from poorly informed family 
and peers: 
 
Well, it has affected my family, like even my parents and stuff.  My mother’s 
afraid to kiss me; she thinks it’s like AIDS, you know.  It caused a divorce. 
 
(Blasiole et al, 2006 p.4668) 
 
 
I lost probably half my friends as they don’t know what the disease is.  They 
just automatically put up a front.  I don’t see them anymore – fear of what 
may happen.  So ignorance is how I like to put it. 
 
(Blasiole et al, 2006 p.4668) 
 
2.3.9 The experience of HCV treatment 
2.3.9.1 Barriers and facilitators 
In addition to offering valuable insights into how HCV impacts on day-to-day life, 
qualitative research also provides understandings into the experience of HCV 
treatment, and explores the decision to pursue a course of therapy.  Anxiety regarding 
49 
 
interferon-based treatment, poor treatment efficacy, the often asymptomatic nature 
of the disease, and fear derived from pervasive side-effect ‘horror stories’ are 
frequently reported as reasons for delaying therapy (Fraenkel et al, 2005; Groessl et al, 
2008; Hill et al, 2015; Kinder, 2009; North et al, 2014; Swan et al, 2010).  In addition, 
social factors such as family commitments and the ability to work are also cited as 
particularly pertinent considerations (Fraenkel et al, 2005; Swan et al, 2010; Treloar, 
Rance, Dore, Grebely and the ETHOS Study Group, 2014). 
 
Fraenkel et al (2005) note that for some, trade-offs such as the risk of side-effects and 
the low chance of a cure do not enter their decision-making process, and treatment is 
seen as a certainty for them rather than an option, offering a chance to exert control 
over the infection (Taylor-Young and Hildebrandt, 2009).  Seeing others from within 
their social network come successfully through treatment, or conversely where HCV 
has contributed to serious illness or death in others, have also both been described as 
motivators to engage with care (Swan et al, 2010).  For those who access treatment 
and undergo a period of interferon-based therapy, a transient decrement in their 
HRQoL as measured by PROM questionnaires has previously been described.  How this 
decrement is experienced, and how it impacts on daily life is further explored and 
given greater depth of understanding by the qualitative literature on the topic. 
 
2.3.9.2 Side-effects 
In addition to the effects of HCV-related fatigue previously described, those individuals 
undergoing treatment have also reported significant fatigue as a result of pegylated-
interferon and ribavirin drug therapy.  Again, the fatigue experienced appears 
discernible from what would be considered ‘normal fatigue’, with participants often 
illustrating how their own experience was different from a ‘typical patient’ and also 
how it differed from any pre-treatment discussion they had had (Sheppard and Hubert, 
2006).  Participant quotes demonstrate its intensity and persistence: 
 
There were times when I could just have stayed 4 or 5 days in bed, and I mean 
23 out of 24 hours of just laying down 
 
(Zickmund et al, 2006 p.383) 
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Sometimes…I’m flat out making it to where I want to sit down because I 
actually can feel myself shutting down…just all of a sudden, I feel like I need to 
sit down, yeah…with this, when you have to stop you have to stop right then. 
 
(Hopwood and Treloar, 2005 p.640) 
 
 
Other physical side effects are also commonly described such as flu-like symptoms, 
insomnia, weight and hair loss, headaches, dysguesia and myalgia as well as upper 
respiratory and gastrointestinal symptoms (Fraenkel, McGraw, Wongcharatrawee and 
Garcia-Tsao, 2006; Hopwood and Treloar, 2005; Sheppard and Hubbert, 2006; Taylor-
Young and Hildebrandt, 2009; Zickmund et al, 2006).  Whilst not unusual or 
unexpected from a physician’s point of view, these ongoing side effects can impact on 
HRQoL in a number of ways.  They compromise employment opportunities and 
contribute to absenteeism (Hopwood and Treloar, 2005); they affect physical 
appearance and changes in demeanour which result in altered perceptions by others 
(Sheppard and Hubbert, 2006); and they also contribute to social isolation (Janke et al, 
2008).  The persistence of these symptoms throughout the course of treatment, and 
the unpredictability of onset were also significant factors contributing to the reduced 
HRQoL experienced (Fraenkel et al, 2006).  In addition, participants often felt under-
prepared for the severity of these side-effects, noting a discrepancy in the information 
provided pre-treatment and their actual experience, commenting that the quantity of 
information often did not equal the quality (Fraenkel et al, 2006; Sheppard and 
Hubbert, 2006).  Interestingly, Treloar and Hopwood (2008) explored the concept of 
unrealistic optimism within the field of preparation for HCV treatment, noting that 
patients often felt information provided pre-treatment was not relevant to them as 
they judged themselves to be at low risk of developing severe side-effects.  Could this 
feeling of being under-prepared expressed by individuals going through treatment be 
partly accounted for by an unrealistic expectation of what was to come? 
 
Although narratives from participants who have experienced serious side effects and 
intensely emotional journeys through treatment are common within the literature, 
there are also examples of individuals finding things much better than expected, 
illustrating the diversity of patient experience: 
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About the worst thing I’ve experienced was some nausea…but it’s not near 
what they said. 
 
(Groessl et al, 2008 p.1962) 
 
 
The neuro-psychiatric side-effects of pegylated-interferon have been repeatedly and 
comprehensively described (e.g. Raison, Demetrashvili, Capuron and Miller, 2005), and 
a general awareness of the risks of mood swings and depression is found amongst 
patient groups (Fraenkel et al, 2006; Sheppard and Hubbert, 2006).   Whilst the impact 
of these symptoms on continued treatment adherence has been studied (Mathes, 
Antoine and Pieper, 2014), the impact on the quality of day-to-day life has been less 
reported.  Perhaps unsurprisingly, a significant impact of any neuro-psychiatric 
symptoms experienced is felt on those closest to the patient, with depression and 
mood swings taking a toll on spousal and family relationships (Sgorbini et al, 2009; 
Taylor-Young and Hildebrandt, 2009).  Janke et al (2008) described participants’ 
depression, anger and irritability, which resulted in difficulties controlling their actions 
and what they were saying to others, subsequently affecting family relationships and 
in some cases expressing a notion that they had lost their sense of self: 
 
I stayed stuck on mean and evil…  Once I get that shot [interferon], I try and 
avoid him [grandson], because I know how mean I’m going to get.  I’m going 
to be hollering at him, which is why I do not want to do that.  But looks like 
everything he does aggravates me… 
(Janke et al, 2008 p.496) 
 
 
Hopwood and Treloar (2005) note that patients may often group numerous psychiatric 
adverse effects under the label of depression as this is the side-effect they had been 
warned about.  However, they found participants in their study describing quite 
different treatment-induced mood disorders such as obsessional thoughts and 
generalised anxiety.  Often these symptoms became increasingly severe and sustained 
as treatment continued, having a major impact on quality of life: 
 
It was like an uncontrollable sense of anger.  I’m surprised I have any friends 
left.  I literally just completely withdrew.  I really didn’t want to deal with 
people in any way, shape or form.  I mean, I felt anxiety and I felt very angry 
and I was starting to lose control. 
(Fraenkel et al, 2006 p.150) 
52 
 
Due to the knowledge that depressive symptoms could be a common side effect, 
Zickmund et al (2006) also highlight that participants who were not affected, often 
feared that it would emerge at some point, living with a sense of lingering inevitability. 
 
2.3.9.3 Social isolation 
In addition to the previous discussion of social isolation occurring following HCV 
diagnosis, the treatment itself can also contribute to this (Fraenkel et al, 2006; Janke et 
al, 2008).  Taylor-Young and Hildebrandt (2009) describe treatment-related fatigue and 
lack of energy presenting barriers for participation in social events, but also physical 
symptoms such as heat-intolerance and photophobia preventing their participant 
leaving the house during the summer months.  Examples of voluntary isolation are also 
evident within the literature, with some participants describing feeling ‘shut in’ during 
treatment, and acknowledging that the only way to obtain breathing space was by 
withdrawing from family and friends (Sgorbini et al, 2009).  A mixed-methods study in 
America highlighted that over half of their 200 study participants reported difficulty 
attending social functions.  However, the qualitative data exposed that this was often 
in a conscious effort to avoid having to explain or discuss their situation (Manos, Ho, 
Murphy and Shvachko, 2013), effectively maintaining a voluntary but enforced social 
isolation during therapy.  Further consequences of this are alluded to by Sgorbini et al 
(2009), who describe participants struggling to maintain a meaningful life whilst 
isolated from their usual social networks.  Of interest, provider-imposed requirements 
for treatment have also been noted to adversely affect social interaction, as a 
reduction in alcohol and illicit drug use often necessitates a reduced interaction with 
friends and acquaintances (Zickmund et al, 2006). 
 
2.3.9.4 Coping during treatment: resilience and support 
With insights into the lived experience of treatment and its side-effects, 
understandings into how these symptoms are managed and strategies for coping are 
also illuminated.  Hopwood and Treloar (2008) focused on resilience theory, describing 
participants drawing on past experience of drug dependence, their history and 
experience of living with a chronic illness and challenges and lessons learned from a 
socially disadvantaged past.  This theory is borne out in other studies, with examples of 
patients undergoing HCV treatment relating their use of anger management 
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techniques learned at an alcohol treatment centre (Taylor-Young and Hildebrandt, 
2009), and eschewing HCV support groups in favour of more familiar 12-step 
programmes previously attended such as Alcoholics Anonymous (Sheppard and 
Hubbert, 2006).  More recent reports from the UK also support this theory, 
highlighting and commenting on resilient coping mechanisms for those undergoing 
interferon-based therapy (North et al, 2014; Ware, Davies, Rowse and Whittaker, 
2015). 
 
In addition to resilience, support from friends and family is also a key factor in 
adherence to and continuation of treatment (Chapman and McManus, 2012; Sgorbini 
et al, 2009; Swan et al, 2010).  Recurrent reports of strong family support are not 
uncommon in the literature (Jiwani et al, 2013; Manos et al, 2013; Sheppard and 
Hubert, 2006), with the practical support offered by family members and spouses 
being highly valued and significantly easing the burden of treatment for patients 
(Sgorbini et al, 2009, Swan et al, 2010).  This can create strain, stresses and challenges 
to family relationships, however.  Sgorbini et al (2009) interviewed patients currently 
undergoing HCV treatment and their partners, and described altered relationships with 
family and friends and a deterioration of social networks.  Research conducted with 
social workers confirms that relationships are often challenged by treatment, and 
interventions that include couple and family work are commonly undertaken and can 
become the core function of the social worker in HCV treatment centres (Mouton, 
2011).  There is a mixture of positive and negative experiences of friend and family 
support during therapy described, however the negative aspects are more widely 
discussed within the literature and appear far more pertinent and relevant to patients 
and family members themselves. 
 
There is an assumption that adequate social support is important for HCV treatment 
success.  However, very few qualitative studies have examined this relationship.  
Blasiole et al (2006) conducted a mixed-methods study and described lower social 
support being associated with higher anxiety, more psychiatric diagnoses and lower 
psychological well-being generally.  In addition, they reported patients with lower 
social support were more likely to report severe physical side-effects during treatment.  
The relevance of this relates to the perseverance with and adherence to therapy.  If 
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patients with lower social support perceive their symptoms as more intense and 
frequent, affecting HRQoL to a degree which becomes intolerable, they may be more 
likely to discontinue therapy early leading to poorer outcomes.  The importance of an 
individual’s support system being as fully informed and educated regarding side-
effects and what to expect during a period of therapy also echoes through a number of 
studies (Manos et al, 2013; Ware et al, 2015): 
 
“Your support network need to be told she could potentially do A, B, C or D, 
are you prepared to support her through this […] don’t just treat the patient, 
treat the support network” 
(Ware et al, 2015 p.998) 
 
 
2.3.9.5 The persistence of side-effects 
Persistent side-effects from interferon-based treatment are reported by both those 
who achieve an SVR, as well as those who do not respond (Hopwood, 2013).  They 
include both physical and psychiatric problems, and due to their endurance post-SVR 
are not commonly investigated or even acknowledged by many medical professionals, 
leaving individuals feeling disregarded and uncared for (Hopwood, 2013; Manos et al, 
2013).  The effect on HRQoL is also marked, increasing anxiety and depression, 
delaying return to work and the ability to work effectively, and affecting personal and 
sexual relations (Hopwood, 2013).   
 
2.4 Discussion 
2.4.1 The limitations of quantitative PROMs 
As the experience of illness and treatment from the patient perspective continues to 
gain importance, this chapter has endeavoured to demonstrate the value of 
considering PROMs from a variety of sources.  Within the field of HCV, PROMs are 
most frequently collected using self-completed questionnaires, which generate 
quantitative data that can be compared to population norms, healthy controls or other 
specific conditions (Foster, 2009).  The most frequent PROM obtained is HRQoL, which 
has been shown to be significantly lower in individuals with HCV than population 
norms (see table 1), due to a complex multifactorial cause.  During treatment for HCV, 
a further transient reduction in HRQoL has historically been observed (Bernstein et al, 
2002; Bianchi et al, 2000; Hassanein et al, 2004; Hollander et al, 2006; Hunt et al, 1997; 
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Marcellin et al, 2011; Mathew et al, 2006; McHutchison et al, 2001; Rasenack et al, 
2003; Sinakos et al, 2010; Vera-Llonch et al, 2013; Ware et al, 1999; Younossi et al, 
2014a; Younossi et al, 2014b) followed by improvement if an SVR is achieved (table 2).    
Such reports describing the health status of individuals at specific time-points provide 
valuable data to satisfy drug licensing requirements, and provide accessible insights 
into HRQoL.  These are beneficial for assessing cost utility and thus the economic 
benefits of an intervention. 
 
However, much of this evidence comes from large multicentre RCTs, whose 
participants are often unrepresentative of the larger HCV population, undermining 
ecological validity and generalisability (Britton, McKee, McPherson, Sanderson and 
Bain, 1999; Van Spall et al, 2007).  To illustrate this point, Beinhardt et al (2012) 
examined whether selection bias was observed within their clinical centre for patients 
who underwent HCV treatment through an RCT.  Those enrolled to an RCT had less 
advanced liver disease, less frequent history of psychiatric disorders and were less 
likely to be prescribed opioid-substitution therapy compared with those receiving 
routine care, which was largely driven by the studies exclusion criteria.  In another 
example, in a large RCT for patients being treated with telaprevir, Vera-Llonch et al 
(2013) reported that trial participants’ baseline EQ-5D scores were actually higher than 
published US population norms making them not only unrepresentative of the HCV 
population, but of the general population as well17.  These types of selection bias 
conspire to present evidence for HRQoL obtained under ‘ideal’ conditions, with far 
fewer reports on the effect in ‘real-world’ populations with HCV.  
 
In addition to concerns regarding generalisability, there are also methodological 
difficulties with psychometric questionnaires measuring HRQoL.  Individuals with low 
literacy skills are frequently excluded from studies that develop and validate self-
completed questionnaires (Jahagirdar, Kroll, Ritchie and Wyke, 2013).  This has 
particular relevance within the field of HCV, as it is estimated that up to 90% of those 
infected in Scotland are current or former PWID (Hutchinson et al, 2006) who typically 
                                                          
17 One possible contributing factor towards this was the frequency and breadth of cytochrome P450-
associated drug interactions with first generation protease inhibitors, resulting in de facto exclusion of 
patients with multiple comorbidities from clinical trials due to higher levels of poly-pharmacy (Talavera 
Pons, Lamblin, Boyer, Sautou and Abergel, 2014).   
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fall into this category.  The use of psychometric questionnaires has not therefore been 
validated in actively substance-using populations (Dalgard et al, 2004).  Further 
methodological difficulties including the complexity of choosing the correct tool, the 
lack of standardisation across a condition-specific field, and the extent to which the 
chosen tool covers the concept being investigated have also been reported (Refolo, 
Minacori, Mele, Sacchini and Spagnolo, 2012). 
 
The extent to which a tool covers all the concepts being addressed, or more accurately 
fails to cover, can lead to a combination of different PROMs being used within the 
same study.  For example, recent trials using DAAs in the treatment of HCV 
administered four separate questionnaires to their patients: the SF-36 - a generic 
HRQoL survey; the CLDQ-HCV - a disease-specific HRQoL survey; the FACIT-F used to 
assess the impact of fatigue; and the WPAI:SHP investigating impairment in daily 
activities and work productivity (Younossi et al, 2014a; Younossi et al, 2015; Younossi 
et al, 2016b; Younossi et al, 2016c; Younossi et al, 2016d; Younossi et al, 2016e).  The 
sheer volume of paperwork involved in completing these questionnaires, and the time 
and concentration required to do so calls into question the quality of the information 
collected.  In addition, questionnaires may not capture the most pertinent concerns of 
the patient.  These instruments do not elucidate what strategies are employed by 
people to cope with any decrements to HRQoL they may be experiencing, or explore 
the impact on behaviour and functioning in wider society.  The burden of illness is 
reduced to figures which may or may not show statistical and clinical significance, but 
the patient experience, and the patient voice, may be lost in the process. 
 
2.4.2 The value qualitative insights 
In addition to the wealth of literature surrounding the quantitative analysis of HRQoL 
in patients with HCV, there is also a body of qualitative research providing more in-
depth focus into the lived experience of the disease (Miller, McNally, Wallace and 
Schlichthorst, 2012).  These studies give a recognisable voice to the everyday 
challenges experienced by individuals living with the virus.  They provide insights into 
the multidimensional nature of fatigue (Glacken et al, 2003); demonstrate the impact 
that concerns over onward transmission can have (Conrad et al, 2006); and explore the 
pervasive and consuming nature of stigma (Butt et al, 2008; Conrad et al, 2006; Faye 
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and Irurita, 2003; Fraser and Treloar, 2006; Fry and Bates, 2012; Hill et al, 2015; 
Paterson et al, 2006; Zickmund et al, 2003).   
 
The qualitative literature complements the quantitative HRQoL data, and also aids its 
interpretation.  For example, the insights gained into how HCV is viewed as a chronic 
illness help explain the variation in HRQoL observed in quantitative studies.  If living 
with HCV is considered along a chronic illness continuum, individuals who have 
achieved varying degrees of HCV-accommodation in their lives will also therefore 
exhibit varying responses to psychometric questionnaire temporal snapshots.  Without 
this insight, it could be argued that compiling these responses and effectively reporting 
a ‘mean value’ has limited relevance and clinical application.  Indeed, this approach 
also masks the disparity of reactions to diagnosis amongst PWID and other groups 
illuminated by the qualitative paradigm.  A lower HRQoL is not necessarily experienced 
in the same way by all those it affects, which may have significant implications for 
engagement in treatment services.  Further, without accounting for the social 
stigmatisation HCV elicits (Paterson et al, 2007), the findings of most questionnaire-
based HRQoL research are left open to conjecture. 
 
Qualitative exploration into the experience of undergoing a period of HCV therapy has 
also proved invaluable.  These richer and more personalised accounts of treatment 
assist a deeper understanding of why certain side-effects may lead to poor adherence 
and treatment discontinuation i.e. the fatigued patient is not just ‘tired’, their HRQoL is 
severely compromised due to emotional, physical and psychological exhaustion 
(Glacken et al, 2003).  This qualitative work also highlights the strategies used to cope 
with any side-effects experienced, for example exploring the importance and 
mechanics of support.  Without this body of work, the significance and relevance of 
data from HRQoL questionnaires would remain unclear, and the patient voice silenced. 
 
Qualitative studies give a recognisable voice to the decrements and improvements in 
HRQoL described in the quantitative work in addition to revealing more nuanced and 
deeper insights which also have important clinical significance.  The two bodies of 
research are therefore not only complementary, but essentially interconnected.  The 
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depth of understanding of the burden of illness is absent unless qualitative accounts of 
the lived experience are reviewed concurrently alongside quantitative research.   
 
2.4.3 A significant gap 
With this in mind, it is significant that there has been a relative absence of published 
qualitative studies focused on the experience of being HCV positive since the start of 
the DAA era.  Exploration of the lived experience of HCV within an age of constantly 
and rapidly improving treatment options is essential if a contemporary understanding 
of the disease is to be achieved.  It is reasonable to suggest that the significant 
pharmacological developments being witnessed may influence how HCV is being 
understood and experienced by those living with the virus.  For example, are 
perceptions of the illness changing in response to the evolution in HCV therapy, or do 
constructions of HCV as a chronic condition and the embodied experience remain 
unchanged?  There appears an incongruity in continuing to apply chronic illness 
models to a disease that is now cured in over 90% of those who are able to access DAA 
treatment.  However, data are sparse.  The search strategy utilised for this review 
found only two publications focused on the experience of being HCV positive with data 
collected during the DAA era.  One of these articles focused exclusively on the 
Aboriginal Australian community (Treloar et al, 2016), and the other restricted itself to 
an examination of the experience of HCV-related fatigue (Zalai et al, 2016). 
 
The experience of undergoing HCV treatment in this new era of therapy has also 
received limited attention.  Whilst the quantitative literature continues to report 
contemporary data on HRQoL with new treatment regimens (e.g. Younossi et al, 
2014a; 2014b; 2014c; 2014d; 2016a; 2016b; 2016c; 2016d; 2016e; 2016f; 2016g), 
qualitative insights into these therapies lag behind.  Only three studies were identified 
which provided qualitative exploration of HCV treatment since the arrival of the DAAs 
(Evon, Golin, Bonner, Grodensky and Velloza, 2015; Rasi et al, 2014; Sublette, Smith, 
George, McCaffery and Douglas, 2015).  As these studies were all conducted with 
individuals taking interferon-based triple therapy, they were also of more historical 
curiosity than contemporary relevance, given such regimens are now largely obsolete 
in Western nations.  To date, there are no published qualitative explorations of 
individuals receiving interferon-free regimens, which are now standard of care for 
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many individuals with HCV living in Scotland (HIS and NHS National Services Scotland, 
2015a).  Without these richer and more tangible patient narratives, a deeper 
understanding of the lived experience of a period of interferon-free HCV treatment is 
absent. 
 
2.4.4 Research questions 
The lack of contemporary qualitative research focused on the lived experience of HCV 
and its treatment inform the three research questions which lie at the heart of this 
thesis. 
 
Research Question 1: 
How is living with hepatitis C experienced and understood within the context of a new 
era of treatment? 
 
Research Question 2: 
How adequate do theories of chronic illness remain to the contextual understanding of 
living with hepatitis C? 
 
Research Question 3: 
How is interferon-free treatment for hepatitis C experienced and contextualised? 
 
 
The remainder of this thesis aims to address these questions through empirical 
research.  The following chapter details the methodology and methods employed, with 
subsequent chapters focused on the analysis and discussion of the collected data.   
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Chapter 3 
Methodology and methods 
 
3.1 Introduction 
This chapter aims to provide a comprehensive overview of the study methodology, the 
study design, and the methods through which the empirical data were generated.  The 
terms methodology and methods are often poorly defined within the literature.  For 
clarity, I employ the term methodology to encapsulate the ontological and 
epistemological positions underpinning this study, in addition to the specific 
theoretical perspective of social phenomenology upon which it is based (Wilson, 2002).  
By methods, I refer to the practical activities of research, the actions which have been 
termed the ‘nuts and bolts’ of research practice (Carter and Little, 2007).  The chapter 
begins by stating the rationale for employing a qualitative approach, making clear the 
ontological and epistemological beliefs which underpin this inquiry.  Discussion of the 
overarching theoretical perspective of social phenomenology follows, including a 
detailed account of how this theoretical framework was selected.  Barbour (2014) 
notes that for the novice qualitative researcher, the wealth and variety of theoretical 
traditions, in addition to the existence of several variants of virtually every approach, 
makes navigating the literature a confusing pastime.  The work is rarely laid out in an 
organised fashion, with the inconsistent use of terminology between different texts 
adding to the confusion (Crotty, 1998).  I have therefore chosen to describe my 
journey through the literature, as explaining my thought process and charting the 
steps that guided my arrival at the door of social phenomenology should provide a 
clear and compelling justification for its appropriation.  This is also the reason I revert 
to writing in the first person for sections of this chapter. 
 
The second half of this chapter provides a rationale and description of the study design 
and methods utilised, focusing on the practicalities of the research process.  These 
practicalities include sampling strategy, participant recruitment, data generation, data 
handling and the approach to analysis.  The ethical considerations which these 
activities necessitate are then discussed.  These applied aspects of the research 
process are fundamentally based on the overarching theoretical perspective of social 
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phenomenology.  By demonstrating how the research methodology shaped and guided 
the methods chosen, a coherent and logical rationale is presented for the research 
design, enhancing the rigour and trustworthiness of this endeavour. 
 
To begin, however, it is necessary to briefly justify my decision to pursue a qualitative 
approach to data collection, and then examine the ontological and epistemological 
positions this decision necessitates.  In the interests of clarity, I intend to address the 
inconsistent use of terminology throughout this chapter by making explicit my 
understanding of theoretical and methodological terms where necessary, in order to 
avoid being misconstrued. 
 
3.2 Methodology 
3.2.1 A qualitative approach 
The research questions posed within this study aim to explore how the rapid evolution 
in the treatment of HCV is shaping the way this disease is experienced, understood and 
realised by those it affects.  As such, it aims to elicit the ‘lived experience’ of being HCV 
positive rather than providing a quantitative assessment of health-related quality of 
life.  Extensive justification for this approach has been made within the previous 
literature review (chapter 2).  Events, or phenomena (such as lived experience), are the 
result of multiple factors coming together and interacting in complex and often 
unanticipated ways (Corbin and Strauss, 2008).  As such, a methodology that is able to 
celebrate this complexity, and accept richness, nuance, depth and context within the 
analysis is a vital consideration (Mason, 2002).  As the research questions have been 
formulated primarily from the lack of contemporary qualitative research in this area, it 
is unsurprising that a qualitative methodology appears most suited to answering them 
(Bryman, 2012). 
 
3.2.2 Ontology and epistemology 
The choice of a qualitative approach to research brings with it some ontological and 
epistemological considerations.  By ontology, I refer to theories about the nature of 
reality, or as Corbin and Strauss (2008) phrase it, our assumptions about the world.  By 
epistemology, I am referring to theories of knowledge and how we come to know the 
world (Barbour, 2014).  Ontologically, I am a realist.  I believe that there is a real world 
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that exists independently of our perceptions, theories and constructions of it.  For 
example, I believe there are trees, animals and mountains irrespective of whether 
human beings are conscious of them.  However, I do not accept that this real world is 
objectively knowable.  The trees, animals and mountains only become meaningful 
when meaning-making beings make sense of them (Crotty, 1998) i.e. the objects only 
become trees, animals and mountains when consciousness is directed towards them.  
As meaning-making is a subjective process, this naturally leads to the acceptance that 
there are many different but equally valid perspectives on reality (Maxwell, 2012).  The 
acceptance of different perspectives on reality should be distinguished from a belief in 
multiple realities as championed by constructivists and grounded in a more relativist 
ontology.  Believing in valid and differing perspectives of the real world as subjectively 
constructed by meaning-making individuals is not the same as accepting that those 
subjective constructions actually constitute reality, and that a ‘real world’ does not 
exist. 
 
With this in mind, I position myself as a critical realist, a perspective which retains an 
ontological realism while accepting a form of epistemological constructivism (how we 
come to know and understand the world is inevitably a construction from our own 
perspective and standpoint) (Maxwell, 2012).  As Crotty (1998) notes, realism in 
ontology and constructivism in epistemology turn out to be quite compatible.  An early 
proponent of this ontological/epistemological union was Herbert Blumer (1900-1987), 
the leading figure in the symbolic interactionist approach to research.  Although the 
‘constructivist’ term was not available to him at that point, Blumer argued that an 
empirical world exists as something available for observation and study, and although 
this world exists to us in the form of human conceptions of it, this does not shift 
‘reality’ from the empirical world to a realm of imagery and conception (Blumer, 1969).  
In other words, the conceptions formed of the world are all equally valid, but are, and 
remain, perspectives of the empirical world.  How we construct these perspectives on 
reality became the key focus of my journey through the theoretical literature, which 
ultimately led to the door of social phenomenology. 
 
Social phenomenology as an approach to research builds on philosophical thought and 
traditions nurtured in early twentieth-century Europe, and then developed in America 
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following the emigration of its key proponent Alfred Schütz (1899-1959) in the wake of 
Hitler’s Austrian Anschluss.  It is therefore prudent to pause and reflect on the 
foundations of this approach prior to examining social phenomenology itself, as a 
more complete appreciation of social phenomenology’s fit to this study can be 
expounded by examining its roots.  In doing so, I take the opportunity to explain my 
reasoning as to why other phenomenological approaches which were considered and 
appraised were ultimately side-lined in favour of Schütz’s perspective.   
 
3.3 Phenomenology 
3.3.1 Phenomenologies 
Phenomenology is a philosophical approach to the study of lived experience founded 
by the German philosopher Edmund Husserl (1859-1938) at the start of the 20th 
century (Smith, Flowers and Larkin, 2009).  It was launched under Husserl’s banner 
that we should go ‘back to the things themselves’, meaning a focus on describing the 
first person account of immediate experience, and allowing that lived experience to 
speak for itself.  At the core of phenomenology lies the attempt to describe and 
understand the essence of phenomena18 as experienced by the individuals who have 
lived through them (Wojnar and Swanson, 2007).  This descriptive approach to 
phenomenology was later challenged by Martin Heidegger (1889-1976), a former 
student of Husserl, and later by other existential phenomenologists, whose 
interpretive stance set them apart from many of the fundamental tenets of the 
Husserlian school.  However, the Husserlian tradition also endured, and was 
elaborated on and developed by, amongst others, Alfred Schütz, who framed 
phenomenology from a sociological perspective.  As different scholars employed 
divergent philosophies under the phenomenology banner, various strands arose with 
differing epistemological and ontological perspectives.  As such, using the term 
phenomenology as a singular entity is perhaps misleading, and the plural term 
‘phenomenologies’ may be better employed (Lawler, 1998). 
 
 
 
                                                          
18 Where a phenomenon is anything that presents itself (McConnell-Henry, Chapman and Francis, 2009).   
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3.3.2 Husserl 
Originally a mathematician, Husserl became disenchanted and disillusioned with the 
natural sciences as a means of studying human experience, and developed the 
philosophy of transcendental19 phenomenology in response (McConnell-Henry, 
Chapman and Francis, 2009).  He opposed the view that empirical science was the 
sovereign arbiter of truth, and saw phenomenology as a way of returning to and 
exploring the reality of life and living, of going ‘back to the things themselves’ (Tuohy, 
Cooney, Dowling, Murphy and Sixsmith, 2013).  Husserl introduced the concept of the 
lebenswelt, or ‘life-world’, meaning the world as it is immediately experienced (Wilson, 
2014), and claimed that the life-world was not readily accessible, as it constituted that 
which is taken for granted and those things which are common sense (and therefore 
go largely unnoticed) (Koch, 1995).  Study of the life-world therefore explores what an 
experience is like ‘pre-reflectively’, focusing on that which is experienced in the 
consciousness of the individual (Smith et al, 2009).  This approach was rooted in the 
philosophical dogma of the day, and elaborated from the mechanistic model of the 
mind-body split, known as Cartesian duality (Koch, 1995).  It is prudent to explore 
some of the critical concepts of transcendental phenomenology, as a deeper 
understanding can serve to help illuminate the contrasting hermeneutic paradigm of 
Heidegger, and discussion of the concept of bracketing will provide a rationale for the 
rejection of pure transcendental phenomenology in this study. 
 
3.3.2.1 Intentionality 
A central tenet of phenomenology is intentionality.  Husserl held that we are never 
simply conscious, but instead, our consciousness is intentional in that it is always 
directed or pointed toward something (LeVasseur, 2003).  Crotty (1998) describes 
intentionality as the relationship between conscious subjects and their objects; 
consciousness is always consciousness of something, and the objects always mean 
something to someone.  These objects can be real, imaginary or conceptual, or 
consciousness can also be directed at the object of itself e.g. our own emotions and 
thoughts (Hein and Austin, 2001).  Phenomenological inquiry therefore focuses on that 
which is intentionally experienced in the consciousness of the individual (Smith et al, 
                                                          
19 This branch of phenomenology is also referred to as Descriptive Phenomenology, Husserlian 
Phenomenology and Eidetic Phenomenology 
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2009).  That is, the first-person subjective experience which occurs independent of 
their actual relationship with the external world.  The context of experience is 
disregarded in transcendental phenomenology and the focus is on the experience 
alone (Tuohy et al, 2013).  For Husserl, intentionality is the key to understanding 
human experience (Earle, 2010). 
 
3.3.2.2 Bracketing 
Despite his disillusionment with the natural sciences as a means of studying human 
experience, Husserl remained a positivist and strived for objectivity and neutrality as 
he believed this was the only way of assuring methodological trustworthiness 
(Fleming, Gaidys and Robb, 2003).  Bracketing20, a fundamental methodological 
principle of transcendental phenomenology, was Husserl’s approach to ensuring the 
researcher does not influence the participants’ understanding of the phenomenon 
under investigation, as in order to understand the nature of phenomena all prejudice 
must be eliminated (Hamill and Sinclair, 2010).  It aims to ensure researchers’ 
preconceptions are held in abeyance and assumptions are not allowed to impose 
understanding (Hamill and Sinclair, 2010).  Bracketing seeks to approach events with 
an investigative mind left deliberately open, consciously trying to ‘bracket out’ 
preconceived ideas and assumptions as the researcher is not studying their own 
awareness and reflections, but the awareness and reflections of the study participants 
(Willis, 2001).  By acknowledging, examining and putting aside one’s beliefs, the 
researcher should attain native data (McConnell-Henry et al, 2009) and achieve the 
transcendental ego: the consciousness Husserl described as necessary for the 
understanding of pure phenomenal experience (LeVasseur, 2003).  This is an etic 
approach which strives for objectivity (Hamill and Sinclair, 2010), and is often distilled 
to simply having a fresh look at the world, leaving our usual understandings21 in 
abeyance (Crotty, 1998). 
 
                                                          
20 Also termed phenomenological reduction, eidetic reduction or epoché. 
21 Exactly what should be bracketed has been a source of discussion within the literature for a number 
of years, with the terms assumptions, judgements, biases, beliefs, presuppositions, experiences, issues, 
knowledge, perceptions, preconceptions and pre-understandings all used within this context (Hamill and 
Sinclair, 2010). 
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The notion of bracketing was subsequently criticised and rejected by Heidegger and 
other existential phenomenologists (LeVasseur, 2003), who espoused the view that 
understanding is never without presuppositions (Earle, 2010) and that understanding 
is already there, and cannot, nor should not, be divorced from our thinking (Smythe, 
Ironside, Sims, Swenson and Spence, 2008).  They also accused Husserl of betraying his 
own doctrine of intentionality, as this was contradicted by the notion of bracketing 
(LeVasseur, 2003).  From a practical viewpoint, Husserl did not offer a method by 
which bracketing could be achieved, and doubts around whether it is attainable have 
permeated the literature.  Is it truly possible to suspend all beliefs, thoughts and 
influences when we are embedded in a world of meaning?  Hamill and Sinclair (2010) 
note that having an awareness of personal feelings and preconceptions is a 
prerequisite for setting them aside.  However, how can one be certain that these have 
been brought to the level of consciousness and acknowledged?  Also, even if the 
researcher were successful in bracketing, what of the participants?  Does the fact that 
participants do not consciously bracket their own conceptual framework when 
narrating their experience mean that our knowledge is based on a fundamentally 
flawed and skewed understanding? (LeVasseur, 2003). 
 
The impetus for this research project came from my experience of working within the 
field of HCV treatment over a number of years.  The accumulated hours of practical 
clinical experience, the associated clinical knowledge, and the countless interactions 
and consultations with patients both before, during and after HCV treatment confers 
on me a wealth of presuppositions, perceptions and beliefs.  The feasibility of 
attempting to ‘bracket out’ this extensive experience is questionable, particularly for a 
novice researcher, and the relative success or failure of such an undertaking would 
have significant implications for the trustworthiness and credibility of this piece of 
work.  In addition, I conducted the literature review detailed in chapter two prior to 
this exploration of qualitative methodologies.  Hamill and Sinclair (2010) note that 
delaying the literature review until after data collection and analysis can assist the 
achievement of bracketing, by ensuring themes known to exist in the literature do not 
dominate question phrasing or analytical techniques, with other authors also 
suggesting a literature review should be avoided if Husserl’s phenomenology is 
subscribed to (McConnell-Henry et al, 2009).  The most pertinent argument against the 
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use of transcendental phenomenology, however, is the philosophical one.  Annells 
(1996) describes the person and the world as co-constituted in an indissoluble unity, 
and as such “man [sic] makes sense of his world from within his existence and not while 
detached from it” (Annells, 1996 p.706).  It is with this in mind that we turn to the 
development of Heidegger’s hermeneutic phenomenology. 
 
3.3.3 Heidegger 
The German philosopher Martin Heidegger (1889-1976) was a student of Husserl.  
However, with his seminal work Sein und Zeit (Being and Time) he moved radically 
away from Husserl’s phenomenological approach (Earle, 2010).  The process of 
bracketing provides information that is epistemological, rather than ontological in 
nature, i.e. you can know something through description, but cannot understand it or 
derive meaning from it (McConnell-Henry et al, 2009).  Heidegger travelled from the 
epistemological emphasis of Husserl to an emphasis on the ontological perspective 
(Earle, 2010), believing the outcome of phenomenological research should be 
understanding and meaning through interpretation rather than a purely descriptive 
science (McConnell-Henry et al, 2009).  He replaced the concept of knowing with that 
of understanding.  Understanding was not possible because of knowing, it was possible 
because of relationships (Fleming et al, 2003). 
 
Heideggerian phenomenology22 is based on the perspective that the understanding of 
individuals cannot occur in isolation from their culture, social context, and the 
historical period in which they live (Wojnar and Swanson, 2007) therefore challenging 
two notions of Husserl: firstly, that meaning can be seen in terms of representation of 
an independent reality, and secondly, that theory can be generated from the 
standpoint of an observer standing outside the situation (the etic position) (Koch, 
1995).  Heidegger held that consciousness could not be separated from what he 
termed in-der-Welt-sein, or being-in-the-world, a term used to emphasise the 
temporary, existential and relational basis of our daily lives and understanding of the 
world (Robertson-Malt, 1999).  Because of this, the bracketing of prior conceptions 
and knowledge was unattainable.  We are necessarily embedded in an historical 
                                                          
22 Also referred to as Existential Phenomenology, Interpretive Phenomenology and Hermeneutic 
Phenomenology within the literature 
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context (LeVasseur, 2003).  This key tenet of Heideggerian phenomenology he termed 
Dasein, or ‘being there’, emphasizing that individuals cannot abstract themselves from 
various contexts that influence their choices and give meanings to lived experience 
(Wojnar and Swanson, 2007).  These experiences are based on our context of the 
world, and as humans we cannot be separate from our contexts (Miles, Francis, 
Chapman and Taylor, 2013).  Central to the notion of Dasein is its spatiality and 
temporality.  There is an attachment in time and space to culture and history, 
providing understandings of beliefs and contexts which in turn shed light on the 
phenomenon of interest: experience is temporally and spatially mediated (Miles et al, 
2013).  This has particular pertinence and relevance for the current study. 
 
The evolution of drug therapy for the treatment of HCV provides the underlying 
rationale for this study.  The experience of living with HCV and undertaking treatment 
will therefore be temporally bound as the historical context is not static: we are 
temporal beings in a temporal world (McConnell-Henry et al, 2009).  For example, 
being prescribed interferon at a time when this was the best and most effective cure 
available may be understood and made sense of by an individual in a different way 
compared with being prescribed interferon at a time when other more efficacious 
treatments exist.  The temporal and spatial context of Dasein therefore impacts heavily 
on both existence and experience.  Because of this, Heideggerian phenomenology does 
not look for generalisable traits, or shared experience, but understands that the truth 
about an experience, as professed by one person, might differ from that believed by 
another.  Truth is intertwined with perception and context, and there can therefore be 
multiple truths of a lived experience (Crist and Tanner, 2003; McConnell-Henry et al, 
2009; Miles et al, 2013).  This fundamentally contrasts with Husserl’s transcendental 
phenomenological stance which aims to expose the absolute truth through 
description.  Both these positions resonate with my clinical experience.  No two 
patients appear to share a common experience of living with HCV and undergoing 
treatment.  However, there can be similarities and common features of distinctly 
differing experiences.   
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3.3.3.1 Heidegger: lost in translation? 
On initial reading, the hermeneutic phenomenological philosophy of Heidegger 
appeared to provide a rational and logical theoretical framework on which to anchor 
this current research.  However, the appropriation of phenomenological theory by 
nurse researchers has not been without criticism, and the writing of one particular 
critic in relation to Heidegger is difficult to ignore.  John Paley has provided a vocal and 
enthusiastic challenge to nursing research which claims theoretical justification by 
citing the tenets of phenomenological philosophy (Paley, 1997; Paley, 2005).  He 
contests the notion that Heidegger’s phenomenology has the methodological 
implications commonly ascribed to it, and ultimately describes the research of ‘lived 
experience’ not as a realisation, but rather as a betrayal of Heidegger’s philosophy 
(Paley, 1998).  Paley constructs his argument by returning to Being and Time, 
Heidegger’s seminal work, and unpicking the common assumptions made by 
researchers who claim to be undertaking ‘Heideggerian phenomenological research’.  
Primarily, Paley argues that research into lived experience would be anathema to 
Heidegger, as he explicitly disowns the concept (Paley, 2014).  Paley contends that 
study of the lived experience is always an attempt to access the subjective experience 
of a phenomenon, not the objective factual account of what actually happened.  For 
example, within this study the objective factual account may be that an individual was 
diagnosed with HCV, and the subjective experience of that would be the thoughts, 
meanings, interpretations, emotions and understandings involved.  This understanding 
of a subjective/objective distinction aligns with the Cartesian duality that Heidegger 
explicitly rejected in favour of his concept of being-in-the-world (Paley, 2014). 
 
“Being-in-the-world cannot be broken up into contents which may be 
pieced together” 
(Heidegger, 1962 p.53) 
 
Reflective recollections of ‘lived experience’ are therefore not possible.  Retrospective 
subjective experience has no place in Heidegger’s work as it reverts to the very dualism 
he is attempting to dismantle.  He does not accept it exists (Paley, 2014).  Paley is not 
the only scholar to critique nurses’ interpretation and utilisation of phenomenology as 
a method for undertaking qualitative research.  Crotty (1996) asserts that much of the 
nursing research that cites a phenomenological foundation has little basis in pure 
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phenomenology as described by its founding philosophers.  Instead, he described 
much of what is claimed as phenomenological research (particularly that emanating 
from North America) to be a hybrid of symbolic interactionism and humanistic 
psychology, providing third-person subjective description of phenomena, rather than a 
critical examination of the phenomena themselves (Barkway, 2001).  As such, Crotty 
(1996) makes a distinction between ‘European phenomenological research’ and ‘new 
phenomenological research’ emanating from the English-speaking world (primarily 
North America), and implicitly implies inferiority in the latter.  The American 
psychologist Giorgi (2000) offers a spirited response to this argument, agreeing with 
Crotty that there are two phenomenologies, but terming them ‘philosophical’ and 
‘scientific’, and in doing so highlighting the fact that neither Husserl nor Heidegger 
intended to develop research methodologies, their interests being most firmly rooted 
in the study of philosophy (Miles et al, 2013).  Indeed, Giorgi (2000) argues that if 
nurse researchers were to adhere to pure phenomenology they would be practising 
philosophy, and not contributing to ‘nursing or caring’ scientific work which is surely 
their original intention. 
 
After reviewing the phenomenologies of Husserl and Heidegger, and exploring the 
criticism levelled at the appropriation of these philosophies within nursing research, I 
felt paralysed.  The basic aim of phenomenology to ‘go back to the things themselves’ 
and describe and understand phenomena as experienced by the individuals who have 
lived through them is clearly appealing and appropriate for this study.  However, how 
could I justify the appropriation of either transcendental or existential phenomenology 
after highlighting the issues discussed above?  Further reading led to a possible 
answer. 
 
3.3.4 Schütz and social phenomenology 
Alfred Schütz (1899-1959) was an Austrian philosopher and economist, who was 
greatly influenced by the work of sociologist Max Weber.  Although impressed with 
Weber’s theory of social action, Schütz sought to overcome what he perceived as its 
weaknesses by integrating ideas from philosophers such as Husserl.  In doing so, he 
approached phenomenology from a sociological perspective (Ajiboye, 2012) which 
resulted in his seminal text The Phenomenology of the Social World (Schütz, 1967). 
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Schütz’s social phenomenology is a descriptive and interpretive theory of social action 
that explores subjective experience and the way in which meaning is socially 
constructed (Fereday and Muir-Cochrane, 2006).  It examines how mundane 
understandings of social life are constituted and organised, both in face-to-face 
interaction and in more remote contexts (Levesque-Lopman, 1988).  He emphasised 
the profound impact of social interaction in establishing meanings in the world.  Thus, 
whilst greatly influenced by Husserl’s phenomenology, he opposed one of his basic 
tenets that intentional consciousness is the driving force in constituting an object’s 
meaning (Shaw and Connelly, 2012).  In essence, Schütz’s main contribution was that 
the way humans classified and attached meaning to the outside world (or constructed 
their perspective) was not a purely individual process.  Hence, whilst other 
phenomenological philosophers focused primarily on consciousness, Schütz rotated 
phenomenology outward to a concern for the inter-subjective social world (Ajiboye, 
2012). 
 
Schütz believed that inter-subjectivity was the foundation of all human knowledge and 
experience, because we do not experience the world alone, we experience it with and 
through others.  People learn about what phenomena mean through an interactive 
process between past experiences and the projected meanings of others in the world 
(Shaw and Connelly, 2012).  Schütz was not primarily interested in the physical 
interaction of people (as a more symbolic interactionist approach may be), but in the 
way they relate to and grasp the consciousness of others and in doing so create a 
common view of the world (Ajiboye, 2012).  Social phenomenology therefore proposes 
that an inter-subjective world is not a private world, but a relational one that is 
common to all.  Put more explicitly, there are common features among people’s 
subjective experiences of any particular social phenomenon that define its meaning.  
Schütz termed these common features ‘ideal type’, a notion drawn from the work of 
Weber and analogous to the notion of ‘essences’ in Husserl’s work.  The ideal type is 
therefore an objective description and understanding of a subjective experience (Shaw 
and Connelly, 2012).  It is the commonalities that are found in the subjective life-
worlds of more than one actor.  The importance of the ideal type being grounded in 
the subjective point of view was paramount to Schütz, however, as this prevented 
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social reality being replaced by a fictional, non-existent world constructed by the 
researcher (Fereday and Muir-Cochrane, 2006). 
 
3.3.4.1 Bracketing revisited 
As social phenomenology therefore seeks objective knowledge through accurate 
descriptions of subjective experience, it remains rooted in the Husserlian school, and, 
as such, the notion of bracketing must once again be considered.  Husserl viewed ‘the 
natural attitude’ (that is, the normally occurring and common-sense meanings that 
characterize everyday life) as sources of bias and distortion for the phenomenologist, 
and advocated their bracketing in order to approach phenomena with an open mind 
(Smith et al, 2009).  This type of bracketing is often termed the phenomenological 
epoché.  To Schütz, the natural attitude was not a discrete consciousness, but a shared 
and inter-subjective consciousness which itself should form the basic subject of 
phenomenological investigation (Silverman and Torode, 1980).  He proposed that 
within the natural attitude, individuals also use a specific bracketing (epoché) which is 
diametrically opposed to the phenomenological epoché.  That is, individuals do not 
suspend belief in the outer world and its objects.  On the contrary, they suspend any 
doubt in its existence: doubt that the world and its objects might be anything other 
than how they appear (Levesque-Lopman, 1988).  This has been termed the epoché of 
the natural attitude.  As researchers, we are also individuals that are part of the inter-
subjective natural attitude.  Therefore, we too suspend doubt that the world is 
anything other than it appears.  For the social phenomenologist researcher, bracketing 
must allow doubt, or more accurately suspension of belief in the existence of the 
world as we know it. 
 
Whilst acknowledging the previous discussion of whether bracketing is achievable 
within Husserlian phenomenology, the discussion of epoché within social 
phenomenology posits a more practical viewpoint.  The suspension of belief in the 
world as we know it suggests the adoption of a questioning, interrogative and 
searching attitude.  I am not asked to remove all experience, knowledge and expertise 
I possess from my consciousness, but to acknowledge that this may comprise only one 
possible account of a phenomena.  I am asked to doubt, to suspend belief in what I 
think I know, and allow the possibility that the world exists in a different way.  When 
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viewed in this way, bracketing becomes a more achievable and realistic goal, moving 
from a purely philosophical realm to one of practical research methodology. 
 
3.3.4.2 A research method 
In contrast to Husserl and Heidegger, Schütz moves phenomenology beyond 
philosophy and discusses the application of practical method within the social 
sciences.  He proposed three essential postulates to be followed during the research 
process to ensure the objective ideal type was founded in the subjective meaning of 
human action (Schütz, 1973 p.43-44 [abridged]): 
 
1. The postulate of logical consistency: the researcher must establish the 
highest degree of clarity and distinctness of the conceptual framework 
and method applied, which must be fully compatible with the principles 
of formal logic. 
2. The postulate of subjective interpretation: any model of human action 
must ground its construction in the subjective meanings the ‘actor’ had 
for the action. 
3. The postulate of adequacy: there must be consistency between the 
researcher’s constructs and those found in the common-sense 
experience; it must be recognisable and understood by the actors within 
their life-world. 
 
These three tenets provide a framework upon which the philosophical underpinnings 
of Schütz can be used to consider more practical research methods for the current 
endeavour.  My hope is this overview of my journey through the literature supports 
Schütz’s first postulate of logical consistency. 
 
For the current study, the theoretical underpinnings of social phenomenology provide 
an attractive fit.  My realist/constructivist union corresponds well with Schütz’s 
teachings.  In addition, the approach encompasses phenomenology’s core attempt to 
describe and understand phenomena as experienced by the individuals who have lived 
through them (Wojnar and Swanson, 2007) with a sociological perspective into the 
way that experience is constructed.  It moves phenomenology on from a purely 
philosophical pursuit, to a methodological approach to research that remains 
committed to understanding lived experience and the ways in which it is constructed.  
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With this in mind, I will now move on to describe the design of the study, recruitment 
process and analytical techniques employed. 
 
3.4 Methods 
Having made my ontological, epistemological and theoretical positions evident, I now 
turn to the more practical discussion of methods employed for data generation and 
analysis.  The design of this study incorporated semi-structured in-depth interviews 
with a purposive sample of HCV positive individuals.  A longitudinal element of the 
study design followed-up a subset of these individuals who subsequently received 
interferon-free HCV treatment.  Previous discussion of the underpinning methodology 
necessarily guided, informed and justified the study design, in addition to its 
appropriateness in answering the research questions posed.  Methods and 
methodology are intricately and inextricably connected, and where necessary, 
discussion will therefore focus on the choice and appropriateness of data collection 
and analytical techniques as the practicalities of the study design are considered. 
 
3.4.1 Sampling 
In qualitative research, sample selection has a profound effect on the overall quality 
and rigour of the study, yet is often poorly described or justified (Coyne, 1997).  This 
study utilised a purposeful (or purposive) sampling strategy, which involved selecting 
participants by virtue of characteristics thought to have some bearing on their 
perceptions and experiences (Barbour, 2014).  There was a need, therefore, to think 
critically about the parameters of the population being studied and choose the sample 
carefully on that basis (Silverman, 2013).  The type of purposeful sampling used was a 
maximum variation sampling strategy, which will now be described. 
 
3.4.1.1 Maximum variation sampling 
Maximum variation is a purposeful sampling strategy that aims to capture and 
describe central themes that cut across a high degree of variation in the participants.  
It assumes that common patterns that emerge from great variation are of particular 
interest and value in capturing core experiences and shared dimensions of a 
phenomenon (Patton, 2015).  As such, the relevance of this approach to the social 
phenomenological perspective underpinning this study becomes immediately 
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apparent: this sampling strategy promotes the illumination of Schütz’s ‘ideal type’.  In 
addition, the variation in characteristics built into the sample allows for meaningful 
comparisons to be drawn during analysis (Mason, 2002). 
 
The maximum variation sample was constructed by the identification of diverse 
characteristics of the potential sample population in relation to their experience of 
HCV and its treatment.  The identification of these characteristics was based on 
personal experience of working with HCV patients as a specialist nurse for a number of 
years, the literature review undertaken in the process of developing the study’s 
research questions, and reflection on what may constitute ‘common-sense’ categories 
(Mason, 2002).  The main characteristics identified were:  
 
• Engagement with specialist HCV care:  Individual experience and understanding 
of HCV may vary depending on whether participants attended specialist HCV 
services and engaged with assessment and clinical work-up for HCV treatment.  
The on-going success of the HCV action plan for Scotland (Scottish Government, 
2015a) means there are fewer individuals diagnosed with HCV who remain 
‘unengaged’ with care.  These individuals were predicted to be the most difficult 
and elusive group to recruit.   
 
• Date of HCV diagnosis:  Following the arrival of DAAs in clinical practice, and 
the significant improvements in treatment options available for people with HCV, 
individual variation in response to HCV may exist based on when a diagnosis was 
made.   As the first DAAs became available for treatment in Scotland in 2011 
(Scottish Medicines Consortium, 2011b), that year was taken as marking the start 
of the new era in drug therapy. 
 
• Mode of acquisition: The manner in which HCV was contracted may influence 
and inform the experience of living with the virus.  Whilst injecting drug use 
continues to be the predominant route of viral transmission (Palmateer et al, 
2013), the study did not aim to focus exclusively on this cohort. 
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• HCV treatment history:  Exposure to previous interferon-based treatment may 
influence and inform perceptions of HCV and new drug therapies. 
 
• Degree of liver disease: The severity of liver disease has been repeatedly shown 
to affect quantitative measures of HRQoL (Orr et al, 2014).  The study therefore 
aimed to include participants who identified as cirrhotic, and those who did not. 
 
In addition to these factors, gender and ethnicity were also incorporated into the 
maximum variation sample.  This was not an attempt to produce a sample that was 
representative of the wider population, but in order to reflect diversity and provide as 
much potential for comparison as possible (Barbour, 2014).  Markers of socioeconomic 
status were not included in the maximum variation sample, as HCV is known to 
disproportionately affect populations who are marginalised and underserved (Public 
Health England, 2016).  As such, it was predicted that the majority of participants 
would be of lower socioeconomic status, but that the parameters of the maximum 
variation sample would naturally draw in individuals from other socioeconomic 
backgrounds.  Demographic data concerning living arrangements and employment 
were collected to examine this. 
 
3.4.1.2 Inclusion and exclusion criteria 
The following inclusion criteria were applied to the sample: 
 
• Participants must be living within Edinburgh and the Lothians, and have been 
infected with HCV for at least six months to allow for any spontaneous clearance 
of acute infection (Seeff, 2002). 
 
• They must be aged 16 years or over, and able to converse in English.  The use 
of a translator within a phenomenological study presents fundamental 
difficulties.  Language is a part of the identity of the person experiencing the 
phenomenon.  Therefore, the way in which a concept or phrase is translated 
could change what the participant actually said, threatening trustworthiness, 
credibility and dependability of the study (Squires, 2009). 
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Two exclusion criteria were applied: 
 
• Individuals with serious mental illness (e.g. psychosis) were excluded; referrals 
would come from health professionals who have access to medical notes and 
would therefore be able to assess this. 
 
• Individuals incarcerated within either of the two prisons served by NHS Lothian 
were also excluded.  The experience of being HCV positive within a correctional 
facility will be influenced by the very specific set of circumstances present within 
that unique environment, along with its associated pressures and stressors (e.g. 
Yap et al, 2014).  Whilst a valuable line of enquiry, it was not within the scope of 
this study. 
 
3.4.1.3 Sample size 
The sample size needed to be large enough to allow for meaningful comparisons 
between the factors identified in the maximum variation sample, but not so large that 
detailed and nuanced analysis of the data would become impossible (Mason, 2002).  
With this in mind, a maximum sample size of 30 HCV positive individuals was decided 
upon.  The predicted sample numbers for the maximum variation characteristics 
identified were based on demographic data obtained from a local HCV patient 
database (A. Wilson, personal communication).  The rationale for this approach was 
not an attempt to produce a sample that was necessarily representative of the clinical 
population, but more a common-sense indication of how prevalent that particular 
characteristic was, and therefore the likelihood of capturing that variation within the 
maximum sample size.  Initial target sample numbers, along with the actual 
composition of the study’s participants are shown in table 3.  Twenty participants in 
total were recruited to the study.  This was considerably lower than the maximum 
figures suggested, principally due to the difficultly in recruiting individuals who did not 
engage with HCV specialist care. 
 
3.4.1.4 A note on saturation  
The concept of saturation is often cited as a guiding principle of sample size during 
qualitative data collection and analysis (Mason, 2010).  Two types of saturation are 
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commonly discussed: data saturation and theoretical saturation.  Both of these 
concepts involve continual sampling until either no new information is obtained, or no 
new themes are identified (Walker, 2012).  The point at which saturation is achieved 
can be an elastic notion (Mason, 2010), and the whole concept has been described as 
vague and lacking definite rules.  Indeed, many authors state saturation has been 
achieved but fail to provide any evidence as to how it occurred (Bowen, 2008). 
 
Table 3: Target recruitment numbers and actual number of participants obtained within the maximum 
variation sample, plus additional socioeconomic demographic data. 
 
Maximum Variation 
Characteristic 
Variable Maximum Target 
Number (n=30) 
Actual Number 
Obtained (n=20) 
Engagement with 
specialist HCV care 
Engaged 20 18 
Not engaged 10 2 
 
Date of HCV diagnosis 
Pre-2011 15 12 
2011 and after 15 8 
 
Mode of acquisition 
Injecting drug use 22 13 
Other 8 7 
 
HCV treatment history 
Previous treatment 8 3 
No previous treatment 22 17 
 
Gender 
Male 18 11 
Female 12 9 
 
Ethnicity 
White British 27 18 
Other 3 2 
Degree of liver disease 
Pre-cirrhotic 20 13 
Cirrhotic 10 5 
Unknown - 2 
Employment status 
Paid employment - 6 
Unemployed - 13 
Retired - 1 
Living arrangements 
Living alone - 8 
Lives with family - 12 
 
The concept of saturation is rooted within grounded theory, and is indelibly linked to 
other grounded theory concepts such as theoretical sampling and the constant 
comparative method (Bowen, 2008).  Whilst saturation has been used within a variety 
of studies claiming differing theoretical perspectives (Walker, 2012), there are a 
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number of reasons why I have not referred to it within my previous discussion of 
sample size selection.  A phenomenological study is fundamentally interested in 
subjective lived experience, and my critical realist ontological/epistemological union 
accepts that individuals will construct multiple equally valid perspectives on reality 
(Maxwell, 2012).  New data will therefore always add something new, as these 
perspectives are theoretically infinite in number and the point at which saturation 
occurs within a phenomenological study would therefore be arbitrary at best.  A 
further consideration is the requirement of NHS research ethics committees (RECs) 
and NHS Research and Development departments to have full details of predicted 
sample numbers along with a clear rationale prior to granting approval for a study’s 
inception.  The concept of saturation does not help in meeting these demands as it 
provides no guidance on estimating sample size prior to data collection. 
 
Whilst a convincing concept saturation has a number of practical weaknesses (Green 
and Thorogood, 2014) in addition to difficulties being aligned with a phenomenological 
perspective.  Any claims to achieving saturation within this study would therefore be 
precarious and may potentially affect the credibility and rigour of the endeavour.  That 
said, whilst not claiming saturation would be achieved, it is clearly the intent of this 
study to describe and explore the phenomenon under investigation as fully as possible.  
The sample numbers, and actual number of participants recruited in this study sit 
within many commonly suggested ranges for an ideal sample size to achieve 
saturation.  However, as Mason (2010) notes, whilst these suggested ranges are 
offered, the authors rarely present empirical arguments as to why these numbers have 
been settled on. 
 
3.4.2 Data generation: interviews 
Patton (2002, p.340) notes that “we interview people to find out from them those 
things we cannot directly observe.”  By doing so, he highlights that interviewing is not 
necessarily better or more desirable than other methods of data collection, but that 
interviewing allows access to participants’ feelings, thoughts and the meanings they 
attach to their experience of the world: things which are not readily observable.  This 
rather simplistic account of qualitative interviewing positions the researcher as an 
impassive earpiece, neutrally ‘collecting’ data from participants.  A research interview 
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does not merely ‘collect’ data, but instead generates accounts of lived experience and 
its meaning through an exchange of views and dialogue between the participant and 
the researcher (Kvale, 2007).  The data is collaboratively produced within the relational 
context of the interview, with the researcher helping the participants to reach beyond 
the superficial layers of their experience in order to generate rich, novel and 
informative insights (Schultze and Avital, 2011).  A social phenomenological 
perspective demands an emphasis on understanding the participant’s experience of 
the world from their own situation, and then interpreting how that understanding is 
inter-subjectively constructed (Wilson, 2002).  In-depth interviews therefore offered 
an appropriate and compelling method to generate data which permitted such insights 
and reflections, allowing participants to reconstruct verbally their understandings of a 
phenomenon (Mason, 2002).  Conducting interviews face-to-face as opposed to over 
the telephone or via email also allowed the establishment of rapport, an important 
consideration when discussing sensitive topics such as HCV and drug use (Nichter, 
Quintero, Nichter, Mock and Shakib, 2004). 
 
The 20 participants undertook their initial interviews between June 2015 and 
December 2015.  All the interviews were audio-recorded on an encrypted recording 
device, and then uploaded onto a secure area of the NHS server.  Once this was 
complete, the original file was deleted from the recording device.  Interviews lasted 
between 19 – 67 minutes with a mean duration of 39 minutes. 
 
3.4.2.1 Semi-structured interviews 
The types of interview used within qualitative research can range from the most open-
ended informal conversational interview with few pre-determined questions, to a 
more standardized affair with the same open-ended questions being asked, in the 
same way and order to each participant (Patton, 2015).  This study utilised a semi-
structured interview approach, which sits between these two extremes.  The semi-
structured aspect refers to the capacity of the interview to elicit data on perspectives 
of salience to participants, rather than the researcher entirely dictating the course of 
conversation (Barbour, 2014).  It aims to balance the need for the researcher’s over-
arching agenda to be addressed, whilst allowing how the interviewee frames and 
understands events to be given primary importance (Bryman, 2012).  In doing so, the 
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semi-structured interview is a valuable social phenomenological tool.  It inherently 
accepts that different individuals experience different versions of reality, and gives 
scope for their version of reality to be co-constructed and expressed within the loose 
confines of the general topic area, and the relational context of the research interview. 
 
The topic areas covered within the interviews were guided by an interview schedule 
(appendix C).  The interview schedule detailed specific questions, probes and prompts 
within each broad topic area to help guide the conversation, and scheduled a logical 
sequence for these topic areas to be approached.  However, the interviews were 
conducted with openness to changes in this sequence and the wording of prepared 
questions in response to specific stories or answers given (Kvale, 2007).  This 
encapsulates a phenomenological interest in the lifeworld of the individual.  Whilst a 
priori assumptions about human nature naturally inform the interview schedule, 
understanding how HCV is experienced from the point of view of the participant, in 
their own words, and in their own way, was of primary importance. 
 
3.4.2.2 Piloting 
The interview schedule was initially piloted with the first couple of participants to 
ensure it functioned well and was adept at generating the kind of information sought.  
This process helped to identify any questions which made respondents feel 
uncomfortable, or seemed not to be understood (Bryman, 2012).  The pilot interviews 
also provided experience of using the schedule and of qualitative interviewing 
generally.  Although I had considerable previous clinical experience of conversing with 
patients during consultations, in-depth qualitative interviewing is a different art which 
requires practice and training (Kvale, 2007).  Piloting therefore provided me with more 
confidence, allowing early mistakes to be identified and a more accomplished 
interviewing style to be developed (Silverman, 2013).  For example, in early interviews 
the question “how has life been since your diagnosis?” produced fairly abrupt and 
bemused responses, yet a minor rewording to “tell me about your life since diagnosis” 
elicited a much richer reaction.  The anonymised transcripts of pilot interviews were 
reviewed with the academic supervisory team, and were included within the analysis. 
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3.4.2.3 Consideration of other data collection methods 
Other data collection methods were considered for this study but were deemed 
unsuitable on ethical and pragmatic grounds.  Focus groups could potentially have 
been used, although it was felt the personal nature of the topic being discussed may 
have resulted in a reluctance of some participants to share their experience.  Other 
commonly cited disadvantages of focus groups also proved pertinent, such as the 
difficulty of assembly, the risk of dominant individuals influencing group dynamics and 
the risks of potential compromise to participant anonymity (Then, Rankin and Ali, 
2014).  Participant observation or an ethnographic approach could possibly have been 
employed, however practical considerations such as exactly what, who and when to 
observe in order to understand the experience of being HCV positive were particularly 
perplexing.  The impact of HCV on day-to-day life could be quite episodic, which does 
not lend itself well to participant observation.  Also, the reconstruction of life events 
(such as HCV diagnosis) or a focus on the future cannot be accomplished through 
participant observation alone (Bryman, 2012).  Ethnographic approaches can also 
become very intrusive in participant’s lives, and overcoming multiple ethical issues 
such as researcher safety and obtaining informed consent could have proved 
insurmountable given the population being studied. 
 
3.4.3 A longitudinal aspect 
For those participants who undertook a period of interferon-free HCV treatment, a 
longitudinal aspect to the study was developed to follow up and conduct further 
interviews immediately after they had completed their course of therapy.  The aim of 
these interviews was to focus specifically on their experience of treatment.  Further 
details of the participants involved, and how these interviews were conducted has 
been given in chapter seven.  The maximum sample size for this longitudinal aspect of 
the study was set at ten.  This figure was based on the number of individuals treated 
for HCV within the main sampling site over the preceding year (A. Wilson, personal 
communication), and practical considerations concerning the time required for 
thorough and detailed analysis of the generated data.  Due to the repeated revision of 
national and local recommendations for the treatment of HCV with DAAs during the 
planning of the study (HIS and NHS National Services Scotland, 2015a; HIS and NHS 
National Services Scotland, 2015b), it was initially unclear how many of the proposed 
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sample may be eligible for interferon-free therapies.  However, once recruitment and 
data collection began, eight of the participants were able to access interferon-free 
treatment and were successfully followed up. 
 
Further interviews with this sub-group of participants were planned once they had 
received the results of their treatment course, focused on their experience of being 
successfully cured of HCV (or not).  The scheduling of this final cluster of interviews 
aimed to provide sufficient time for the participants to acclimate the treatment result 
into their lives.  Therefore at least three months following the news of their treatment 
outcome needed to have passed.  As recruitment progressed, it became clear that this 
final stage of data generation was too ambitious.  The quantity of data generated 
during the previous two rounds of interviews was not insignificant, and I began to 
doubt my ability, as a single novice researcher, to handle additional material in a 
meaningful way.  Also, by their very nature, these interviews needed to be conducted 
towards the end of the three-year period available to this study, leaving insufficient 
time for an immersive, thorough and rigorous analysis.  Whilst three interviews were 
conducted with participants approximately six months after their treatment had 
ended, the data generated within these encounters has not been included within this 
thesis. 
 
3.4.4 Recruitment process 
Details of sampling strategy and the rationale for the use of interviews do not address 
the practicalities of how potential participants would be located and approached.  
Recruitment to the study focused on three participant identification sites within NHS 
Lothian, which were identified to maximise the potential exposure to individuals who 
fitted the inclusion/exclusion criteria and maximum variation sampling matrix.  These 
sites were also all locations which fostered and encouraged a culture of research, and 
which I had experience of working in to a greater or lesser extent in my role as an HCV 
nurse specialist.  It was hoped that these factors would help in the negotiation of my 
access to the sites, but they also raised ethical issues which will be discussed further in 
due course. 
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The first recruitment site was an infectious diseases outpatient clinic based within a 
university hospital.  This site was one of two hospital-based clinics providing specialist 
care and treatment to HCV positive individuals in Edinburgh.  The second site was an 
inner city GP practice serving one of the most deprived areas of Scotland (Scottish 
Government, 2016).  The practice had a long tradition of engaging in research, with 
many of the medical staff maintaining special interests in areas related to social 
deprivation, such as blood-borne viruses and drug use.  The third recruitment site 
comprised a network of ‘recovery hubs’ situated around Edinburgh.  These hubs 
provided a range of drug and alcohol treatment and support services on a ‘drop-in’ 
basis, run by a collaboration of NHS, social work and voluntary sector staff. 
 
The initial approach to potential participants in all sites was via the healthcare staff 
who worked in each of these locations.  A participant information sheet was provided 
for staff to give to eligible candidates when they attended routine appointment or 
walk-in clinics (appendix D), and if interest was shown, verbal consent obtained to pass 
on their contact details to me so I could phone to discuss the study in more detail and 
arrange to meet.  It was suggested that this meeting occur when they next expected to 
be at the recruitment site, in order to avoid creating additional appointments, unless 
the potential participant wished to meet at a different time/place.  At this meeting, I 
discussed the participant information sheet and consent form, answered all questions, 
and obtained written informed consent.  Arrangements were then made to perform 
the research interview at a time/place convenient for the participant. 
 
Following the research interview, the participant was asked if they would be happy to 
speak with me again, should they commence a course of HCV treatment.  I explained 
that I would like to conduct two further interviews, one at the end of treatment, and 
one approximately six months after that.  If the participant agreed, I obtained consent 
to liaise with the HCV treatment team to monitor the participant’s progress through 
treatment, and contact them again when an end date for their period of therapy was 
known.  Arrangements would then be made to conduct the second research interview 
at a time/place convenient for the participant, but as close to the end of their HCV 
treatment course as possible.  Following the second interview, a provisional date for 
the third interview would be arranged for six months hence.  I would contact the 
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participant nearer the time to confirm details and finalise plans for the final research 
interview.  
 
3.4.4.1 Payment for participation 
All participants were offered reimbursement for any out-of-pocket expenses incurred 
as a result of taking part in the study, in line with good practice recommendations for 
members of the public involved in NHS, public health and social care research 
(INVOLVE, 2010).  Expenses payments have been shown to be a significant motivator in 
research involving PWID (Fry and Dwyer, 2001), and are associated with increased 
follow-up rates (Festinger et al, 2005) which was an important consideration given that 
the study contained a longitudinal element.  In view of the ethical issues surrounding 
the award of cash payments to potentially substance-using participants, and difficulties 
in administering a cash payment through the hospital finance system without 
disclosing their identity, a £15 supermarket gift voucher was offered for each interview 
attended.  Whilst this voucher was gratefully received by most participants, three 
individuals expressed discomfort at what they perceived as payment for their 
participation in a study they had voluntarily signed up for. 
 
3.4.5 Data management and analysis 
3.4.5.1 Transcription 
Verbatim transcriptions of the recorded interviews were made using Olympus AS-7000 
transcription software and stored in a secure area of the NHS server.  Patton (2015) 
suggests that completing your own transcription offers an opportunity to become 
immersed in the data, an experience which can help with the generation of emergent 
insights.  Indeed, Ryan and Bernard (2003) note that the process of analysis probably 
begins with the transcription of audio recordings.  For these reasons, I transcribed all 
the interviews myself.  During this process, the data was anonymised by giving each 
participant a pseudonym (which they were invited to choose), and changing any other 
potentially identifiable information such as the names of friends and family, locations, 
dates, name and titles of professionals etc.  Once anonymised, the transcripts were 
checked to ensure they were non-identifiable by a member of the supervisory team.   
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3.4.5.2 Thematic analysis 
Thematic analysis is a method for identifying and analysing patterns of meaning 
(themes) within a data set, and illustrating the importance of those identified themes 
to the phenomenon under investigation (Braun and Clarke, 2006; Fereday and Muir-
Cochrane, 2006).  It is not tied to a particular theoretical framework, and can be 
applied across a range of epistemological positions (Joffe, 2011) being a method which 
can equally illuminate realist and constructivist paradigms, both reflecting reality and 
unpicking and unravelling the surface of ‘reality’ (Braun and Clarke, 2006).  Thematic 
analysis has only relatively recently been acknowledged as a qualitative analytical 
method in its own right, having previously been regarded more as a component of 
other ‘branded’ forms of analysis such as interpretive phenomenological analysis (IPA), 
discourse analysis or grounded theory (Braun and Clarke, 2006; Bryman, 2012; Joffe, 
2011).  Whilst the identification and analysis of themes is indeed a necessary generic 
skill and unifying principle for much qualitative research, thematic analysis as a defined 
qualitative method strives to do this in a systematic and transparent way, upholding 
the importance of the pervasiveness of themes without sacrificing depth of analysis 
(Joffe, 2011). 
 
The lack of explicit recognition thematic analysis historically invited masks the disparity 
between its perception as being unsophisticated and indistinctive, and its wide, though 
frequently unacknowledged use in qualitative research.  Braun and Clarke (2006) argue 
that because thematic analysis is poorly demarcated and defined, analysis that is often 
claimed as following other methods, or more often not identified as a particular 
method at all (e.g. ‘data subjected to qualitative analysis for recurring themes’) is in 
actuality, thematic analysis.  By clearly appropriating and naming thematic analysis as 
the analytical technique employed in this research, I seek to avoid ‘method-slurring’ 
(the blurring of distinctions between various theoretical perspectives and 
methodological techniques [Baker, Wuest and Stern, 1992]), and to improve clarity, 
consistency and coherence, whilst contributing to the overall integrity and rigour of 
the study (Holloway and Todres, 2003).  As a hallmark of thematic analysis is its 
theoretical flexibility, it is necessary to discuss the appropriateness of its adoption 
within the social phenomenological framework of this research. 
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3.4.5.3 Social phenomenology and thematic analysis 
The approach to data analysis employed within any research project should be driven 
by its appropriateness to the research questions and the theoretical perspective 
underpinning the investigation, rather than by staunch ‘methodolatry’ (Holloway and 
Todres, 2003).  Joffe (2011) notes that thematic analysis lends itself well to a critical 
realist social phenomenological perspective, and examples of previous research 
employing this union are found within health and social science.  These examples 
include studies where thematic analysis has been explicitly stated as the data 
analytical tool (e.g. Carroll, Rothe and Ozegovic, 2013; Fereday and Muir-Cochrane, 
2006), and also where thematic analysis is not specifically asserted but its methods are 
described (e.g. Carvalho, Merighi and Jesus, 2010; Ferreira-Umpiérrez, 2013; 
McWilliam et al, 2009). 
 
Thematic analysis can capture the divergence and subjectivity of individual participant 
responses, in addition to describing and interpreting meanings across participants, 
however does not share the idiographic focus of a methodology such as IPA (Braun and 
Clarke, 2006).  As previously discussed, Schütz believed that inter-subjectivity was the 
foundation of all human knowledge and experience, and that the way humans 
construct their perspective and attach meaning to the outside world is not a purely 
individual process (Ajiboye, 2012).  He made a distinction between first- and second-
order constructs within social science research.  The first-order, reflecting the 
common-sense experience of the everyday inter-subjective world by the people being 
studied (McWilliam et al, 2009), and the second-order being the researchers own 
constructs and interpretations of the commonalities and meanings within those 
subjective experiences (Aspers, 2009): 
  
“The thought objects constructed by the social scientist, in order to grasp this 
social reality, have to be founded upon the thought objects constructed by the 
common-sense thinking of men [sic], living their daily life within the social 
world.  Thus, the constructs of the social sciences are, so-to-speak, constructs 
of the second degree, that is, constructs of the constructs made by the actors 
on the social scene” 
 
(Schütz, 1962 p.59) 
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By describing these orders, Schütz sought to distinguish between practical (first-order) 
and theoretical (second-order) modes of interpretation, arguing they involve 
fundamentally different ways of relating to an experience (Ostrow, 1990).  These 
second-order ‘theoretical’ constructs should always be founded on first-order 
subjective experiences, but are in effect the researcher’s inter-subjective 
interpretations of the phenomenon’s meaning.  These inter-subjective interpretations 
are Schütz’s ideal-type.  That is, the commonalities (or themes) among people’s 
subjective experiences, or the essence of a phenomenon.  With this in mind, thematic 
analysis within this theoretical framework offers a compelling fit, as it allows the 
exploration, description, construction and interpretation of these commonalities of 
experience, using an analytical approach which recognises themes across an entire 
data set rather than focusing meticulously on the individual. 
 
3.4.5.4 Identifying themes 
The identification of themes within the data set can be one of the most mysterious 
tasks in qualitative analysis (Ryan and Bernard, 2003).  Indeed, it is not uncommon for 
research reports to describe themes ‘emerging’ from the data in lieu of detailed 
description of the actual analytic procedures undertaken (Braun and Clarke, 2006).  
What constitutes a ‘theme’ is also often poorly defined, and is not helped by the 
wealth of terminology used throughout the literature to describe similar analytical 
ideas e.g. categories, patterns, codes, labels, memos, expressions, incidents, segments, 
thematic units, data-bits, chunks, concepts, units etc. (Ryan and Bernard, 2003).  
Bryman (2012) provides some broad clarity, noting that a theme is a category 
identified by the analyst through their data, relating to the research focus and building 
on the codes identified in transcripts and/or field notes.  A theme should also provide 
the researcher with the basis for a theoretical understanding of the data (Bryman, 
2012).  For clarity, the analytical process which led to the identification of the three 
over-riding themes from the main body of data (chapters four to six), and the three 
themes related to the experience of interferon-free HCV treatment (chapter seven) 
will now be detailed. 
 
The six phases of thematic analysis described by Braun and Clarke (2006) formed the 
basis of the analytical approach.  The first phase involved familiarisation with the 
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complete data set, which was achieved through the transcription of interviews and 
repeated reading of the resulting transcripts.  During this immersion in the data, a 
research diary which had been kept throughout the planning and implementation 
stage of the study was used to take initial notes, and record features of the data which 
seemed significant or interesting.  The second phase involved coding the transcripts, 
which contained both deductive and inductive elements.  A broad coding framework 
was initially devised, informed by categories found in previous qualitative research 
concerning the lived experience of HCV (see chapter two).  It was considered 
reasonable to assume that wide-ranging categories derived from previous studies 
would remain a feature of living with HCV, despite the witnessed advances in 
treatment.  For example, ‘stigma’ and ‘symptoms’ formed two of the initial deductive 
codes, which were then augmented by more detailed inductive codes formed from 
initial impressions of the corpus of data.  This approach served to assist with the early 
analysis of the data, but inductive codes were also developed as novel and unexpected 
insights were met.  The transcripts of the initial interviews with all 20 participants were 
coded in this manner. 
 
The transcripts of the second interviews with the eight participants who undertook a 
period of interferon-free treatment were handled in a similar way.  Again, a broad 
framework of deductive codes was devised based on previous qualitative research 
focused on interferon-based therapy.  It was deemed reasonable to assume that 
expansive categories such as ‘side-effects’ and ‘support’ would transcend the specifics 
of the medications involved.  Inductive codes formed from readings of the data set 
were added to this basic structure, and then further enriched as coding of the 
transcripts progressed.  Treatment related codes from the initial interviews of these 
eight participants were included within this branch of analysis to allow for the 
comparison of pre- and post-treatment narratives. 
 
In both branches of analysis, the deductive and inductive codes were then combined, 
reviewed and revised, a process which drew groups of codes together to form a 
number of sub-themes (phase three).  Whilst depicted as a linear progression, the 
interviewing, transcribing and coding process occurred in parallel, with each activity 
informing the others.  Phase four of analysis drew the sub-themes together, combining 
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them into candidate themes which were examined in relation to the corpus of data, 
field notes, and the research diary.  During this process, I met regularly with three 
academic supervisors to review, challenge and interrogate the evolving analysis.  The 
fifth and sixth phases of analysis entailed defining the candidate themes, and writing-
up the findings in a concise, coherent and logical manner.  NVivo v.10 software was 
utilised during the thematic analytical process.  All anonymised transcripts were 
uploaded within this application, which aided the organisation, coding and retrieval of 
data.   
 
The iterative approach to research continued throughout all six phases of analysis.  For 
example, coded fragments of data which had been drawn together into sub-themes 
were recurrently re-examined within their original narrative flow to ensure their 
meaning had not been decontextualised.  During the writing process, interpretations 
of candidate themes were interrogated in relation to the raw data found within the 
transcripts, grounding the analysis in the subjective life-worlds of the participants and 
ensuring the findings remained recognisable and familiar.  This iterative approach to 
research aimed to address Schütz’s postulates of subjective interpretation and 
adequacy (section 3.3.4.2), which state that constructions of human action must be 
grounded in the subjective meaning the ‘actor’ had for the action, and be recognisable 
and understood by that actor (Schütz, 1973). 
 
3.4.5.5 Trustworthiness and rigour 
The trustworthiness and rigour of this endeavour were further enhanced in a number 
of ways.  Regular meetings with the academic supervisors to this project helped to 
contest and question the analysis as it progressed, aiding the suspension of belief in 
the existence of the world as I know it.  Immersion in the full dataset by one of the 
supervisors helped to ensure the findings remained data-driven and rooted in the 
narratives, rather than becoming too removed from the participants’ voice.  Also, 
nonconforming cases were identified during the analysis and presented as part of the 
findings, providing, where available, an alternative and legitimate perspective on the 
lived experience of HCV and its treatment.  
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3.4.6 Ethical considerations 
Ethical issues relate directly to the integrity of a piece of research, and discussion of 
ethical issues forms a central focus when planning research and obtaining approvals 
from funding bodies, professional associations and recruitment sites (Bryman, 2012).  
During the planning of this study I intuitively engaged in constant reflection of the 
ethical issues involved, although the process became more formalised whilst preparing 
my submission to the NHS REC.  The ethical issues discussed here are therefore those 
which primarily relate to the relationship between the research participants and 
myself, which were the main focus of that submission. They include recruitment, 
informed consent, potential risks of harm to participants, handling sensitive topics and 
the disclosure of sensitive personal information, and my own personal safety in 
conducting fieldwork. 
 
3.4.6.1 Recruitment 
As I had previously worked as an HCV nurse specialist, there was a possibility that I 
would be known to some of the potential participants.  To avoid influencing individual 
decisions as to whether to take part, I did not approach potential participants directly, 
until they had been introduced to the study by their regular healthcare professional 
and shown interest in participating.  If a participant showed any recognition towards 
me, or asked about my background I was upfront and honest regarding my previous 
role, but made it clear that I was currently working as a researcher and was not part of 
the clinical team. 
 
3.4.6.2 Informed consent 
The principle of informed consent is enshrined in research practice, and mandates that 
prospective research participants should be given as much information as they require 
in order to make an informed decision about whether or not they wish to participate in 
the study (Bryman, 2012).  However, this presents informed consent as a one-off 
procedure, attended to during the recruitment of participants and never thereafter 
revisited (Barbour, 2014).  In reality, informed consent presented a number of ethical 
issues within this study in addition to ensuring potential participants had sufficient 
information.  For example, as previously discussed I was aware that a requirement of 
the NHS REC was that I did not approach potential participants myself to avoid any 
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intended or unintended coercive influence.  However, it is also important to 
acknowledge the latent persuasive influences other people may exert (Mason, 2002).  
For example, HCV positive individuals were initially approached by their regular 
healthcare workers which could result in individuals agreeing to participate, and giving 
‘informed’ consent, out of a wish to please their care providers and not appear 
‘difficult’.  Or conversely, the healthcare worker could exert inadvertent and subliminal 
pressure on the individual to agree to participate out of friendship or loyalty to me, or 
a wish for my study to succeed. 
 
The discussion of giving potential participants sufficient information to make an 
informed decision is also interesting, as it is extremely difficult to present prospective 
participants with absolutely all the information that might be required (Bryman, 2012).  
For example, one of the main research questions within this study focuses on whether 
HCV positive individuals view their infection as a chronic condition.  This information 
was not disclosed to the potential participants due to concerns about contaminating 
their answers.  This meant that although the goal of understanding what it is like to 
live with HCV was clearly stated, the reasons why I wanted to know this were 
consciously omitted.  As a result, participants agreed to be interviewed about living 
with HCV, but ultimately were not aware of what questions or aspects of their lives I 
would be focussing on.  Mason (2002) highlights this when she advises that giving 
informed consent to be interviewed, is not consenting to answer anything the 
interviewer may ask.  For this reason, informed consent was revisited throughout the 
interview: checking participants were OK to carry on during difficult topics; offering to 
move to other subjects; or suggesting the interviewee take a break. 
 
The issue of capacity to give informed consent was also an important consideration 
within this study given participants may present with comorbid substance use.  The 
condition of being dependent on a drug does not in itself preclude capacity to give 
informed consent, but it may impair that capacity by affecting an individual’s ability to 
weigh up information, make free and informed decisions and exercise autonomy e.g. if 
they were in an extreme state of intoxication (Smith, 2008).  Capacity is also not 
absolute, and could fluctuate between the point of obtaining consent and conducting 
the interview, or possibly within the timeframe of an interview itself.  For these 
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reasons the decision about whether an individual had the capacity to give informed 
consent was taken on a case-by-case basis, and constantly monitored throughout the 
subsequent interview.  If an individual was deemed too intoxicated to make an 
informed decision, which occurred on one occasion, the interview was rearranged for 
another time.   
 
3.4.6.3 Risks of harm to participants 
Harm comes in many guises, and good ethical practice encourages researchers to 
anticipate and guard against any harmful consequences which can be predicted 
(Bryman, 2012).  The main risk of harm identified for participants in this study was 
potential for emotional distress during the interview process due to the sensitive 
nature of some of the topic areas being discussed.  Patton (2015) notes that qualitative 
methods are highly personal and highly inter-personal, and because in-depth 
interviews are designed to open up and probe participants’ experiences of a 
phenomenon they may be more intrusive and involve greater reactivity than 
quantitative methods.  It was therefore necessary to incorporate the potential for this 
into my interview style, approaching sensitive topics carefully and thoughtfully, pre-
emptively reassuring the participant that they would receive an empathetic and 
considerate response should they become upset and wish to stop.  It was also 
important not to simply ‘take the data and run’ (Barbour, 2014), and an emphasis on 
how the interview was drawn to a close and the importance of debriefing were vital.  
Thompkins, Sheard and Neale (2008) discuss the benefits of ending interviews with 
female PWID by focusing on more positive topics, concentrating on plans and hopes 
for the future.  This strategy was employed within this study, in addition to utilising a 
debrief sheet containing contact details for a number of local support groups and 
charities.  However, only one participant took the debrief sheet away after the 
interview, although it was offered to all participants. 
 
Within the interviews, it was also likely that criminal activity in relation to drug taking 
would be disclosed, in line with the level of disclosure found in routine clinical practice.  
It was considered unlikely that a participant would disclose anything more serious, but 
in order to mitigate risk to my own legal position and the need to break confidentiality, 
I advised interviewees not to disclose information regarding serious offending for 
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which they had not been convicted (Orb, Eisenhauer and Wynaden, 2000).  They were 
also advised that I may need to speak to others should they discuss anything which 
indicated harm to themselves or others in line with NHS Lothian child and adult 
protection procedures. 
 
3.4.6.4. Confidentiality 
The issue of maintaining a participant’s confidentiality stems from the same ethical 
principle as minimising the risk of harm (Bryman, 2012).  Confidentiality and anonymity 
are often used as analogous terms within qualitative research, and within this study all 
participants were assigned a pseudonym and patient identifier number during the 
process of taking informed consent.  Further, during the process of transcription, any 
other identifiable information such as the names of family and friends, specific 
locations, number and gender of children etc. were also changed.  Barbour (2014) 
notes, however, that names are only one among many details which can lead to 
individuals being identified, and it can be difficult to anticipate which aspects of the 
descriptions might give rise to an individual being recognised.  This line of thought was 
pursued by the NHS Caldicott Guardian during the study’s approval process, which had 
implications for data storage, data management and subsequent analysis.  To ensure 
the anonymised transcripts were sufficiently non-identifiable, they were initially sent 
via secure nhs.net email to Dr Anne Whittaker, a supervisor of this study who also has 
an NHS contract of employment.  Only once they had been assessed in this manner 
(and necessary alterations made where appropriate), were the transcripts moved from 
the secure NHS server and analysed through NVivo software available at Edinburgh 
Napier University. 
 
Whilst protecting the privacy of research participants is a dominant ethical principle, 
there are reports of participants who wish to be identified and recognised for the 
contributions they have made (e.g. Patton, 2015; Silverman, 2013).  A number of 
participants in this study also voiced their desire to be visible within the final report.  
This highlights an interesting debate; in our rightful quest for ethical practice, are we 
removing the right of participants to make free and informed decisions about how 
their data is used? 
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3.4.6.5 Researcher safety 
The safety of researchers during data collection is an important ethical consideration, 
but one which is often overlooked (Barbour, 2014).  As I would be working alone and 
conducting interviews in various locations, including participants’ homes, safeguards 
were put in place to address this.  Where interviews took place in one of the 
recruitment sites, I notified reception staff when entering the interview room and 
advised how long the interview was expected to last.  I also employed personal 
security devices in places where these were routinely used by staff.  In locations where 
reception staff were unavailable, the NHS Lothian lone working policy was adhered to. 
 
3.4.7 Summary 
This chapter has aimed to provide a comprehensive overview of the methodology 
which underpins this study, and the practical methods employed in the generation and 
analysis of data.  It has illustrated how the theoretical perspective of social 
phenomenology has guided applied research practice, and addressed the ethical 
considerations which such applied research methods demand.  The following four 
chapters present the outcome of this process: the study’s findings.  Chapters four to six 
each focus on one of the three major themes which resulted from the analysis of the 
data, describing the contemporary lived experience of HCV.  Chapter seven sits apart 
from the main body of results, and examines the three additional themes which 
collectively explore the lived experience of interferon-free treatment.  The final 
chapter, chapter eight, considers these themes together, and discusses them in light of 
the research questions.  Implications for policy, service delivery and clinical practice 
are then examined, along with the limitations of this piece of work. 
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Chapter 4 
Positioning hepatitis C 
 
4.1 Introduction 
Analysis of the data generated during the participant interviews resulted in three 
predominant themes which capture the central common features of the participants’ 
subjective experiences, exemplifying Schütz’s ‘ideal type’.  The explication of these 
principal themes over the next three chapters aims to describe and interpret the inter-
subjective understandings in light of existing knowledge and associated theories, 
whilst also illustrating how the social reality portrayed remains grounded in the 
subjective point of view of the participants (Schütz, 1973).  The themes have been 
named ‘positioning hepatitis C’, ‘beyond a physical burden’, and ‘reconstructing 
uncertainty’.  The titles of these overarching themes seek both to capture the internal 
homogeneity of the data collected therein, and to highlight the external heterogeneity 
between them (Patton, 2015), whilst giving a practical sense of the analytical thrust 
each theme contains (Braun and Clarke, 2006). 
 
The theme ‘positioning hepatitis C’ proved resilient and robust during data analysis.  It 
illustrates how the experience of being HCV positive was not understood in isolation by 
the participants, but positioned within wider sociocultural, medical and politico-
economic contexts.  It describes how the lived experience of HCV was negotiated and 
renegotiated over time in relation to multiple factors, rather than being an invariant 
and static reality.  Comparisons and assessments were commonplace within the 
participants’ narratives, contrasting and evaluating their own experience of being HCV 
positive in light of the circumstances of their daily lives, others they knew, and broader 
external influences.  ‘Positioning hepatitis C’ aims to emphasise the contingent nature 
of the lived experience, by exploring how understandings of the disease were 
comparative and positional. 
 
The descriptions of diagnoses which begin this chapter establish this theme well.  
Participants’ situated the disease within the sociocultural context of their lives at the 
time, which resonates with earlier work in this area.  However, the theme goes further 
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and expands on these familiar reactions, to illustrate how understandings of the 
disease itself became fractured as contextual comparisons were drawn to other people 
living with HCV, the condition of their liver, and the inequalities of access to treatment.  
This chapter aims to illuminate how the lived experience of hepatitis C was dynamic 
and relative, describing how participants positioned the disease in relation to multiple 
internal and external factors.  
 
4.2 Diagnosis 
4.2.1 Starting points 
I started each of the pre-treatment interviews by asking the participants to tell me 
about their diagnosis23.  This was a conscious decision, designed to allow the 
participant to ease into conversation by speaking about a verifiable situation, prior to 
being asked more conceptual questions related to their thoughts, feelings and 
understandings (Kvale, 2007).  However, it also immediately designated and labelled 
the participants as members of a particular category - that of someone with HCV - and 
subsequent descriptions of their experiences of diagnoses were therefore imbued with 
specific qualities (Potter, 1996).  For example, whether it was good or bad, significant 
or trivial, unpredicted or expected, distanced or aligned them with notions of what 
being part of that category signified within society.  Subjective meaning was 
embedded into objective description during these conversations, conveying a sense of 
self, or more accurately a cluster of traits which suggested a particular persona (Harré 
and van Langenhove, 1999a).  This served to make ensuing discussion of their version 
of reality seem more credible and dependable (Potter, 1996).  These diagnostic stories 
were generated within the context of a qualitative research interview, and should be 
treated as selective and potentially strategic (Barbour, 2014).  That is not to say they 
are apocryphal, merely that the participants were producing an account of their 
diagnosis and offering a narrative and persona that was purposeful and deliberate to 
the circumstances they were in. 
 
These purposeful narratives of diagnosis offer a pathway into the data, and provide a 
natural starting point for the examination of participants’ experiences of HCV.  
                                                          
23 “I’d like to start by talking about when you were diagnosed.  Can you tell me what happened?” 
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Diagnosis is integral to the system of medicine and the way it creates social order 
(Jutel, 2009), and for social scientists the process of making that diagnosis is central to 
subsequent constructions of the illness (Brown, 1995).  Diagnosis embodies the time 
and place when permission is given to be ‘ill’, when medical professionals confer 
legitimacy on a condition and begin to offer an explanatory framework.  As Jutel and 
Nettleton (2011) note, diagnosis is a starting point; the foundation from which sense-
making and experience are crafted. 
 
The starting points for the participants in this study were many and varied.  Diagnoses 
were received following routine GP appointments, antenatal checks and following 
blood donation.  A number of participants were diagnosed whilst hospitalised with 
other conditions, primarily drug related, or tested and notified whilst in the process of 
accessing opioid substitution therapies.  Not all diagnoses were made in traditional 
healthcare settings however.  Prison, a health food shop, and a private detoxification 
clinic also featured in the collected narratives, which covered a period of 24 years from 
1991 to 2015.  For two participants, the diagnosis of HCV was received on more than 
one occasion due to reinfection, one following successful treatment and the other 
after spontaneous clearance of the virus.  The following analysis seeks to describe and 
interpret the participants’ accounts of their diagnosis experience, positioning it within 
their lives at the time and providing a foundation for subsequent discussion of how 
these understandings of HCV were modified and revised as participants lived with the 
virus and came to understand it from a new standpoint. 
 
4.2.2 A contextual diagnosis: drug use 
The participants described a reaction to their medical diagnosis of HCV which 
positioned it within the sociocultural context of their lives at the time, and echoed the 
findings of earlier work in this area (e.g. Olsen et al, 2012).  For those who had no 
history of drug use, or who had moved on from a drug using past, feelings of shock, 
anger, denial and depression were widespread, with fears and concerns for an 
indefinite future and disbelief that this could happen to them writ large within their 
narratives.  The impact of the diagnosis was often explicitly stated and emphasised 
with the use of metaphor and idiom: 
 
99 
 
…it was more, more it jus’ hit me like a tonne a’ bricks when he jus’ walked in 
an’ said it an’ walked out, y’know.  I didn’t get an explanation or anything… 
 
(Jacqueline, 70, diagnosed 1991) 
 
 
So I’d made appointments, made a lot of, few appointments wi’ my own 
doctor, taken blood samples, an’ then got a letter through the door that said 
she would like to speak to me, an’ then she jus’ dropped a bombshell on me.  
An’ that’s when I found out…  
(Stewart, 52, diagnosed 2015) 
 
For those participants who situated their medical diagnosis of HCV within a period of 
drug use, a less traumatic reaction to the news was portrayed.  Although participants 
recounted feeling foolish, upset and angry, these feelings were played down within the 
narratives as participants sought to produce a socially acceptable account of their 
response at the time.  The participants portrayed their anguish at being diagnosed with 
HCV as mitigated by a view that their own behaviour was primarily to blame for the 
infection, and a perception that they had put themselves at risk.  The distress felt at 
the diagnosis was depicted as tempered by their sociocultural environment at the 
time, and a life revolving around a frenzied addiction.  Descriptions of life around the 
time of diagnosis vividly related accounts of unsafe injecting practice, overdose and 
“constantly chasing your next fix”24.  Ultimately, the medical diagnosis of HCV was 
portrayed as foreseeable and almost predetermined, demonstrated by the lack of 
surprise that suffused these narratives: 
 
I: So when you found out, how did you feel? 
 
K: [pause] Gutted.  But, it was, it wasn’ae a big shock, because I knew I had 
been really un-careful an’, ‘cause I was in the madness an’ stuff I jus’ 
wasn’ae really caring about mysel’ an’ was jus’ sharing wi’ loads a’ 
people eh an’ [draws in breath], so, no, I was gutted but it wasn’ae a big 
surprise. 
(Kelly, 34, diagnosed 2008) 
 
…but aye, it was, it was pretty devastating, but the same time I sort a’ had 
that attitude well ken what, you knew what you were doing at the time, you 
knew the risks you were taking, things we do a’ get stoned eh? 
 
(Eilidh, 39, diagnosed 2013) 
                                                          
24 Paul, 37, diagnosed 2000 
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For these individuals, a process of social diagnosis had begun prior to being medically 
labelled as HCV positive.  A social diagnosis considers not the presence or absence of a 
particular virus or bacterium, but the larger political, economic, cultural and social 
structures which contribute to making that diagnosis (Brown, Lyson and Jenkins, 2011).  
By identifying as a person who injects drugs, the narratives generated here reveal a 
socially-produced diagnosis of ‘pre-HCV’, which explicitly considers the potentiality of 
this future condition.  The presence of such a social diagnosis constrained the way 
these individuals were able to talk about their reaction to the subsequent medical 
categorisation, producing accounts which positioned a diagnosis of HCV as inexorable 
and normalised.  These accounts reduced the primacy and authority of HCV, and 
reinforced prevailing societal attitudes to drug use and PWID.  The way in which HCV 
was characterised as a disease of addiction was reflected in the discourse that PWID 
themselves used to position HCV within the context of their own lives: 
 
I didn’t really take a lot of notice of it, to be honest.  Err, if I’m honest about it, 
looking back on it now, in hindsight (…). To me, it was jus’ another, oh, you’ve 
got this, or you’ve got that, or whatever, y’know, who cares like? 
 
(Phil, 60, diagnosed 1997) 
 
This insight resonates with the work of Davis and Rhodes (2004), whose interviews 
with PWID in London depicted HCV as a ubiquitous risk, and an almost inevitable 
consequence of a drug using lifestyle.  Drug use and HCV become conflated into one 
expected life trajectory, where the eventual medical diagnosis of HCV was portrayed as 
a predictable and preordained destiny. 
 
4.2.3 A contextual diagnosis: co-morbidities 
Whilst those diagnosed within a period of drug use still reported dismay at the news, 
albeit moderated by the context of their lives at the time, a comorbid HIV infection 
appeared to almost negate such emotional reactions entirely.  For these individuals, a 
diagnosis of a further blood borne virus was portrayed as holding little significance 
when placed within their experience of living with HIV.  The participants produced 
accounts which emphasised a keen sense of apathy and disinterest: 
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I was actually, no’ numb or anything, jus’ indifferent, because of my HIV 
status, I jus’ thought oh that’s another disease I’ve got, an’ even when I got 
told it was genotype one which is the best-yun [laughs ironically], sorry – err, I 
mean I dunnae go for things by half eh? But err aye, I jus’ thought it’s another, 
disease; ’cause, I always assumed that HIV was gonna kill me anyway. 
 
(Keith, 54, diagnosed 2004) 
 
 
I: Did anything change for you when you were diagnosed hep C? 
 
C: No, I just, I just took it, I was hepatitis B, and then “oh, alright”, an’ then, 
I dun’ ken what year I was hep C, an’ it wasn’t a big deal to me, y’know 
what I mean?  
 
(Callum, 52, diagnosed approx. 1995) 
 
 
I actually erm, I sometimes forget that I’ve got hep C, it’s just away back there 
somewhere [indicates back of her head] and err, I think “Oh yeah, I’ve got that 
as well” 
 
(Sheila, 59, diagnosed 1991) 
 
 
Accounts of a diagnosis of HCV being over-shadowed by an existing HIV infection also 
echoed previous studies, where HCV was often framed as less significant in terms of its 
gravity when considered alongside the more knowable and definite HIV (Copeland, 
2004; Davis and Rhodes, 2004).  This was not the only disease comparator utilised by 
the participants, however, with other chronic conditions such as diabetes and various 
cancers also recurrently providing context.  Cancer was consistently framed as a more 
serious and onerous diagnosis, and stories of personal experiences with cancer, or of 
others known to the participants were used to illustrate the perception that, despite 
everything, things could be much worse: 
 
…she walk through the door, when I saw her, I went like ‘Oh. My. Gosh’.  She 
has cervical cancer, and it went downhill in a way that [pauses] you can 
imagine.  And she just burst into tears, and say ‘Oh Peter, look what’s 
happened to me’ and I thought, what’s the point for me to tell her I have 
hepatitis C, it’s nothing comparing what she’s going through.  
 
(Peter, 51, diagnosed 2015) 
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4.2.4 The influence of treatment 
Whilst the sociocultural context of individuals’ lives at the time of diagnosis shaped 
their reaction, the timing of that diagnosis within the context of HCV treatment 
evolution and advancement appeared to have little influence.  Roughly equal numbers 
of participants were diagnosed before and after the start of the DAA era in 2011, yet 
narratives around response to diagnosis did not reflect any recognition of these 
biomedical developments.  Participants diagnosed after the advent of DAAs continued 
to report significant emotional distress.  Indeed, some of the most vivid and striking 
accounts of intense reactions to diagnosis came from participants who received the 
news most recently: 
 
I remember going to the, the nurse, and err, my mum was with me, an’ I 
remember they read out, y’know the hep B, hep A blah blah blah, AIDS an’ all 
that, an’ [pauses] it, we were sitting there, an’ they said hep C – positive 
[pauses] an’ [pauses] I was, I jus’ [blows out air] God, blanked out, I, I, I went 
into shock, ‘cause all I remember hearing was, my mum going “oh my God” 
and they ended up having to go an’ get the doctor because I had went into 
shock... 
(Anita, 46, diagnosed 2014) 
 
Of note, Anita professed to have very limited understanding of HCV at the time of her 
diagnosis, and her explanation for her intense reaction centred on a half-remembered 
story she had read concerning a celebrity with HCV taking interferon.  While the 
influence of interferon on the understanding of HCV will be examined in greater detail 
within chapters six and seven, a discourse which comprised intense distress, disbelief 
and depression remained critical to the participants’ experiences of HCV diagnosis in 
the era of DAAs.  Accounts of diagnosis post-2011 were indistinguishable from those 
who had been diagnosed further in the past, strongly resembling the stories of HCV 
diagnosis made during the height of the interferon era.  Similar findings have been 
reported previously in relation to other conditions which resonate here.  Flowers, 
Davis, Larkin, Church and Marriott (2011) focused on accounts of HIV diagnosis made 
to gay men in Scotland after the introduction of Highly Active Antiretroviral Therapy 
(HAART).  They described reactions to HIV diagnosis that resembled those documented 
in the stages of the epidemic which preceded the advent of HAART, and cautioned that 
despite the ‘brilliance’ of effective HIV treatment, the psychological and social 
concerns about HIV endured, or were reshaped in light of the contemporary situation.  
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Similarly, in their review of the impact of HAART on the psychological distress of 
people living with HIV, Siegel and Lekas (2002) found no clear evidence to suggest that 
the availability of these drugs had lessened the impact on individuals’ emotional 
response to infection. 
 
4.2.5 Re-evaluation of life: alcohol 
Following an HCV diagnosis, a re-evaluation of life and an attempt to regain control 
have previously been well described in the literature (e.g. Faye and Irurita, 2003).  
Illustrations of this reconsideration of priorities were manifest within this study too.  
For example, a diagnosis of HCV provided impetus to change the relationship with 
alcohol cultivated by a large number of the participants, bringing established drinking 
patterns and habits into question.  Many of the participants described themselves as 
heavy drinkers or alcoholics in the past.  However, the implications for their health of 
an excessive alcohol intake appeared to be unfamiliar, or disregarded, until an HCV 
diagnosis was made.  This is well illustrated in the following quote.  Happy recounts 
her thoughts on her pre-diagnosis lifestyle, juxtaposing an idea of ‘health’ alongside an 
acknowledgement of drinking to excess: 
 
…all along, I’ve, I’ve been thinking that I was healthy, I haven’t been paying 
much attention, and I was also drinking a lot. 
 
(Happy, 51, non-cirrhotic) 
 
 
An HCV diagnosis provided a point of re-evaluation for the participants, placing their 
drinking under scrutiny in the context of a perceived greater threat.  For many, 
stopping drinking was seen as a protective action, aiding the recuperation of what was 
frequently assumed to be an already damaged liver, presented within the narratives as 
adhering to healthcare messages and ‘doing the right thing’ (Harris, 2010).  However, 
eliminating alcohol was also framed as a pre-emptive assault on HCV itself, preparing 
and galvanising the body for a period of treatment: 
 
I’m not jumping on the temperance bandwagon or anything like that, erm, but 
I would say that, cutting out alcohol ages prior to treatment is a good thing, I 
can’t imagine if you were, y’know, erm, an alcoholic with an already y’know, 
erm, overloaded liver, erm, an’ then you was gonna go through the treatment 
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[blows out cheeks] I mean it’s like sort of making life as incredibly difficult for 
yourself… 
 
(John, 54, non-cirrhotic) 
 
 
Complete abstinence was not a uniform reaction, with some participants describing a 
more measured and nuanced approach to addressing their alcohol consumption, 
echoing previous work in the area (Stoller et al, 2006).  The moderation of frequency, 
volume and type of alcohol were offered within the narratives as evidence of moral 
agency, but with the caveat that they permitted a variant of normal life to continue: 
 
I’m, to this day, I’m no’ totally alcohol free, I have been since the first of 
January, for a dry January for me, but, I’m, I’d still say that, goin’ oot, or 
having someone round, I’ll still will have a couple a’ beers but I’ll no’ be 
drinking a case a’ beer a night, or drinking like your vodka, or anything like 
that.  
(Stewart, 52, cirrhotic) 
 
 
Whilst these findings align with some previous studies suggesting an HCV diagnosis is 
associated with reduced alcohol consumption (e.g. McCusker, 2001), the published 
literature remains divided on the topic, with the complex interplay between HCV and 
alcohol consumption explored more fully by a small body of qualitative research 
focused on the issue.  For example, in work conducted with HCV positive individuals in 
Australia and New Zealand, Harris (2010) described how the ubiquity and 
normalisation of alcohol use in Western culture, equivocal medical advice espoused by 
various health professionals, and a misplaced faith in ALT results presented social and 
psychological barriers to the renegotiation of alcohol use for individuals with HCV.  
Alcohol consumption was not a specific topic within the interview guide for this study, 
and the insights presented here are drawn solely from spontaneous discussion 
precipitated by the participants, possibly contributing to their uniform discourse of 
alcohol reduction.  It is also possible that the homogeneity of the healthcare team 
providing care for the participants had instilled a consistent message regarding alcohol 
use, which was reproduced in the interview setting to present a persona of compliance 
to the researcher. 
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4.2.6 Re-evaluation of life: drugs 
Transformation narratives were evident within many of the interviews, as participants 
described making dietary changes and actively seeking out HCV information.  The 
diagnosis of HCV spurred a general desire to live a healthier, socially conventional and 
more routine lifestyle, positioning the disease as a turning point and the start of a 
fresh chapter in their lives.  For a couple of participants who were using drugs at the 
time, the diagnosis also provided the impetus to engage with drug services and start to 
address wider concerns: 
 
…an’ then it was like, now I’ve got a’ start taking care a’ myself, I’ve got a’ 
start eating better, I’ve got a’ start trying a’ maintain some sort a’ routine in 
my life to hold my job down… 
(Fiona, 40, diagnosed 2012) 
 
I started thinking right, obviously certain things in my life were gonna have to 
change, it, it focused me as well and it pushed me to just get rid of the heroin 
and get that out the way an’, an’ an’ jus’ move on with getting onto the 
Subutex. 
        (Gary, 38, diagnosed 2013) 
 
 
It wasn’t all such optimistic news, however, as a re-evaluation of life did not always 
equate with an attempt to regain control.  A more common reaction to being 
diagnosed with HCV amongst those who were using drugs at the time was a descent 
into ever greater drug use associated with feelings of hopelessness, and that there was 
now nothing to lose: 
 
but, I think that sort a’ made my drug habit out a’ control when I found out I 
had hep C very out a’ control, I jus’ felt that, now I had that, I didn’t have 
anything else to live for after that, erm, so, all I done was took more an’ more 
drugs, constantly, for all they years… 
(Danielle, 43, diagnosed 2009) 
 
 
S: …when you think you’ve got a fatal illness ‘cause of what you’re doing in 
your life (…) it’s always in the back of your mind like, y’know, an’ you jus’ 
get that don’t care attitude - don’t care, don’t care, don’t care, don’t 
care - so you use more, do more - don’t care, don’t care - go to prison - 
don’t care - stick me in a psychiatric ward - don’t care - y’know, jus’ don’t 
care.  Y’know, err… 
 
I: Because you think… 
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S: Yeah, because you think you’re dying. 
(Steve, 45, diagnosed 2005) 
 
 
Whilst similar findings have been reported in the past, there is still merit in providing 
brief discussion of these familiar themes from the literature here, as these diagnostic 
narratives align the participants in this study with the wider body of research in this 
area.  Strong parallels between previous work and the testimonies generated here 
confer dependability and trustworthiness on this endeavour, and provide a solid 
foundation for subsequent discussion of new emergent themes within these 
contemporary accounts. 
 
4.3 An illness continuum 
Discussion of diagnosis provides a useful basis for gaining insight into how participants 
positioned and contextualised the disease within their testimonies.  Whilst initial 
reactions to an HCV diagnosis hold up a mirror to society’s inter-subjective 
understanding of HCV and how it has been constructed, the continuing forms in which 
people go on to experience that disease contributed to a changing perception (Brown, 
1995).  Reactions to an HCV diagnosis were modified, tempered and revised as 
individuals experienced the illness, and came to understand it from a new perspective.  
It is these modified understandings that will now be examined.  Embedded within 
these narratives, an enduring sense emerged of participants constructing HCV as an 
illness of degrees.  The singularity of the diagnostic HCV label disguised a range of 
illness trajectories and outcomes which gradually revealed themselves during post-
diagnosis engagement with a variety of health professionals, support agencies and 
other individuals with HCV.  Participants re-evaluated, reformed and repositioned their 
understanding of HCV, in light of the experience and health of others, and more 
significantly in light of the health and condition of their liver.  The perception of 
degrees of HCV was further enforced by the inequality of access to new HCV 
treatments, as the following analysis will demonstrate. 
 
4.3.1 Feeling fortunate 
Participants often framed their own experience of living with HCV in terms of how they 
were faring in relation to others.  Their narratives measured and positioned their own 
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health and the impact of the disease against others who were HCV positive, whether 
personally known to them or not.  The majority of participants recounted their own 
perceptions of how HCV was having less impact on their life than it was for other 
individuals.  However, tangible examples of this dynamic were few and far between.  A 
broad perception pervaded instead that ‘others have it worse’.  Participants described 
feeling generally fortunate and lucky in comparison to other people: 
 
M: Hmmm, I think, compared to a lot of people with hep C, I have been 
really, really lucky.  You know what I mean? 
 
I: Why? 
 
M: It’s not really had that much of an impact on my life day-to-day, you 
know what I mean? Compared to people with this an’ that, an’, I can see, 
no it hasn’t.  I’m very, very lucky. 
(Marilyn, 52, non-cirrhotic) 
 
 
…I think I’ve been a little bit lightweight here because, you know, there’s a lot 
of people out there that are, really in much worse chance with hep C than I 
have, so I’m, you know, considering myself to be quite fortunate… 
          
(John, 54, non-cirrhotic) 
 
A major contributing factor to this perception was often the relative health of their 
liver compared to others, information which was obtained post-diagnosis from scans 
and blood tests following engagement with HCV treatment services25.  News of their 
liver’s comparative health began to contextualise the diagnosis and fracture their 
understanding of HCV as a single disease.  HCV could be both a malignant killer and a 
benign inconvenience: 
 
…and I have [the ultrasound scan] done today, and according to the person 
who did it, I say please I need to know something, I cannot wait another week, 
she say everything seems to be normal, no damage at all, which I feel like I 
won the lottery and [pauses] I know it’s not, I know many people die of 
hepatitis C in the past; and it’s not that easy to cure, or some people have 
more complication than other, but to be honest with you, I feel relief knowing 
that there is no damage in the liver. 
 
(Peter, 51, non-cirrhotic) 
                                                          
25 It is worth noting that for Eilidh, the only participant who had not engaged with HCV treatment 
services on any level, this discourse was absent. 
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Examples of feeling fortunate were even present amongst the narratives of those with 
more advanced liver disease, although these tended to be framed not in relation to 
other people, but in relation to their own mortality.  Despite being cirrhotic, a 
diagnosis of HCV had given Steve the impetus to make changes to his lifestyle, and his 
understanding of HCV therefore included elements which were protective and 
beneficial: 
 
…over three years now I’ve been sober, d’y’know, err, an’ my liver’s knackered 
[laughs] an’ it kind a’ makes you feel wow – that’s, what would I ‘ave been like 
if I was [pauses] - I’d be dead.  I would’ve been dead [laughs], d’you know 
what I mean? Wow.  Y’know, it’s like wow, there’s no way I’d have survived 
that, nah, err, so you’re thinking well I’m very very lucky… 
 
(Steve, 45, cirrhotic) 
 
By framing their experience in terms of feeling fortunate, the participants were 
attempting to regain control of their situation, and positively positioning their own 
health in relation to a worst case scenario.  This can be viewed as a discursive strategy, 
used to construct an identity which emphasises survivorship, supports coping with 
situational change and locates the individual as strong in relation to weaker others 
(Harré and Langenhove, 1999b).  It also resonates with social comparison theory, 
which suggests human beings have a drive to compare themselves with similar others, 
especially in times of uncertainty and stress (Gibbons and Buunk, 1999).  Previous work 
drawing on social comparison theory in other conditions, such as ovarian cancer and 
motor neurone disease, has demonstrated patients most frequently compare 
themselves to individuals they perceive to be worse-off, allowing them to view their 
own situation in a better light, and enhancing their sense of self (e.g. Locock and 
Brown, 2010; Morrell et al, 2012).  Such downwards comparisons can increase self-
esteem, manage mood, and function as an emotional coping strategy (Carrick Taylor et 
al, 2007).  However, there may also be undesirable affects. The following quote 
demonstrates how Fiona’s engagement in social comparison acted as a personal 
barrier to accessing services and care: 
 
…an’ there’s far more needy patients in front a’ me, y’know, my liver’s healthy 
an’, things like that Dave, but that’s always my out, y’know, it’s like, oh well 
you’ve only got one room up in [the respite facility], well give it to that person, 
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‘cause they need it more than me, y’know, I’ve got a house, I can go home an’, 
it’s always that - it’s, no Fiona, you need it jus’ as much as, y’know, but I’m 
always like, no, no, gi’ it to them, y’know, they need it more than me… 
 
(Fiona, 40, non-cirrhotic) 
 
 
By socially comparing their situation to others, the participants fractured HCV into 
degrees.  There were those who ‘had it worse’ or who were ‘more in need’.  Hepatitis 
C became a continuum of illness rather than a uniform disease.  This understanding 
was further enforced as participants confronted the inequality of access to new HCV 
treatments, and came to understand that their position on the illness continuum had 
direct consequences for their entitlement to new medications. 
 
4.3.2 The disparity of access 
As the degree of liver disease has emerged as the central tenet of distributive justice 
for accessing DAAs in international, national and local guidelines (Pawlotsky et al, 
2015b; Scottish Government, 2015a), the importance placed on liver health by the 
participants reflected both a concern for their immediate and future health, but also 
for their own trajectory of care.  Whilst news of a healthier liver conferred a positive 
prognosis, it could also mean denial to the most effective treatment and could 
therefore be recognised as a double-edged sword. 
 
For a number of participants, the disparity of access to new HCV drugs created a 
perception that these medications were for the prioritised few, whose need was 
greater than theirs.  Consequently, participants with mild to moderate liver disease 
described themselves as almost not requiring treatment at this time, and/or that they 
were ‘too healthy’ to gain benefit from the new medications.  Treatment therefore 
remained a task for the future: 
 
I’ve been had a…the scan done an’ stuff, an’ they’re saying that everything 
looks alright, I’ve not got erm, what d’you call it?  Thing wi’ the liver?  Cirrhosis 
o’ the liver or anything, erm, so now they deal wi’ that first before, y’know 
they deal wi’ people that are doing alright… 
 
(Kelly, 34, non-cirrhotic) 
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I: How do you feel knowing that there are treatments out there, but you’re 
not eligible for them? 
 
S: That’s fine.  Err, no problem wi’ that.  People who need it should get it, 
and we can just wait, y’know, until our time comes, err, we have to have 
it, but no, the people who really need it should have it, that’s it. 
 
(Sheila, 59, non-cirrhotic) 
 
I: And, this new treatment…is it available? 
 
K: No [laughs].  I thought it was, but it’s not, ‘cause the money.  My liver’s 
not destroyed enough, err, not sick enough to get treatment now… 
 
(Keith, 54, non-cirrhotic) 
 
 
For some, the awareness that they were unable to gain access to new HCV therapies 
was embraced as a positive endorsement of the health of their liver.  New treatments 
were associated with a greater degree of liver damage, and therefore not being 
prioritised to receive interferon-free regimens further affirmed and corroborated the 
reassuring results previously received from blood tests and scans: 
 
…after doing the test on the [mimes fibroscan®], seeing how the liver is being 
damaged, I felt a bit like err, relieved in the sense that err, even though I’ve 
had hepatitis for a long time, and err, with all the alcohol I’ve been drinking, 
the damage was not that bad that I should be put on the priority of the people 
who are more severe.  So, kind of, it was a bit comforting for me. 
 
(Happy, 51, non-cirrhotic) 
 
 
[the HCV nurse] said the only way that you will qualify for this one, (is) with 
advanced cirrhosis, and I say oh I rather not qualify.  So that, that made me 
feel better that, if I see it from that point of view, that to qualify for I have to 
be in a kind of bad stage, so I rather don’t go through that because that mean 
I will have, I have damage. 
 
(Peter, 51, non-cirrhotic) 
 
The denial of new treatments to a few patients resulted in a very different attitude.  
Within a narrative that discussed a lengthy and hard-fought recovery from drug and 
alcohol use, combined with a long history of intermittent engagement with HCV 
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services, Paul recounted his thoughts at being informed he did not meet the eligibility 
criteria for the treatment he had been working towards for many years: 
 
…an’ then (to)day I’ve sort a’ been told that I dunnae fit the criteria, if [pauses] 
because my liver’s quite healthy which is, a bit of a’ shock but hey, wait a 
minute, you want me a’ go to start using?  Or you want me to, y’know, make 
mysel’ worse so I could, get an easier (treatment)? 
 
(Paul, 37, non-cirrhotic) 
 
Despite sporadic narratives such as this, an acceptance and understanding prevailed 
that those with a greater degree of liver damage and further along the HCV illness 
continuum should be treated first, and that this prioritisation was necessitated by 
financial constraints within the NHS and the costs of the drugs.  The acceptance of 
health inequalities demonstrated within these narratives is symptomatic of the 
tolerance of rights violations and lack of entitlement, control and power that 
disenfranchised HCV communities have grown accustomed to over the years (Wolfe et 
al, 2015).  It resonates with the work of Rhodes et al (2013) who, in their exploration 
of patient citizenship, described few of their participants positioning HCV therapy as an 
automatic entitlement.  They described how eligibility negotiations served to further 
distance their participants from treatment, reinforcing perceptions that they were 
undeserving of care.  
 
The rationalisation and adoption of arguments for the prioritisation of HCV treatment 
was present in the discourse of participants who would not benefit from such 
treatment rationing.  Whilst a weak entitlement to therapeutic citizenship, or the  
recruitment of a particularly altruistic group of patients may be the reason, the illusory 
truth effect, which describes the increased tendency to believe information to be 
correct upon repeated exposure, may also play a role (Fazio, Brashier, Payne and 
Marsh, 2015).  If you tell someone they are not entitled to access new treatments 
enough, they will eventually believe it. 
 
The common acceptance of this situation amongst the participants contrasts with the 
global activism demonstrated by patient advocacy groups, which have been highly 
critical of restricted access policies for new HCV medications and vocal in appealing for 
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the removal of HCV treatment rationing (e.g. Treatment Action Group, 2016).  The 
disparity between the study participants’ acceptance and patient groups’ campaigning 
is curious.  Whilst it could signal that a potentially atypical group of participants were 
recruited, it is perhaps more likely to highlight the atypical nature of individuals who 
join HCV advocacy movements.   
 
4.3.3 A continuum of merit 
The insidious integration of the treatment prioritisation mantra into the participants’ 
discourse continued when discussion turned away from liver health, and distributive 
justice was discussed in terms of merit, rather than need.  These narratives positioned 
people as less deserving of treatment if they were perceived as likely to waste 
resources due to ongoing drug and/or alcohol use, conforming to the notion that these 
individuals were not entitled to parity of healthcare and social participation (Harris, 
Albers and Swan, 2015): 
 
I: You said if people are still drinking or using drugs then maybe they 
shouldn’t… 
 
K: [pauses] I know, eh, that’s a hard one.  I, I do believe that if they’re still 
drinking an’ that they shouldn’ae be getting the treatment, because it’s 
a waste a’ time.  It’s no’ because I dunnae want them a’ get better or 
anything like that, it’s jus’ ‘cause they’re wasting resources an’ money, 
y’know what I mean, it’s stupid, (…) when you’re getting a drug that 
costs so much, even if it didn’ae cost a lot, it’d still be stupid, y’know 
you’re jus’ wasting your time, you’re wasting the doctors time, an’ really, 
if you’re jus’ gonna keep taking, drinking, ken fucking up… 
 
(Keith, 54, non-cirrhotic) 
 
 
An impression emerged that in order to access new HCV treatments, some work on 
the part of the recipient should be engaged in with relation to drug and alcohol use.  
Therapeutic citizenship reproduced an expectation that individuals should engage in 
self-improvement, becoming more responsible and reliable in order to neogiate their 
entitlement to treatment (Rhodes et al, 2013).  Stewart’s account referenced this on a 
number of occasions, positioning himself as more deserving of treatment, not due to 
the condition of his liver, but because of the way he perceived others were living their 
lives: 
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And, to tell you the truth, I fee...sometimes coming here, I feel, pretty broken 
when I see some people that [mumbles to self as thinks of words], that aren’ae 
looking after their-selves, I mean I’ve been sitting here, people have been 
phoning up like for appointments, an’ coming in, an’ jus’, you jus’ know they’re 
no’ looking after their-selves an’ I’m jus’ sitting there, on time, trying a’ help 
myself, fed up, an’ it jus’ sometimes, blows you away that, why are they 
getting treated better than me eh? 
(Stewart, 52, cirrhotic) 
 
 
…but then there’s, the other side is [pauses], if you’re a, if you’re a [whispers to 
self: oh God] if you’re a drug user, then, if you know the risks, you must know 
the risks [pauses], something like that that’s jus’ bad thoughts like; [takes deep 
breath] they shouldn’ae be as high as the list.  That’s jus’ my thoughts on it 
like.  
(Stewart, 52, cirrhotic) 
 
Concurrent narratives of distributive justice by need and merit could sit side-by-side 
within a single participant’s account, with little sense of conflict.  This is perhaps 
unsurprising, as beliefs about justice are often pluralistic, in the sense that they cannot 
be accounted for by reference to a single basic principle of distribution (Miller, 1992).  
Rather, individuals typically invoke several criteria and reach an overall judgement by 
considering these criteria against each other.  A complex social understanding of HCV 
treatment allocation is therefore evident within these narratives.  Individuals balance 
need, merit, and other factors against a perception of their own position on the HCV 
illness continuum, whilst adopting an almost unquestioning tolerance of inequality. 
 
4.3.4 Theme summation 
The theme ‘positioning hepatitis C’ resulted from a compelling thread which wound 
through the collected narratives.  Beginning with the accounts of diagnosis, HCV was 
constructed by participants as a contextual illness, positioned in relation to wider 
socio-cultural, medical, and politico-economic contexts.  For those diagnosed within a 
period of drug use, the reaction to being HCV positive was moderated and tempered 
by a pre-existing social diagnosis of ‘pre-HCV’.  Other comorbidities were also 
employed to provide context to the disease, with HIV and cancer consistently 
positioned as more significant diagnoses.  Of note, the timing of diagnosis in relation to 
advances in HCV treatment did not impact on participants’ understandings of the 
disease, or responses to it. 
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Following diagnosis, participants described a repositioning of other aspects of their 
lives in relation to HCV.  Transformation narratives wove through the discourse as 
alcohol and drug use were reconsidered.  Slowly, a changing perception of HCV 
became evident for those who had engaged with HCV services.  Participants described 
multiple experiences of HCV, which fractured the understanding of a singular and 
uniform disease into a continuum of illness.  Hepatitis C was positioned within the 
narratives in relation to others with the same disease, the comparative health of their 
liver, and the discourse of distributive justice which accompanies the arrival of 
interferon-free therapy. 
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Chapter 5 
Beyond a physical burden 
 
5.1 Introduction 
This chapter aims to explore how participants predominantly situated the impact of 
their HCV infection within the mental and emotional, rather than physical, dimensions 
of illness.  The emotional burden of HCV formed a central and crucial theme within 
their narratives, which differed from the transient and irregular influence the infection 
demonstrated on their physical health.  To illustrate this disparity, this chapter 
primarily focuses on two enduring motifs of HCV: fatigue and stigma.  The discourse 
surrounding fatigue is considered first, and the weak and insubstantial pattern it 
produced within the data revealed.  In contrast, the clear and compelling construction 
of HCV as a psychological burden is then explored, with an emphasis on the continued 
significance of stigma to the inter-subjective lived experience.  This discussion of 
stigma explains the concept of ‘felt’ stigma, and provides insight into how felt stigma 
was produced and embodied within the narratives.  It then identifies strategies which 
the participants used to manage their discreditable identity.  The experience of felt 
stigma is then contrasted with how incidents of ‘enacted’ stigma proved relatively rare, 
and how disclosure of their HCV status often met with an unexpectedly positive 
response.  The importance the participants placed on emotional support is then 
addressed. 
 
This chapter reveals how the participants firmly located the psychological burden of a 
somatic disease as their predominant concern.  In doing so, it emphasises that whilst 
the much vaunted developments in HCV drug therapy are clearly important in 
eradicating the virus and improving treatment outcomes, they do little to address the 
components of the daily lived experience which matter most to those infected.  The 
findings from this study suggest that stigma, and the emotional (felt) burden of illness, 
have not reduced in the current era of more effective treatment.  Concurrent 
strategies for challenging the ongoing and deep-seated stigma associated with HCV 
must therefore form a vital element of any patient-centred global response to the 
disease.   
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5.2 A physical affliction? 
5.2.1 Fatigue 
The impact of HCV on the physical health of those infected has received significant 
attention in previous studies.  Fatigue has been cited as the most important 
contributing factor in reduced HRQoL (Kallman et al, 2007), and has formed an 
enduring theme in qualitative work focused on the experience of living with HCV 
(Conrad et al, 2006; Fry and Bates, 2012; Glacken et al, 2001; Glacken et al, 2003; 
Groessl et al, 2008; Sutton and Treloar, 2007).  The emphasis that fatigue has received 
within the scientific literature made it an expected theme within this study, and whilst 
the physical impact of HCV did feature in a number of the participants’ narratives, it 
did not form a compelling analytical refrain. 
 
Indeed, the physical aspect of HCV infection was absent from almost half of the 
participants’ testimonies, and where it did occur, the primacy which fatigue has 
commonly been assigned was not in evidence.  The discourse of physical disruption 
was rarely emphasised as particularly significant, with reduced energy and general 
fatigue mentioned anecdotally, and framed by most as a manageable and slight 
inconvenience, rather than as a life-changing disorder: 
 
No, I jus’…I jus’ feel [pauses] a little bit drained but not sick, sick.  My body’s 
jus’ went through like a, a big deal, y’know, a big thing, that’s it, but I don’t 
feel like - oh my God, y’know, I’m dying, I’m dying, y’know… 
 
(Anita, 46, diagnosed 2014) 
 
  
References to fatigue were found in the narratives of those who described their liver 
as cirrhotic, but also in the testimonies of those with a lesser degree of liver disease.  
There were no clear associations with any of the participant demographics.  Fatigue 
appeared sporadically and infrequently in some narratives, and remained entirely 
absent from others, producing a fragile and insubstantial candidate theme during the 
analytical process (Braun and Clarke, 2006).  The vast majority of participants 
constructed accounts which primarily made reference to not feeling especially 
exhausted or noticing any particular physical symptoms, with many speaking about the 
ordinariness and normality of their daily life: 
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I dunnae really, aye, I dunnae focus much on it, an’ then when I do think about 
it, I think well, it’s no’ like it changes my lifestyle or, y’know there’s things that 
I cannae do, I can still live a normal life an’, aye… 
 
(Kelly, 34, diagnosed 2008) 
 
I: Does [HCV] stop you doing anything? 
 
G: I’ve not found that, as yet.  Jus’, my normal problems that I have anyway 
jus’…just, balance it so I wouldn’t (…) I wouldn’ae say that it’s [pauses] 
nah, I wouldn’t say that it has at all, hasn’t stopped me from getting 
anywhere or doing anything. 
(Gary, 38, diagnosed 2013) 
 
 
5.2.2 A disproportionate focus 
The absence, or relative insignificance, with which fatigue was framed within the 
majority of narratives demands further attention.  Fatigue has been described as the 
most frequent extrahepatic manifestation observed in individuals with HCV in both 
quantitative and qualitative investigation (e.g. Lang et al, 2006; Poynard et al, 2002).  
Therefore, its marginal influence within this study is curious.   It is, however, not 
unique.  In a recent phenomenological study, Hill et al (2015) considered fatigue only 
briefly in one of their six themes describing the experience of living with HCV during 
the interferon-era, with their themes predominantly focused on the psychological 
impact of the infection.  Of note, they conducted unstructured interviews with their 
participants, opening with just one question: “can you tell me how it has been for you, 
living with hepatitis C?”  Similarly, the interview schedule within this study did not 
address fatigue explicitly (appendix C), and this manifestation of HCV was only 
discussed if the participants specifically made reference to it within their discourse. 
 
It could be argued, therefore, that where fatigue is looked for, it will be found.  This 
focus on the symptom does not necessarily equate with its significance to those 
infected with the virus.  For example, quantitative investigation of fatigue uses patient-
reported outcome measures such as the Fatigue Severity Scale or the Brief Fatigue 
Inventory, in order to study fatigue based on a priori assumptions about the 
population they are investigating (e.g. Fabregas et al, 2013; Kallman et al, 2007).  
Qualitative research is not immune from this approach either.  A recent study 
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investigating HCV patients’ experience of fatigue used criterion sampling to interview 
only those individuals who had previously reported clinically significant fatigue on the 
Fatigue Severity Scale as part of another study (Zalai et al, 2016).  It is possible that this 
investigator-led focus on fatigue has created a disproportionate wealth of literature on 
the topic, which in turn reinforces its reputation as one of the most significant patient-
reported outcomes of HCV infection. 
 
A further consideration arises.  Has the emphasis which has been placed on fatigue, 
both within the scientific literature and subsequently within clinical practice, resulted 
in a self-fulfilling prophecy?  The awareness that HCV and fatigue have been 
constructed as inseparable bedfellows provides a convenient hook on which to hang a 
physical symptom which may also be explained by consideration of numerous other 
factors.  The following quote illustrates this well.  After identifying a number of 
influences which could have accounted for her constant exhaustion, Fiona instinctively 
aligned her symptoms to an (as then) undiagnosed HCV infection: 
 
I was jus’ constantly tired, erm, my immune system was run down a lot, but I 
jus’ thought it was bad living, taking drugs, not eating well, going out five in 
the morning, doing my job, things like that, I mean, basically jus’ not thinking 
it could a’ been anything like [HCV]… 
 
(Fiona, 40, diagnosed 2012) 
 
 
Whilst fatigue formed a significant aspect to the lived experience of HCV for a small 
minority of individuals within this study, it was not the all-encompassing and unifying 
experience that previous studies have proposed.  In focusing on the life-world of the 
participants, and describing and interpreting those aspects of the lived experience 
constructed as the most significant by the participants themselves, this study 
questions the centrality commonly attributed to fatigue in the lived experience of HCV. 
 
5.3 An emotional illness 
5.3.1 Always on my mind 
Whilst the physical burden of HCV formed a weak and insubstantial pattern within the 
data, the impact on the participants’ psychological health was richly constructed and 
comprised multiple strands.  Hepatitis C was framed as an illness which caused a 
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persistent disquiet and underlying worry.  It was frequently described as occupying a 
permanent space at the back of participants’ minds, producing a constant unease 
which they tried not to dwell upon or brood over: 
 
I don’t, I don’t, I try not to obsess about it, you know, it’s kind of running away 
in the back of your mind the whole time but I try not to you know, let it kind of 
affect me too much… 
        (John, 54, diagnosed 2012) 
 
 
I: How do you cope with having hep C Jacqueline? 
 
J: [pause] to tell you the truth, to be honest, I can’t, I can’t cope with it.  
I’m having a job coping with it.  I don’t like to, I know it’s got to get 
mentioned now’n again, but I’d rather put it [indicates the back of her 
head] back… 
 
(Jacqueline, 70, diagnosed 1991) 
 
 
The lack of physical impact from HCV contributed towards this enduring worry at the 
back of their minds.  Whilst some participants used the lack of symptoms to try and 
block HCV from their thoughts, others found being unable to monitor the effect HCV 
may be having on their body unsettling.  The idea that HCV might be doing something 
“that I can’t see, I can’t feel, I can’t detect”26 produced its own set of anxieties and 
concerns, which fed the underlying psychological burden. 
 
In addition to this tenacious and unrelenting torment at the back of their minds, the 
participants related specific factors which served to bring this underlying disquiet to 
the fore.  The fear of transmitting the virus to others was framed as a significant source 
of anxiety.  However, the greatest psychological burden was evident in the 
participants’ narratives of stigma.  Each of these factors will now be examined. 
 
5.3.2 Onward transmission 
The majority of participants expressed significant concerns over the risks of passing 
their HCV infection onto others.  Specific fears over transmitting HCV to children and 
partners were commonplace, and the potential risk to the health of close family and 
                                                          
26 Sheila, 59, diagnosed 1991 
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friends formed a central concern.  The discourse surrounding onward transmission was 
compelling and consistent, with the narratives accentuating how this was not a 
periodic and irregular anxiety, but one which influenced their lives on a daily basis: 
 
I struggle wi’ it, I struggle wi’ jus’ being around people an’, an’ jus’ knowing 
that I could put them at risk, it’s jus’ a worry, I worry, a day a’ day worry… 
 
(Eilidh, 39, diagnosed 2013) 
 
 
The protection of others from contracting their HCV infection was constructed as a 
fundamental component of the lived experience.  Fictional ‘what-ifs’ were routinely 
presented within the discourse to underscore the imagined horror that would be felt 
should the worst come to pass, with the act of accidentally cutting themselves 
recurrently presented as a nightmare scenario.  Whilst the majority of participants 
described exercising proportional caution and risk avoidance in relation to identified 
risks, Anita accentuated her fears of onward transmission by suggesting she had 
effectively placed her life on hold as a result: 
 
I’ve always had that thing where I’m so scared that, erm, if I cut myself, 
y’know, being very wary, y’know, around people (…) and that’s why I’ve, 
basically I’ve put my life on hold because I’m like, I am not going to put anyone 
at risk, so like, like going, an’ doing a job or whatever, an’ put someone at risk, 
that’s something that I’m, I’m so scared about… 
(Anita, 46, diagnosed 2014) 
 
 
Anxiety over onward transmission also exerted a significant toll on a number of the 
participants’ sexual relationships.  Despite a general awareness of the relatively low 
risk of sexual transmission, an understanding prevailed that this was not a risk to be 
taken lightly, or indeed a risk worth taking at all.  This discourse was more pronounced 
amongst the single participants, who spoke about deferring the search for a long-term 
partner and often avoiding casual sex entirely: 
 
I jus’ thought, well that’s my life ruined, y’know, err, an’ since then, I’ve never, 
I’ve never even been wi’ another woman, again, that’s it.  Since I got divorced, 
that was it, I jus’ thought, nah, I can’t.  Y’know, an’ that’s been over, I don’t 
know, seven year?  I jus’ thought well you cannae have sex again, ‘cause you’ll 
end up likes, giving it to somebody else. 
(Steve, 45, diagnosed 2005) 
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The psychological burden presented by the fear of onward transmission within this 
study is consistent with that described in previous investigations into the lived 
experience of individuals with HCV (Conrad et al, 2006; Fraser and Treloar, 2006; 
Grundy and Beeching, 2004; Temple-Smith et al, 2004).  Whilst the emotional toll from 
this hypothesised scenario was clearly evident, it was the discourse surrounding stigma 
which presented participants with the source of their most significant distress. 
 
5.3.3 Stigma 
5.3.3.1 Theoretical basis 
That HCV is a highly stigmatised disease has been a stubborn and consistent refrain 
throughout the scientific literature for many years (see chapter 2).  The theoretical 
basis for much of this discussion has been founded on Erving Goffman’s (1963) 
enduring theory of social stigma.  Goffman defined stigma as a discrediting ‘mark’ or 
attribute which is socially devalued, and sets an individual aside as a deviant, rather 
than as a ‘normal’ member of society.  As such, Goffman clearly defined stigmatisation 
as an interactive social process, where the reaction of others ‘spoils’ an individual’s 
identity.  However, Goffman noted that not all stigma are equally discrediting, since 
some ‘marks’ or attributes are less visible than others.  He proposed that stigma 
incorporates two key aspects: the visible (discredited) identity and the invisible (or 
discreditable) identity.  These terms refer to the visual conspicuousness of the 
stigmatised attribute (Chaudoir, Earnshaw and Andel, 2013), with the discreditable 
identity resonating with the transient and non-specific physical manifestations often 
found in individuals with HCV.   
 
The concept of stigma can be further delineated between ‘enacted’ and ‘felt’ stigma.  
Enacted stigma encompasses the overt discrimination against those who possess the 
socially devalued ‘mark’ on the sole grounds of their social unacceptability, and ‘felt 
stigma’ denotes both a sense of shame and/or an attendant fear of encountering 
enacted stigma (Scambler, 2009).  This dichotomy was developed in work conducted 
with people diagnosed with epilepsy during the early 1980s, which found many 
individuals expressed the view that their condition was highly stigmatised, despite 
being unable to provide actual instances of this stigma operating against them 
(Scambler and Hopkins, 1986).  The following section of analysis takes these concepts 
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of stigma as a theoretical basis.  It begins by examining how felt stigma was 
constructed within the narratives, exploring the close association between HCV, drug 
use and HIV/AIDS.  Strategies for managing the HCV discreditable identity are then 
considered.  Finally, the felt stigma experienced is contrasted with accounts of enacted 
stigma, and the discrepancy between the perceptions and experiences of HCV stigma 
found amongst the participants’ narratives highlighted and discussed. 
 
5.3.3.2 Felt stigma 
The concept of felt stigma incorporates two predominant components: fear and shame 
(Scambler, 2004).  For a discreditable disease such as HCV, fear arises from the 
possibility of being treated differently, labelled or ‘found out’, and is referred to as 
anticipated stigma within much of the scientific literature (e.g. Quinn et al, 2014).  The 
other component, shame, is often considered self-stigma or internalised stigma.  In 
this case, the self-concept of individuals with the stigmatising ‘mark’ is congruent with 
the (expected) stigmatising response of others, accepting their discredited status as 
valid (Scambler, 2009).  In short, internalised stigma reflects stigma directed at the self, 
from the self (Chaudoir et al, 2013).  This internalised shame was evident in the way 
participants spoke of how their HCV infection made them feel.  They recurrently 
employed phrases such as ‘dirty’, ‘branded’ and ‘like a leper’, with one participant 
describing how she felt she had “beasties crawling about in my bloodstream”27.  For 
Stewart, the intensity of this internalised stigma had led to external physical 
manifestations of how unclean and polluted he felt: 
 
Once, a couple a’ months ago, thinking about it, I start scratching, I start – oh, 
I’m no’ bothered brushing my teeth today, I dunnae need to do it, what’s the 
point when I’ve got this? 
(Stewart, 52, diagnosed 2015) 
 
 
Similar insights from studies focused on individuals with HCV have been reported for 
many years, with participants habitually describing themselves as contaminated, dirty 
and leprous (Glacken et al, 2001; Grundy and Beeching, 2004; Hill et al, 2015; Miller et 
al, 2001; Sutton and Treloar, 2007; Zickmund et al, 2003).  Such findings illustrate how 
                                                          
27 Fiona, 40, diagnosed 2012 
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HCV challenges the normative and powerful ideal of the pure, closed and clean body28 
(Fraser and Treloar, 2006), and demonstrate how individuals with HCV accept and 
internalise their spoiled identities.  That this discourse persists unchanged and 
unchallenged throughout the body of work conducted in this area, and remains an 
enduring motif of the lived experience of HCV within the current study, stresses the 
ongoing strength of HCV stigma within society.  Why this may be so can be illuminated 
by exploring the frequent associations drawn by the participants between HCV and 
drug use, and HCV and HIV/AIDS. 
 
5.3.3.3 Hepatitis C and injecting drug use 
The participants’ narratives drew recurrent associations between the internalised 
stigma they felt as a result of their HCV infection, and predominant societal attitudes 
towards drug use and PWID.  The two were often indissoluble within their discourse, 
framing HCV as a disease which afflicted PWID, and often placing all those with the 
infection within this socially vilified group: 
 
I think most people jus’ treat hep C as a, as just a dirty, dirty, disgusting 
virus…an’ I think most people (…) jus’ think you’re a bloody drug user.  It’s, 
that’s the way most people think. 
(Stewart, 52, diagnosed 2015) 
 
 
For those participants who had moved on from a drug-using past, HCV provided an 
unwelcome reminder of those bygone days.  It served to resurrect the stigma they had 
encountered during their period of addiction, and brought back memories of an old life 
which they had tried to leave behind.  The sense of shame and embarrassment felt at a 
drug-using past was revived and galvanised by the arrival of HCV in their lives.  
Hepatitis C was a badge of dishonour, a relic of a life once lived: 
 
It’s just err, it’s the same as when I, I mean I dunnae wear T-shirts because I’ve 
got track marks, old, old scar marks fae injecting an’ stuff [indicates arms] it, 
jus’ that old life y’know, an I’ve moved away fa’ that, an’ I’m real, I mean I’m 
like seven year off, off heroin an’ that, I’ve been clean for a lot a’ years (…) But 
like I say, I do feel a sense, I am ashamed a’ myself through the hep… 
 
(Paul, 37, diagnosed 2000) 
                                                          
28 An ideal which ignores the frequent ingress of micro-organisms to the human body, and the 
permanent presence within the body of beneficial flora (Fraser and Treloar, 2006). 
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…it kind of reminds me of some of the horrific things that happened whilst I 
was using [pauses], erm, not, yeah – not proud, you know, distinctly not proud 
looking back…  
 
(John, 54, diagnosed 2012) 
 
 
In addition to this internalised shame, the participants also produced narratives which 
were replete with anxieties and fears regarding how disclosure of their HCV positive 
status would indelibly connect them with drug use in the eyes of friends, family and 
wider society.  This anticipated stigma was evident within the discourse of those who 
did not identify as people who use drugs (PWUD) (see the quote from Stewart above 
for example), but also for those who readily divulged an extensive drug-using history.  
This perhaps surprising insight echoes previous work which challenged the common-
sense notion that PWUD have little concern for what others may think of their 
behaviour (Simmonds and Coomber, 2009): 
 
I guess again, that, that sort a’, that stigma around it, I don’t want people 
thinking that it’s something that it isn’t, like if you tell people “oh, I’ve 
contracted hep C” y’know, there’s potential that they’re gonna think that 
you’re y’know, knee-deep in drug use, y’know you’re like a complete junkie, 
everything like that.  
(Dan, 27, diagnosed 2013) 
 
 
Dan framed himself as a recent, but former heroin user.  He repeatedly stressed that 
he had never injected heroin, and vigorously positioned himself apart from those who 
had.  Other participants gave similar testimonies, differentiating between activities 
which constituted acceptable and unacceptable drug use.  Steve described his drug use 
as “a lot of cocaine, a lot a’ speed, but that’s like a party drug” and distanced himself 
from heroin use, which he categorised as “a filthy drug”.  For Fiona, despite her 
mother being aware that she smoked heroin, the act of injecting the drug was framed 
as a source of particular shame: 
 
Y’know, it’s like oh you’ve gotta be a junkie a’ catch hep C.  So it was bad 
enough knowing my mum knew that I was a heroin smoker, I, I mean I was 
scared a’ needles, I was never ever a heroin injector, I was always just a 
smoker, so straight away it was like, she’s gonna think I’ve been injecting… 
 
(Fiona, 40, diagnosed 2012) 
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These narratives produced an understanding that amongst those who identified as 
PWUD, the stigma surrounding injecting drug use was of a significantly greater 
magnitude, and it was this weightier stigma that conflated with HCV.  Hepatitis C did 
not just designate you as a generic drug user, it branded you an injecting drug user.  
That stigmatisation impacts both on drug-using populations and also operates within 
drug-using groups has been noted in numerous previous studies.  Furst, Johnson, 
Dunlap and Curtis (1999) detail a long history of PWUD denigrating other PWUD as a 
discursive strategy to raise their social status.  For example, they describe how cocaine 
users would call themselves ‘base smokers’ to avoid the stigmatised category of ‘crack 
head’ in the 1990s.  More recently, Simmonds and Coomber (2009) described a 
hierarchy of stigma within PWID based on perceptions of responsible versus 
irresponsible behaviour, and upon the type of drug injected.  The catch-all terms of 
‘PWUD’, ‘PWID’ and ‘substance users’ belie the complex social hierarchies that can 
exist within drug-using communities, and the degrees of stigma which specific types of 
drug taking can attract.   
 
5.3.3.4 Hepatitis C and HIV/AIDS 
In addition to drug use, over half the participants entwined their discourse concerning 
the stigma of HCV with understandings of HIV/AIDS.  For many, the two had been 
synonymous upon diagnosis, and only on subsequent engagement with HCV services 
had the difference between these viral infections become clear.  Whilst some 
participants had known individuals with HIV/AIDS, and others mentioned infamous HIV 
media campaigns from the 1980s, it was ultimately unclear how this understanding 
had originated: 
 
I think I took it on that it was more to do with HIV than hep C, I didn’t know it 
was like, two separate things, I actually thought that if I had hep C then I had 
HIV as well, for so long I thought that way… 
 
 (Danielle, 43, diagnosed 2009) 
 
…but when I found out, I was horrified.  ‘Cause I thought it was the same as 
AIDS, in my head, it’s like, it was like, when somebody says hep, hepatitis C an’ 
you’re thinking “it’s like HIV” y’know, it was jus’ in my head, so I was horrified, 
an’ it destroyed me.  Y’know? 
 
(Steve, 45, diagnosed 2005) 
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Previous studies have also reported this intimate association between HIV/AIDS and 
HCV, emphasising the additional negative stereotyping which can result (Lekas, Siegel 
and Leider, 2011).  A societal understanding which positions HCV and HIV together also 
conflates the stigma which accompanies each of these infections.  Hepatitis C can 
therefore invoke prejudice more commonly directed at people living with HIV, such as 
accusations of sexual promiscuity or association with socially devalued groups such as 
gay men (in addition to PWID as previously discussed) (Zickmund et al, 2003): 
 
…oh if you’ve got hep C you must be taking drugs or injecting…or gay, y’know, 
things like that… 
 
(Fiona, 40, diagnosed 2012) 
 
 
Significantly, stigma associated with HIV has been described as more pervasive and 
detrimental to wellbeing compared to HCV-related stigma (Lekas et al, 2011), a 
contention supported by the narratives of those HIV/HCV co-infected participants in 
this study.  For the mono-infected group, a vehement desire to dissociate themselves 
from a potentially greater source of stigma was evident in a number of the 
participants’ accounts: 
 
I’ve had people coming up to me an’ asking me “Phil, are you HIV?” an’ I’ve 
said “Erm, no I dunno who told you that but I’m, I’m H.C.V., I’ve got hepatitis 
C, OK, not HIV, I’m not HIV, don’t get that wrong, don’t make that mistake, 
alright?” 
 
(Phil, 60, diagnosed 1997) 
 
 
5.3.3.5 Managing a discreditable identity 
Most participants sought to manage their discreditable identity by strategically and 
cautiously selecting who they would confide in.  The majority of participants 
acknowledged these acts of concealment were driven by fear of the reaction they may 
receive (anticipated stigma), and were found in the narratives of those who had no 
history of drug use, as well as those who identified as PWID: 
 
An’ people didn’ae, people used to hide a lot a’ things, because, I mean it was 
still spoken about but I think there was a lot a’ people that wouldn’ae have 
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turned around an’ says that I’ve got hep C because then people wouldn’ae 
have wanted to share anything, so I think that’s what it was… 
 
(Danielle, 43, diagnosed 2009) 
 
 
Selective disclosure served to maintain the participants’ social status amongst their 
peers, and gave them a sense of control, allowing a vestige of ‘normal’ life to continue.   
However, a discourse was also evident in a number of narratives which presented 
these selective disclosures nobly, in terms of concern for others: 
 
…y’know I could have told them and they would have understood, erm, but I 
chose not to, I chose not to tell a few people, jus’ because I didn’t want to 
complicate their lives really, to be honest, my dad for one, my mother-in-law… 
  
(John, 54, diagnosed 2012) 
 
 
Although allowing a sense of control, this selective strategy could also carry an 
emotional cost of its own.  Guilt and remorse at the deception of close friends and 
family were felt regularly, and voiced frequently.  In addition, Happy recounted how 
concealing her HCV diagnosis from potential partners had resulted in a broken 
relationship and a stalled social life: 
 
…when I’m meeting people out there, you never know, that’s why I’m just like 
now, I broke up with that guy in [names city], and my social life is on hold, 
‘cause it’s just, it’s like I’ve got this secret in me, yeah?  Like when I meet 
somebody, how, how, how do I say, hmm, by the way…! So for me, I’ve just 
blanked [relationships] out… 
(Happy, 51, diagnosed 2005) 
 
 
In addition to simply disclosing or not disclosing their HCV status, a small number of 
participants engaged in practices which conveyed the fact they were unwell, but which 
avoided specific mention of HCV.  For example, Fiona spoke to friends about her 
hospital appointments, but ascribed them to other conditions.  Peter counselled his 
family that his “blood was being poisoned” without further elaboration, whilst Gary 
avoided any mention of blood or viruses at all: 
 
I wasn’t lying I just never said that I had hepatitis C, I jus’ said listen, my liver‘s 
knackered, there is a chance a’ having cirrhosis, if I don’t get it treated.  And I 
128 
 
kind of jus’ left it at that, nobody seemed to come back with oh, you’ve got 
this, or you’ve got that, they were quite happy with that… 
 
(Gary, 38, diagnosed 2013) 
 
 
This strategy of disguised disclosure sought to maintain control over their discreditable 
identity and provide protection from stigma, whilst also allowing access to help, 
support and sympathy from friends and family.  As the narratives progressed, 
however, this approach was rarely successful.  Fiona became embroiled in ever more 
elaborate lies, and the internet soon provided Peter’s family with the specifics he had 
failed to deliver. 
 
For a further small number of participants, managing a discreditable identity was 
tackled head on by disclosing their HCV status widely.  It was better to be open and 
honest with everyone than contend with the complexities of selective or disguised 
disclosure.  Participants justified this uncompromising approach by emphasising the 
personal gain to be achieved (“opening up does help”29; “I tell people right up front 
‘cause I dinnae wanna waste time wi’ somebody who’s gonna be my fair-weather 
pal”30), and by citing altruistic intentions.  Anita positioned herself as a cautionary tale: 
 
I’m straight up with people, y’know, because if I can sort a’ make someone 
think y’know, hey, I’m no’ away a’ do that, then, yeah, I’ll, I’ll, I tell people. 
 
(Anita, 46, diagnosed 2014) 
 
 
Whilst the intentional transformation of a discreditable identity into a discredited one 
may seem a surprising strategy, previous research suggests that internalised and 
anticipated stigma may be similar for both discreditable and discredited identities 
(Chaudoir et al, 2013).  Indeed, some studies suggest that internalised stigma may be 
greater for those with concealable stigma than those with a discredited one (Cook, 
Arrow and Malle, 2011).  By adopting this approach, participants weighed the risks of 
encountering greater social devaluation and enacted stigma against the potential 
benefits of reduced psychological distress and internalised shame. 
                                                          
29 Stewart, 52, diagnosed 2015 
30 Keith, 54, diagnosed 2004 
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A further strategy for managing a discreditable identity was evident within the 
narratives.  Participants disparaged and criticised those who were anticipated to hold 
stigmatising views, and in doing so sought to enforce a discreditable identity on them.  
These individuals were frequently referred to as ‘small-minded’, ‘uneducated’ and 
‘ignorant’, terms which carry a socially devalued status, and positioned the people 
using them as more understanding, progressive and enlightened.  The participants 
launched a pre-emptive discursive attack: 
 
…but that’s small-minded people, that’s the way I see it, I, if you’re that small-
minded to think like that then, you, you think like that ‘cause there’s people 
out there that dunnae think like that, d’you know what I mean? 
 
(Eilidh, 39, diagnosed 2013) 
 
 
…you know what you’ve got, an’ you accept, you accept it.  Anybody else 
doesn’ae wanna accept it, then, they’re no’ worth talking to, simple as that.  
That’s how I look at things. 
(Dean, 54, diagnosed 1997) 
 
 
5.3.3.6 Enacted stigma 
Enacted stigma refers to the degree to which individuals have experienced 
discrimination or social rejection as a result of their discrediting ‘mark’ (Scambler, 
2009).  Whilst the participants constructed narratives rich in anxiety concerning 
anticipated stigma, and replete with accounts of internalised shame, discussion of first-
hand experiences of stigma were often hard to pin down.  Participants spoke of 
“seeing stigma about”31, but when pressed for specific details of their personal 
experiences often reverted to speaking in generalisations and relaying generic second-
hand accounts.  For example, Gary’s description of enacted stigma positioned him as 
an observer to a stigmatising practice, rather than as a direct recipient of 
discrimination: 
 
…people just have it on automatic assumption, to what it is, and how it’s gon’ 
affect you an’, I’ve seen people say “ooo, can’t touch you, ‘cause you’re 
infected” an’ it’s jus’ like silliness. 
 
(Gary, 38, diagnosed 2013) 
                                                          
31 Fiona, 40, diagnosed 2012 
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That is not to say primary accounts of enacted stigma were not present.  A small 
number of participants related specific occasions where they had encountered 
discrimination from family, friends or co-workers.  The majority of these anecdotes 
were framed as rare, one-off episodes, transiently troublesome but a relatively minor 
annoyance.  However, for Jacqueline, a more profound and long-term negative 
psychological outcome was apparent: 
 
…these friends, they actually make me feel as if [pauses] I’m like, not say like 
an alien but like, they’re further away from me than they used to be that close, 
y’know?  They always used to say oh, give you a cuddle cheerio an’ now they 
don’t do that y’know, an’ I think that, I don’t think they realise how much that 
hurts, y’know to think that that’s what they could catch. 
 
(Jacqueline, 70, diagnosed 1991) 
 
 
For those participants who disclosed a history of incarceration, the prison setting 
featured as a significant source of enacted stigma in their narratives.  The participants’ 
testimonies recounted anecdotes of fellow prisoners refusing to share a cell, or stand 
next to them in a queue for the dining hall, and constructed prison as “the worse place 
to ever, ever have it”32.  Enacted stigma within the prison setting was constructed as 
commonplace, unexceptional and routine, invading every aspect of the participant’s 
life and experienced on a daily basis:  
 
…they wouldn’ae go in the shower cubicle you had jus’ come out a’.  An’ you 
could actually see them looking around an’ going into another one, d’ya know 
what I mean? Or physically waiting, if I come out the shower, an’ there was 
like guys, maybe going for visits an’ stuff, an’ the other showers were full, an’ 
seen me coming out they’d go a’ go in an’ then, they’d stop an’ they’d stand, 
an’ then another guy would come out an’ they’d go into that one.  An’ it’s 
because people knew that I had hep C… 
 
(Keith, 54, diagnosed 2004) 
 
 
This study did not seek ethical approval to recruit individuals who were incarcerated.  
However, the findings suggest a notably different experience of enacted stigma within 
the prison setting than found more generally within the community.  Further research 
                                                          
32 Steve, 45, diagnosed 2005 
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specifically focused on the experience of stigma by incarcerated HCV positive 
individuals would help elucidate this phenomenon. 
 
Whilst considering enacted stigma within institutional settings, the relative absence of 
stigmatising behaviour from healthcare professionals within the collective discourse 
was notable.  Previous studies have repeatedly described the healthcare setting as a 
frequent source of enacted stigma (Butt et al, 2008; Fry and Bates, 2012; Grundy and 
Beeching, 2004; Hill et al, 2015; Janke et al, 2008; Miller et al, 2001; Sgorbini et al, 
2009; Temple-Smith et al, 2004; Tompkins et al, 2005; Zickmund et al, 2003), yet only 
one participant, Kelly, recounted anything other than praise for the care they had 
received: 
 
…the nurses put me in a wee side room, an’ then they were coming in, they 
were putting on masks an’ err…pinny-things o’er their, their…uniform an’, err, 
washing they hands an’ putting like two sets a’ gloves on an’, an’ it was 
horrible, an’ it would’ve been on my form, my, records an’ stuff about me 
having it (…), even the auxiliary nurses, erm, weren’ae come to my door or 
anything, know they used to come round wi’ like, tea an’ toast an’ stuff, it was 
like they were missing me out deliberately an’ stuff eh? 
 
(Kelly, 34, diagnosed 2008) 
 
 
That accounts of healthcare related stigma such as Kelly’s were a scarcity within the 
discourse should not be taken as evidence that stigmatising attitudes towards HCV 
patients amongst healthcare staff are changing.  All participants in this study were 
recruited through their healthcare team, and the majority were interviewed within an 
outpatient clinic.  Despite assurances of confidentiality and anonymity, participants 
may have consciously edited their narratives to avoid any possibility that reports of 
stigmatisation by healthcare staff would be attributable to them.  In addition, the 
outpatient clinic which provided the main recruitment location may have presented an 
atypical experience of healthcare related stigma, given that it was an infectious 
diseases unit which specialised in treating marginalised groups: 
 
…the horror stories I’ve heard of other places, I’ve not experienced it because 
I’ve not had another hospital apart from here, so I jus’ think everything’s 
great, y’know, but the stories that I’ve heard are pretty bad, an’ that kind a’ 
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put me really off, I was like wow, I’m glad I didn’t have to go to them hospitals, 
y’know, so I was very lucky that I ended up [here]… 
 
(Steve, 45, diagnosed 2005) 
 
 
Of note, Kelly did not attend the outpatient unit which served as the main recruitment 
site, and was interviewed within her own home.  Her account of healthcare related 
stigma also took place on a general hospital ward, where she had been admitted for 
reasons unrelated to her HCV infection.  All these factors may have contributed to the 
ease with which Kelly related this anecdote.  
 
5.3.3.7 An unexpected response 
Whilst sporadic reports of enacted stigma featured in a number of the participants’ 
narratives, the overwhelming impression of other people’s reactions to their diagnosis 
was a positive one.  Over half the participants recounted how family, friends and 
acquaintances had taken the news that they were HCV positive in their stride, offering 
non-judgemental support and challenging the expectation of a negative response: 
 
…so my mum was a lot more understanding than I thought she would a’ been, 
I thought she would a’ been really angry – right, that’s it, y’know, I’ve seen 
this, sort a’, dirty, she’s been doing more than she’s letting on for her a’ have 
this kind a’ disease, ‘cause this is, sort a’, somebody, that takes drugs, so she’s 
gonna have caught that through taking drugs - so I thought that she would a’ 
had that view, an’ she really didn’t, y’know, an’ neither did my brother… 
 
(Fiona, 40, diagnosed 2012) 
 
 
This positive reaction was evident not just from close friends and family members, but 
in wider social circles.  Encounters which had been supportive and encouraging were 
related by those who had also recounted experiencing episodes of stigmatisation, in 
order to set their negative anecdotes into context.  After discussion of the strains of 
prison life with HCV, Steve was quick to acknowledge that everyone else he had 
confided in “were fine about it, y’know.  They were much more understanding than you 
think, y’know, it was like, yeah, that was cool”.  Where disclosure to individuals who 
may have been at risk of transmission occurred, participants described receiving a 
grateful response, with people thankful for letting them know: 
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I: And what sort of reactions have you had? 
 
E: Appreciation. 
 
I: That you’ve told them? 
 
E: That I’ve told them, aye. 
 
I: Who’s that from? 
 
E: Like people that I’ve used wi’, like obviously my kids dunnae understand, 
err, so, so they’re busy – thanks for telling me mum – like other people 
that I’ve used, used wi’ an’ ken like they’re quite appreciative that, that 
I’ve told them that. 
(Eilidh, 39, diagnosed 2013) 
 
 
Given the earlier discussion of stigma operating within drug-using groups, this insight 
from Eilidh is perhaps surprising.  Where a negative and stigmatising response could 
have been expected, she recounted gratitude and appreciation from drug-using 
acquaintances for being informed.  Eilidh’s discourse alludes to the presence of a 
moral code among her peers, where stigmatising responses may have been 
constrained by her consideration of their welfare.  Eilidh’s disclosure allowed others 
within her social circle to exercise caution, and resonates with other literature which 
has examined the etiquette surrounding the order of injecting in a socially interactive 
context (Crisp, Barber and Gilbertson, 1998; McElrath and Harris, 2013). 
 
5.3.3.8 Covert enacted stigma 
This analysis of the discourse surrounding stigma suggests a significant discrepancy 
between the stigma felt by participants, and actual reports of stigma operating against 
them.  Whilst this could imply that the participants’ experiences of felt stigma were 
out of proportion to the level of stigma found within society, the narratives of a few 
participants also hinted at another explanation. 
 
Enacted stigma is commonly framed within the scientific literature as the experience of 
overt discriminatory practices, which are episodic and discrete in nature (e.g. Lekas et 
al, 2011; Scambler, 2009).  This framing produces an impression that enacted stigma 
occurs solely in memorable instalments, where specific instances of observed 
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discrimination and prejudice stand out in the participants’ minds.  The previous quote 
from Kelly describing her experience on a hospital ward illustrates this well.  It is this 
perception of enacted stigma which initially guided the analysis of this section of data, 
scouring the narratives for specific examples or striking anecdotes of observed 
discriminatory behaviour.  Enacted stigma, however, was not always so explicit.  
Within his narrative, Keith touched on experiences of stigma which were often more 
covert and unremarkable:  
 
An’ people’ll not sit beside you or, y’know what I mean (…) an’ you, you can, 
you can feel, you can actually, it’s physical, you can actually feel people 
moving away from you, y’know what I mean?  
 
(Keith, 54, diagnosed 2004) 
 
 
Such accounts allude to the passive nature of much stigmatising practice within 
society, which may often go unnoticed or be disregarded by those it targets.  Enacted 
stigma is not always overt and notable, but pervades daily life in ways which have 
become so routine and commonplace that they are no longer noteworthy or 
noticeable, and therefore remain largely unreported.   Keith was attuned to such acts 
of covert enacted stigma, but because similar accounts were absent from the majority 
of other participants’ narratives, is it safe to assume such incidents never occurred?  
Accounts of enacted stigma were rare within the discourse, because participants 
looked for occurrences of discrimination which were overt, above and beyond the 
accepted, and often unseen or unnoticed incidents that formed a part of their daily 
lived experience.   
 
Stigma could also be enacted against individuals remotely in ways which were not 
directly observed and would therefore also remain unreported.  Eilidh related how a 
chance encounter with an acquaintance revealed a concealed act of discrimination 
which may otherwise have gone undetected: 
 
…there is a woman doon at the shops, erm, she used a’ go a’ the [community 
centre], now she’s got a cup in the [community centre], an’ she stood at the 
bus stop – now I never told her I’d hepatitis C, ‘cause I, I dunnae use or that wi’ 
her, I dunnae take drugs an’ that wi’, so I never had the need to feel that I had 
135 
 
to say to her well I’ve got hep C – she’s standing at the bus stop “aye, fuckin’ 
I’m gonna get my cup ‘cause, what if they’ve got hepatitis C”… 
 
 (Eilidh, 39, diagnosed 2013) 
 
 
Such acts of passive and covert discrimination formed only a minor refrain within the 
analysis, because by their very nature, they are often unobserved and largely go 
unnoticed.  The absence of such everyday acts of discrimination from the collected 
discourse speaks not of the absence of enacted stigma within society, but of the 
unconscious acceptance and routine nature of such prejudice, which makes it 
unmemorable, unexceptional and therefore rarely voiced.   
 
5.4 Support 
5.4.1 Family and friends 
The emphasis on the psychological burden of HCV within the narratives produced a 
discourse which also highlighted the importance the participants placed on emotional 
support.  The sources of this support were diverse, and particular to each participant’s 
individual circumstances.  However, where present, close family and friends were 
commonly positioned as central to preserving their emotional welfare, and regularly 
praised for their encouragement, reassurance and care: 
 
…[HCV] takes a bit of your emotional energy away but, I’ve got so much 
support from, from my family, my kids, they were, they’ve been absolutely 
fantastic.  They’ve been really really amazing about it.  My daughter in 
particular went out and, she would, err, she would investigate everything that 
came back and gave me lots of positive support about what to expect. 
 
(John, 54, diagnosed 2012) 
 
 
5.4.2 Peer support 
This broad and comforting support from family and friends could only go so far, and 
more HCV specific support from third sector agencies, support groups and peers was 
also frequently acknowledged and praised.  Speaking to someone ‘outside the family’, 
who had personal experience of living with HCV, was particularly valued, and was 
repeatedly described as the first time many of the participants had started to learn 
more about their condition.  Peer support and peer-led support groups allowed 
136 
 
participants to recount their experience within an environment that permitted them to 
let down their guard temporarily, safe amongst others who could personally relate to 
their experience: 
 
D: …but the groups an’ everything that I went to, oh, they were amazing… 
 
I: What do you get out of those? 
 
D: Other people talking aboot what they go through erm, an’ you’re no’ 
sort a’ looked at as being different fae anybody else, where if you go to, 
like if I go to a nursery group, an’ things are spoken about, I wouldn’ae 
turn ‘round an’ let parents at the nursery know exactly what I was going 
through, where people at [the HCV support group] I would.   
 
(Danielle, 43, diagnosed 2009) 
 
 
The importance placed on peer support was underscored by the wish some 
participants expressed to become involved in supporting others.  A number of 
participants spoke of the immense value which peer support had contributed to their 
lives, and positioned repaying that support, and using their own experience to benefit 
others, as a natural and obvious step in their HCV journey: 
 
I’m gonna start using my experiences maybe to try an’ help people wi’ hep C 
an HIV.  If they want a’ talk about it ‘cause I’ve been through that experience – 
how am I coping wi’ it?  I mean even though sometimes I’m no coping wi’ it, 
that’s good an’ all because people…it’s jus’ normal, y’know what I mean? 
 
(Keith, 54, diagnosed 2004) 
 
 
Peer support has previously been recognised as an important factor in the facilitation 
of access to HCV services for populations that may experience significant barriers to 
accessing care (Crawford and Bath, 2013).  The ETHOS project in Australia has 
repeatedly demonstrated how peer support workers within opioid substitution clinics 
perform a valuable role in reducing barriers to HCV care, and how these workers are 
regarded as highly credible and trustworthy by those they support (Keats et al, 2015; 
Treloar et al, 2015).  Peer support has been cited as one of ten priorities for expanding 
access to HCV treatment amongst PWUD in low- and middle-income countries (Ford et 
al, 2015), and the prominence of peer support amongst the participants’ narratives in 
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this study suggests its value also extends to other more traditional care settings in 
high-income nations.  Whilst family and friends were valuable sources of general 
comfort and reassurance, most participants placed a greater emphasis on support 
from individuals who had been through, or were going through, the same experience. 
 
Whilst the participants’ narratives predominantly framed their peers as valuable and 
beneficial sources of support, not everyone subscribed to this discourse, and atypical 
cases did exist.  For Dean, who did not identify as a person who uses drugs, and 
vehemently positioned himself apart from those who did, the idea of speaking to 
others with HCV provided little comfort: 
 
D: Groups?!  What do the groups do?  What, what do they hope to do, 
what do they hope to achieve? [pauses] Would I be in groups?  Groups of 
what?  People with hep C? [laughs] – so, you’ve got hep C? Err, yeah – 
you have?  Err, yeah.  So what do we do now?!  [laughs] 
 
I: So, you don’t see any value in… 
 
D: Not really no, no, to be honest.  I mean, if there is a value in it, by all 
means, whoever can see that and get off on, get off on it or whatever, 
use it, put it to use, then by all means, indulge!  But, I can’t see any err, 
any, I can’t see any kind of erm, anything I’d get out of it, any positive. 
 
(Dean, 54, diagnosed 1997) 
 
Dean’s disparaging view emphasises that one size does not fit all.  He mocks the idea 
that a group of HCV positive individuals could achieve anything together, and contests 
the notion of peer support being of value, framing it as a fix for those who indulge in 
the experience of being HCV positive.   Whilst not as explicit, a more subdued 
endorsement of peer support was also located within the narratives of other 
participants who did not identify as PWUD, in comparison to those who did.    
 
5.5 Discussion 
5.5.1 Theme summation 
By juxtaposing how participants framed the physical and emotional aspects of living 
with HCV, this chapter has aimed to illustrate how the burden of illness went beyond 
the physical manifestation of symptoms.  Examination of the sporadic and inconsistent 
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accounts of the physical impact of HCV, contrasts with the pervasive and inescapable 
psychological and emotional burden produced by the participants’ narratives.  The 
burden of illness was multi-faceted.  However, the exploration of stigma has illustrated 
how this enduring motif remained a key component of HCV’s emotional toll, and 
continues to hold a stubborn and commanding grip on the experience of living with the 
virus.  Due to the emotional burden of infection, the importance of support from 
friends, family and peers was repeatedly emphasised. 
 
5.5.2 Addressing stigma 
Stigma associated with HCV was an expected refrain within this study.  Whilst the 
exposition of stigma within this chapter may not break new ground, the continued 
presence of significant tracts of analysis on the topic in contemporary HCV research 
stresses the influence it continues to exert on the lived experience of people infected 
with the virus.  It exposes stigma as an immobile and obstinate presence, which has 
doggedly endured the dawn of a new era in the treatment of HCV, and remained 
untouched by the growing authority of HCV as a public health priority.  The findings 
from this study are inconsistent with arguments that the stigma associated with ‘long-
term’ conditions may be diminishing in light of technological and cultural changes in 
contemporary society (Green, 2009), and maintains stigma as a central and enduring 
motif of HCV infection. 
 
Hepatitis C-related stigma continues to incite anxiety, shame and fear in those 
infected, contributing to detrimental outcomes in terms of both physical and mental 
health, and HRQoL (Miller et al, 2012; Treloar, Rance and Backmund, 2013).  In 
addition, the persistence of stigma also has wider public health implications, as an 
adverse impact on the prevention of transmission, testing and diagnosis, access to 
treatment, and treatment adherence have also been repeatedly described (Harris, 
Ward and Gore, 2016; Hopwood, Treloar and Bryant, 2006; Miller et al, 2012; Treloar 
et al, 2013).  Addressing HCV-related stigma therefore remains an important and vital 
part of the global response to the disease, yet governmental strategies for tackling this 
stigma, in conjunction with improving treatment outcomes, are poorly defined.  Whilst 
there is a growing body of literature on how specific models of care can help reduce 
HCV stigma in a healthcare setting (Treloar et al, 2013), there is an absence of reports 
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evaluating population-level interventions aimed at addressing societal stigma more 
broadly.  For example, even though the Scottish Sexual Health and Blood Borne Virus 
Framework 2015-2020 (Scottish Government, 2015a) positions stigma reduction as 
one of its five major goals, strategies to reduce stigma are discussed in relation to HIV 
and sexual health, with no mention of strategies to address HCV-related stigma.  This is 
despite evidence suggesting a range of interventions aimed at reducing the stigma of 
substance use disorders (of which, given its intimate association with injecting drug 
use, HCV could be considered comparable) have achieved meaningful results 
(Livingston, Milne, Fang and Amari, 2012). 
 
Developments in drug therapy heralding a new era in the treatment of HCV may fail to 
reach their full potential without concurrently addressing the tenacious influence that 
stigma continues to exert on the lived experience of those infected. 
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Chapter 6 
Reconstructing uncertainty 
 
6.1 Introduction 
6.1.1 Chapter aim 
The aim of this chapter is to explore how the concept of uncertainty was fundamental 
to the inter-subjective experience of living with HCV.  Uncertainty proved a persistent 
and compelling theme throughout the analysis, underpinning the participants’ 
discourse and evident within multiple narrative threads.  Uncertainty was present in 
the way participants spoke about the virus itself; in their understandings of how HCV 
had been acquired; and in their reflections on the effects of HCV to their health.  
Whilst these findings are briefly discussed, it is consideration of the nature of 
uncertainty around HCV treatment which provides novel and fresh insight into this 
much reported concept, and it is therefore this facet of uncertainty which constitutes 
the main focus of exploration. 
 
By exploring the discourse surrounding HCV treatment, the main body of this chapter 
considers how interferon-based treatments were portrayed with conviction and 
assurance as an arduous undertaking, positioning a gruelling period of therapy as an 
unqualified certainty.  It then contrasts this with the participants’ narratives 
concerning interferon-free regimens, and unpicks the antecedents which have 
contributed to growing uncertainty around these novel therapies: the paucity of first-
hand experience; confusion regarding multiple treatment options; and perceptions 
that the drugs are relatively untested.  These insights are discussed in light of Mishel’s 
theory of uncertainty in illness, which explores how this uncertainty was appraised as 
desirable and necessary, and considers the strategies participants employed to 
maintain this preferable ambiguity. 
 
This chapter suggests that participants’ understandings of HCV treatment have 
transitioned from certainty to uncertainty, a narrative at odds with the predominant 
medical discourse of an uncertain interferon-based era being replaced by the certainty 
of new, more efficacious, therapeutic regimens. 
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6.1.2 Uncertainty in illness theory 
Uncertainty in illness has been defined as the inability to determine the meaning of 
illness-related events (Mishel, 1988).  The concept of uncertainty in illness is widely 
recognised and reported, and a number of theoretical perspectives have been utilised 
to gain insight into the phenomenon (Han, Klein and Arora, 2011).  Mishel’s theory of 
uncertainty in illness concentrates exclusively on uncertainty experienced by patients, 
and, as such, resonates with the focus of this thesis.  The theory originally focused on 
uncertainty in acute phases of illness (Mishel, 1988), but was later reconceptualised to 
include the experience of living with the continual uncertainty found within chronic 
conditions (Mishel, 1990).  It is composed of three main themes: antecedents of 
uncertainty; appraisal of uncertainty and coping with uncertainty.  The theory 
proposes that uncertainty exists in illness situations that are characterised by four key 
factors: ambiguity, complexity, unpredictability and inconsistency.  It further proposes 
that uncertainty can be reorganised over time (Mishel, 1988; Mishel, 1990).  The 
uncertainty in illness theory has previously been employed to gain insight into the lived 
experience of a number of other conditions, including fibromyalgia, multiple sclerosis 
and HIV (Brashers et al, 2003; Johnson, Zautra and Davis, 2006; Mullins et al, 2001), 
and provides a compelling foundation for the examination of understandings and 
insights gained in this chapter. 
 
6.2 The antecedents of uncertainty in HCV 
6.2.1 Uncertainty at diagnosis 
A discourse of uncertainty was etched throughout the collected narratives, often 
established during discussion of how HCV was understood at the time of diagnosis.  
For many, HCV was a complete unknown, with participants commonly producing 
accounts of their diagnosis which emphasised their lack of familiarity with the 
infection, and stressed the uncertainty they felt at the time.  The virus was an enigma, 
only vaguely comprehended and poorly understood.  Associations were made with 
HIV/AIDS and other viral hepatitides, which raised questions and nurtured doubts in 
their minds: 
 
…and [my GP] was like, can you sit down, an’ I’m like I’m just in a’ get my 
prescription, I’m in an’ oot, an’ she was like no I need a’ speak to you, an’ I 
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didn’t even know what hepatitis C was, I was like, is this like HIV, is this gonna 
kill me?  
 
(Fiona, 40, diagnosed 2012) 
 
Further ambiguities and worries persisted: could friends and family have contracted 
HCV from shared plates, cups and cutlery?  Could partners become infected through 
sexual contact?  Could pets become infected?  The lack of familiarity with HCV meant 
that participants possessed insufficient cues to structure or adequately categorise the 
diagnosis, and encountered difficulty when constructing a cognitive schema to make 
sense of it (Mishel, 1988).  Additional antecedents such as the inconsistency of physical 
symptoms (described in chapter 5) contributed to the uncertainty, reinforcing a vague 
interpretation and ambiguous understanding of the meaning of their diagnosis. 
 
6.2.2 Uncertainty of acquisition 
Uncertainty was not limited to retrospective reflections on diagnosis, but pervaded 
and persisted throughout the collected narratives and across the illness trajectory.  For 
participants who disclosed no history of injecting drug use, uncertainty was evident in 
the confusion frequently voiced as to the origin of their infection.  Potential sources of 
contagion were often visited and revisited spontaneously by participants as the 
interviews progressed, with the uncertainty of when and how they had acquired HCV 
vehemently emphasised.  This may have served as a discursive strategy, aimed at 
producing a persona which did not align with typical representations of individuals 
with HCV.  However, the passion which often accompanied the words and the 
unprompted re-examination of the topic time and again suggested a deeper and more 
profound significance to their illness experience.  The uncertainty of not knowing how 
it began, created difficulties in accepting the diagnosis and moving forward: 
 
…and to be honest, I don’t, I don’t know how I caught it, I, I’d like to be trying 
a’ get an explanation a’ how I got it, err, they don’t know if it was through the 
blood transfusion or not, I don’t know, an’ but, I’ve never had an explanation 
(…)  I’m not, I’m not saying, not saying that I’m stupid but I don’t, I jus’ can’t 
get my head round to why, why I’ve got it, y’know, because I don’t know, an’ 
that really does frighten me a bit as well, I’d like, if I could get an explanation. 
It makes it harder to accept it.  All I’m wanting is to try an’ get an explanation 
to why, because I’m, say I’ve never used anything in my life, y’know… 
 
(Jacqueline, 70, diagnosed 1991) 
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6.2.3 The effects of HCV 
In addition to uncertainty in the past, concerns surrounding the future progression of 
liver disease were frequently alluded to and/or explicitly focused on by the 
participants.  Disease advancement was constructed as a pervading and preoccupying 
concern, particularly amongst those who had been diagnosed the longest.  The 
discourse demonstrated confusion about the rate of liver disease progression, and 
whether advancing liver disease would display corporeal signs: 
 
…you don’t know how it could progress, it could, is it changing?  How fast is 
progressing?  Even though the appointments are six months apart what’s 
happening in between?  You think well, because I’m post-menopause, things 
could change an’, oh, will I know about it?  
 
(Marilyn, 52, diagnosed 1997) 
 
 
These concerns resulted in participants seeking reassurance, and attempting to 
manage their uncertainty through interaction with healthcare services and seeking 
social support.  Such actions provided structure and cues to aid the development of a 
cognitive schema to interpret and provide meaning to their illness experience, and 
ultimately reduce the uncertainty they felt (Hummel, 2016): 
 
I think I’ll be OK but I don’t know what to look for if I’m not OK, so err, it’s a 
matter of if I’m needing a test done, I’ll get a test done.  
 
(Sheila, 59, diagnosed 1991) 
 
 
Uncertainty in relation to HCV disease progression has been described previously, with 
studies focused on individuals who were undergoing watchful waiting.  Watchful 
waiting is a management strategy which defers treatment for those with mild- or 
moderate-liver disease in favour of monitoring by healthcare professionals, and was 
particularly prevalent prior to the arrival of DAAs due to the poor efficacy of the drugs 
available at the time (Colagreco et al, 2014).  These studies emphasised the physical 
and emotional impact that illness uncertainty had on overall health, detailing 
associations with fatigue and depression which in turn negatively affected HRQoL 
(Bailey et al, 2009; Bailey et al, 2010; Colagreco et al, 2014).  Watchful waiting remains 
a relevant strategy for patient management, as the high costs of interferon-free 
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therapies have led to treatment rationing (Wolfe et al, 2015).  For Peter, the option of 
living with the uncertainty of disease progression whilst awaiting access to new 
therapies, or facing an interferon-based regimen was a no-win situation: 
 
…the doctor said, we can maybe wait one year or two and see you every six 
months, so don’t worry about it.  An’ I was worried at that point, because I jus’ 
say to the doctor, err, I jus’ want to start.  I cannot keep that in the back of my 
mind (…) I thought can I live with that for a year on my mind, or do I go 
through hell an’ take the interferon?  
 
(Peter, 51, diagnosed 2015) 
 
 
6.2.4 A familiar refrain 
The discourse of uncertainty formed a compelling theme within the narratives, which 
resonated with previous published works.  In a review of how HCV was socially 
produced amongst PWID, Rhodes and Treloar (2008) described uncertainty in relation 
to a number of factors, including understandings of transmission routes and the 
meaning of blood tests.  Conrad et al (2006) reported uncertainty associated with the 
emergence of new symptoms in relation to HCV, and the lack of effective management 
strategies to deal with them.  More recently, a phenomenological study from the UK 
described a multitude of antecedents of uncertainty including a lack of practical 
advice, information and support in people’s daily lives, in addition to the uncertainty of 
disease progression and plans for the future (Hill et al, 2015). 
 
Whilst the significance of uncertainty to the participants’ experience of HCV within this 
study is a central theme, it is not a surprising one.  The insidious nature of uncertainty 
has long been described as an inherent component of chronic illness (Hummel, 2016), 
and, as this brief discussion has shown, previous research focused on HCV, in addition 
to numerous other conditions, has repeatedly emphasised uncertainty as a key aspect 
of the lived experience (Brashers et al, 2003; Conrad et al, 2006; Hill et al, 2015; 
Johnson et al, 2006; Mullins et al, 2001; Rhodes and Treloar, 2008).  The finding is 
evidently nothing new.  Where fresh and novel insight can be found, however, is by 
the exploration of uncertainty within the context of HCV treatment.  By first exploring 
the dogged embrace that interferon exerted, and continues to exert, over 
understandings of HCV treatment, a discourse of certainty can be traced, albeit a 
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certainty of suffering and misery.  By then focusing on understandings of newer 
therapies, a transition from certainty to uncertainty in the inter-subjective 
understanding of HCV treatment becomes apparent, at odds with the certainty 
surrounding interferon-free therapies demonstrated within the medical discourse. 
 
6.3 The certainty of interferon 
The tenacious hold that interferon33 exerted over the participants’ narratives 
emphasised how the drug continued to influence the experience of being HCV positive 
in an age of interferon-free therapies.  Chapter seven will examine how this interferon 
legacy was fundamental to the experience of participants taking interferon-free 
                                                          
33 Interferons are categorised as glycoproteins, with their name deriving from their ability to ‘interfere’ 
with viral replication within a host cell (Kemp and Roberts, 2012).  Their identification was reported in 
1957 (Isaacs and Lindenmann, 1957), and they first came to public attention one year later with press 
reports branding them as potential ‘antiviral penicillin’ (Pieters, 2005).  Interferons were framed as a 
magic bullet for viral disease, however early hopes failed to be realised and they soon returned to 
relative obscurity.  As laboratory technologies and understandings of these drugs advanced during the 
1970s, interferons were trialled in the treatment of hepatitis B (Greenberg et al, 1976) and multiple 
sclerosis (Jacobs, O’Malley, Freeman, Murawski and Ekes, 1982) with encouraging results.  However, it 
was their possible clinical use in the treatment of human tumours which really revived their fortunes.  
Interferons were reframed as potential anti-cancer drugs within public and scientific discourse, leading 
to widespread optimism that a general cure for cancer may be within reach (Friedman, 2008).  Global 
public expectation of these ‘wonder drugs’ was high, fuelled by media reports which eulogised their 
scarce and costly nature, christened them as ‘weapons’, ‘miracles’ and ‘natural wonders’, and likened 
them to ‘God’s own elixir’ (Pieters, 2004).  However, once again, such mounting hopes failed to be 
realised.  In the early 1980s, the euphoria around a cancer panacea foundered on the back of 
uninspiring results from clinical trials, and interferons faded from public discourse once more (Pieters, 
2005). 
 
Although discouraging, this period of research into the interferons’ anti-cancer properties had not been 
in vain.  Interest in their potential as a cancer cure-all had led directly to the cloning of genes for human 
interferon-α (Nagata et al, 1980), which in turn led to the production of quantities of interferon-α 
suitable for use in clinical trials (Friedman, 2008).  Clarification of the potential uses of interferons in 
treating human disease followed steadily, and their third incarnation as the most effective treatment 
against HCV took shape. 
 
The use of interferon in the treatment of HCV predates the identification of the virus itself with early 
work focused on its activity against non-A, non-B hepatitis (Hoofnagle et al, 1986).  Following the 
identification of HCV in 1989 (Choo et al, 1989), interferon monotherapy emerged as the most effective 
treatment option available (Poynard, 2004), and the drug remained a backbone of HCV therapy 
throughout the 1990s, 2000s and into the early part of this decade.  Its name has been synonymous with 
HCV treatment for over 25 years, and has treated a generation of HCV positive individuals whose 
experiences have contributed to a growing notoriety and folklore.  Details of treatment-related distress 
and a general deterioration in health-related quality of life have been consistently recounted in the 
scientific literature throughout this period (chapter 2).  In addition, woeful SVR rates from interferon-
based therapy conflicted sharply with its previous construction as a miracle cure-all (Fried et al, 2002), 
and its historical association with cancer and chemotherapy emphasised its toxicity and positioned it as 
a drug to be avoided.  A combination of these factors led to interferon-free regimens becoming touted 
within the scientific and popular press as the ultimate goal of HCV treatment (e.g. Sulkowski, 2011) 
reinforcing the social understanding that interferon was a damaging, dangerous and harmful 
medication.  This construction of interferon has proved a potent and compelling force. 
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treatments.  Yet, it was the manner in which this notorious therapy was framed by the 
participants which provides meaning here.  Although a demanding and onerous period 
of treatment was commonly discussed, it was done so with confidence, conviction and 
certainty. 
 
6.3.1 An arduous certainty 
For a number of participants, the initial impressions formed about HCV treatment 
were vague and ill-defined, gathered from various ‘horror stories’, and picking up 
information ‘on the grapevine’ or through ‘Chinese whispers’.  Whilst ambiguous in 
nature, these notions of HCV treatment were unvaryingly negative, recounting a 
difficult and demanding course of therapy, which instilled fear and anxiety in the 
listener.  The ethereal nature of where and how this knowledge was gained within the 
narratives speaks of its ubiquity within the social consciousness.  There were often few 
specifics of the manner in which this understanding was acquired, more a general 
sense that this knowledge was somehow omnipresent, and absorbed without 
conscious effort: 
   
J: Initially, it was just fear of the, the, fear of the medication because, you 
know, I had it in my head just-ju by, from what I could gather from, you 
know, without having done any research but I just had it in my head that 
the treatment for hep C at that point was gonna be really rough.  That, 
that was the most, kind of, the most worrying thing. 
 
I: And have you any idea where you’d picked that…where that…? 
 
J: I don’t know, just from hearsay I guess, from knowing something on, on 
the, some documentary on TV or, just subliminally absorbing this 
information from wherever you know? 
        
(John, 54, diagnosed 2012) 
 
 
The underlying perception of the gruelling and demanding nature of a course of HCV 
therapy pervaded participants’ constructions of treatment.  The harrowing nature of 
therapy was spoken about in terms of being an absolute truth, despite participants 
often having little awareness of what was practically involved or the origin and veracity 
of the claims.  The perception of an arduous treatment was widespread, and was 
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inherent in the way the majority of participants framed their understanding of what 
treatment demands.  The reputation of interferon preceded itself: 
 
 I: Tell me what you know about treatment; you said earlier that you knew, 
at the time when you were diagnosed, you knew the treatment was 
‘hellish’…? 
 
 D: Yeah, quite severe.  Erm, I mean, at that point, I didn’t know, other than 
that it was severe I didn’t know anything about it, I didn’t know the 
names of the drugs or anything like that, I knew that, they could, 
basically what I’d been told is it would make you feel like you were in 
withdrawal. 
 
(Dan, 27, diagnosed 2013) 
 
 
I: What do you know about hep C treatment? 
 
E: Err, that I jus’…all I know that it’s maybe make you really no’ well.  Err… 
 
I: OK, can you tell me anymore? 
 
E: I can’t tell you any more than that; that’s no’ meant a’ be nice 
treatment! [laughs] 
 
I: Do you know what treatment involves? 
 
E: I don’t, no. 
 
(Eilidh, 39, diagnosed 2013) 
 
 
The significance of HCV ‘horror stories’ to the participants’ understandings of 
treatment emphasises the importance of storytelling as one of the foundations for 
communicating human experience (Haigh and Hardy, 2011).  Oral histories and 
personal stories align with ideas of common sense, and appear appealingly authentic 
and engaging compared to abstract elitist rhetoric (Polletta, Chen, Gharrity Gardner 
and Motes, 2011).  Discouraging stories and bleak anecdotes of interferon experience 
have persisted and flourished in the understanding of HCV treatment, creating a 
powerful and pervasive communal comprehension.  Hepatitis C treatment was 
positioned with certainty as a demanding and challenging beast. 
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6.3.2 Confirmatory experience 
Some participants had direct experience of treatment in the interferon era and 
therefore possessed a greater understanding of what that treatment comprised.  For 
those who had been through a previous course of therapy, or who had witnessed 
friends and family going through treatment, their experiences served to confirm and 
validate these societal understandings of what HCV treatment was assumed to be like.  
The ‘horror stories’ were not apocryphal tales, but rather experiential histories.  The 
participants who had been through a previous course of interferon-based therapy 
described many of the familiar side-effects such as depression, weight-loss, fatigue and 
rashes commonly found within the existing literature (Fraenkel et al, 2006; Hopwood 
and Treloar, 2005; Taylor-Young and Hildebrandt, 2009).  They spoke in general terms 
about their period of treatment being ‘a nightmare’, ‘hellish’ and ‘horrendous’.  Dean’s 
account of his previous therapy vividly captured the trauma and distress he had 
endured:   
 
…I’ll tell you exactly what happened aboot the fucking treatment.  I work in 
[states occupation], right, so basically [describes working outside at height as 
a result of his occupation], so I started the treatment, it was sound at the 
start, nae problems, but then, the brain started t’ bloody go, right, an’ I was 
coming home, an’ I was greet…crying, an’ it were at nights an’ every’hing else 
[pauses].  Three times, I did it, just about [mimes letting go whilst standing at 
height] – standing there, holding on, looking doon, an’ saying “I’ve fucking had 
enough” – easy jus’ let go, done, down, finished, wouldn’t have to worry about 
anything else.  That was enough, an’ I swear this, and I’ll tell you the truth, the 
amount a’ times I come in like that situation, I just…the brain couldn’ae handle 
what was going on… 
 
(Dean, 54, diagnosed 1997) 
 
 
For those who had witnessed others taking the medication, the experience of watching 
people struggle through a course of interferon–based treatment did little to motivate 
them for their own period of therapy.  The support provided to others was framed by a 
couple of participants as almost as exhausting as taking the treatment itself: 
 
…my partner went through it, two years ago an’ she was the worst advert for 
treatment ever, erm, she actually had like two nervous breakdowns, had to go 
to [a respite facility] an’ things.  And, I was due to start like six month after she 
had finished and, well, I needed to, sort a’ take a step back for a wee while 
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‘cause, it was actually draining, helping her through it was, took a lot oot me 
as well y’know. 
 
(Paul, 37, diagnosed 2000) 
 
 
I’d seen people who’d been on it as well, an’ that kinda scared me, because 
they were just like, ‘this is, this is killing me man, an’, I’ve never been right 
since I started the, the, the interferon’ and stuff and ‘it’s really knocking me for 
six’.  I thought, ‘oh no’ [makes scared groan], obviously worrying at times… 
 
(Gary, 38, diagnosed 2013) 
 
 
Perhaps unsurprisingly, this pervasive awareness of an arduous treatment had 
profound implications for the decisions participants made in relation to accessing HCV 
therapies.  Many of the participants related accounts of having deferred taking 
treatment in the past due to concerns about interferon-related side-effects, and 
described being content to wait for alternate options rather than putting themselves 
through this difficult, but often little understood, therapy.  Some recounted feelings of 
fear and terror at the thought of being prescribed HCV treatment and the impact this 
would have on their lives. 
 
A: Oh my God, oh…I was sort a’ like, oh my God, y’know, I, I don’t want a’ 
do it, I don’t want a’ do it.  Erm, I was, I was actually making myself 
really ill with the thought of, y’know, oh my God, I may be put on this 
stuff an’ I may be ill an’ all that an’ err, nah, it was, I was like, nah, I 
really jus’… 
 
I:  Would you have rather not had the treatment than go through it? 
 
A: Yeah, ‘cause I was that, I was that petrified of, y’know, because, you’re 
jus’ going to be, ill, an’ jus’ basically probably housebound or whatever 
or, y’know, I, I jus’ couldn’t handle that thing, where y’know, you, you 
were going to feel like crap. 
         
(Anita, 46, diagnosed 2014) 
 
 
Whilst most participants’ narratives subsequently embraced, to a greater or lesser 
extent, the arrival of new therapies, the reaction of Eilidh, an injecting drug user on a 
daily methadone prescription and who had not engaged with HCV treatment services, 
is noteworthy.  It exemplifies the tenacity of interferon folklore in the absence of any 
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tempering influences, and also highlights the impact this has on the lowly placement of 
HCV treatment within a life of competing priorities: 
 
I:  You’ve heard that treatment’s terrible [E: um-hm], so – is that, has that 
affected you, from the point of view of you thinking about treatment? 
 
E: Aye, ‘cause it’s almost put me off, it’s almost putting me off want a’ go 
for it.  ‘Cause I stay on my own… 
 
I:  Almost…? 
 
E: Almost – I know that I’m gonna have to have it, to, to get better, but 
because I stay on my own an’ I dunnae have like a…a network around 
me – I’m on a daily prescription so, if I’m no’ well I’m gonna have to try t’ 
drag myself oot a’ my bed along a’ that chemist a’ get my script, an’ the 
last thing you want a’ do, when you’re no’ well – floored – is, go oot 
galavanting for a fucking prescription. 
 
(Eilidh, 39, diagnosed 2013) 
 
 
This experientially-based and pervasive understanding of an arduous treatment for 
HCV has been produced and reinforced over more than 25 years of interferon-based 
therapy.  Individual experiences of treatment interweave with second-hand accounts 
of witnessing others on therapy, and are shared and passed on through friends, 
families, support networks and treatment services themselves, producing a version of 
HCV treatment which is tough and unrelenting, and giving rise to the ‘horror stories’ 
which in turn bolster the interferon folklore.  Whilst it is recognised within healthcare 
settings that not all individuals experience such a hard time on interferon treatment, 
almost all the participants related only negative perceptions and experiences of the 
drug, which highlights the dominating role these accounts play in the social inter-
subjective understandings of HCV therapy.  The account of Marilyn, an HCV positive 
woman who had also performed some support work for others with HCV, 
demonstrates the partiality of bad experiences being discussed over the experiences of 
those who may not have encountered as many problems: 
 
I:  Do you know people who’ve been through hep C treatment? [M: Yes] Tell 
me what you’ve heard… 
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M: I’ve had people phoning me, depression phone calls, worse thing they’ve 
ever done, wish they hadn’t done treatment, erm, it’s ruined their life, 
they’re not clear, depression, people crying, greeting on me, crying their 
eyes out, erm…an’ then I’ve other people saying that’s alright, I’ve had 
the whole spectrum.  I’ve had people suicidal on it, all their benefits been 
stopped, telling sort my benefits out, can’t get back to work, I’ve had 
other people’s been fine.  But I suppose you’re gonna hear the worst of 
things, an’ the people who’re benefits have stopped rather than the 
good luck stories… 
 
(Marilyn, 52, diagnosed 1997) 
 
 
The data generated in this study reveal a hard-wearing societal understanding of 
interferon-based HCV treatment as an arduous and gruelling ordeal.  Significantly, this 
idea of HCV treatment was spoken about with absolute conviction.  The participants 
were definite and unambiguous in the way they constructed this recurring narrative.  
Interferon-based treatment was framed as an unpleasant and punishing regimen with 
certainty and confidence.  In contrast, the discourse around new therapies emphasised 
uncertainty and ambiguity, as will now be explored. 
 
6.4 The uncertainty of interferon-free therapies 
6.4.1 A nebulous grasp 
For those participants who had engaged with HCV services, the discourse surrounding 
new treatments for HCV revealed a range of understandings about what these 
therapies might entail34.  However, a common feature of all these notions and 
projections was a prevailing impression of uncertainty and confusion.  Accounts of new 
treatment options were vague and superficial with declarations of complete ignorance 
not uncommon: 
 
I: And what is the treatment? 
 
S: I have no idea!  Probably another pill to throw in a box, I have no idea 
what the treatment is. 
 
(Sheila, 59, diagnosed 1991) 
 
                                                          
34 For Eilidh, the one participant who had never engaged with secondary care, the discourse surrounding 
new treatments for HCV was absent from her narrative entirely. 
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I: So if I asked you specifically what is the treatment now? [C: yeah] what 
would you say? 
 
C: Tell me! [laughs] 
(Callum, 52, diagnosed 1995) 
 
 
In addition to the nebulous grasp of emerging therapies demonstrated within the 
discourse, the narratives also exposed a seam of distortions and misinformation that a 
number of participants presented as factually accurate: the drugs had fewer side-
effects but didn’t work any better; the tablets would help, but not cure, the disease; 
pills would need to be taken at least every three hours.  Such misrepresentations of 
new treatments had been assimilated from hearsay and anecdotes told by friends and 
peers, illustrating the continued importance of storytelling to the communication of 
experience (Haigh and Hardy, 2011).  These inaccuracies also echoed the confusion 
which resonated throughout the testimonies around the plethora of new regimens 
becoming available.  Counsel should be cautiously sought: 
 
This is what…so it’s hearing from other people, I mean it’s good to talk to 
other people who’ve got the virus, but at the same time, you got a’…had to 
realise that there’s all different treatments an’ different stages… 
 
(Stewart, 52, diagnosed 2015) 
 
 
…there was jus’ a lot a’ misinformation about what treatment drugs people 
were on, whether it be first, the first treatment that came out, or the second 
one, or the newer one, because they’re coming out so fast… 
 
(Gary, 38, diagnosed 2013) 
 
 
The provision of written information by healthcare staff on the practicalities of taking 
the drugs did little to challenge the confusion and uncertainty.  The specifics of what, 
how many, and how often were framed as trifling concerns, with questions regarding 
side-effects and the treatment experience positioned as more significant but less 
addressed anxieties.  Despite having literature on how to take his drugs, Phil still felt 
he knew nothing about them: 
 
I, I know nothing about this stuff, all I know is err, I’ve been err, described on, 
how to take it, err, erm, an’ how many times to take it, y’know, dosage, erm, 
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frequency of dosage an’ all that, all that bumf, or whatever you wanna call it.  
Err…it, it is, it’s all in here [refers to drug booklet] look - what is [names drug], 
what does it look like, what does it, err, do…an’ all that err, stuff. 
 
(Phil, 60, diagnosed 1997) 
 
 
These insights are curious given the majority of interviews were conducted with the 
participants at the hospital outpatient clinic, often following an appointment with an 
HCV specialist specifically to discuss their potential treatment.  However, research in 
other areas has reported the amount of information correctly recalled by patients 
following discussion with medical professionals is strikingly small (Kessels, 2003; van 
der Meulen, Jansen, van Dulmen, Bensing and van Weert, 2008).  Therefore, the 
uncertainty and vague comprehension around new HCV therapies is unsurprising.  Of 
note, level of education has often been cited as an important sociodemographic 
determinant of recall (Selic, Svab, Repolusk and Gucek, 2011; Watson and McKinstry, 
2009).  Although this was not recorded in the demographics for this study, the link 
between drug use and poor educational attainment has been well made previously 
(Fothergill et al, 2008).  Another possibility is that participants actively avoided learning 
more about these new therapies for reasons which will be discussed further in due 
course. 
 
6.4.2 Suspicion and scepticism 
Expressions of suspicion and scepticism about new HCV therapies were also made by a 
number of participants.  These apprehensions about the drugs were tied to personal 
previous experience of both illicit and prescribed drug use, and also a prevailing 
perception that the medications were currently in development and ‘on trial’.  Despite 
acknowledging the reassuring and optimistic rhetoric coming from healthcare 
professionals, a discourse emerged which emphasised the importance of caution and 
experience over blind faith. 
 
For example, a belief that individuals would respond differently to the drugs based on 
unspecified innate factors was repeatedly voiced.   As such, a perception that nothing 
could be taken at face value persisted.  This notion was found predominantly amongst 
the narratives of those currently using drugs, or those who had done so in the recent 
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past, suggesting expectations of new HCV therapies were shaped by personal 
experience of illicit drug use (Maisto, Galizio and Connors, 2011).  The testimony of 
Phil, who injected heroin daily, revealed measured expectations of new HCV therapies 
in line with his considerable drug experience: 
 
I’m not expecting anything, I, I wait for, for what’s gonna happen.  If it turns 
out to be err, something that affects me, ‘cause everything affects everybody 
differently, everyone’s different, every drug affects everybody differently as 
you know, err…it, it might be, I might be jus’ one of these people err, these 
awkward, err buggers [chuckles] that err, that erm…it, it doesn’t, err, agree 
with. 
 
(Phil, 60, diagnosed 1997) 
 
For those co-infected with HIV, the familiarity of antiretroviral medications also 
imbued their narratives with significant drug experience.  Doubts around novel HCV 
drugs were discussed in relation to understandings of the HIV therapies they had been 
prescribed over the years.  All HIV/HCV co-infected participants had extensive histories 
of various HAART regimens, and a cautionary rather than all-embracing tone was 
adopted when it came to HCV therapy.  Suspicions were voiced in relation to the 
perceived lack of scientific knowledge of the new drugs, rooted in their experience of 
failed HIV regimens, and novel HIV therapies which had subsequently been found to 
produce unforeseen side-effects.  Hepatitis C therapies would need to be monitored 
closely, and treatment expectations echoed their experience with HIV drugs: 
 
I: What do you envisage that treatment to be? 
 
S: [long pause] I think it would be a matter of me being in [the hospital] for 
a few days, to see that it’s settling down ok, then let me out and come 
back an’, y’know, just keep it, a good eye on me. 
 
I: So similar to HIV meds? 
 
S: Yeah, yes.   
(Sheila, 59, diagnosed 1991) 
 
 
During the study, the main recruitment site also hosted two phase III randomised 
controlled trials for new HCV drugs, for which a number of participants had been 
approached by members of their multidisciplinary team.  An awareness of clinical trials 
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was therefore common amongst the participants, and often underpinned many 
aspects of their testimonies.  Apprehensions and suspicions about new HCV therapies 
arose from their perceived status as ‘trial drugs’, and were founded on the uncertain 
and unknown nature of such medications. 
 
I mean the other night there, although there’s no’ been…I don’t think there’s 
been any deaths through the treatment an’ things like that, but, I still sat an’ 
wrote [my child] a letter an’ things like that jus’ in case anything did go wrong.  
Jus’ explaining to her that, this only happened because I was trying a’ make 
things better for us an’ things like that… 
 
(Danielle, 43, diagnosed 2009) 
 
 
This perception was not limited to only those drugs actually being used in clinical trials, 
but more commonly applied in blanket fashion to refer to all new HCV therapies which 
were available in the clinic.  A couple of participants who were not considering taking 
part in clinical trials still referred to themselves as ‘guinea pigs’ when contemplating 
their potential course of treatment, emphasising the novelty and nascent nature of the 
regimens.  For a number of participants, scepticism was evident surrounding how 
representative and trustworthy the results of clinical trials may be, illustrating the 
perception that despite being licensed, these drugs were still largely unknowns: 
 
I ken they’ve obviously done clinical tests an’ that, but, that’s in a sort a’ 
controlled environment, but when you’re talking about people who’re, normal 
people who’re suffering from depression an’ drug problems an’ all a’ that, 
y’know what I mean, that kind a’ goes oot the window, that clinical test… 
 
(Keith, 54, diagnosed 2004) 
 
 
The wariness of participants in relation to medications framed as ‘trial drugs’ can be 
illuminated by consideration of their relatively untested nature, and the inherent risks 
the actual medications may pose (Cox and McGarry, 2003).  However, a further 
narrative strand embedded within the existing literature also offers some insight.  
Mistrust of the pharmaceutical industry and the drug development process has 
previously been observed in studies focused on patient attitudes to medication use 
(Bezreh, Laws, Taubin, Rifkin and Wilson, 2012), and may have influenced the 
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participants’ discourse here.  Disgust at the high costs of the drugs, and denigration of 
pharmaceutical giants were familiar refrains within the data: 
 
I think pharmaceutical companies should be shot!  They should get down a 
place.  It doesn’ae cost that much to make, it’s jus’ them making money oot 
the hospital, playing wi’ people’s lives. 
(Stewart, 52, diagnosed 2015) 
 
6.4.3 Conflict 
The uncertainty around access to new therapies, and the contemporaneous use of 
interferon-based regimens alongside interferon-free options created a sense of conflict 
for the participants.  Whilst new, less onerous therapies were available, the chances of 
accessing these drugs in the immediate future were often deemed to be slim due to 
the need to fit stringent criteria.  Decisions about HCV treatment were therefore 
framed as a trade-off: living with the virus and waiting indefinitely for access to 
improved therapies, or taking an interferon-based option: 
 
[if the doctor] says there’s a chance we could gi’ you this new treatment, but 
you’ll have to wait two year or three year, then I would wait y’know, but if 
they says no that’s no’ going to happen, then I would jus’ have to deal wi’ it 
an’ get on wi’ [the interferon]… 
(Kelly, 34, diagnosed 2008) 
 
 
Whilst some participants eschewed the interferon option, in favour of an uncertain 
wait, others embraced whatever treatment regimen was offered.  This latter approach 
was underpinned by the protracted and challenging journeys to treatment which many 
participants described, and which created a sense that they had already waited long 
enough.  Some participants spoke about the years they felt they had already wasted by 
not addressing the infection previously, and repeatedly voiced a desire to ‘jus’ get on 
wi’ it’35.  For others, a prevailing sense of wanting to be free of HCV at any cost 
developed, and a willingness to accept the ordeal and disruption of interferon-based 
regimens pervaded: 
 
I mean, the end game is, erm, I want a’ go through the treatment, if, if it has 
to be a six month one that’ll have to be, I mean I’ll, have to grin an’ bear it eh?  
 
(Paul, 37, diagnosed 2000) 
                                                          
35 Gary, 38, diagnosed 2013  
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Because I feel like I have a, a, a time bomb inside my body, that it can trigger 
any, any minute (…) I’d rather take the twenty-four injections now, all at once!  
Another box!  
(Peter, 51, diagnosed 2015) 
 
 
This discourse echoes the acceptance of health inequalities and lack of entitlement 
that disenfranchised HCV communities have become acclimatized to, previously 
discussed in chapter four36 (Wolfe et al, 2015).  The readiness to accept an inferior 
treatment in an age of interferon-free therapies positioned the participants as 
submissive recipients of healthcare, rather than active and emboldened consumers, 
emphasising weak and undeserving notions of therapeutic citizenship (Rhodes et al, 
2013).  Within an age of improving therapy, the experience of seeking treatment for 
HCV constructed in the narratives was one of passivity and deference, to both medical 
authority and economic restraints. 
 
6.5 Discussion 
6.5.1 A return to theory: appraisal and coping with uncertainty 
A discourse of uncertainty was woven throughout the participants’ narratives of new 
HCV therapies.  The multiplicity of available regimens, the perception of their new and 
‘untested’ nature, and the doubts around being able to access the drugs all 
contributed to the construction of new HCV treatments as ambiguous unknowns, often 
met with wariness and apprehension.  However, this exploration of the antecedents of 
uncertainty gives only partial insight into the concept, as it is how uncertainty is 
subsequently appraised and coped with that provide Mishel’s theory of uncertainty in 
illness with its second and third key themes. 
 
Mishel (1988; 1990) proposed that uncertainty is neutral until it is appraised as either a 
danger or an opportunity, with such appraisals established on individual attitudes, 
beliefs and personality dispositions.  She suggested that the appraisal of uncertainty as 
an opportunity would occur when the alternative is a negative certainty, or where not 
knowing is better than knowing (Greenwood, Mackenzie, Wilson and Cloud, 2009).  
Whilst this aspect of the theory has not been applied to advances in drug therapy 
                                                          
36 Section 4.3.2 
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before, it resonates with the findings discussed in this chapter.  Interferon-based 
treatment was unequivocally constructed as a negative certainty: it would be a 
gruelling, protracted and toxic endeavour, which placed newer therapies as uncertain 
opportunities.  The uncertainty ascribed to interferon-free treatments was preferable 
to the certainty of a negative experience with interferon-based regimens for the 
majority of participants.  The uncertainty was a desirable uncertainty, as were it to 
disappear, the belief in a positive treatment experience could be destroyed (Mishel, 
1988).  The maintenance of uncertainty served as a coping strategy, preserving hope 
for the future (Hummel, 2016). 
 
Maintaining this preferable uncertainty required buffering strategies aimed at blocking 
additional information which may have served to challenge the uncertain status quo 
(Baldwin, 2005).  Buffering strategies include evasion and selective ignoring (Mishel, 
1988), which sheds new light on previous discussion of how participants expressed 
poor information recall and limited understanding of new therapies.  By actively 
avoiding further information regarding new HCV treatments and producing a narrative 
which emphasised unfamiliarity and ignorance, the participants circumvented any 
challenges to their hopes for these drugs.  Knowing less, or constructing a persona of 
knowing less, maintained the desirable uncertainties which had been constructed 
around these medications, and upheld their appraisal as opportunities.  Similarly, by 
framing these treatments with scepticism and suspicion, uncertainty was preserved 
and sustained, allowing participants to maintain hope, or at least avoid having their 
hopes dashed, and adapt to this new era of therapy. 
 
6.5.2 Theme summation 
This chapter has focused on the primacy of uncertainty within the collected narratives.  
Whilst uncertainty has long been observed as an intrinsic feature of both chronic and 
acute illness, it is the exploration of uncertainty with regard to the evolving landscape 
of HCV therapy which provides relevant and novel insight here.  The negative certainty 
with which a period of interferon-based therapy was constructed by the participants 
has transitioned to a desirably uncertain framing of interferon-free regimens.  This 
uncertainty is maintained by information avoidance, suspicion and scepticism: 
strategies which work to sustain hope.  Whilst this juxtaposition of scepticism and 
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hope may seem paradoxical, it underlines how uncertainty was framed as an 
opportunity within the narratives.  Maintaining a protective veil of uncertainty (by 
being sceptical, suspicious and poorly informed) allowed the opportunity of new 
therapies to persist.  This argument gains clarity if considered from a different 
perspective: if participants viewed these much vaunted drugs as guaranteed, cast-iron 
certainties, then any perceived challenges to that construction could destroy their 
hopes entirely.  Uncertainty was therefore beneficial, protective and advantageous to 
the lived experience. 
 
This narrative contrasts with the conviction and assurance which greets new HCV 
therapies in much of the medical literature.  Interferon-free regimens have been 
framed as ‘a triumph’ (Pawlotsky et al, 2015a), with ‘spectacular response rates’ 
commonly eulogised (Chung and Baumert, 2014) supported by a ‘robust evidence 
base’ (Thiagarajan and Ryder, 2015).  Note the discussion of pharmaceutical 
developments in chapter one.  The disparity between the ubiquitous medical discourse 
of success, and the perception of a protective and desirable uncertainty found within 
this study is striking, and has implications for clinical consultations.  Healthcare 
professionals’ attempts to quell misgivings, dispel rumour and resolutely educate may 
not always produce the desired response in those infected with the virus.   
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Chapter 7 
The lived experience of interferon-free treatments for hepatitis C 
 
7.1 Introduction 
Following their initial interviews, eight participants who subsequently completed a 
course of interferon-free HCV treatment were invited to meet with the researcher 
again for a further semi-structured interview more specifically focused on their 
treatment experience.  These interviews were conducted at the hospital out-patient 
clinic which had prescribed their medication, and took place between September 2015 
and March 2016.  Four of the participants were interviewed on their final day of 
treatment, with the others meeting the researcher after routine follow-up clinic 
appointments between two to four weeks after the end of therapy.  Whilst an 
interview schedule was used to structure the discussion (appendix C), the transcripts 
from the participants’ initial interviews were also employed to revisit some of their 
specific pre-treatment expectations and beliefs. 
 
The aim of this chapter is to present the thematic analysis of this treatment-related 
interview data, focusing on three overriding themes which encompassed the 
experience of interferon-free therapy37.  The themes are described and developed 
individually in order to structure and explore the intersubjective commonalities which 
unified the participants’ narratives.  However, it is only by considering how these 
themes converge and interact, and the similarities, tensions and discrepancies 
between them, that a richer and more complete insight into the lived experience of 
interferon-free HCV treatment can be expounded.  The relationship between the three 
themes will therefore be examined. 
 
The three themes which resulted from the thematic analysis of this interview data 
have been named ‘expectations and realisations’, ‘an honour and a pleasure’ and 
‘treatment needs’.  The naming of these themes sprang directly from the immersive 
and iterative experience of analysis, and aim to encapsulate the insights and 
understandings gained (Braun and Clarke, 2006).  The theme ‘expectations and 
                                                          
37 The findings from this chapter have been published separately, and are found in appendix A 
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realisations’ describes the influence that interferon continued to cast over the 
interferon-free treatment experience, contrasting the practicalities of taking 
interferon-free therapy and its associated side-effects with preconceived notions.  ‘An 
honour and a pleasure’ integrates the persuasively upbeat and optimistic discourse 
around taking interferon-free therapies which pervaded the narratives, with the 
concurrent feelings of guilt and luck which were also manifest within the participants’ 
accounts.  Finally, the theme of ‘treatment needs’ grew from the combination of two 
elements, the discourse concerning support, and the participants’ approaches in their 
search for treatment efficacy.   
 
7.1.1 The participants 
Prior to examining these themes in more detail, it is necessary to provide some context 
to the individual participant testimonies.  The eight interviewees were a purposefully 
diverse group, whose eventful journeys to HCV treatment and personal circumstances 
were often conspicuous in their narratives.  As such, a brief precis of each participant’s 
disclosed history and social circumstances provides some background context and 
perspective to their experience (table 4). 
 
7.1.2 A shifting landscape 
Whilst these participants all received interferon-free treatment for HCV, they did not 
all receive the same drug combination.  During the study, national guidelines and local 
recommendations for the treatment of HCV with DAAs were revised and amended 
continuously, in response to economic considerations and emerging scientific 
evidence.  For example, HIS and NHS National Services Scotland (2015b) published 
guidelines for the treatment of HCV in August 2015 recommending the combination 
pill Harvoni® as first line therapy for those with HCV genotype 1.  Only four months 
later, these recommendations were revised to favour first line treatment with the 
combination drug Viekirax® and Exviera® (HIS and NHS National Services Scotland, 
2015a) following a contract award by NHS National Procurement to the 
pharmaceutical company AbbVie in September 2015, worth over £20 million (Public 
Contracts Scotland, 2015). 
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Table 4: Biographical information on the eight participants who shared their experience of interferon-
free HCV treatment.  
 
Participant Biographical Profile 
Danielle 43-year-old female, diagnosed HCV positive in 2009 most likely from sharing 
injecting equipment. Intermittent history of engagement with HCV care since 
that time.  Currently prescribed methadone following a long history of 
injecting drug use.  Lives with her mother and youngest child. 
 
Gary 38-year-old male, diagnosed HCV positive in 2013, identifies injecting drug 
use as the cause.  Currently receiving a methadone prescription, and 
disclosed regular cannabis use in addition.  Lives with daughter and son-in-
law, and describes himself as a voluntary worker.  Relates concurrent anxiety 
and depression as on-going concerns, along with other physical 
comorbidities. 
 
Happy 51-year-old female, lives with her two children and grandchild.  Reports a 
history of significant alcohol use, but despite having partners who were 
regular drug injectors, denies any use herself.  Diagnosed in 2005, presumes 
infection is sexual in origin.  Currently unemployed. 
 
John 54-year-old male, diagnosed in 2012.  Reports a brief history of injecting 
drug use in the 1980s, and dates the infection from this time.  Lives with his 
wife, and has a supportive wider family.  Works full-time and has deferred 
HCV treatment in the past due to concerns over side-effects. 
 
Keith 54-year-old male, diagnosed in 2004.  Has a long history of injecting drug use 
and extensive prison experience.  Co-infected with HIV, is currently stable on 
HAART and receives a methadone prescription.  Lives alone, unemployed, 
and describes depression as a significant co-morbidity.   
 
Peter 51-year-old male, diagnosed in 2015.  Self-employed running his own 
business, and living with his long-term partner, the source of infection 
remains an unresolved issue. Reports no significant medical history or drug 
use, and is a social alcohol user. 
 
Steve 45-year-old male, diagnosed in 2005.  Describes himself as being in recovery 
for the last three years following an extensive history of drug use.  Has 
comorbid psychiatric diagnoses, is currently unemployed and lives alone.   
 
Stewart 52-year-old male, diagnosed in 2015, confused as to the origin of his 
infection.  Comorbidities include anxiety and depression, however remains in 
full-time employment.  No history of drug use reported, although alcohol use 
features regularly in his discourse.  Lives alone, and has a long-term partner. 
 
 
This rapidly shifting landscape was further complicated by variations in treatment 
regimens which were governed by the degree of liver disease and specific HCV 
genotype of individual participants.  In addition, the hospital out-patient clinic which 
prescribed the HCV therapy was also a centre for a number of phase III RCTs for 
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unlicensed DAAs, which were recruiting in tandem with this study from the same 
cohort of patients.  Due to a combination of all these factors, variation existed 
between the interferon-free regimens which were prescribed, and further details of 
the four different regimens used amongst the eight participants are given in table 5.  
However, the primary focus of analysis within this chapter is not the variation between 
interferon-free treatments, but how HCV treatment is understood and experienced 
when it no longer includes the one drug, interferon, which has defined and 
characterised it for over 20 years.  In order to protect participant anonymity, the 
specific treatment each individual received has not been specified.  However, whether 
this treatment was a single or multi-tablet regimen has been noted alongside 
participant quotes, to illustrate how the themes described were common to all and not 
connected to specific therapies. 
 
 Table 5: Details of the four different HCV treatment regimens taken by participants. 
 
Treatment Regimen Single- or Multi-
Tablet Regimen 
Number of 
Participants 
Sofosbuvir/ledipasvir (Harvoni®): combination tablet taken 
once daily.  Licensed for use within Scotland for the 
treatment of HCV genotype 1 and 4, and for restricted use 
in genotype 3 (Scottish Medicines Consortium [SMC], 
2015a). 
 
Single-Tablet 4 
Ombitasvir/paritaprevir/ritonavir (Viekirax®) + dasabuvir 
(Exviera®) + ribavirin: a combination tablet taken once 
daily, in conjunction with two twice daily medications.  
Licensed within Scotland for the treatment of HCV 
genotype 1 (SMC, 2015b). 
 
Multi-Tablet 2 
Sofosbuvir (Sovaldi®) + daclatasvir (Daklinza®) + ribavirin: 
combination of two once daily tablets in conjunction with 
one twice daily medication.  Licensed in Scotland for use in 
the treatment of patients with significant fibrosis or 
compensated cirrhosis in genotypes 1,3 and 4 (SMC, 
2014). 
 
Multi-Tablet 1 
Glecaprevir + pibrentasvir: fixed dose combination with 
pangenotypic action, currently in phase III clinical trials.  
Not currently licensed for use in Scotland (UK Medicines 
Information, 2016) 
 
Single-Tablet 1 
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7.2 Theme: Expectations and realisations 
7.2.1 Interferon’s influence 
Despite each participant receiving treatment for HCV with an interferon-free regimen, 
the discourse surrounding treatment expectations was permeated and entangled with 
societal understandings of interferon-based therapy.  The manner in which 
participants spoke about interferon emphasized and reinforced the fiercely negative 
societal perception of this drug (see chapter 6) and accentuated its disconcerting and 
distressing aspects over any curative benefits it may have shown.  The influence of the 
drug that defined and characterised HCV treatment for over 20 years was prominent 
within the narratives of the participants. ‘Normal’ life would surely be forfeit for the 
duration of their interferon-free therapy, and the potential cure would come at a 
short-term cost: 
 
…I mean, if I spent three months of feeling a bit groggy, tired and miserable 
and I come out in the end of the [hesitates over next few words], with err, you 
know, with err, good err, blood, err then it’s, you know, it’s worth that 
sacrifice… 
(John, 58, multi-tablet regimen) 
 
…‘cause I jus’ said that to my daughter it must a’ been about two-three days 
ago, I said it’s bizarre, I said like, here I am, as I am, all, getting on wi’ it, an’ in 
three days time I start medication, erm, I could, look like I’m, I’m on death’s 
door.  I said, how bizarre is that, you know what I mean, when you think, that 
there’s actually something wrong wi’ me but you’re aw’right, up until you take 
the medication and that’s when, symptoms kick in.  
 
(Gary, 38, multi-tablet regimen) 
 
Common side-effects of interferon such as lethargy, depression and weight-loss were 
referenced explicitly as expectations for interferon-free treatment by a number of 
participants.  These expectations were not just trivial speculation however, as 
participants discussed how practical preparations were made to forestall the impact of 
these perceived inevitabilities.  For Stewart, the strength of his beliefs around the 
detrimental effect that HCV treatment would have on his physical and emotional 
wellbeing was demonstrated in the meticulous planning that accompanied his first 
dose of the drugs: 
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First tablet, left [the clinic], went home, sick bowel, towel, duvet, tissues, 
waiting for it to come on. (…) I prepared ready a’ be sick, I’d, I’d sent my 
partner away in case I was, really ill, know, kind a’, I don’t want a’ be sick or, 
or screaming at people.  I, I, I thought I was gonna be agitated, angry... 
 
(Stewart, 52, single-tablet regimen) 
 
 
Interferon was styled as a powerful drug within the narratives, repeatedly referred to 
as ‘strong’ by a number of participants.  This perception of pharmacological strength 
was maintained when conversation turned away from interferon and towards DAAs.  
Participants believed that drugs still needed to be potent and powerful in order to 
treat the disease, and this perceived strength of drug equated with the expectation of 
physiological collateral damage.  The idea of ‘no pain no gain’ prevailed; an unpleasant, 
demanding and strenuous period of treatment must surely result from drugs 
formidable enough to eradicate such a virulent and persistent virus.  The notion that 
effective treatment must be accompanied by toxicity and short-term suffering is not 
unique to HCV.  The concept of ‘no pain no gain’ has long been discussed in the realms 
of oncology, where reports of cancer patients requesting more aggressive and noxious 
therapies in the belief that these equate with improved efficacy are intermittently 
found (Gradishar, 2015)38.  A recent qualitative study describes the delight of one 
participant with breast cancer whose hair began to fall out during chemotherapy 
(Trusson and Pilnick, 2016): due to a lack of side-effects she had been convinced her 
treatment was ineffective, however the onset of alopecia assuaged her doubts.  
 
In line with the ‘no pain no gain’ mentality, a general pre-treatment strategy of 
‘prepare for the worst, hope for the best’ prevailed amongst the participants.  
Although frequently reporting that they had been reassured by healthcare 
professionals about the lack of side-effects, accounts of preparing for the worst 
created a compelling and undeniable narrative within the data, with ‘the worst’ 
commonly framed in terms of interferon folklore.  This strategy served as a mental 
safety-net for participants, safeguarding them against the optimistic expectations of 
                                                          
38 This belief has some basis in the research literature; for example, the development of an acne-like skin 
rash during treatment for non-small cell lung cancer has been shown to be predictive of overall disease 
free survival (Liu et al, 2013).  Similarly, women who experience hot flushes whilst treated with 
tamoxifen for early-stage breast cancer may be less likely to develop a recurrence (Mortimer et al, 
2008). 
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treatment that healthcare staff advocated, but which clashed too greatly with their 
societal understanding of how HCV treatment would be: 
 
I don’t know how this is gonna affect me.  I’ve prob’ly been, lookin’ at it, ‘cause 
it’s jus’ how I do is – worse-case scenario, this is gonna wipe me out, I’m gonna 
feel completely utterly terrible, hoping, well no hoping but if anything, if it’s 
not as bad as that, then at least, I can balance it, it’s jus’ my, my thought 
process an’ that’s jus’ kinda how I work things, I look at worse-case scenario 
an’ if it’s not that bad then, hey – that’s a bonus to me as far as I’m 
concerned…  
 
(Gary, 38, multi-tablet regimen) 
 
Once treatment had started, a sense that participants continued to await the expected 
onslaught of side-effects persisted.  Whilst mild symptoms and treatment-related 
ailments were acknowledged and dealt with, there remained a feeling that these were 
only a precursor or a prodrome for more significant and unmanageable complaints yet 
to come.  Participants described a period of constant waiting, which was ultimately 
unwarranted: 
   
 …this tiredness is gonna trigger something, like vomiting, or really really being 
really exhausted or something; but it never really does. 
 
(Happy, 51, single-tablet regimen) 
 
The pervasive understanding of the experience of HCV treatment remains grounded in 
interferon folklore, shaping contemporary discourse around treatment expectations.  
This intersubjective understanding of HCV treatment as gruelling and arduous counters 
any assurances of minimal side-effects and an easier time on therapy, fundamentally 
mitigating their impact.  The disparity between the social understanding of HCV 
treatment and the discourse from healthcare professionals around these new 
medications leads to individuals hoping for the best, but ultimately preparing for the 
worst. 
 
For the majority of participants, the realisation of their worst fears and expectations 
did not materialise during their therapy39.  However, a discourse surrounding 
                                                          
39 The exception to this was Gary, who presented a nonconforming case.  This will be discussed in due 
course (section 7.5) 
167 
 
treatment side-effects did become evident as analysis of the post-treatment data 
progressed.  Examination of these narratives revealed a generally mild and 
manageable experience, significantly removed from the imagined horrors of therapy 
which had been so vividly constructed. 
 
7.2.2 Side-effects 
A number of familiar physical side-effects recurred within the participants’ accounts of 
their treatment experience.  Headaches were described by the majority of participants, 
commonly depicted as occurring near the start of therapy and often framed as a sign 
that the body was adapting to the medication.  The headaches ranged in severity, 
described as anything from transient and quickly resolving, to an intensity that had not 
previously been encountered: 
 
Err, headaches are like, supposed to be a really common cause, but I’ve never 
experienced headaches like that, it’s like migraines, an’ err, I’ve had it similar 
before likes drinking energy juice a lot, an’ then stopping it, an’ that gives you 
a, a blinding headache, rights, an’ that’s what it reminded me of… 
 
(Steve, 45, multi-tablet regimen) 
 
Similarly, bouts of nausea were also fairly commonplace, particularly at the beginning 
of the treatment, with a lack of appetite and increased lethargy also denoted as 
episodic features of therapy.  However, these physical complaints were rarely stressed 
or emphasised by the participants, more commonly mentioned in passing or casually 
alluded to as minor inconveniences.  Descriptions of specific physical ailments were 
embedded within concurrent narratives of feeling well, and having little to complain 
about: 
 
Erm, because physically I was fine, I cannae say there was anything really bad, 
the first two weeks, the headaches an’ I got quite a lot a’ bleeding noses, but 
then I jus’ started sort a’ taking painkillers for the headaches, then, when I 
came [to the clinic], I had quite a bit a’ constipation, so they gave me 
something for that, but that was it, nothing else. 
 
(Danielle, 43, single-tablet regimen) 
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Participants were able to manage their physical side-effects with little difficulty, 
relating strategies which encompassed both alleviative medications and adaptive 
behaviours.  Daily routines were slightly altered, dietary intakes were adjusted and 
plans were temporarily put on hold.  However, none of this was framed as particularly 
onerous or taxing.   A couple of participants also hesitated to ascribe these general and 
non-specific complaints to the HCV treatment at all, noting other potential sources and 
explanations within their narrative: 
 
I got two days of a very - I feel like I’ve been run by a bus, y’know, an’ I 
thought, ahh, that must be the flu symptom they were talking about, an’ I feel, 
an’ I feel like no energy, none, two three o’clock in the afternoon I jus’ want to 
go to bed, but, I don’t know it was the tablet?  Or, I got the, the flu jag before 
the start a’ the treatment… 
  
(Peter, 51, single-tablet regimen) 
 
Whilst most of the physical side-effects within the narratives appeared routine, 
expected and reasonably innocuous, a couple of participants experienced side-effects 
which had not been anticipated.  Stewart related his surprise at the effect his therapy 
had on his libido, but presented this as a temporary and manageable situation, and 
one that hadn’t impacted on his relationship to any great extent: 
 
…it’s no’ very good for your sex life (…) it’s no’, it’s a, it’s a passion killer havin’ 
a’ use fucking durex anyway like, it’s like brewer’s droop, that’s the way, I 
mean, I’m going out for a freebie dinner tonight wi’ [my partner], an’ she’s 
already jus’ decided that one way or the other we’re going away fae the 
weekend [laughs], so we do talk, y’know what I mean, it’s no’ like I’m saying 
oh you jus’ lie on that bed I’ll go a’ that bed, so it’s, we have a laugh about it 
as well of course… 
 
(Stewart, 52, single-tablet regimen) 
 
The removal of interferon from the HCV treatment regimen had not therefore 
removed the physical aspect of therapy from the equation.  Somatic side-effects 
continued to be experienced, requiring action from the participants to address and 
manage them, but the overriding impression was not of dramatic disruption, but of 
minor inconvenience.  The weight of importance placed on these physical ailments 
within the narratives was low, their significance often minimised by participants 
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comparing them to what they understood of interferon-based therapy, their own 
preconceived notions of treatment, and to challenging times in their own life when 
they had experienced much worse.   
 
Physical side-effects were not the only ailments attributed to HCV treatment however.   
A number of participants also related accounts of psychogenic ill-health, which they 
resolutely ascribed to their HCV therapy.  This discourse was predominantly situated 
within the narratives of participants who disclosed a history of mental illness pre-HCV 
treatment, and was virtually absent from those for whom mental health had never 
previously been a concern40.  A couple of participants described exhausting alterations 
in their mood, spontaneously fluctuating from happiness to dejection: 
 
Well, I’d say, emotionally, it’s very draining, one minute you can feel on top a’ 
the world, an’ then within half an hour, forty-five minutes, you’re so 
depressed, everything jus’ seems - hectic. 
 
(Danielle, 43, single-tablet regimen) 
 
Emotional side-effects were most commonly framed in terms of low mood and 
transient depression, and their detrimental impact on relations with family and friends 
were often emphasised.  However, the psychological impact of interferon-free 
treatment wasn’t limited to this, and for Steve, who reported multiple additional 
psychiatric diagnoses, a more debilitating experience emerged: 
 
I struggle really bad daily now, I mean likes a’, err, it’s got that bad it’s like, 
really bad.  Don’t know how it done it like, but erm, even when I’m at [the 
respite facility], I, I could sit there in, in my room, an’ jus’ have a full blown 
panic attack going wow, where did that come from? At home it’s worse, 
y’know, err, it’s terrible, it’s absolutely terrible, y’know.  Maybe it’s the anxiety 
of the - I don’t know, it could be anything, it could be anything, but, it’s got 
worse since I took the tablets, ten times worse. 
 
(Steve, 45, multi-tablet regimen) 
                                                          
40 The exception to this was Happy, who had no history of mental illness but spoke generally of “feeling 
moody” during her interview.  Happy was treated with an interferon-based regimen initially prior to 
being switched to an interferon-free course, and her narrative was somewhat ambiguous as to whether 
her emotional difficulties were experienced during the interferon-free period in addition to the 
interferon-based therapy. 
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After some brief reflection, Steve offered potential explanations for his emotional 
instability which encompassed more than the pharmacology of the treatment.  He 
acknowledged that the physical act of having to take HCV therapy twice a day had 
brought it to the forefront of his mind, and positioned his future as contingent on the 
outcome.  For Steve, a period of HCV treatment meant confronting a reality he had 
previously been able to put to one side, and this in itself generated anxiety and 
concern: 
 
…it’s got a lot to do wi’ the mental side of it like, y’know, because you’re really 
wanting this treatment a’ work an’ you’re conscious of it ‘cause you’re taking 
the morning an’ at night, you’re conscious of always being on this treatment, 
so likes, when I wasn’t I, I’d forget about it for months, I forgot all about I had 
hep C.  Y’know what I mean?  
 
(Steve, 45, multi-tablet regimen) 
 
Similarly, Danielle’s narrative positioned undertaking HCV treatment as an act which 
allowed increased scrutiny into other aspects of her life, creating additional strain and 
worry.  She repeatedly related concerns about how others would appraise her ability 
to look after her child during therapy, magnifying the vulnerability she already felt as a 
‘drug-using mother’.  These anxieties focused her to present a version of interferon-
free HCV treatment where she coped and managed with ease, but the disparity 
between this and her actual experience generated significant stress: 
 
I’m no’ gonna say everything’s perfect, because my housework an’ things like 
that sort a’ hit rock bottom an’ that, ‘cause I was exhausted, but, where [my 
child] was concerned, I knew I had to keep on top a’ that or people would 
start, right, well we’ll jus’ get a social worker out to see how you’re coping, so, 
I jus’ pushed myself a’ make sure it was done. 
 
(Danielle, 43, single-tablet regimen) 
 
The physical act of taking interferon-free HCV treatment, irrespective of the specific 
drug combination, appeared to exacerbate pre-existing mental illness in some 
participants.  Anguish, depression and emotional strain during the treatment process 
grew from the importance participants placed on being cured of HCV, and from the 
increased scrutiny they felt a period of treatment placed them under.  However, these 
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difficulties were still largely framed as being considerably less onerous than if 
prescribed an interferon-based therapy.  For example, the account above appeared 
towards the end of Steve’s narrative, almost as an afterthought or addendum.  Earlier 
in his interview Steve had described his treatment as “nowhere near as bad on your 
mental health as [interferon]” and how he “thought the medication was fantastic”.   
The impact on mental health from interferon-free treatment was considered and 
framed in respect of the imagined greater influence that interferon-based therapy 
would have, and, as such, its significance was diminished and symptoms became 
manageable. 
 
Whilst the discourse surrounding the experience of side-effects created an impression 
of largely unmet expectations, there were still aspects of interferon-free treatment 
which the participants framed as more problematic than they had anticipated, most 
notably the number of tablets they were required to take. 
 
7.2.3 Practicalities 
A number of factors relating to the practicalities of taking the medications became 
evident within the participants’ narratives.  These formed a further thread to the 
theme of expectations and realisations.  Despite a preponderant impression of the 
side-effects of interferon-free therapy being comparatively innocuous, every 
participant noted that their experience had been shaped by other difficulties which 
they had encountered during the treatment period.  The physical size of the tablets 
and the difficulty in swallowing them were emphasised by a number of participants. 
For those on multi-tablet regimens, a sense of being misled as to the simplicity of 
treatment became noticeable: 
 
The, the biggest thing that I think, I find was erm, the fact when the new 
treatment came out it was, it sounded more like it was jus’ like more or less a 
single or two single type a’ tablets (…) even though the course was of three, 
four, five – ten different tablets that I was taking during the day anyway, so, I 
think that, that was the only thing that I was slightly sceptical in the way that 
that came across, but that’s still a hell a’ lot a’ drugs to be packed into a small 
amount, an’ it still is a hell a’ lot smaller compared to…what the older 
treatments could a’ been, so, I get that, but it is jus’ the way it kinda sounds. 
 
(Gary, 38, multi-tablet regimen) 
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The accounts of participants on multi-tablet regimens underscored how the therapy 
was not taken in isolation, but incorporated into a life which was often already 
crowded with complex polypharmacy.  The HCV treatment was an addition to 
catalogues of pre-existing medications such as opioid substitution therapy, anti-
psychotics, anxiolytics, antiretrovirals, analgesics and other over the counter remedies 
which constituted an existing everyday routine.  In addition, adjuncts to HCV treatment 
to combat nausea, headaches and other side-effects were also added into this 
expanding pill burden: 
 
Erm, but they, they’re quite hard, hard to swallow, ‘cause there’s quite a lot ‘a 
tablets, especially, and you’ve got to take your other tablets with them as well 
so you end up like taking a big pile of them… 
(Steve, 45, multi-tablet regimen) 
 
 
This discourse contrasts with the accepted assertions of low pill burden with 
interferon-free HCV treatments expounded in much of the published literature.  For 
example, Lam, Jeffers, Younoszai, Fazel and Younossi (2015) and Coppola et al (2015) 
both explicitly cite low pill burden as one of the benefits of interferon-free treatment 
in the abstracts to their reviews of second-generation DAAs.  However, they fail to 
contextualise or quantify this within the articles.  The casual and nonchalant use of the 
phrase ‘low pill burden’ belies that it is not an absolute truth in relation to new HCV 
therapies, and for those on multi-tablet regimens within this study, pill burden 
remained a significant feature of their course of treatment.  The importance of this 
narrative is evident when research from other medical fields is considered.  For 
example, lower pill burden and reduced dosing complexity have been related to better 
adherence in studies focused on HIV antiretrovirals (Nachega et al, 2014), and in 
haemodialysis patients with end-stage kidney disease (Ghimire, Castelino, Lioufas, 
Peterson and Zaidi, 2015) amongst others.  Similarly, recent qualitative work from 
India has described pill burden as an influencing factor in the high percentage of 
patients lost to follow-up whilst receiving treatment for multi-drug resistant TB 
(Deshmukh et al, 2015; Shringarpure et al, 2016).  The significance of pill burden to 
treatment adherence and completion is well described within the scientific literature, 
emphasising the importance of policy-makers including patient experience of 
interferon-free HCV treatments in their decisions concerning first-line therapies. 
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Given the need to take these regimens consistently, routine and aides-memoire 
became important in structuring the course of treatment.  Participants on both single- 
and multi-tablet regimens described using calendars and alarms to keep track of their 
adherence, as well as appending it to existing regimes: 
 
I: How did you remember? 
 
D: By setting my phone alarm.  I missed it once, when I came my first time, 
erm, but I managed to work all that out after that, I made sure I had my 
alarm set at a certain time an’ jus’ took them. 
 
I: And it fitted into your life? 
 
D: Aye, it didn’ae sort a’ bother me, I think because I jus’ took them along 
when I was taking my methadone every morning… 
 
(Danielle, 43, single-tablet regimen) 
 
 
…remembering was alright because I knew I had to take them every day, an’ I 
didn’ae want a’ miss any, ‘cause I didn’ae want a screw up, so that’s why I 
was, I always remembered to take them, always made a point [repeats as a 
mantra] - tablet the night, tablet the night… 
(Keith, 54, single-tablet regimen) 
  
Despite these practises, reports of missed doses were still apparent.  Some 
participants on multi-tablet regimens described becoming lackadaisical and forgetful 
as the treatment course progressed, or struggling to fit multi-daily dosing into their 
existing routine.  Fears around the consequences of missing doses were discernible, 
however, adding to the anxiety previously described: 
 
I didn’t want a’ miss any, any a’ the pills, an’ it’s really easy a’ do, y’know, err, 
it’s not as if you can double-dunt them either, y’know, so it’s like oh no, an’ 
you’re always nervous about likes, oh I’m suppose to take them regular, if 
you’re missing a gap out here an’ there what happens? 
 
(Steve, 45, multi-tablet regimen) 
 
7.2.4 Theme summation 
The ‘expectations and realisations’ theme aims to illustrate how the participants’ 
experience of taking interferon-free therapies contrasted with their acknowledged 
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preconceptions of how that experience might be.  These preconceived notions were 
rich with the predominant understanding of HCV treatment as a rigorous and 
demanding undertaking, informed by the interferon folklore that continued to 
permeate contemporary societal discourse.  Whilst both physical and emotional side-
effects were experienced during treatment, their magnitude and significance were 
diminished by comparison to the historical touchstone of interferon-based therapy, 
positioning them as relatively minor inconveniences and ailments which could be 
managed and overcome.  Conversely, unforeseen difficulties such as a high pill burden 
for those on multi-tablet regimens contrasted unfavourably with assurances of 
improved treatment simplicity and straightforwardness. 
 
7.3 Theme: An Honour and a Pleasure 
7.3.1 A positive experience 
The majority of participants related a positive and favourable account of their time on 
treatment, describing it as physically undemanding, a minor inconvenience, and 
nothing to complain about.  The major exception to this discourse was Gary, whose 
narrative detailed a laborious and difficult treatment period, replete with a catalogue 
of side-effects reminiscent of a period of interferon-based therapy.  This 
nonconforming case will be analysed in greater detail in due course.  Primarily, 
however, the participants constructed their experience of interferon-free therapy as 
uncomplicated and relatively straightforward: 
 
I’d, six o’clock at night, come home, have my dinner, take my inhaler, take my 
tablet, ten o’clock – bed.  Nothing, nae, nae disruption whatsoever.  Absolutely 
fantastic… 
 
(Stewart, 52, single-tablet regimen) 
 
 
I hate to use the term but it didn’t, it didn’t feel, I could say, if I was, y’know, at 
all arrogant or whatever ‘oh it’s a cakewalk, y’know, jus’ go through the, the 
medication it’s a cakewalk’ I mean I could quite in a blasé way say that…  
 
(John, 54, multi-tablet regimen) 
 
Participants framed the short length of treatment as one of the most significant 
benefits of interferon-free therapies, with many reporting surprise and disbelief that 
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their treatment course had come to an end after such a relatively brief period of time.  
The reduced length of therapy was emphasized with the use of simile, described by 
one participant as “like a sort a’ antibiotic treatment, it’s been that quick”41, and for 
some, the benefits of a speedy therapy overrode any other apprehensions or concerns 
they may have harboured: 
 
…that’s jus’ the way I look at it, y’know, I think positive like, y’know, I don’t 
think about the treatment going ‘oh it was terrible, it was this, it was that’, 
because it was quick. 
 
(Steve, 45, multi-tablet regimen) 
 
In addition to the comparatively rapid duration of therapy, the reduction in side-
effects when compared to interferon-based treatments was also a significant element 
of the positive treatment experience, as previously described.  For the majority, a 
comparison with interferon-based treatment was hypothetical, made through their 
socially informed understanding of what that therapy entailed.  The two participants 
who had previous first-hand encounters with interferon-based treatment, however, 
were able to contrast their eventful and side-effect laden experiences with a relatively 
benign course of interferon-free therapy: 
 
…it was all easy, compared to the last time, ‘cause I, ’cause I done the 
treatment, the interferon one, an’ compared to that, this was a breeze 
[laughs], this was like, jus’ like taking y’know, Lemsip or something y’know… 
 
(Keith, 54, single-tablet regimen) 
 
 
it was really really – the only thing it was like, erm, mmm, I would say, even 
the side-effects, like being tired, it was like not the tiredness that I’d 
experienced with the other one… 
 
(Happy, 51, single-tablet regimen) 
 
Despite not yet knowing whether the treatment had been successful, a positive impact 
from the therapy was already apparent in a number of the narratives.  Prudent 
optimism that the drugs had taken effect permeated the participants’ accounts, with 
                                                          
41 Keith, 54, single-tablet regimen 
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individuals cautiously expectant that they would obtain an SVR in due course.  This 
confidence in the treatment was aided by beneficial physical effects noted by the 
participants during therapy, such as increased energy, and improvements to their 
complexion and general wellbeing.  For Danielle, the positive aspects of treatment 
completion were not solely expressed in terms of health.  She identified the end of her 
period of HCV therapy as a driver for more fundamental changes in her life: 
 
…the last couple a’ weeks of it, I was fine, absolutely brilliant, an’ now, that it’s 
finished, it’s even better, my life’s just totally changed altogether, I’m now 
working, everything has really changed for the best now, so, I’m glad I done it. 
 
(Danielle, 43, single-tablet regimen) 
 
Tellingly, there was scarce discourse around treatment failure, which, when 
mentioned, was generally positioned as a temporary state, and couched in positive 
language.  Many participants recurrently remarked on the success rates of the drugs, 
with figures given of over 90% and in some cases 100%.  Participants were sanguine, 
buoyant and optimistic about their futures even before their end of treatment blood 
tests had been taken and reported: 
 
I’m no’ going a’ leave here today an’ let it play on my mind I’m jus’ going to, 
I’m jus’ gonna come back in two weeks’ time an’ find out the, the results, .an’ 
if it hasn’t totally cleared, I’m feeling better, I’m looking, it’s no’ gonna beat 
me, y’know, I know what the situation is.  I’ve totally changed aye, I’ve flipped 
fae one side to the other now like, I’ve even, even, partner says it, my sister 
says it, she says you’re no’ even bothered about it, I says nah, it’s no’, it’s no’ 
gonna get me down. 
 
(Stewart, 52, single-tablet regimen) 
 
Whilst previous accounts of interferon-based HCV treatment often construct it as an 
immersive and all-consuming experience (e.g. Hopwood and Treloar, 2005; Janke et al, 
2008), the narratives generated within this study suggest participants were able to 
take a more disengaged and detached stance to an interferon-free therapy.  Treatment 
was commonly framed as something which fitted into an existing life, and for which 
only minor adjustments and concessions were required.  Because of this, participants 
were often able to take a step back from treatment, disconnecting themselves from 
the reality of their situation: 
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…an’ it’s been so successful, erm, I kind of do feel like – well, that was, it’s like 
being in, almost, in a bad accident, but something that all happens round 
about you, but it doesn’t actually affect you, somehow. 
 
(John, 54, multi-tablet regimen) 
 
7.3.2 Guilt 
Whilst the participants’ narratives surrounding their experience of interferon-free 
therapies were largely complimentary and positive, a perception that they had been 
fortunate and lucky to access these treatments underpinned the discourse.  A number 
of individuals described feeling guilty at what they perceived as good fortune of being 
in the right place at the right time, underlining an understanding that interferon-free 
therapy was not commonplace and available to everyone, but a privilege and an 
honour. 
 
I was really lucky, I got given my treatment within three years of diagnosis, I 
got put on the, the quicker treatment, the most effective treatment, I was put 
in all the right places, given all the right directions, an’ then there’s other 
people who were like… Maybe it’s jus’ me, jus’ the way my mind works, but it 
did, I, I felt a, a bit guilty, an’ a bit like, well, I’ve had more advantages an’ a 
step forward than you. 
(Gary, 38, multi-tablet regimen) 
 
Feelings of luck and guilt were framed within the discourse as two sides of the same 
coin, and were compounded by participants favourably comparing their own situation 
to others with HCV, emphasising the differences in their own treatment trajectory to 
what were considered less fortunate individuals.  These comparisons were made with 
people who were known to the participants, but also with the socially produced 
archetype of what HCV treatment should encompass.  Despite any concurrent 
discussion of treatment side-effects, disappointments or hardships, the impression of 
feeling lucky to have gone through interferon-free therapy, and guilty of their 
experience in relation to others prevailed in all participants’ narratives. 
 
I’m glad I done it, I mean I’d tell anybody that was gonna start the treatment 
to do it, because I mean it’s a lot better than what the other therapies have 
been, no’ that I’ve been on them, but what I’ve heard aboot the triple therapy 
an’ everything you dunnae go through anywhere near as much as that. 
 
(Danielle, 43, single-tablet regimen) 
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Well, me personally, I’ve seen other people going through it, an’ err, I’m very 
very lucky in comparison to what they looked like y’know… 
 
(Steve, 45, multi-tablet regimen) 
 
For John, the guilt he experienced was rooted in his perception that some degree of 
atonement should be necessary to cure a disease which he felt he had brought upon 
himself.  The ease and simplicity of his treatment experience jarred with his belief that 
a penance should be paid for the removal of HCV from his life, and that he had got 
away lightly compared to others he knew.  Throughout his discourse, John made a 
number of comparisons to close friends who lived with chronic illnesses, praising the 
way they coped with their situations, and denigrating his own struggle in comparison.  
John felt he had escaped HCV with impunity, and this unsettled him: 
 
I’ll tell you why I felt guilty about it – I’ve got a really close friend who’s got like 
a, this medical situation, an’ he copes with it brilliantly, an’ he, erm, he hadn’t, 
he hadn’t caused it himself or anything, he was jus’, y’know, erm, suffering 
from this condition, an’ he marches through it brilliantly, y’know, and I’ve got 
another friend who’s diabetic, an’ I didn’t even realise he was diabetic until 
fairly recently, and I’ve known him for a long time, an’ I thought these people 
deal with these things all the time an’ they have to struggle along an’ get on 
with it, y’know, an’ I’ve jus’ been more or less given a solution to my problem 
an’ have kind of got away with it scot-free. 
 
(John, 54, multi-tablet regimen) 
 
The term ‘survivor guilt’ has previously been applied in studies of chronic illness where 
patients compare themselves to others with the same diagnosis, but who may face a 
worse prognosis, such as in chronic myeloid leukaemia (Patenaude and Rappeport, 
1982) or long-term non-progressors with HIV (Schönnesson and Ross, 1999).  The 
concept of survivor guilt is now recognised as encompassing a broad and diverse 
pattern of health behaviour, and is commonly framed as an interpersonally driven 
emotion, aimed at mediating the relationship between the individual and wider society 
(Carnì, Petrocchi, Del Miglio, Mancini and Couyoumdjian, 2013).  Although no single 
widely accepted clinical or conceptual definition exists, a recent concept analysis by 
Hutson, Hall and Pack (2015) described seven attributes of survivor guilt which 
resonate with this study: the presence of loss; being spared from harm; that it is 
adversely experienced; individualised; interpersonal; variably manifested and context-
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driven.  Whilst discussion of survivor guilt within the context of HCV has remained 
absent from the scientific literature to date, journalistic accounts of individual 
experience (e.g. Olds, 2016) provide anecdotal support that the disparities in access to 
interferon-free treatments may be influential in creating a substantial cohort of 
individuals for whom a condition akin to survivor guilt may pose on-going concerns. 
 
In addition to feeling fortunate in comparison to other people, participants’ awareness 
of the cost of the drugs contributed to their sense of honour in receiving these 
therapies.  Whilst feelings of shock and disgust at the expense of the medications were 
voiced, these views contributed to a sense of privilege in gaining access to medications 
which were not universally available.  The price tags of these medications were not 
only discussed in relation to other treatments for individuals with HCV, but also in the 
wider context of distributive justice within other diseases: 
 
Because I know they can’t give it to everybody, because it is expensive, y’know, 
err, but, I got told, it’ll be jus’ like taking any drug after a long while – the 
prices go down.  It’s the same as anything, prices eventually go down an’ 
that’ll be, there won’t be the injections any more it’ll jus’ be the tablets an’ 
things, err, but I jus’ felt so grateful that I could get it right now, while it’s still 
that expensive.   
 
(Steve, 45, multi-tablet regimen) 
 
 
I: …so you’ve had access to these drugs that are really expensive [K: 
thirteen thousand pound a month!]; how does that make you feel? 
 
K: It makes me feel, bloody privileged, ‘cause, y’know what I mean, ‘cause 
no’ many people are getting that, I mean there’s people oot there 
that’ve got cancers an’ stuff an’ they’re getting knocked back for 
treatments that cost that much. 
 
(Keith, 54, single-tablet regimen) 
 
A few participants mentioned the media as the source of their information on 
medication costs.  However, a number of others implied that this knowledge was 
explicit in the discourse of the treating healthcare team, with participants trained in 
the price of their cure from an early stage: 
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I knew that fae, the first week, how much these, all these cost an’ all that, I 
mean coming here you get taught, you get told what they’re trying a’ do here, 
an’ you find out how expensive they all are… 
 
(Stewart, 52, single-tablet regimen) 
 
The inflated costs of the drugs, and the associated sense of privilege in accessing them, 
generated a discourse which positioned commitment to treatment as an important 
consideration.  Participants alluded to the battles they believed had been fought by 
healthcare professionals on their behalf in order to secure access to interferon-free 
therapies.  A perception imbued the narratives that those deserving of access to 
interferon-free medications therefore needed to be serious and dedicated to their 
course of therapy, presenting themselves as candidates worthy of treatment, or 
‘deserving citizens’ (Rhodes et al, 2013):   
 
…for [names specific DAA], it should be appreciated more, it shouldn’t be taken 
just for a chancer, it should be for someone who’s truly truly committed to 
taking it, an’ also keeping healthy…  
 
(Happy, 51, single-tablet regimen) 
 
In addition to commitment during treatment, a perception emerged that the guilt and 
privilege felt at being able to access such expensive therapies had more enduring 
implications.  The experience of being prescribed these drugs strengthened, or built a 
resolve in a number of participants that the investment made in them, both financially 
and personally, would reap long-term rewards. 
 
I feel sort a’ - so, it makes me, it’ll make me think twice about going back 
taking drugs or alcohol or getting kind, going back on that kind a’ thing when 
you, you’ve been privileged enough for people a’ fight to get you better. 
 
(Keith, 54, single-tablet regimen) 
 
 
Similar findings have been reported previously by Rhodes et al (2013) in their study 
conducted during the interferon era.  They interviewed individuals with histories of 
injecting drug use, and described access to treatment as constructed in terms of 
gratitude rather than entitlement.  Hepatitis C treatment was an exception rather than 
an expectation among their participants, echoing the discourse of privilege and guilt 
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found in this study.  Eligibility for treatment needed to be negotiated within a culture 
of limited treatment expectations even before the arrival of interferon-free DAAs 
presented additional restrictions and barriers.  The notion of treatment ‘privilege’ is 
not solely a result of treatment rationing, but of historically produced rationed 
treatment expectations. 
 
7.3.3 Theme summation 
‘An honour and a pleasure’ unites the dialogue of a positive and encouraging 
treatment experience, with concurrent sentiments of good fortune and privilege.  The 
reduced duration of treatment, perceived reduction in side effects and a prudent 
optimism in the efficacy of therapy combined to construct an optimistic and upbeat 
discourse, which positioned treatment as a routine component of life, rather than as a 
detached and all-consuming experience.  Entwined within this perception, participants 
described feelings of luck and guilt at their own treatment trajectory compared to 
others in similar situations, and privilege at accessing medications known to be 
exorbitantly expensive.  Interferon-free HCV treatment, although agreeable, was not 
portrayed as the norm. 
 
7.4 Theme: Treatment needs 
The theme ‘treatment needs’ grew from the combination of two unmistakeable 
elements which pervaded the participants’ narratives: the discourse concerning 
support, and the approaches participants described in their search for treatment 
efficacy.  These two components created a persuasive account of how participants 
continued to seek affirmation during a course of interferon-free treatment, and 
require professional involvement despite a perception that the drugs were easier to 
take. 
 
7.4.1 Support: existing support networks 
Participants described a range of existing support throughout their interviews which 
pre-existed HCV treatment, involving both individuals within their homes and wider 
networks of friends and professional support workers.  John and Peter lived with long-
term partners, Danielle lived with her mother and young child, and Happy and Gary 
lived with grown-up adult children.  The remaining three participants reported living 
182 
 
alone, although as his narrative progressed it became clear that Stewart’s long-term 
partner was a de facto resident in his house.  In addition to family, many of the 
participants related details of friends whom they had confided in, as well as a number 
of support workers from various third sector agencies and charities working within the 
fields of drugs and alcohol, and blood-borne viruses. 
 
Six of the participants therefore described comparatively developed and mature social 
support networks. However, the existing support networks of Keith and Steve were 
noticeably diminished in comparison to the others.  For Steve, this was through 
personal choice.  Following a period of drug rehabilitation, he had tenaciously avoided 
attending support groups or contacting anyone from his past, cutting himself off from 
a previous life.  In addition, he described his family and friends as physically distant and 
unavailable, positioning himself as a loner: 
 
…but, you got to remember, not a lot a’ people like me, I mean likes I don’t 
have any friends up here, or family up here, at all, y’know, mines are miles 
away, y’know, near a hundred mile away, so, err, I’m on my own… 
 
(Steve, 45, lives alone) 
 
For Keith, a lifetime of previous drug use also offered a potential reason for his 
relatively self-contained current life.  He felt he had missed the opportunity to make 
long-lasting friendships and close ties due to the social circles he had spent much of his 
life moving in: 
 
…you know it yoursel’, the drug lifestyle can be a lonely lifestyle.  Even though 
you’ve got acquaintances, that’s all they are, they’re acquaintances, they’re 
no’ friends.  You maybe take drugs wi’ them but then you go away, an’ live in 
your own wee world.  
(Keith, 54, lives alone) 
 
Existing support networks therefore varied between the participants.  However, their 
narratives were consistent in the primacy given to the support provided by healthcare 
professionals during their treatment regimens, as will now be examined. 
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7.4.2 Healthcare professionals 
Participants eulogised the support and care provided by the healthcare professionals 
who were directly involved in prescribing their HCV treatment.  Accounts of their 
encouragement, professionalism and patience were commonplace within the 
narratives, with participants often extolling the sense of connection they perceived 
with their nurses and doctors.  At times, the descriptors used by participants to 
illustrate the therapeutic relationship evoked a deeper sense of belonging: 
 
…you guys give me the support, even the hug (…) that my family couldn’t give 
me because they’re far away, an’ I say, an’ for me, I feel like you people are my 
family looking after me, it’s actually better, because my family can look after 
me but they don’t have the tablets! 
 
(Peter, 51, single-tablet regimen) 
 
The care provided was not solely focused on the practicalities of HCV treatment, but 
viewed as a broader and more comprehensive type of support, encompassing the 
emotional care of the participants and their multi-morbidities.  Support was framed as 
something holistic, focused on the complete individual rather than on the treatment of 
a disease, and the time taken by health professionals to listen to participants’ wider 
concerns was particularly prized: 
 
…aye, you’re supporting people, you’re giving people a purpose, if you get 
what I mean.  No’ just for a’ get your treatment, but ken others things, to 
come up for a cup a’ coffee an’ a chat (…) or talk to the nurses, or talk to the 
lassies at the front desk an’ stuff… 
(Keith, 54, single-tablet regimen) 
 
…jus’ being able a’ pick up the phone, an’ jus’ – have a, even, an’ jus’ have a 
laugh an’ say “ah, shut up Gary, you’re being silly” or – it can be as simple as 
that (…), helped me massively.  Like, like, I owe them my life as far as I’m 
concerned, quite literally, that’s how I feel, that’s how much of an impression 
people have made here, for me… 
(Gary, 38, multi-tablet regimen) 
 
 
The discourse from those with a significant history of drug use intimated the support 
experienced differed from some of their previous encounters with healthcare.  
Discrimination towards substance users by healthcare professionals has been widely 
reported for many years (van Boekel, Brouwers, Van Weeghel and Garretsen, 2013), 
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with negative attitudes from health professionals associated with a detrimental impact 
on treatment outcomes and patient self-esteem.  In contrast, some participants in this 
study spoke of being treated exceptionally, like “some kind of VIP”42.  However, the 
overriding sense was of normality; an appreciation of receiving a level of care 
commonly experienced by the wider population: 
 
…this hospital’s a delight, an’ everybody I’ve spoken to agrees with me, they 
say it’s amazing, how you get treated, jus’, jus’ absolutely normal, like 
anybody else an’, that’s exactly what I’ve felt… 
 
(Steve, 45, multi-tablet regimen) 
 
This positive perception of the support provided by healthcare professionals to 
participants during their treatment featured extensively within the narratives.  For the 
four participants who engaged with a local respite facility run by a third sector HIV and 
HCV charity, this positive perception also extended to their time spent there.  Support 
from professional quarters emerged as more integral to the experience of HCV 
treatment than support provided by family and friends, and whilst incidences of 
support from other sources in their established networks were mentioned, they largely 
appeared as isolated anecdotes, delivered to order when prompted by the interviewer.  
A couple of participants disclosed how concern from family members could often 
become more tiring than helpful, and almost necessitated a reversal of role resulting in 
the participant supporting them: 
 
I mean like, [my son] would be phoning up, and asking my wife “how’s dad, 
what is he, y’know, is he, doing all these…” y’know, they were suggesting all 
these mad side effects I might be having, erm, and even [my daughter] 
y’know, who’s phoning up an’ saying, erm, y’know, she’s imagining that I’ll be, 
y’know, having difficulty with the medication, an’ I was having to convince her 
“Look, I’m fine” y’know… 
 
(John, 54, multi-tablet regimen) 
 
I think [my partner] been too many hours on the internet.  Too many.  Him, 
and my brother, because they were calling each other, an’ when they hear 
that, one said to the other, well you check if he has this, you check if he has 
that, an’ I say, guys!  It’s too much!   
 
(Peter, 51, single-tablet regimen) 
                                                          
42 Gary, 38, multi-tablet regimen 
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One notable exception to the positive discourse around health professional support 
during therapy came from Danielle.  For her, a feeling that she had not received the 
support she should get during treatment was evident, with her narrative recounting 
feeling abandoned and neglected by healthcare professionals, and being left with an 
onus to monitor her own welfare.  As discussion progressed, an understanding 
emerged that these feelings were positioned in relation to people who had received 
other, interferon-based HCV treatments, and a perception grew that she felt short-
changed by her interferon-free experience: 
 
I jus’ felt you didn’t have enough sort a’ communication wi’ people, erm, like 
[the HCV nurse] maybe phones me, oot the whole treatment, I think she 
contacted me three times, oot the whole treatment.  An’ I think, d’you know, it 
was like you were jus’ left to get on wi’ it, erm, if you need any help jus’ phone 
us, but I’m that sort a’ person I’ll no’ ask for it, y’know what I mean? So I do 
think that’s what they really need to gi’ people a bit more support through it. 
 
(Danielle, 43, single-tablet regimen) 
 
 
…oh, I don’t know how a’ explain this one really.  I think people are all getting 
treated differently, right, when you’re on triple therapy, right, you’re getting 
all the support, all the support, money-wise, mentally, the doctors, all the rest 
a’ it, this therapy you dunnae get nothing. 
 
(Danielle, 43, single-tablet regimen) 
 
Support was a treasured commodity for Danielle, and the perceived absence of any 
value-added services and care during HCV treatment had a significant detrimental 
impact on her experience, leaving her feeling cheated that she had had to rely on her 
existing support network alone.  When explored further, it became evident that 
Danielle’s narrative on the value of support during treatment shared key insights with 
other participants. 
 
7.4.3 Perspectives on the value of support 
A sharp contrast became evident in the perceived value of support during a period of 
interferon-free HCV therapy between participants who recounted an extensive and 
graphic history of drug use, and those who did not.  Stewart, Happy and Peter related 
uncertainty as to where their infection had originated, and their discourse positioned 
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themselves apart from drug using communities.  John, who had contracted HCV 
through drug use in the 1980s, also fell into this group as he constructed an account of 
his life which placed his drug-using days in the dim and distant past.  For these 
individuals, support during treatment, although gratefully received and highly 
regarded, was ultimately deemed unnecessary on retrospective reflection: 
 
In retrospect, now that you ask me that, I can quite clearly say, erm, y’know, I 
could have breezed through that without telling anybody, and, if I really chose 
to, I wouldn’t have needed any support through the actual medication itself.  If 
I’d realised it was going to be that easy, I wouldn’t have been freaking out 
about it beforehand. 
(John, 54, multi-tablet regimen) 
 
I: Because you were feeling good though, did you need that support? 
 
S: Err, no’ really, I was, I was really helping myself, mostly helping myself, I 
don’t think I’d, honestly, two, two tablets down, an’ I dun even think 
aboot it, jus’, it jus’ went out my head… 
 
(Stewart, 52, single-tablet regimen) 
 
 
No, no, not at all, no, no.  No.  Not with [names medication], nothing at all, I 
never felt I needed any support with [names medication], not at all, not at all.   
 
(Happy, 51, single-tablet regimen) 
 
 
By contrast, Keith, Steve, Danielle and Gary all related contracting HCV through 
injecting drug use, and their narratives were rich with stories of addiction, drug taking 
and attempted recovery.  Their discourse emphasised the significance of support, 
highlighting its value to both the practical and emotional aspects of treatment: 
 
…it is quite hard to jus’ keep it, doing it yourself, unless you’ve got somebody 
to remind you, err likes, like I said, to wake you up in time an’ things like that, 
it’s really quite difficult, erm, you may think oh it’s easy jus’ take it err next, 
nine in the morning, nine at night, but likes, when you’re not working an’ 
you’re likes, err, like I said, really heavily medicated, it doesn’t work out like 
that… 
(Steve, 45, multi-tablet regimen) 
 
I: Was support important to you? 
 
K: Aye, it was good to come here. 
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I: Why? 
 
K: The mental, the friendship, the feeling a’ care, people caring about you, 
d’you get what I mean? If you do that in the community you’re jus’ going 
in a’ see somebody, you’re getting your tablets an’ you’re fucking off for 
three months, it’s no’ gonna be the same.  You’re no’ gonna have that… 
 
(Keith, 54, single-tablet regimen) 
 
The importance of support is ingrained into the substance use recovery agenda, with 
many studies highlighting the importance of structural and functional components of 
support to an individual’s recovery trajectory (e.g. Day et al, 2013).  Adaptive changes 
in social networks from those supportive of illicit substance use to ones that are 
supportive of recovery have been shown to have a positive impact on sustained 
abstinence (Boisvert, Martin, Grosek and Clarie, 2008), and are often mediated by 
referrals to mutual-help groups such as Narcotics Anonymous (Kelly, Stout, Greene and 
Slaymaker, 2014).  Social support is a prominent and fundamental cornerstone of the 
substance use recovery discourse, and for those participants who had engaged with 
drug treatment in the past, the collected narratives suggest that this understanding of 
the importance of support had filtered through to other aspects of their lives.  For 
these participants, support was not framed as an additional bonus to HCV therapy, but 
as an expected and essential component of the HCV treatment package.  A culture of 
support has been built around individuals who have engaged with drug recovery, 
which, when bolstered by the legacy of interferon, has been applied to expectations of 
HCV therapy: 
 
Even with the new treatment, I think you need that support there, no matter 
where it may come from. Jus’ someone saying here, there you go, like you 
would at your pharmacy an’ no’ having any, I think that puts people onto an 
illusion of fear, an’ it prob’ly confuse more people, an’ an’, an’ on balance, I 
think, from my own point of view, that err, I would be quite sceptical about jus’ 
turning up in pharmacy having my drugs an’ then not having an angle, or no’ 
knowing that there’s someone to talk to after it, an’ no putting as much in… 
 
(Gary, 38, multi-tablet regimen) 
 
For these individuals, support has become an expected commodity, where increased 
contact with professionals, added services, and greater provision of resources when 
delivering an intervention are de rigueur.  Experience of HCV treatment is shaped by 
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an expectation that added support will be available, and a high degree of importance is 
placed on obtaining and utilising it rather than relying on existing networks.  A need for 
support grows out of these expectations, despite an acceptance and awareness that 
the treatment has improved: 
 
An’ you also need somebody that’s a professional like, especially in the 
hospital so you can talk about the treatment, ‘cause most people’ll not talk to 
their partners, or their friends or their family about the treatment, ‘cause they 
don’t know about it, an’ it can, it can really freak them out I suppose, so you 
do need a professional to speak to, ‘cause you will have low days an’ different 
days, but likes a’, it’s, it’s a great treatment. 
 
(Steve, 45, multi-tablet regimen) 
 
Support was not the only need which emerged from the participants’ discourse, as a 
need to know that the treatment was working also became apparent.  This search for 
efficacy during therapy manifested itself in a number of forms which will now be 
examined. 
 
7.4.4 Searching for efficacy: hunting for side-effects 
The lack of physical effects from the medications led to doubts around the efficacy of 
the drugs.  Participants expressed concerns that the scarcity of side-effects equated 
with a reduced effectiveness, querying the authenticity of the medications they had 
been given.  A discord arose between the interferon-influenced expectations of how a 
course of HCV treatment should be, and the general lack of physical side-effects that 
were subsequently experienced: 
 
Nothing happened at all, an’ I’m like, have they, have they gave me dummies?  
What’s happening here?  I should be ill.  But nothing, absolutely nothing 
happened… 
(Stewart, 52, single-tablet regimen) 
 
 
…when I came after four week I ask [the HCV nurse], I say, she said do you feel 
anything?  Are you tired or this? An’ I say no, I say actually sometime I think I’m 
on a placebo, because there is no any effect at all. 
      
(Peter, 51, single-tablet regimen) 
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D: …it jus’ made me think, ’cause I was expecting something totally 
different, I think I was expecting to feel, if it was working there was 
going a’ be a sort a’, an effect to me, that would notice that it was 
working… 
 
I: Like a physical…? 
 
D: Aye, an’ there was none a’ that, I was thinking well, should I no’ be being 
sick an’ all the rest a’ it, all the time?   
       
(Danielle, 43, single-tablet regimen) 
 
The belief that HCV treatment should be a rigorous and onerous undertaking, rather 
than a straightforward and undemanding process, constructed a compelling discourse 
relating how participants subsequently searched for signs and indicators that their 
treatment was working.  A need to substantiate the effect of the drugs permeated the 
participants’ narratives, shaping a perception that side-effects were almost desirable 
and advantageous: 
 
J: I mean, you wrack your brains looking for possible signs of side-effects, 
an’ you kind of start to imagine them a little, y’know? Err, little things 
get exaggerated in your head, y’know – I’m feeling a bit tireder than I 
normally do, or would I?  No? No, no after all, y’know, you were busy 
doing this, and doing that, you’ve been running about – you’re just tired 
like anybody else, y’know? 
 
I: Why do you think you’re wracking your brains? 
 
J: I don’t know, it’s jus’ looking for signs really… 
 
(John, 54, multi-tablet regimen) 
 
This hunt for side-effects increased the likelihood that any physical irregularities 
experienced may be attributed to treatment, despite an awareness that transient 
ailments can occur at any time, whether taking HCV therapy or not.  This perception 
was not confined to the participants alone, but conveyed in accounts of how friends 
and family were also eager to attribute non-specific symptoms to the drugs: 
 
…when I took the tablet at lunchtime, twice, with a meal, after couple of hours 
I have diarrhoea.  But, I thought, I cannot, know everything that happen I 
cannot relate it to the tablet, because without treatment, sometime happen 
that you eat something an’ then you have diarrhoea. So, because every time I 
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say something, [my partner] say you no’ telling me!  An’ I say, because, if I say 
to you, oh, I jus’ have diarrhoea, you would relate it to the treatment an’ 
maybe it was your cooking!  
 
(Peter, 51, single-tablet regimen) 
 
Side-effects attributed to medications are typically viewed unfavourably, and have 
been frequently linked to poor medication adherence in HCV treatment (e.g. Sublette 
et al, 2015).  A small body of literature from other disciplines indicates patients may 
sometimes interpret such symptoms as indicating drug effectiveness.  For instance, 
studies concerning patient perceptions of rheumatoid arthritis medication have 
described side-effects as a natural reaction to ‘powerful’ drugs (Lorish, Richards and 
Brown, 1990; Goodacre and Goodacre, 2004), and research in the field of oncology 
continues to describe patients equating toxic therapies with increased efficacy as 
previously discussed (Gradishar, 2015).  The insights gained from this study feed into 
this discourse and provide a new perspective on the experience of side effects during a 
period of HCV treatment.  Participants actively sought out adverse effects from 
interferon-free treatments as biomarkers for the effectiveness of the drugs. 
 
7.4.5 The importance of results 
The identification of possible side-effects was not the only method by which markers 
of efficacy were sought however.  The importance to participants of hearing how they 
were progressing through treatment from healthcare professionals also became a 
recurring refrain within the narratives.  Routine blood tests to monitor the HCV viral 
load were taken two to four weeks into treatment, and the significance of receiving 
these blood test results detailing the downward trajectory of the HCV viral load was 
emphasised repeatedly, and provided reassurance that the drugs were taking effect: 
 
…it’s went down fairly rapid, y’know what I mean, within the three months, 
ken what I mean, even though I’ve only been taking it for three months it’s jus’ 
went wham [indicates a downward trajectory with his arm], an’ hearing 
results has been like, good, sort a’ like, oh it’s working, ‘cause it gives you that, 
that thing, that it is working ken if it’s going doon an’ doon an’ doon… 
 
(Keith, 54, single-tablet regimen) 
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…I started off really high, I was [x] million, which is very very high, an’ I went 
down to [states much lower figure] within three weeks – that’s impossible.  I 
never thought that was even possible.  Err, so, it’s when you find out how 
quickly the treatment is working, err, in the first three-week period an’ you’re 
thinking – that’s only three weeks, so it gives you that massive hope, y’know… 
 
(Steve, 45, multi-tablet regimen) 
 
In addition to providing reassurance about the drug’s efficacy, and strengthening hope 
for a successful treatment outcome, the viral load results were also motivators for 
participants to continue adhering to their HCV treatment regimen, in the face of scant 
physical evidence that they were making any progress: 
 
I had to like, phone them, an’ erm, they were – [states result of most recent 
viral load test], I was, I mean I couldn’t even believe it, there was, I was asking, 
I say, oh – write it down, let me see!  [States starting viral load in disbelief] - 
y’know, that’s, like motivation to, kind of really made me like be more 
determined, I, I have to clear this… 
 
(Happy, 51, single-tablet regimen) 
 
 
The value of laboratory medicine is most often spoken about in terms of supporting 
clinical decision making, patient safety, health economics and resource management 
(Hallworth et al, 2015), but rarely in terms of the patient experience.  However, these 
insights stress the value that participants taking interferon-free HCV therapies placed 
on hearing encouraging test results, situating them as beacons of reassurance, hope 
and motivation and implicitly demonstrating a surprising degree of health literacy 
when compared to other conditions.  For example, Wolf et al (2004; 2005) described 
poor understandings of HIV viral load and CD4 count amongst American cohorts of HIV 
positive individuals receiving anti-retroviral therapy in the late 1990s and early 2000s, 
correlating limited literacy skills with a poor appreciation of biomedical results.  More 
recent work continues to describe this association in HIV (Laws, Danielewicz, Rana, 
Kogelman and Wilson, 2015), suggesting the literacy of participants within this study 
may have played a role in the value and significance they ascribed to laboratory test 
results.  Unfortunately, educational achievement was not recorded within the 
collected demographics and is a limitation of this study.  However, it would provide a 
fertile area for further investigation. 
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The dialogue concerning the importance of results also resonates with the growing 
scientific discourse around ‘self-tracking’ and the ‘quantified self’.  Although these 
terms have emerged in response to the increasing use of wearable technologies in the 
monitoring of personal health, and the focus of self-tracking is more commonly framed 
around the concept of healthism than degrees of illness, the primary objective of self-
tracking is the achievement of self-knowledge through numbers (Lupton, 2013).  The 
quantified self uses technology to invest individuals in health decisions, moving them 
from passive recipients of healthcare to active participants in their treatment, by 
framing the numeric data generated as direct access to a truth about the self (Abend 
and Fuchs, 2016).  As Lupton (2013) argues, as bodily states and functions become 
ever more recordable and visualised, it becomes easier to trust numbers over physical 
sensations.   
 
7.4.6 Feeling better 
That is not to say that physical sensations did not play a role within the treatment 
experience.  In addition to seeking out side-effects and focusing on laboratory tests, a 
couple of participants described a further instinctive approach to evaluating the 
effectiveness of treatment: they simply felt better whilst taking it.  Primarily describing 
a feeling of reduced fatigue, these accounts begin to provide context to quantitative 
measures of HRQoL which have reported improved scores from interferon- and 
ribavirin-free HCV regimens during the period of therapy (Younossi et al, 2015): 
 
…maybe the hepatitis made me slow down but I didn’t realise, an’ I thought it 
was jus’ age!  An’ then I thought, I supposed to be feeling less energetic [on 
treatment], but, I want to do things all the time (….), it was fantastic, because 
I, I was feeling better after the four weeks, I say I feel more energy, where 
before by the end of the day I feel like I did too much, an’ with this is was not. 
 
(Peter, 51, single-tablet regimen) 
 
Aye, it, it got even better, I mean, you’ll no’ see it now like [rubs belly] but, I 
mean all my fruit smoothies, my shakes, I’ve got a belly now [chuckles] after 
the eating, erm, there’s no’, I haven’ae, there’s no’ one day where I’ve went 
back, err, jus’ lay about, I’m, I’m up, I have to, go clean something, or do 
something, or go a’ work, I’m no’ at the jogging stage yet like [smiles] but, it’s 
jus’ euphoria jus’ took over since I’ve been on [the tablets]… 
 
(Stewart, 52, single-tablet regimen) 
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Whilst anecdotal, it is interesting to note that the HRQoL domains in which on-
treatment improvements met the minimal clinically important difference in the study 
by Younossi et al (2015) were vitality and general health, two concepts which 
undeniably resonate in the quotations above. 
 
7.4.7 Theme summation 
The ‘treatment needs’ theme comprises two main elements: the prevalent discourse 
around support which featured heavily in every participant interview, and the need to 
know the treatment was having an effect.  In general, participants were 
overwhelmingly positive about the support they received through treatment.  
However, retrospective reflections on whether this support was necessary varied in 
line with their past experiences of drug use and recovery.  For those participants who 
had a significant history of drug use, additional support from healthcare professionals 
and third sector agencies was constructed as a greatly valued and integral part of HCV 
treatment, despite an awareness that the actual therapy was much less physically 
demanding than interferon-based regimens.  In addition, the dearth of physical side-
effects from the drugs led to participants seeking reassurance that they were taking 
effect through a combination of approaches, the search for side-effects, the 
importance placed on blood results, and the self-assessment of improvements in their 
own wellbeing.  These strategies were employed in lieu of more obvious 
manifestations of drug action, and provided encouragement, reassurance and 
motivation to continue with therapy. 
 
7.5 A nonconforming case 
7.5.1 The case of Gary 
The strength and credibility of an analysis can be tested by how well it relates to 
exceptions to the rule.  So-called deviant case analyses can illuminate and enhance the 
thematic patterns within the data, producing a richer, more in-depth understanding of 
the phenomenon in question (Silverman, 2013).  Gary’s experience of interferon-free 
HCV treatment grated with the predominant discourse emerging from the other 
participants, contradicting the largely positive and optimistic outlook espoused by the 
majority.  His narrative was rich in the detail of an eventful and arduous treatment 
period, and began with an extended account of the many side-effects he had suffered 
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in the early stages of treatment.  The experience he related was reminiscent of a 
period of interferon-based therapy, recalling both the physical and psychological side-
effects commonly experienced with that drug: 
 
…but anyway we got to the third week, erm, I started getting quite violently ill, 
sick, migraines, constant headaches were coming along, I spent about two 
weeks, literally, feeling like vomiting, couldn’t move off the sofa, lying in the 
same clothes, never had any energy, very lackadaisical, very very aggravated, I 
got myself so agitated, they ended up putting me on erm, chloropazine [sic], 
‘cause a’ my, I was so, getting so stressed… 
(Gary, 38, multi-tablet regimen) 
 
 
Whilst Gary was not alone in experiencing side-effects, his account was unusual in the 
prominence he gave them.  He characterised his experience of treatment as one of 
illness and disorder, in contrast to other participants whose narratives mainly 
emphasised wellness and vitality punctuated by occasional complaints.  Gary 
constructed a self-fulfilling prophecy, embracing the negative experience of HCV 
treatment that he had predicted and prepared for: 
 
…‘cause I jus’ said that to my daughter it must been about two-three days ago, 
I said it’s bizarre, I said like, here I am, as I am, all, getting on wi’ it, an’ in 
three days time I start medication, erm, I could, look like I’m, I’m on death’s 
door… 
(Gary, 38, pre-treatment interview) 
 
 
…an’ then it got to six-seven weeks, jus’ before I went into [the respite centre] 
that’s when I kinda had that, I didn’t feel ill before [I started the treatment], 
an’ now I feel like, at death’s door. 
(Gary, 38, post-treatment interview) 
 
An association between the expectation of treatment side effects and the subsequent 
realisation of those symptoms has been repeatedly shown in other conditions.  For 
example, Mondaini et al (2007) demonstrated that sexual side-effects from a β blocker 
drug were reported three times more frequently amongst a group of patients 
specifically informed about that potential side effect, in comparison to a control group 
who were not.  Similarly, Nestoriuc, Orav, Liang, Horne and Barsky (2010) described an 
association between heightened concerns amongst patients prior to starting arthritis 
medications, and a subsequent higher incidence of side-effects during treatment.  
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Whilst this phenomenon is widely reported, the expectation of a difficult and 
demanding course of interferon-free HCV therapy was widely held amongst the 
participants and not limited to Gary.  Therefore, why was he alone in having his worst 
expectations confirmed? 
 
Whilst it is possible that these medications may have severe adverse side-effects for a 
minority of people taking them, the nocebo phenomenon, in which placebos produce 
adverse side-effects, has also been used to offer insight into the reporting of 
nonspecific side-effects in patients taking active medications (Faasse and Petrie, 2013).  
Patient expectations and pre-treatment conditioning are often designated as key 
components of this phenomenon, and Gary’s narrative displayed a depth and intensity 
of expectation which was noticeable among the collected testimonies, positioning 
temporary illness as an absolute necessity in order for his therapy to be effective: 
 
…I, I, I kinda got to that stage where I knew, for treatment to be successful, 
there’s gonna be, there’s gonna be elements a’ illness in there, it’s gonna do 
things to your body, so – aye, I kinda jus’ kept my mind in that… 
 
(Gary, 38, multi-tablet regimen) 
 
 
…jus’ because I knew, listen, this is part of it, an’ I kinda structured my mind so 
I know I’ve gotta get ill to get better type a’ thing. 
 
(Gary, 38, multi-tablet regimen) 
 
In addition to expectations and patient conditioning, a range of further factors have 
been associated with the nocebo effect, including psychological characteristics of the 
individual, physical and symbolic features of the medication itself, and situational and 
contextual factors (Barsky, Saintfort, Rogers and Borus, 2002).  Gary lived with his 
grown-up children who were no longer dependents, and he had limited work 
commitments due to the voluntary nature of his occupation.  The comparatively 
commitment-free setting of his narrative provided Gary with the freedom to realise his 
worst HCV treatment expectations, and granted him permission to act in ways which 
would otherwise be socially unacceptable.  In addition, the HCV treatment also 
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provided Gary with a plausible explanation for other comorbidities which he possibly 
found less easy to address: 
 
I suffer from anxiety and depression at the best a’ times, so aye, it was easy to 
point to the treatment an’ say “aw, I’m feeling like this because it’s the 
treatment” even though, I know, if I wasn’t taking treatment, I’d be having 
days like that anyway, so aye, I suppose it makes it easier on your whole mind 
and body jus’ to say well, that’s the treatment, an’ then it kinda takes you off-
a that it’s not jus’ my head… 
 
(Gary, 38, multi-tablet regimen) 
 
 
In contrast, other participants’ accounts principally emphasised the importance of 
maintaining normality and routine during their therapy, and not wishing their pre-
treatment concerns to be realised.  John had not disclosed his HCV status to his 
employers and therefore wished to continue working full-time during his treatment 
period.  Danielle repeatedly expressed concerns over how she would be perceived as a 
mother if she allowed her routine to slip.  For Happy and Keith, a desire not to repeat 
their previous interferon-based treatment experience was manifest, and as Peter was 
self-employed, any significant adoption of a sick role may have considerable financial 
implications.  Whilst Gary expressed hopes that his treatment would not be as 
laborious as he imagined, there was a distinct lack of such mitigating circumstances in 
his narrative.  Indeed, Gary’s account reveals a set of circumstances which combined 
to form a perfect storm.  His unambiguous pre-treatment expectations of an arduous 
and intensely disruptive HCV therapy, conditioned by his understanding of interferon-
based treatment, were supported by a comparatively commitment- and dependent-
free personal situation which allowed these expectations to be fully realised and 
assumed. 
 
At first glance, Gary’s narrative seems contradictory to the prevailing understandings 
of interferon-free HCV treatment which have emerged from the thematic analysis of 
this data.  Discussion of interferon-free treatment as a mild inconvenience or relatively 
benign is inconsistent with the central thrust of Gary’s account.  However, rather than 
disproving the analysis, this deviant case reinforces some of the key findings previously 
discussed, and emphasises the importance of considering the themes collectively, 
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rather than in isolation.  Although at odds with the idea of interferon-free treatment as 
a generally positive experience, Gary’s narrative strengthens other themes within the 
data, such as the discourse previously considered around treatment needs and the 
hunt for efficacy.  The side-effects he experienced were borne of a belief that HCV 
therapy needed to be powerful and potent, and the more toxicity he experienced, the 
greater the chance of the treatment working.  His testimony suggests that despite his 
difficulties, he believed the treatment he was taking was having a curative effect: 
 
I never ever thought to myself I’m gonna stop this treatment, but there was, 
that niggling in the back of my head saying – can you carry on?  I thought, no, 
I’ve come this far, I’m, I’m not gonna back out an’ stop my treatment, no 
matter how hard-core it is… 
 
(Gary, 38, multi-tablet regimen) 
 
 
Gary’s narrative also reinforces the importance of HCV treatment-specific support to 
individuals with significant drug histories.  Whilst he positioned his family and close 
friends as a valuable support network, his testimony also recounts how access to wider 
groups of professional support workers and peers with the same diagnosis was 
particularly prized.  By becoming ill during his treatment, Gary maximised the 
supportive value of his therapy: 
 
Erm, there’s mainly really jus’ me an’ my daughter, erm an’ a few close friends 
that, that was my support up until I started networking wi’, wi’ everybody 
down at [the respite centre], an’ then obviously that opened up so many more 
avenues, erm, so many more support workers an’ people to talk to… 
 
(Gary, 38, multi-tablet regimen) 
 
 
Whilst initially appearing divergent from the prevailing discourse surrounding 
interferon-free HCV treatment, a closer examination of Gary’s narrative reveals how it 
strengthens and augments many of the key themes found within the collected data.  
Although he did not experience the primarily positive experience of treatment 
constructed by the other participants, he did acknowledge the luck he felt at receiving 
it, and assembled an account which reinforced the discourse concerning treatment 
needs.  In addition, Gary’s narrative accentuates the importance of a contextual 
understanding of interferon-free treatment.  He realised and embraced his interferon-
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based pre-treatment expectations due to his understanding that HCV treatment should 
be gruelling in order to work, but also because his social and personal circumstances 
allowed him to. 
 
7.6 Discussion 
7.6.1 The relationship of themes 
The intersubjective experience of interferon-free HCV treatment constructed by the 
participants is well illustrated by the three overriding themes previously described.  
These themes do not exist in isolation, but interweave, connect and collide within and 
between each individual narrative, demonstrating how understandings which have 
been presented here discretely are necessarily intertwined.  Reflecting on the interplay 
between these themes and their relationship to each other, produces a more complete 
understanding of the lived experience of interferon-free HCV treatment, which is much 
richer than the sum of its parts (figure 1). 
 
Figure 1: A pictorial representation of the themes and sub-themes which encapsulate the lived 
experience of interferon-free HCV treatment described and illustrated within this analysis. 
 
 
The theme ‘expectations and realisations’ has intentionally been presented first within 
this analysis, as it acts both as a precursor to the treatment experience and also as a 
foundation upon which the subsequent themes are built.  The influence of interferon-
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fuelled expectations of treatment lies at the heart of the other theme constructions.  
For example, the positive experience and feelings of privilege espoused in ‘an honour 
and a pleasure’ are not produced in a void, but in relation to the growing awareness 
that treatment was not corresponding to preconceived expectations.  Similarly, the 
hunt for side-effects and importance of support illustrated within ‘treatment needs’ 
are hinged on understandings of how an interferon-based period of treatment should 
be.  The pervasive authority that the drug interferon continues to exert over 
expectations of interferon-free regimens is central to how these newer therapies are 
then experienced and realised.  Interferon-free treatment is positioned in relation to 
understandings and perceptions of interferon-based therapy, it does not stand solely 
on its own merits but in comparison to what might have been. 
 
The two other themes may at first appear the antithesis of each other.  Consider the 
apparent disjoint between the theme ‘treatment needs’ and the relative ease of 
therapy proposed by ‘an honour and a pleasure’.  If treatment was relatively benign, 
then why were individual needs positioned so centrally within the narratives?  Rather 
than being oxymoronic, such tensions highlight the manner in which each theme is 
fundamentally contingent on the other, and how examination of themes in isolation 
may lead to a limited understanding of the overall treatment experience.  For example, 
a treatment experience which failed to correspond with pre-treatment fears fed the 
notion of ‘an honour and a pleasure’, focusing participants on the positive aspects of 
their therapy and creating an understanding that they were lucky to evade a more 
gruelling treatment trajectory.  In doing so, concerns and doubts about the treatment 
emerged.  How could such a relatively benign therapy be working, and what 
implications did that have for the provision of support?  ‘Treatment needs’ grew from 
the insights and understandings gained from ‘an honour and a pleasure’, rather than in 
opposition to them. 
 
Although the above example traces a linear movement, the interaction between the 
themes of ‘treatment needs’ and ‘an honour and a pleasure’ was reciprocal and 
dynamic in nature.  For example, the self-monitoring and importance of support 
described within ‘treatment needs’ was not only the product of participants 
questioning an easier than expected time on treatment, but was also integral to the 
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construction of that positive experience.  Hearing encouraging blood results, noticing 
improvements in general health and wellbeing, and feeling supported and cared for 
were part of the foundations upon which ‘an honour and a pleasure’ was established.  
These themes reinforce and enhance one another, emphasising the interrelation and 
unity of the analysis. 
 
This is not to say that conflict does not exist.  For example, the accounts of both 
physical and emotional side-effects discussed in ‘expectations and realisations’ sit 
uneasily next to the discourse which described participants hunting for non-existent 
side-effects in ‘treatment needs’.  How can both these positions be part of the same 
experience?  These two positions should be considered in counterpoise to one 
another, where equilibrium was maintained between the volume and intensity of side-
effects experienced and the proactive search for further signs of efficacy.  Where few 
side-effects were noticed, a greater emphasis was placed on hunting for them, and 
where the treatment experience was defined by side-effects, the search for efficacy 
was deemed unnecessary.  Consider the conflicting testimonies of John and Gary.  
John’s account of searching for side-effects and evidence that the drugs were working 
is situated within a narrative which barely mentions any detrimental effects from the 
treatment at all, whereas Gary, who experienced a treatment period laden with side-
effects, instinctively felt that it was taking affect: 
 
I mean, you wrack your brains looking for possible signs of side-effects, an’ you 
kind of start to imagine them a little, y’know? Err, little things get exaggerated 
in your head, y’know… 
(John, 54, multi-tablet regimen) 
 
 
…even though it does have its negatives, it, it’s been nothing but a positive in 
the long run.  An’ I know it’s knocked the shit out a’ me, but at the same time I 
know, that doing that it’s having an effect – to kill off the hepatitis.  
 
(Gary, 38, multi-tablet regimen) 
 
Although these accounts represent extremes of the scale, they illustrate the way in 
which apparently contradictory aspects of these themes wax and wane in relation to 
each other, emphasising the fundamental way in which the themes described are 
interdependent. 
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The nonconforming case study of Gary also highlights an important consideration.  
These themes must be considered within the context of the individual.  There are 
numerous personal, psychological, situational and contextual factors which have been 
identified as potential components of the nocebo phenomenon (Barsky et al, 2002), 
and whilst the thrust of this analysis stems from a realisation of largely unmet pre-
treatment expectations, there may be particular individuals whose specific set of 
circumstances and attributes allows those expectations to be realised.  This analytical 
model therefore provides a platform on which to base understandings of patient 
treatment experience with interferon-free HCV regimens, but does not claim to be 
applicable to each and every individual prescribed these therapies throughout the 
world. 
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Chapter 8 
Discussion 
 
8.1 Introduction 
8.1.1 A brief overview 
This thesis began by illustrating how the growing authority of HCV as a public health 
priority provided impetus for the rapid developments in drug therapy which have been 
observed over the last five years.  The arrival of interferon-free regimens in clinical 
practice has improved the success rate of HCV treatment to over 90%, whilst 
substantially reducing the burden of side-effects and radically shortening the length of 
therapy compared to previous interferon-based standards of care (Asselah et al, 2016; 
Pawlotsky et al, 2015a).  This sea-change in the nature of HCV treatment has been 
hailed as the dawn of a new era in the fight against the disease (Chung and Baumert, 
2014), and has bolstered academic discussion of conceivable global eradication 
(Borgia, Maraolo, Buonomo, Scotto and Gentile, 2016; Hagan and Schinazi, 2013).  It 
also constitutes the underlying rationale for this study’s re-examination of the lived 
experience of HCV and its treatment. 
 
A qualitative focus on individuals living with HCV has long provided insight into how 
the disease and its treatment are understood and experienced (Miller et al 2012; 
Treloar and Rhodes, 2009).  This paradigm offers rich and nuanced understandings of 
the personal burden of illness, giving a recognisable voice to the decrements in HRQoL 
which are commonly reported in the quantitative literature (Speigel et al, 2005).  
However, the wealth of qualitative research in this area was conducted during the 
interferon era, and it is reasonable to speculate that the significant advances in HCV 
treatment observed in Scotland over the last five years may have influenced how the 
disease is being perceived and realised by those it affects.  Experience is, after all, 
mediated by its social context.  The timely re-examination of the lived experience of 
HCV and its treatment within this thesis is therefore justified, and the research 
questions which have guided this endeavour were founded on this reasoning. 
An empirical study involving qualitative interviews with 20 individuals living with HCV 
was undertaken.  Eight of these individuals were followed longitudinally and re-
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interviewed after a period of interferon-free HCV treatment.  The generated data were 
interrogated using a thematic analysis, and the preceding four chapters have aimed to 
explore the major themes which were evident within the participants’ narratives.  
These chapters have drawn on relevant social theories, and other published works to 
help illuminate the findings.  In doing so, each chapter provides a detailed analysis and 
interpretation of one facet of the inter-subjective experience of living with HCV, or in 
the case of chapter seven, a multi-themed exploration of interferon-free HCV 
treatment.   
 
8.1.2 Chapter aim 
In order for a more integrated and meaningful understanding of the participants’ lived 
experience to be achieved, the aim of this chapter is to contemplate the broader 
‘collective’ stories told by the participants.  How do these themes articulate with the 
wider discourse of HCV and its evolving treatment?  The original research questions 
will be addressed by reflecting on the themes collectively, and examining the factors 
which underpinned the participants’ experience.  Why the themes exist as they do, 
and what conditions gave rise to them will be interrogated.  Following this, the 
limitations of the study will be considered, prior to discussion of the implications this 
work may have for policy, the organisation and delivery of treatment, and individual 
clinical practice.  The chapter ends with a personal reflection on conducting the study 
and a clear statement of the contribution to knowledge made. 
 
8.2 Addressing the research questions 
It is prudent, in this final chapter, to return to the original research questions which 
guided the empirical work conducted within this thesis (section 2.4.4).  These 
questions form the fundamental core of the study, and relating the analytical findings 
to the central research problems identified must be the ultimate objective of this 
endeavour.  The following discussion has therefore been structured around addressing 
each of the three research questions explicitly, and considering what the analytical 
themes mean in relation to them. 
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8.2.1 Question one 
 
How is living with hepatitis C experienced and understood within the context of a new 
era of treatment? 
 
8.2.1.1 Familiarity 
The lived experience of HCV constructed by participants in this study was characterised 
by both striking familiarity, and more novel and original insight.  The familiarity 
stemmed from recognisable and longstanding refrains which have dominated previous 
research in this area, and which continued to permeate these contemporary themes.  
For example, socio-culturally mediated reactions to a HCV diagnosis during the era of 
DAAs suggested an improving cure had done little to lessen the emotional impact of 
infection.  Participants described responses aligning with the shock, fear and 
depression which typified previous research conducted during the interferon era 
(Glacken et al, 2001; Groessl et al, 2008; Olsen et al, 2012; Sgorbini et al, 2009; Sutton 
and Treloar, 2007).  Similarly, discussion of the uncertainty of life with HCV, and the 
enduring and consuming emotional burden of infection also echo findings from 
previous studies.  Uncertainty has long been explored as an important facet of the 
experience of being HCV positive (Conrad et al, 2006; Hill et al, 2015; Rhodes and 
Treloar, 2008), and the tenacious hold which stigma exerted over the participants’ lives 
resonated with accounts of discrimination and prejudice from previously published 
works (Butt et al, 2008; Conrad et al, 2006; Faye and Irurita, 2003; Fraser and Treloar, 
2006). 
 
The importance of these resilient themes to contemporary narratives lies in their 
exposition of the lack of influence a rapidly improving cure has yet to exert on the 
emotional burden of illness.  The fact that enduring motifs of stigma and distressing 
uncertainty remained a fundamental component of the participants’ realities, speaks 
of how the ‘medical triumph’ (Chung and Baumert, 2014) of HCV treatment has yet to 
influence significant domains of the participants’ lives.  The cultural memory of what it 
means to be HCV positive persists.  This finding exposes how the advances witnessed 
in HCV therapy, and the lived experience of being HCV positive, appear in many ways 
detached and isolated from one another.  Improvements in one, do not necessarily 
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equate with improvements in the other.  Academic, scientific and medical attention on 
treating and curing the somatic disease has decontextualised HCV from peoples’ lives, 
priorities and realities.  It has largely failed to concurrently address those aspects of 
living with HCV which the participants constructed as most significant and detrimental 
to their wellbeing.  A medical focus on rapidly improving therapeutic options, has side-
lined an emphasis on person-centred care, and disregarded the psychosocial sphere 
within which the burden of illness is most keenly felt.  This study highlights domains of 
the HCV illness experience which have so far proved immune and unyielding to this 
new era of therapy.  However, that is not to say that the advances in HCV treatment 
did not impact on participants’ lives at all.  Indeed, whilst a familiarity pervaded many 
aspects of the participants’ testimonies, the preceding chapters have demonstrated 
that fresh and novel insights into the lived experience of HCV were also established. 
 
These novel insights were underpinned by the manner in which developments in drug 
therapy were understood and articulated by the participants.  It is therefore necessary 
to reflect on how these understandings were formed.  The majority of participants in 
this study were accessing specialist care for the management of their HCV infection, to 
a greater or lesser extent.  As the way humans classify and attach meaning to the 
outside world is not a purely individual process, and understandings of disease are 
shaped in part by the perceptions of others, this interaction with healthcare 
professionals had significant influence on the participants’ comprehension of HCV and 
its treatment.  The prevailing discourse from the healthcare team, and the manner in 
which they framed the developments in HCV drug therapy, contributed to how 
participants contextualised their experience of living with the virus. 
 
8.2.1.2 Treatment rationing 
The inequality of access to new HCV treatments encountered by participants during 
the study had considerable influence on their experience of the disease.  The shifting 
eligibility criteria for accessing DAA regimens (HIS and NHS National Services Scotland, 
2015a; 2015b; Scottish Government, 2015b) created the conditions for many of the 
key thematic findings within this study to become established.  For example, an 
understanding of how treatment eligibility could be connected to liver health, gave rise 
to uncertainty in the participants about their access to such therapies, and reinforced 
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existing uncertainty related to liver disease progression.  Treatment rationing also 
fractured the understanding of HCV as a singular disease.  Individuals positioned 
themselves as more or less deserving of treatment than others, strengthening a 
perception that receiving such therapies was an honour and a privilege, rather than a 
right.   
 
This inter-thematic discourse illustrates how implicit acceptance of the health 
inequality status quo underpinned the participants’ experience of being HCV positive.  
The participants constructed narratives around the assumption that HCV treatment 
rationing was an absolute, and adapted their outlook and understanding to 
accommodate that assumption, rather than challenge it.  This instinctive tolerance of 
health injustice speaks to theoretical arguments which suggest that an individuals’ 
capability to be healthy can be constrained by their physical and social environments, 
as well as the political, economic, cultural and legal determinants of those 
environments (Venkatapuram, 2011).  The participants’ implicit acceptance of 
treatment rationing emphasises the lack of moral entitlement to health felt amongst 
this group of disenfranchised individuals, and further, the lack of capacity to achieve a 
state of wellbeing.  This finding resonates with the lack of entitlement and tolerance of 
rights violations which have been reported within HCV communities over the years 
(Wolfe et al, 2015), and underscores the lack of entitlement to therapeutic citizenship 
felt amongst the participants (Rhodes et al, 2013).  It exposes how treatment 
guidelines which emphasise disparity of access serve only to reinforce notions of 
discrimination and prejudice, further marginalising and stigmatising already 
marginalised and stigmatised groups.  Indeed, the subtext of treatment rationing, 
implying some are undeserving or unworthy of care, becomes explicit when the 
sustained and tenacious influence of internalised stigma on the participants’ lives is 
considered.  It is perhaps unsurprising that participants continued to feel dirty, 
ashamed, and to blame for an infection that their providers may not always deign to 
treat.   
 
Of course, the issue of rationing is not unique to the treatment of HCV.  A cursory 
literature search reveals recent articles pertaining to rationing in fields as diverse as 
palliative care (O’Connor and Casarett, 2016), surgical interventions (Orchard, Wright, 
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Kelly, McCabe and Hewes, 2016; Owen-Smith, Donovan and Coast, 2016) and drug 
resistant tuberculosis (Martin et al, 2016).  The rationing of treatment has been argued 
as an inevitable consequence of medical advances (ter Meulen, 2008), and global 
ethical and economic debate surrounding distributive justice and treatment rationing 
permeate medical and academic discourse (e.g. Carter, Gordon and Watt, 2016; Fleck, 
2016; Scheunemann and White, 2011).  In light of such complex arguments, merely 
stating that the rationing of HCV treatments is detrimental to those living with the 
infection and should therefore be abolished would be simplistic and naïve.  However, 
this study does add to the growing dialogue by demonstrating how this scholarly 
debate is firmly embedded within the lived experience of HCV positive individuals.  For 
participants accessing care, the inequality of treatment was a tangible and 
fundamental factor underpinning multiple aspects of their daily life, rather than just an 
academic concern. 
 
One further consideration with regard to treatment rationing is how this relates to the 
global reconstruction of HCV as a public health priority.  The two processes appear ill 
at ease.  The significance of highlighting HCV as an international public health 
challenge, comparable to tuberculosis, HIV and malaria (World Health Assembly, 
2016), is weakened and undermined by a response from care providers which could 
often position treatment as a future consideration.  The inequality of access to 
treatment in this study supported an opinion amongst the participants that HCV need 
not always be an immediate concern.  For some, liver disease was mild and 
insignificant therefore treatment could be safely deferred to a later date.  Whilst this 
discourse served to strengthen arguments for treatment rationing, it also clashes with 
the urgency and precedence invoked by axioms such as ‘major public health threat’ 
(Public Health England, 2016, p.1), and framings of HCV as ‘deadly’ and a ‘time-bomb’ 
in the popular press (BBC, 2009; Johnston, 2014).  Treatment rationing confuses and 
blurs the constructed identity of HCV as a public health priority, and may threaten its 
authority amongst those infected with the virus. 
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8.2.2 Question two 
 
“How adequate do theories of chronic illness remain to the contextual understanding of 
the experience of living with HCV?” 
 
8.2.2.1 Theories of chronic illness 
Previous studies conducted during the interferon era have drawn on a variety of 
sociological theories of chronic illness to illuminate their findings (Glacken et al, 2001; 
Hill et al, 2015; Olsen et al, 2012; Paterson et al, 2006; Sutton and Treloar, 2007).  
Predominant amongst these have been Bury’s (1982) theory of chronic illness as 
biographical disruption, and Paterson’s (2001; 2003) model of shifting perspectives.  
Bury (1982) posits that a diagnosis of chronic illness can lead to the disruption of an 
expected life biography, and necessitate a renegotiation and reformulation of one’s 
self-identity.  He described three aspects of disruption to the unfolding chronic illness: 
disruption of taken-for-granted assumptions and behaviours; disruption in explanatory 
systems; and finally, the response to this disruption.  In doing so, he conceived a 
process of accommodation to the disruptive event, which resulted in an altered life 
trajectory with some acceptance of the disease.  He notes: 
 
“…chronic illness involves a recognition of the worlds of pain and suffering, 
possibly even death, which are normally seen as distant possibilities or the 
plight of others (…) Further, the expectations and plans that individuals hold 
for the future have to be re-examined” 
 (Bury, 1982 p.169) 
 
 
In contrast, Paterson’s (2001; 2003) model of shifting perspectives opposes such an 
end-goal conception, theorising living with a chronic-illness as an on-going process, in 
which people experience a complex dialectic between themselves and the world.  The 
model illustrates how perceptions of chronic illness contain the dual perspectives of 
illness and wellness, with each of these perspectives alternately taking the foreground, 
dependent on people’s needs and situations.   
 
In order for such theories to remain relevant to contemporary narratives, the 
construction of HCV as a long-term condition must endure.  In previous research, 
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socially mediated notions of HCV chronicity have been repeatedly tied to the poor 
tolerability and efficacy of treatments available at the time (Fraenkel et al, 2005; 
Groessl et al, 2008; Hill et al, 2015; Kinder, 2009; North et al, 2014; Swan et al, 2010), 
in addition to a lack of information relating to the virus (Fry and Bates, 2012; Glacken 
et al, 2001; Groessl et al, 2008; Jiwani et al, 2013; Roy et al, 2007; Tompkins et al, 
2005).  Whilst these factors persist in many regions of the world, the political and 
economic response to HCV in Scotland has created an environment which may have 
challenged these notions.  Although rationed, access to highly effective and tolerable 
HCV therapies has been granted for many with the infection (HIS and NHS National 
Service Scotland, 2015), and a strategic framework raising awareness of HCV at a 
population level has been in place for over ten years (Scottish Executive, 2006; Scottish 
Government, 2008; 2011; 2015a).  Did perceptions of socially produced chronicity 
therefore still hold true for the participants in this study?  Indeed, is continuing to 
contextualise HCV as a chronic condition a misnomer given how readily it can now be 
eradicated for those accessing treatment?   
 
8.2.2.2 Chronicity within the themes 
To answer these questions, it is necessary to reflect on how an overarching discourse 
of disease progression and HCV chronicity were woven throughout the themes.  The 
narrative of positioning HCV was underpinned by an assumption that it was not a static 
and unchanging entity, but an advancing threat which could ultimately get worse over 
time.  The discourse of participants feeling fortunate, and favourably comparing 
themselves to others with the disease, was only possible if HCV was understood as an 
unequal illness, with degrees of severity and diverse trajectories.  The foundations of 
‘positioning HCV’ rest on the participants’ often implicit acknowledgement that they 
were at a particular point along an illness continuum: that HCV could progress and 
become more debilitating, and potentially life-threatening, in the future.   
 
Of course, participants’ understanding of HCV as a progressive disease with long-term 
implications, does not automatically equate with a notion that they expected to 
remain HCV positive, and move along that illness continuum.  There is a difference 
between constructing HCV as a potentially chronic and debilitating condition, and 
perceiving that such long-term effects will be directly experienced.  Hepatitis C is, after 
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all, curable for the majority of those who complete a period of treatment, and as 
previously stated, most participants in this study were already accessing specialised 
HCV care.  Was acknowledgement of disease progression therefore solely a discursive 
positioning strategy, used protectively to emphasise the participants own perceived 
good fortune?  Consideration of the discourse emphasising the emotional strain of 
living with HCV suggests not.  The persistent unease and emotional burden which were 
integral to the experience of being HCV positive were fed by multiple worries, which 
included the inability to self-monitor the effects of HCV, and related fears of long-term 
disease progression.  The progressive nature of HCV infection did not therefore 
constitute part of an improbable and unlikely illness trajectory, alluded to but 
ultimately disregarded.  Rather, it established a very tangible recognition in the 
participants that they may experience the effects of advancing liver disease at first-
hand.  The emotional burden of infection illuminates how the existence of an effective, 
and well-tolerated cure, did little to calm anxieties over the potential long-term 
implications of HCV, or negate the perception that the disease may prove a chronic 
concern. 
 
Why the arrival of effective, well-tolerated treatments for HCV did not appear to have 
effectively challenged socially mediated notions of chronicity is intriguing.  Previous 
discussion of treatment rationing could be presumed to play a considerable part, in 
addition to the lack of impact these therapies wielded in crucial domains of the lived 
experience.  However, the data also reveal more nuanced contributory factors, such as 
the manner in which participants articulated their understanding of the nature of 
these therapies.  These effective, well-tolerated regimens, feted and lionised within 
medical discourse (Chung and Baumert, 2014; Pawlotsky et al, 2015a) were not met 
with the same chorus of adoration by the study participants.  Rather, a discourse of 
uncertainty and confusion emerged, emphasising a vague understanding and 
ambiguous grasp of HCV treatment evolution.  This uncertainty may have been actively 
maintained as a coping strategy (section 6.5.1) nevertheless, its presence provides 
further insight into why an infection that now achieves a cure in over 90% of those 
taking treatment, continued to be framed as a chronic disease.  Understandings of new 
treatments were too insubstantial and remote to challenge deeply-rooted beliefs 
forged in the interferon era, and perceptions of a progressive, long-term illness 
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persisted.  How long this situation may endure is unknown.  Within high-income 
nations, cultural memory of the interferon-based therapy era will naturally fade as the 
costs of interferon-free treatments reduce, and their use proliferates.  In the short- to 
medium-term however, theories of chronic illness remain integral to illuminating the 
experience of those living with HCV, and the paradox of chronic illness models, for an 
increasingly curable disease, continues.   
 
8.2.3 Question three 
 
How is interferon-free treatment for hepatitis C experienced and contextualised? 
 
8.2.3.1 The legacy of interferon 
The exploration of undertaking interferon-free therapy in this study emphasises how 
the participants’ prevailing discourse was informed by an awareness of treatment 
during the interferon era.  Interferon-free regimens were not solely appraised, 
considered and experienced on their own merits, but in the context of previous 
standards of care.  Treatment of HCV during the interferon era was characterised by a 
range of physical and psychological side-effects, whose severity and persistence 
perniciously impacted on self-identity, social interaction and relationships with family 
and friends (Fraenkel et al, 2006; Hopwood and Treloar, 2005; Janke et al, 2008; 
Kinder, 2009; Sgorbini et al, 2009; Sheppard and Hubbert, 2006; Taylor-Young and 
Hildebrandt, 2009; Zickmund et al, 2006).  The participants’ experience of interferon-
free regimens in this study was intricately tied to this historical touchstone, with the 
legacy of interferon underpinning and shaping their discourse.  For example, discussion 
of side-effects continued to dominate the participants’ narratives.  However, whilst the 
burden and severity of these ailments had been the historical focus of concern, it was 
disbelief at the relative absence of such side-effects which now took precedence in 
their accounts.   
 
8.2.3.2 A cultural lag 
The disparity between underpinning expectations of interferon-free treatments and 
the participants’ subsequent experience of them illuminates a cultural lag between the 
rapid pharmacological developments which have been witnessed, and the social 
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understanding of them.  Ogburn’s (1922) durable theory of cultural lag suggests that 
this societal phenomenon exists when swift advances in material culture (such as new 
technologies or therapeutic developments) are not matched by equally swift cultural 
adaptation to such innovations.  As a result, a period of maladjustment occurs, when 
non-material culture struggles to adapt to new material conditions (Schaefer, 2012).  
The findings from this study suggest that such a period of maladjustment is currently 
being witnessed with regard to new HCV therapies, offering insight into how these 
treatments are experienced, but also articulating with previous discussions of 
chronicity and the persistence of resilient themes for those living with the virus.  The 
societal adjustment to a new era of HCV therapy trails behind the observed 
pharmacological advances. 
 
8.3 Limitations of the study 
Prior to considering the implications of this thesis, it is necessary to focus attention on 
the limitations of the study.  Limitations have the potential to affect the quality of the 
findings, and may restrict the transferability of those findings to other settings.  
Pragmatic consideration of conceivable limitations therefore contributes to the rigour 
and credibility of the work. 
 
8.3.1 Personal limitations 
The most obvious limitation within any doctoral study, must be the ability of the 
doctoral student themselves i.e. my own aptitude and capacity for conducting the 
work.  The common description of a PhD as a period of training, aimed at developing 
and honing research skills (Petre and Rugg, 2010), underlines that this thesis is not the 
work of an experienced and expert researcher, but that of a novice trainee.  The very 
nature of a doctoral study therefore presents possible limitations to the quality of the 
findings.  For example, I interviewed the participants, coded the data and developed 
the analytical narrative, despite never having attempted these tasks previously.  Whilst 
my own inexperience may therefore cast doubt on the credibility of the work, the 
nature of a doctoral study also demands supervisory expertise, which seeks to counter 
such concerns.  This supervisory expertise was present from the conception of the 
study, and throughout the planning and completion of the work.  Frequent meetings 
with the full supervisory team sought to review, challenge and interrogate multiple 
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aspects of the research design, data generation and the developing analysis. Such 
regular and robust feedback created an instructive and supportive learning 
environment, in which my limitations as a novice researcher were recognised, 
appropriately addressed and, hopefully, adequately overcome. 
 
In addition to my inexperience as a qualitative researcher, my previous role as a HCV 
nurse specialist also posed potential limitations to practical aspects of recruitment and 
data generation.  For example, as I was well-known to the healthcare team within the 
main recruitment site, some members of that team unintentionally limited my access 
to potential participants through a wish to make my research journey as smooth and 
straightforward as possible.  Soon after the inception of the study, I noted a reluctance 
of some staff to approach potential participants who they considered insufficiently 
verbose, unreliable or too chaotic to trouble me with.  A well-intentioned desire for me 
to succeed with my research was inadvertently making that outcome less likely.  I 
hadn’t fully appreciated the impact so-called ‘gatekeepers’ would have on my ability to 
recruit the diverse sample of participants I had planned, but these individuals’ own 
idiosyncratic sampling strategies proved a major barrier to enrolling people in the 
study in its early stages.  To avoid alienating myself from the team, challenging this 
required a tactful and diplomatic approach.  However, by liaising with staff on a one-
to-one basis, and explaining the aims of my research in greater detail, some headway 
was quickly made, and a broader range of potential participants were gradually 
referred. 
 
My interview technique was, at times, also limited by my previous professional 
experience.  Reflective readings of the interview transcripts illustrated how prior 
familiarity with some of the participants’ discourse resulted in a failure to always 
prompt for richer data.  Anecdotes were prefixed with assertions of “you know it 
yourself” or “you know what it’s like Dave”43, to which I found I sporadically concurred, 
rather than seeking deeper insight from the participant’s perspective.  The concept of 
bracketing in social phenomenology demands the suspension of belief in the world as I 
know it (Levesque-Lopman, 1988), yet demonstrations of my own unquestioning 
                                                          
43 Keith, 54, known to me from my clinical role prior to the study 
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acceptance in what I thought I knew intermittently appeared within the data.  Whilst 
clearly a limitation of the study and an area for further personal development, 
reflecting on the transcripts throughout the process of data generation helped to 
improve and sharpen my phenomenological technique for subsequent interviews.  The 
iterative nature of data generation and analysis therefore helped to ameliorate the 
impact of this limitation to the study. 
 
8.3.2 Methodological limitations 
In addition to the inexperience of the researcher, a common limitation levelled at 
research underpinned by a phenomenological methodology, is to what extent the 
work aims to illuminate the phenomenon in general (as an experience shared by 
many), or focus on more idiographic understandings of individual experience, 
eschewing broader insights (Finlay, 2009)?  The importance of this question lies in the 
transferability of a study’s findings to other settings, which contributes to the overall 
rigour and trustworthiness of the endeavour (Morse, 2015).  By adopting a social 
phenomenological perspective, the aim of this study was to explore the commonalities 
found in the inter-subjective experience of being HCV positive, and the analytical 
techniques employed served to achieve this goal.  However, the commonalities 
(themes) revealed within this thesis are those constructed by analysis of the narratives 
of these particular study participants, and in order to consider the limits of 
transferability, the composition, setting and socio-political contexts of those 
participants must be reflected on (Polit and Beck, 2010). 
 
The purposive sample of study participants were all drawn from one geographical 
region of Scotland, and from one Health Board area.  The maximum variation sampling 
strategy aimed to produce a high degree of variation amongst these participants 
(section 3.4.1.1).  However, recruiting individuals who were not engaged with HCV care 
proved more problematic than had been anticipated (table 3, p.77).  The principle 
reason for this lay in the difficulty of maintaining productive and fruitful relationships 
with multiple recruitment sites spread over a wide area.  Although staff in various 
recruitment locations were supportive of the study, the demands of their daily 
workload and my inconsistent presence at the sites contributed to a lack of impetus in 
identifying potential participants.  This group were also particularly inconsistent in 
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their attendance at the recruitment locations, and often unreachable by phone, which 
resulted in numerous missed opportunities to engage.  The result of these difficulties 
was a sample composed predominantly of individuals who were already engaged with 
specialist HCV services to a greater or lesser extent44, and as such may represent a 
fairly restricted population.  The latest figures available estimate 28% of those 
diagnosed with HCV in Scotland attended a specialist centre for care in 2014 (Public 
Health England, 2015), therefore caution should be exercised when relating these 
findings to those infected with HCV more generally. 
 
The scarcity of participants who did not engage with HCV services, also contributed to 
the relative dearth of those who identified as active PWID in the sample.  Whilst this 
restricted the comparative potential of the data, and limits the transferability of the 
findings, this research project was never intended to focus primarily on individuals 
who reported ongoing injecting drug use (table 3, p.77).  Previous studies suggest that 
the experience of living with HCV for this group of individuals differs markedly from 
those who identify as previous PWID, and those who have no drug-using history at all 
(Copeland, 2004; Davis and Rhodes, 2004; Harris, 2009; Wozniak et al, 2007).  As such, 
a specific contemporary investigation focused on current PWID, would serve to 
illuminate the influence an evolving era of HCV drug therapy may be having on their 
experience of living with the disease.  Recent academic discussion of the benefits of 
pursuing HCV treatment as prevention (TasP) strategies amongst this population would 
make this a particularly relevant and enlightening endeavour (Harris et al, 2015; 
Hickman, De Angelis, Vickerman, Hutchison and Martin, 2015). 
 
Finally, the Scottish setting of this study should also be considered within this 
discussion of limitations.  Globally, national strategies to address the HCV epidemic 
demonstrate considerable variation, with Scotland frequently acknowledged as leading 
the way in tackling the disease (Ulmer and Hughes, 2013) alongside other high-income 
nations such as Australia (Australian Government, 2014).  Whilst world-leading, the 
Scottish experience of a nationally coordinated action plan, and regulated access to 
new medications differs vastly from the current situation in low- and middle-income 
                                                          
44 The two study participants who were not engaged with specialist care, Eilidh and Dean, were 
recruited through a GP practice with the aid of a particularly motivated and dynamic GP. 
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countries (Graham and Swan, 2015) where the global burden of infection is 
predominantly felt (Mohd Hanafiah et al, 2013).  The findings from this study are 
located within a particular socio-political context which should not be overgeneralised. 
 
8.4 Implications of the study 
The obvious question which arises from this exploration into the contemporary lived 
experience of HCV is why does it matter?  The purpose of health-related social science 
research is ultimately to inform action, and therefore consideration of how the 
findings from this study connect with strategy, service delivery and frontline care must 
be made.  What implications does this work have when considered within the contexts 
of policy aimed at addressing the HCV epidemic, the strategic delivery of treatment 
and the clinical practice of those working with HCV positive individuals on a daily 
basis?   
 
8.4.1 Implications for policy 
Within Scotland, the strategic framework for addressing HCV originated in a two phase 
action plan launched in 2006 (Scottish Executive, 2006; Scottish Government, 2008).  
This action plan was later subsumed into a national framework with a broader remit, 
addressing sexual health and blood borne viruses in an integrated, cross-agenda 
approach (Scottish Government 2011).  The framework is guided by five high-level 
outcomes, of which four connect directly to HCV: 
 
Outcome 1: Fewer newly acquired hepatitis C infections. 
 
Outcome 2: A reduction in the health inequalities associated with hepatitis C. 
 
Outcome 3: People affected by hepatitis C lead longer, healthier lives. 
 
Outcome 5: A society whereby the attitudes of individuals, the public, 
professionals and the media in Scotland towards hepatitis C are 
positive, non-stigmatising and supportive. 
 
 (Scottish Government, 2011, p.32) 
 
These outcomes are based on key aims identified in the second phase of the original 
HCV action plan (Scottish Government, 2008), and as such, are firmly rooted in the 
interferon-era.  Whilst much progress has been reported in addressing these objectives 
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(Scottish Government, 2015a), the findings from this research cast doubt on whether 
they remain collectively achievable, and fit for purpose, in a new age of therapy.  The 
significant influence of treatment rationing on the experience of living with HCV, 
implies the stated outcomes are contradictory and no longer compatible with each 
other.  For example, the prioritisation of treatment to those with a greater degree of 
liver disease (advocated within the 2015 framework update [Scottish Government, 
2015a]) serves to work towards the realisation of outcome three.  However, in doing 
so, it creates and imposes an array of new health inequalities associated with HCV, in 
direct opposition to outcome two.  In addition, the acceptance and tolerance of those 
inequalities, evident throughout the participants’ narratives, reinforces discrimination 
and stigma which sits uneasily alongside outcome five.  Within the context of a new 
therapeutic era, this research implies these outcomes are mutually exclusive, rather 
than parts of a unified whole.  The strategies in place to address particular outcomes 
are actively working against the realisation of others. 
 
8.4.2 Implications for treatment delivery 
The cultural lag exposed by this study has implications for how novel HCV treatments 
are delivered in clinical practice.  It creates conflict between what patients ought to 
need during periods of therapy with interferon-free regimens, and what they actually 
require.  All participants in this study, who commenced a period of therapy, received 
their treatment through a hospital-based clinic.  However, moving therapy away from 
secondary care and into more diverse settings is now a key priority in Scotland 
(Scottish Government, 2015a), and there is an emerging evidence base to support that 
objective (Alavi et al, 2013; Brew, Butt and Wright, 2013).  Interferon-based 
treatments have been successfully delivered in opioid substitution settings and 
prisons, achieving comparable adherence and response rates to those reported in 
more conventional locations (Grebely et al, 2016; Litwin et al, 2009; Rice et al, 2012).  
However, these support-intensive models of treatment delivery may be reviewed in 
light of fewer perceived patient requirements with ‘easier’ drugs.  As interferon-free 
(and increasingly ribavirin-free) treatments proliferate, the clinical need for close 
haematological and side-effect monitoring of patients recedes (Lam et al, 2015), yet 
the significance of knowing the treatment to be working, and the continued 
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importance of support for individuals with significant histories of drug use and drug 
treatment are key findings within this study. 
 
Global HCV discourse tends to focus on improving SVR rates, reduced side-effect 
profiles and decreasing treatment times (Asselah et al, 2016; Chung and Baumert, 
2014; Pawlotsky et al, 2015a), yet understanding what motivates and reassures 
individuals whilst taking the drugs is essential in ensuring improved adherence and 
integral to interferon-free treatments reaching their full potential.  In the often quoted 
words of former US Surgeon General C. Everett Koop “drugs don’t work in patients 
who don’t take them” (Osterberg and Blaschke, 2005).  The cultural lag observed 
within this study suggests caution should be exercised in any reconsideration of how 
best to deliver interferon-free therapies to patients, as the experience of interferon-
free treatment continues to demonstrate a significant and essential discourse of 
needs.  This finding could also have implications for the large-scale implementation of 
HCV TasP initiatives, which whilst theoretically possible (Hickman et al, 2015), have yet 
to be empirically tested. 
 
8.4.3 Implications for practice 
Discussion of treatment delivery emphasises how the care of individuals with HCV is 
governed by an acute focus on curing the disease.  This acute care model positions 
those with HCV as patients who receive expert advice from healthcare practitioners, 
rather than informed individuals who live, and have lived, with the disease on a daily 
basis.  It also perpetuates common assumptions about acute illness, for example that it 
should be the patient’s predominant concern and highly prioritised (Paterson et al, 
2006).  Such a model concentrates on disease process, symptom management and 
viral eradication, whereas the findings from this study suggest the burden of HCV 
infection is felt in much wider social and emotional contexts, which often remain 
unrecognised and unaddressed.  The acute model of HCV care is attentive to physical 
manifestations of disease, yet much of the burden of illness appears psychogenic and 
social in nature. 
 
Acute models of care also clash with the enduring perception of HCV as a chronic 
condition for those living with the virus (Paterson et al, 2006).  Despite improving 
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therapies, the understanding of HCV as a long-term concern continued to underpin the 
discourse of participants in this study.  This discord, between acute care and chronic 
disease, may result in patients and healthcare practitioners harbouring competing 
agendas, potentially undermining the therapeutic relationship by negatively impacting 
on patient-provider interactions (Haworth and Dluhy, 2001).  The findings from this 
study imply an acute model of care fails to address the experience of living with HCV.  
An overriding emphasis on treatment ignores the broader meaning of HCV in the lives 
of the individuals affected, and fails to tackle key anxieties and concerns.  A more 
person-centred approach to HCV care is needed, if the true burden of illness is to be 
confronted. 
 
8.5 Recommendations 
The findings and implications of this work give rise to a number of recommendations 
for policy, future research and clinical practice.  Discussion of these recommendations 
aims to demonstrate how this thesis offers practical application at a range of different 
levels, and to a variety of stakeholders. 
 
8.5.1 Recommendations for policy 
As previously stated, the findings from this thesis suggest that the key aims of the 
strategic framework for addressing HCV in Scotland are no longer compatible in a new 
era of treatment.  As such, a critical review of the existing Sexual Health and Blood 
Borne Virus Framework (Scottish Government, 2011; 2015a) and how it relates to the 
contemporary experience of HCV should be made.  A practicable and relevant 
framework is essential in guiding governmental responses towards the elimination of 
HCV as a public health threat by 2030 (Hepatitis B and C Public Policy Association, 
2016; World Health Assembly, 2016). 
 
In addition, this study has emphasised how stigma continued to exert a pervasive and 
obstinate influence on the lives of the participants.  The reduction of stigma is stated 
as a key outcome within the existing Sexual Health and Blood Borne Virus Framework 
(Scottish Government, 2011), and whilst the Ministerial foreword to the 2015 update 
celebrates being “proud of our bold commitment to challenge stigma in all its forms” 
(Scottish Government, 2015a, p.2), the document itself fails to report any HCV-specific 
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progress on this.  Indeed, discussion of stigma is entirely absent from the section of 
report dealing with viral hepatitis, with the identification of key developments since 
2011, and key priorities up to 2020, making no reference to stigma whatsoever.  It is 
therefore necessary for governmental policy to pay more than lip-service to HCV 
stigma reduction, and initiate specific interventions with measureable outcomes to 
begin to address the problem.  A government funded nationwide intervention has 
been initiated within the framework focused on the stigma and discrimination of 
individuals with HIV (Waverley Care, 2012), and a comparable approach for HCV 
should also be employed. 
 
Of course, it is not solely HCV-specific policy which is of relevance to the lives of those 
afflicted by the disease.  The burden of HCV in Scotland is associated with deprivation 
and substance use, and predominantly located within some of the most vulnerable and 
disenfranchised sections of society (Scottish Government, 2011).  This thesis has 
underscored how the implicit acceptance of health inequalities was integral to the 
experience of the participants, which speaks of how their capability to be healthy was 
fundamentally constrained (Venkatapuram, 2011).  As such, it is recommended that 
the Sexual Health and Blood Borne Virus Framework is not progressed in isolation, but 
forms strategic links with other governmental schemes and policies which seek to 
address social determinants of health.  Whilst it is acknowledged that this is a fairly 
broad and non-specific recommendation, an insular focus on the prevention, testing 
and treatment of HCV may disappoint, if the ability of HCV positive individuals to 
engage with that programme of care is constrained by their social environment (and its 
political determinants). 
 
8.5.2 Recommendations for future research 
The findings from this study also suggest areas where further academic research would 
be beneficial.  This thesis presents a temporal snapshot of the lived experience of HCV 
and its treatment, offering valuable insight into how individuals understand and make 
sense of the disease.  However, the context in which this study is located continues to 
evolve.  As recurrently stated, the developments in HCV treatment are ongoing, and 
further interferon-free options for multiple HCV genotypes are set to become available 
within Scotland over the coming years (e.g. SMC, 2016).  As the cultural memory of 
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interferon fades, additional qualitative research will be needed to allow comparable 
insight into the influence these continued pharmacological advances have on the 
experience of living with HCV. 
 
Further, as previously discussed, this research is limited by the lack of active PWID 
recruited to the study.  As the discourse of HCV TasP continues to gain more attention 
and authority (Cousien et al, 2016; Hickman et al, 2015; Leask and Dillon, 2016), 
understanding how HCV and its treatment are experienced by individuals actively 
injecting drugs gains greater significance.  Theoretical discussion of scaling up HCV 
treatment among active PWID has so far failed to account for how these communities 
perceive this new era of therapy.  The patient perspective appears to have been 
overlooked as irrelevant and inconsequential within the population-based rhetoric of 
HCV TasP (Harris et al, 2015).  Contemporary qualitative research focused on the lived 
experience of HCV positive PWID is needed to inform empirical HCV TasP initiatives, 
and support them reaching their full potential. 
 
8.5.3 Recommendations for clinical practice 
Finally, the findings from this study also produce recommendations for clinical 
practice.  The acute model of care which currently dominates service delivery largely 
fails to address the multiple social and emotional aspects of living with HCV, and 
disregards the ongoing construction of the disease as a chronic concern.  The extent to 
which care can be characterised as ‘person-centred’ is therefore debatable.  Whilst the 
treatment of HCV is an understandable and expected goal for care providers, this 
ultimate ambition should be embedded within holistic patterns of care which seek to 
treat not just the biological pathogen, but also the ongoing effects and consequences 
of the virus.  As stated at the beginning of this thesis, the name HCV does not simply 
designate an invariant biological reality, and the care of individuals living with the virus 
should therefore entail more than a focus on virus removal.  This recommendation is 
elucidated in the following personal reflection. 
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8.6 Concluding remarks 
8.6.1 A personal reflection 
I began this thesis by relating my personal interest in, and experience of, the field of 
HCV, and reflecting on how I perceived the medical and academic discourse 
surrounding improving HCV treatment to be marginalising the experience of those 
living with the disease (section 1.1.6).  My ambition throughout this work has been to 
honour the voice of the HCV patients I nursed over the years, and give a scholarly 
platform to their contemporaries’ experiences, understandings and insights in a new 
era of therapy.  Whilst I hope the preceding chapters have realised that ambition, 
conducting this research study has also provided me with innumerable personal 
opportunities for learning and reflection.  Each step in the research process has 
presented me with new challenges, from exploring theoretical debates into the nature 
of reality, to the more practical development of effective interviewing and analytical 
skills.  Significantly, my three-year immersion in the research process has also 
compelled a timely re-examination of my own professional practice as a nurse, and 
forced me to question whether my avowed commitment to person-centred care has 
always been demonstrated in my actions.  Whilst my intent to honour the voices of 
HCV positive individuals within this study is apparent, it has obliged me to interrogate 
the value I had previously placed on those voices within my own clinical practice. 
 
It was during my second interview with Happy, one of the study participants, that this 
thought really took hold.  When asked about her treatment experience, she described 
her most significant help during therapy as something disregarded and comparatively 
disparaged by the treatment team: 
 
I wasn’t asked about my lifestyle, I was asked about it but they seemed not to 
really pay any attention, to be not really seriously considered (…) it was more 
important to me.  Like, when I said I was introducing to yoga, I wasn’t asked 
about it, but it really really played a big role, because like with hot yoga, I was 
like sweating, so it was detoxifying the body, so for me I think that’s what 
helped me… 
 
(Happy, during her second interview) 
 
Whilst reflecting on the interview afterwards, I queried whether my own reaction as a 
HCV nurse specialist would have been any different from that of the healthcare team 
223 
 
when confronted with Happy’s idiosyncratic faith in the benefits of hot yoga.  This 
anecdote made me question more broadly the value I had previously placed on 
patients’ narratives in clinical consultations, and the gulf that can exist between the 
priorities and predominant concerns of HCV care providers, and those of individuals 
living with the virus.  In hindsight, the mantra of viral eradication through effective 
treatment, which had always guided my clinical practice, had also been instrumental in 
necessitating a relative disregard for those aspects of living with HCV which may not 
affect, or seem peripheral to, the treatment pathway.  I had heard the patient’s voice 
when it spoke to my predetermined agenda, but turned down the volume when it 
spoke to theirs.  Conducting this study has rebalanced my outlook between a clinical 
need for focused and directed treatment, and a care pathway which acknowledges and 
addresses those aspects of living with HCV which are most significant to the people 
concerned.  The value of the patient perspective is not just an academic interest: it is a 
guiding principle for my future practice. 
 
8.6.2 Thesis contribution 
This study provides the first contemporary insights into the lived experience of HCV 
since the arrival of DAAs in clinical practice.  It has illuminated what this new era of 
therapy means to individuals living with the virus, and exposed social and emotional 
spheres of illness, and a perception of illness chronicity, which remain untouched by 
the treatment revolution.  Further, this work has emphasised that treatment 
inequalities are integral to how those with HCV articulate the disease, fundamentally 
underpinning multiple aspects of their daily lived experience. 
 
This study also provides the first qualitative exploration of interferon-free treatments 
for HCV.  It has revealed how the interferon legacy continues to cast a long shadow 
over the experience of interferon-free treatment, and exposed a cultural lag between 
the pharmacological advances currently being witnessed, and societal understandings 
and experiences of them.  As such, it challenges notions of ‘easier’ therapy, and 
suggests the undemanding nature of these drugs may belie the challenges still faced in 
delivering these medications to the people who need them. 
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This thesis forms a timely addition to the global HCV discourse, which increasingly 
speculates on how improving therapies may lead to greater numbers of individuals 
accessing care, and potential global eradication of the virus.  Such epidemiological 
conjecture often fails to account for how those living with HCV understand the illness, 
and the wider socio-political and cultural context within which treatment is 
undertaken.  The individual, and their perception, beliefs and rights, are removed from 
the equation.  This study has served to place the voice of those individuals back on the 
table, and underscore the importance of rich, vivid and recognisable insights to a 
contemporary understanding of living with hepatitis C. 
 
__________________________________________ 
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Table 6: Initial search strategy for quantitative articles detailing the HRQoL for individuals with HCV 
within each individual database, and the results achieved.  Searches last run 17 November 2016. 
 
Search Engine Search Terms (ST)/Subject Index Terms (SIT) # Retrieved # Remaining following 
title/abstract exclusions & 
duplication exclusions 
 
Medline S1: Hepatitis C (SIT) OR Hepatitis C, Chronic (SIT) 
OR Hepatitis C (ST) 
76,577  
Medline S2: Patient Outcome Assessment (SIT) OR Patient 
Reported Outcomes (ST) 
7,336  
Medline S3: Quality of life (SIT) OR Health Related Quality of 
Life (ST) 
77,738  
Medline S4: HRQL (ST) 2,843  
Medline S5: HR-QOL (ST) 554  
Medline S6: HRQOL (ST) 10,716  
Medline S7: S2 OR S3 OR S4 OR S5 OR S6 83,758  
Medline S8: S1 AND S7 402 143 
Database Total:   143 
CINAHL S1: Hepatitis C (SIT) OR Hepatitis C, Chronic (SIT) 
OR Hepatitis C (ST) 
12,054  
CINAHL S2: Outcome Assessment (SIT) OR Outcomes 
[Health Care] (SIT) OR Patient Reported Outcomes 
(ST) 
59,271  
CINAHL S3: Quality of life (SIT) OR Health Related Quality of 
Life (ST) 
40,279  
CINAHL S4: HRQL (ST) 783  
CINAHL S5: HR-QOL (ST) 128  
CINAHL S6: HRQOL (ST) 3,170  
CINAHL S7: S2 OR S3 OR S4 OR S5 OR S6 97,662  
CINAHL S8: S1 AND S7 279 10 
Database Total:   10 
Embase S1: Hepatitis C (SIT) OR Hepatitis C Virus (SIT) OR 
Hepatitis C (ST) 
122,750  
Embase S2: Outcome Assessment (SIT) OR Outcomes 
Research (SIT) OR Patient Reported Outcomes (ST) 
36,864  
Embase S3: Quality of Life (SIT) OR Health-Related Quality 
of Life (ST) 
113,752  
Embase S4: HRQL (ST) 4502  
Embase S5: HR-QOL (ST) 876  
Embase S6: HRQOL (ST) 17,155  
Embase S7: S2 OR S3 OR S4 OR S5 OR S6 147,265  
Embase S8: S1 AND S7 887 25 
Database Total:   25 
Cochrane Library S1: Hepatitis C (ST) 702  
Cochrane Library S2: Quality of Life (ST) 5128  
Cochrane Library S3: S1 AND S2 486 0 
Database Total:   0 
JBI COnNECT+ S1: Hepatitis C (ST) 12 0 
Database Total:   0 
PsycINFO S1: Hepatitis (SIT) OR Toxic Hepatitis (SIT) OR 
Hepatitis C (ST) 
3,031  
PsycINFO S2: Quality of Life (SIT) OR Quality of Life (ST) 69,363  
PsycINFO S3: S1 AND S2 185 5 
Database Total:   5 
ASSIA S1: Hepatitis C (ST) 1,117  
ASSIA S2: Quality of Life (SIT) OR Health Related Quality 
of Life (ST) 
14,852  
ASSIA S3: S1 AND S2 32 0 
Database Total:   0 
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Table 7: Initial search strategy for qualitative articles detailing the lived experience of HCV used within 
each individual database, and results achieved.  Searches last run 18 November 2016. 
 
Search Engine Search Terms (ST)/Subject Index Terms (SIT) # Retrieved # Remaining following 
title/abstract exclusions & 
duplicate exclusions 
 
Medline S1: Hepatitis C (SIT) OR Hepatitis C, Chronic 
(SIT) OR Hepatitis C (ST) 
76,588  
Medline S2: Quality of life (SIT) OR Quality of life (ST) 
OR Life Changes Events (SIT) OR Experience 
(ST) 
756,245  
Medline S3: S1 AND S2 2,748  
Medline S4: Qualitative Research (SIT) OR Qualitative 
(ST) OR Interviews as Topic (SIT) OR 
Interview, Psychological (SIT) OR Interview* 
408,096  
Medline S5: S3 AND S4 166 46 
Database Total:   46 
CINAHL S1: Hepatitis C (SIT) OR Hepatitis C, Chronic 
(SIT) OR Hepatitis C (ST) 
12,054  
CINAHL S2: Quality of Life (SIT) OR Quality of Life (ST) 
OR Life Experiences (SIT) OR Experience (ST) 
240,348  
CINAHL S3: S1 AND S2 540  
CINAHL S4: Qualitative Studies (SIT) OR Qualitative 
(ST) OR Interviews (SIT) OR Interview* (ST) 
251,558  
CINAHL S5: S3 AND S4 104 14 
Database Total:   14 
Embase S1:Hepatitis C (SIT) OR Hepatitis C Virus (SIT) 
OR Hepatitis C (ST) 
122,750  
Embase S2: Quality of Life (SIT) OR Quality of Life (ST) 
OR Experience (SIT) OR Personal Experience 
(SIT) OR Experience (ST) 
1,138,011  
Embase S3: S1 AND S2 6,240  
Embase S4: Qualitative Research (SIT) OR Qualitative 
Analysis (SIT) OR Qualitative (ST) OR 
Interview (SIT) OR Semi-Structured Interview 
(SIT) OR Interview (ST) 
454,320  
Embase S5: S3 AND S4 288 11 
Database Total:   11 
Cochrane 
Library 
S1: Hepatitis C (ST) 702  
Cochrane 
Library 
S2: Quality of Life (ST) 5128  
Cochrane 
Library 
S3: S1 AND S2 486 0 
Database Total:   0 
JBI COnNECT+ S1: Hepatitis C (ST) 12 0 
Database Total:   0 
PsycINFO S1: Hepatitis (SIT) OR Toxic Hepatitis (ST) OR 
Hepatitis C (ST) 
3,032  
PsycINFO S2: Quality of Life (SIT) OR Quality of Life (ST) 
OR Life Experiences (SIT) OR Life Changes 
(SIT) OR Experience (ST) 
534,435  
PsycINFO S3: S1 AND S2 413  
PsycINFO S4: Qualitative Research (SIT) OR Qualitative 
(ST) OR Interviews (SIT) OR Interview* (ST) 
358,022  
PsycINFO S5: S3 AND S4 138 4 
Database Total:   4 
ASSIA S1: Hepatitis C (SIT) OR Hepatitis C (ST) 1,117  
ASSIA S2: Quality of Life (SIT) OR Quality of Life (ST) 14,852  
ASSIA S3: S1 AND S2 44 0 
Database Total:   0 
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INTERVIEW 1 
 
1A. Welcome and Introduction 
__________________________________________________________________________________ 
 
- Thank the participant for agreeing to be interviewed. 
- Explain why the participant has been approached for this study and re-state the purpose of 
the research; to explore patient’s views and experiences of having hep C.  Go through the 
participant information sheet allowing time for questions, and review the signed consent 
form. 
- Explain that the interview will be recorded and transcribed, and that quotes from the 
interview may be used in the final report.  Advise that a pseudonym will be assigned to the 
transcript, and any identifying information will be changed.  Ask if the participant wishes to 
choose their own pseudonym. 
- Discuss confidentiality, being explicit that the contents of the interview will not be shared 
with the clinical team, although they will have access to the final report.  Note that the 
interview transcript may be seen by other members of the small research team however.   
Advise participant not to disclose illegal activity for which they have not been convicted. 
Advise that disclosure of sensitive information during the interview (e.g. if ‘significant harm’ 
to children is disclosed) would mean the researcher would have a duty to act and 
confidentiality in that case would be broken. 
- Advise that notes may also be taken during the interview. 
- Ask whether the participant has any questions and answer appropriately.  
- Offer tea/coffee/water if able. 
 
Start the audio recorder 
 
Key Topic Areas for interview 1 
• The experience of diagnosis 
• The Illness experience in everyday life 
• Treatment knowledge and perception 
• Future outlook 
 
Questions in bold are proposed as questions to initiate conversation within each key topic area, with 
areas for exploration and examples of possible follow up questions given in plain text.  Further 
examples of general prompts and probes are given at the end.  
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2A. Diagnosis 
__________________________________________________________________________________ 
 
“I’d like to start by talking about when you were diagnosed.  Can you tell me what happened?” 
 
Examples of potential further questions/areas for exploration: 
“When were you diagnosed and who told you?” 
“What did you know about hep C at the time?” 
Explore reaction to diagnosis; if not mentioned prompt: 
“How did you react to being told you were hep C positive?” 
“What do you think caused you to react in that way?” 
 
“Thinking about the time before you were diagnosed with hep C; can you tell me a little about 
how your life was then?” 
 
Explore drug use and social circumstances/support: 
“How do you think you got hep C?” 
“Tell me more about who was around at that time; any family?  Close friends?” 
Probe any mention of stigma or attitudes prior to diagnosis 
 
“How has life been since your diagnosis?” 
 
Explore changes that have occurred: 
“Has anything (else) changed?” 
“What do you think contributed to/caused [those changes]?” 
What is their experience of stigma (explore any mention of both internal and external stigma): 
“What was it like telling other people?”;  ”how did their reaction affect you?” 
“How do you feel about having hep C now?” 
 
3A. The Illness Experience in Everyday Life 
__________________________________________________________________________________ 
 
“I’d like to focus a little more on your day-to-day life now.  What’s it like for you having hep C?” 
 
Explore physical, emotional and social impacts of living with hep C: 
“Does having hep C affect your life in any way?” 
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“Has having hepatitis C brought about any changes to your life?” 
“What are the downsides to having hep C?  Are there any positives?” 
“Is there anything you do, or don’t do, because of having hep C?” - “What are the reasons 
for that?” 
“You mentioned ____________________, can you describe what happens?” 
 
“How do you cope with having hep C?” 
 
Explore the burden of living with hep C and support mechanisms: 
“What are the main challenges you face because of having hep C?” 
“Is there anyone you can turn to for help?” 
“Do things ever get too much…?” 
  
“Is there any other way that hep C affects your daily life that we haven’t talked about yet?” 
 
4A. Treatment Knowledge and Perception 
__________________________________________________________________________________ 
 
“Can you tell me what you know about the treatment for hep C?” 
 
What level of understanding do participants have about the current treatment options? 
“Where do you/would you find out information about hep C treatment?” 
“Have you ever had treatment for hep C before?” 
“Tell me about that experience, what happened?” 
OR 
“Do you know anyone who’s been through treatment for hep C?  Have they told you 
anything about it?” 
“You mentioned new/better drugs, can you tell me more about that?  How are they better?” 
  
“How do you feel about hep C treatment?” 
 
What perceptions do participants have about hep C treatment? 
“Is treatment something you expect to do?  What are the reasons behind that?” 
“Do you have any concerns or worries about hep C treatment?” 
“Has the way you feel about hep C treatment changed at all?” 
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5A.  Future Outlook 
__________________________________________________________________________________ 
 
“Can you tell me a little about any plans you have for the future?” 
 
“Has having hep C played a part in your plans in any way?” 
“Have your plans changed at all? 
“How does looking to the future make you feel?  What do you think are the reasons behind 
that?”  
 
6A. Ending the Interview 
__________________________________________________________________________________ 
 
“Is there any other way that hep C affects your life that we haven’t discussed, or anything you 
think it might be important for me to hear that I haven’t asked you about?” 
 
Check information obtained during the interview covers all required patient demographic data. 
 
“Finally, what would you say to someone who had just been diagnosed with hep C today?” 
 
“Has what you would say changed in any way over the years?  Why?” 
“Would you give any specific advice?” 
 
Stop audio recorder 
 
- Thank the participant for their time and for sharing their experiences.  Ask if they have any 
questions. 
- Explain that you are also interested in peoples’ experience of taking hep C treatment, and 
ask if they would be happy to speak to you again should they begin a course of therapy.  If 
yes, give further details of what this would involve. 
- Offer the participant voucher reimbursement for time and expenses 
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INTERVIEW 2 
 
Revisit the welcome and introduction described in section 1A. 
 
Start the audio recorder 
 
Key Topic Areas for interview 2 
• Experience of treatment 
• Perceptions of the treatment service 
• Suggestions for how the treatment service may be improved 
 
2B. Experience of Treatment 
__________________________________________________________________________________ 
 
“You’ve just finished your hep C treatment.  Can you tell me how that’s been for you?” 
 
Examples of potential further questions/areas for exploration: 
Explore any mention of side effects – probe for further detail. 
Explore any comparison with previous treatment (will have this information from interview 1). 
Explore any mention of coping – support etc., how was this utilised? 
Explore any mention of adherence issues. 
“What happened?  Can you tell me what your treatment period was like?” 
“Was there anything you found easier or more difficult than you expected?” 
“How did your treatment fit into your daily life?” 
“How did taking hep C treatment make you feel?” 
 
“I’ve heard doctors and nurses talking about ‘preparing patients for treatment’.  Now you’ve been 
through treatment, do you think you were prepared for it?” 
 
What is the participant’s view of being prepared for hep C therapy? 
Was the emphasis on preparing for treatment from the clinical team appropriate? 
Explore any mention of under/over-preparation – in what areas?  Why did they feel that way?  
“Could you tell me a little about anything you did to prepare for treatment?” 
 “What advice would you give to someone preparing for treatment now?” 
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3B. Perceptions of the Treatment Service 
__________________________________________________________________________________ 
 
“Can you tell me about your relationship with the staff here at RIDU during your treatment?” 
 
Explore the relationship with doctors and specialist nurses 
How much contact was there, what was their role? 
“Was there anything particularly good or bad that stands out in your mind?” – example. 
 
“How would you rate the treatment service?” 
 
What is the overall perception of being treated for HCV at RIDU? 
Explore any positive or negative mentions of HCV drugs specifically (if not already covered) 
  
4B. Suggestions for Improvement 
__________________________________________________________________________________ 
 
“If you could change anything about the hep C treatment service, what would it be?” 
 
“If you could give advice to someone preparing for treatment now, what would you say?” 
 
5B. Ending the Interview 
__________________________________________________________________________________ 
 
“Is there anything else that you want to say about the treatment, good or bad, that we haven’t 
covered already?” 
 
Stop audio recorder 
 
- Thank the participant for their time and for sharing their thoughts and experiences.  Ask if 
they have any questions. 
- Explain that you would like to catch up with them again once they know their treatment 
result, and arrange a date and time if possible (3 months hence). 
- Offer the participant voucher reimbursement for time and expenses 
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PARTICIPANT INFORMATION SHEET 
 
PATIENTS’ EXPERIENCES OF HEPATITIS C 
AND ITS TREATMENT 
 
 
 
 
 
 
 
 
What is the purpose of the study? 
The aim of the study is to find out what life is like for people who have hep C.  
We are interested in what day-to-day life is like, as well as what it’s like for 
people when they take treatment.  Knowing how hep C affects people can 
help doctors and nurses to provide better care for the patients they see. 
We would like to invite you to take part in our research study.  Before you 
decide, we would like you to understand why the research is being done 
and what it would involve for you.  Please take time to read the following 
information and discuss it with others if you wish.  One of our team will go 
through the information sheet with you and answer any questions you 
might have.  We’d suggest this should take around 15 minutes. 
Ask us if anything is not clear. 
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Why have I been invited to take part? 
You have been invited to take part by your doctor/nurse as they know you 
have hep C. 
 
Do I have to take part? 
No.  It is entirely up to you whether you decide to join the study.  If you agree 
to take part we will ask you to sign a consent form; however, you are free to 
withdraw at any time, without giving a reason.  A decision not to take part, or 
to withdraw at any time, will not affect the care you receive. 
 
What will happen to me if I take part? 
• If you decide to take part, your doctor/nurse will ask if you agree to 
your contact details being passed to the study team. 
• The study team will then ask you to meet with a researcher for an 
interview which should last about one hour.  The interview will be 
recorded with a digital audiotape recorder. 
• The interview will be held at a time and place convenient for you; this 
might be where you usually see your doctor/nurse, or maybe in your 
home.  After this, most people’s input to the study will be over. 
• If you are going to start hep C treatment soon, the researcher may 
ask if you would be interested in meeting again after your treatment 
is finished.  Agreeing to this part of the study means meeting for 
another 2 interviews at some point over the next 6 months. 
 
Will I get expenses for taking part? 
Yes.  At all interviews you will be given a £15 gift voucher to cover any out-of-
pocket expenses you might have for taking part. 
 
What are the possible benefits of taking part? 
There is no immediate benefit to you, but the information we get from this 
study could help improve the treatment of people with hep C. 
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What are the possible risks of taking part? 
During the interviews, we ask that you talk as honestly as you can about how 
living with hep C has been for you.  This may be upsetting, and the researcher 
will ensure your thoughts and feelings are respected. 
 
What will happen if I don’t want to carry on with the study? 
You may choose to withdraw from the study at any point.  If this happens, we 
will destroy any information already collected from you if that is what you 
want.  At all times, the treatment and care you receive will not be affected. 
 
Will my taking part in this study be kept confidential? 
• All information collected about you during the study will be kept 
strictly confidential.  The researcher will ask you to choose a false 
name, which will then be used to identify you on everything other 
than the consent form we ask you to sign. 
• Your consent form will be kept securely on hospital premises. 
• All interviews will be recorded and then written up word-for-word.  In 
addition to using a false name, anything else which could identify you 
(such as names of friends, family, places near to where to live etc.) 
will also be changed.  Once written up, recordings will be erased from 
the digital recorder and destroyed completely at the end of the study. 
• All written out interviews will be securely disposed of within 5 years.  
Anonymised quotes may be used in the final report. 
• However, the researcher would need to speak to relevant people if  
you talk about anything which indicates harm to yourself and others. 
 
Will my general practitioner (GP) know I have taken part? 
Yes, with your consent a letter will be sent to your GP to tell them about your 
involvement in the study. 
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What will happen to the results of the study? 
The study is part of a post-graduate degree and will be written up as a thesis, 
as well as being published in academic journals.  A summary of results will 
also be made available in your clinic/surgery. 
 
Who has reviewed and funded this research? 
• The work is funded by the Clinical Academic Research Careers (CARC) 
scheme; a body which includes NHS Lothian, Edinburgh Napier 
University, Queen Margaret University, the University of Edinburgh 
and NHS Education Scotland. 
• All research in the NHS is looked at by an independent group of 
people, called a Research Ethic Committee, to protect your interests.  
This study has been reviewed and given a favourable opinion by 
South East Scotland Research Ethics Committee 1. 
 
What if there is a problem? 
If you have concerns about any aspect of this study, you can speak with an 
independent person who is not involved with the study; either Sheila Morris, 
Research Coordinator based at the Western General Hospital.  Phone: 0131 
537 2842; Email: sheila.morris@luht.scot.nhs.uk ; or Norrie Brown, Edinburgh 
Napier University.  Phone: 0131 455 5712; Email: n.brown@napier.ac.uk  
 
If you remain unhappy and wish to complain formally, you can do this by 
contacting NHS Lothian Customer Relations and Feedback Team, Waverley 
Gate, 2-4 Waterloo Place, Edinburgh EH1 3EG.  Phone: 0131 536 3370; Email: 
craft@nhslothian.scot.nhs.uk or Barbara Neades, Edinburgh Napier University 
Ethics Convener, Phone: 0333 900 6040 Email: B.Neades@napier.ac.uk  
 
For further information on this study please contact: 
David Whiteley, Substance Misuse Directorate, c/o Ward 41 OPD, Western 
General Hospital, Crewe Road South, Edinburgh EH4 2XU. 
Phone or text: 07972 248470; Email: dwhiteley@nhs.net   
